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Abstract 
Mutations in the melanocortin 2 receptor (MC2R) and its accessory protein (MRAP), in the 
ACTH signalling pathway, and the antioxidant genes nicotinamide nucleotide 
transhydrogenase (NNT) and thioredoxin reductase 2 (TXNRD2) have been associated with 
familial glucocorticoid deficiency (FGD). Using a tandem affinity purification and mass 
spectrometry approach to identify interacting partners of MC2R and MRAP failed to identify 
putative candidate genes for further FGD cases. However in a male patient a homozygous 
mutation in another antioxidant gene, glutathione peroxidase 1 (GPX1), was identified. In 
vitro studies showed H295R cells with knockdown of GPX1 had 50% less basal GPX activity 
and were less viable than wild-type when exposed to oxidative stress. Adrenals from Gpx1
-/-
 
mice showed no gross morphological changes and corticosterone levels were not significantly 
different from their wild-type counterparts (in contrast to the Nnt mutants). Sequencing of 
>100 FGD patients did not reveal any other GPX1 mutations. This equivocal data lead to the 
hypothesis that there could be a second gene defect present in this proband contributing to his 
disease.  
Whole exome sequencing revealed a homozygous loss-of-function mutation in peroxiredoxin 
3 PRDX3 (p.Q67X) in this patient, that was also present in his unaffected brother.  In vitro 
studies revealed both single and double knockdown of the two genes in H295R cells reduced 
cell viability, but redox homeostasis and cortisol production were unaffected. 
GPXs and PRDXs work simultaneously to reduce H2O2, preventing cellular damage.   My 
data suggest that loss of PRDX3 alone is insufficient to cause adrenal failure and further that 
mutation in GPX1, either alone or in combination with PRDX3 mutation, may tip the redox 
balance to cause FGD. 
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Chapter 1: Introduction 
1.1 Hypothalamic-Pituitary-Adrenal Axis 
 
The Hypothalamic-Pituitary-Adrenal (HPA) axis is a major endocrine system that mediates 
the stress response. The main structural components are the paraventricular nucleus (PVN) of 
the hypothalamus, the anterior lobe of the pituitary, and the adrenal cortex (Fig. 1.1).  The 
stress response involves endocrine, neuronal and immune systems in order in evoke 
behavioural and physiological changes to cope with the external environmental or internal 
homeostatic sources of stress.   
Stress stimuli are conveyed to the hypophysiotropic neurons in the PVN which express and 
secrete corticotropin-releasing factor (CRF) (Sawchenko and Swanson, 1985). These neurons 
project to hypophysial portal vessels that access the anterior pituitary gland.  CRF secreted 
into hypophysial portal vessels, activates the CRH receptor on anterior pituitary corticotroph 
cells leading to corticotrophin release (ACTH) into peripheral circulation.  CRF is the 
principle regulator of ACTH release, however vasopressin (AVP) is an additional regulator 
that is released from parvocellular neurons of the PVN into portal vessels, and acts via V1b 
receptors on anterior pituitary corticotrophs to potentiate ACTH release (Smith and Vale, 
2006). ACTH is synthesised from its precursor proopiomelanocortin (POMC), in addition to 
α-, β- and γ-Melanocyte-stimulating hormones (MSHs). 
Once released into circulation ACTH acts on melanocortin 2 receptors (MC2R) in the adrenal 
cortex to induce the production of glucocorticoids, the effectors of the HPA axis.  MC2R is a 
class A G Protein-coupled receptor (GPCR), that when activated, induces adenylyl cyclase 
activity which generates cyclic adenosine monophosphate (cAMP), leading to an increase in 
Protein Kinase A (PKA) activity. 
20 
 
 
 
Figure 1. 1: The HPA axis 
Hypophysiotropic neurons of the hypothalamus secreting CRF extend to the anterior 
pituitary and act on CRF receptors to stimulate ACTH synthesis and release into the 
circulation. Simultaneously parvocellular neurons secreting AVP also extend to the 
anterior pituitary and potentiate ACTH release. Circulating ACTH acts on MC2R 
receptors in the ZF and ZR of the adrenal cortex to activate cortisol synthesis.  Cortisol 
acts on peripheral tissues and negatively feeds back to the hypothalamus and pituitary 
to prevent further ACTH release.  
 
ACTH induced cAMP/PKA activity increases glucocorticoid production through various 
mechanisms.  Firstly cAMP/PKA increases the availability of free cholesterol, the first 
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substrate in steroidogenesis, by stimulating the uptake of low-density lipoproteins (LDL) via 
LDL receptor-mediated endocytosis, and stimulating hormone sensitive lipase (HSL) whilst 
inhibiting acyl-coenzymes-A-cholesterol-acyl-transferase (ACAT), leading to the de-
esterification of cholesterol stored in lipid droplets (section 1.2.2, Fig. 1.3) (Miller, 2013). 
In the acute phase of ACTH stimulation, PKA increases transcription of steroidogenic acute 
regulatory protein (StAR) (Stocco et al., 2005) and phosphorylates existing StAR at Ser195, 
doubling its activity (Arakane et al., 1997). StAR mediates the transport of cholesterol from 
the outer to the inner mitochondrial membrane where the first step of steroidogenesis takes 
place.  In the later stages of ACTH stimulation, cAMP activates cAMP element binding 
protein (CREB) which increases the transcription of steroidogenic genes (Chan et al., 2011).  
The major glucocorticoid in humans is cortisol, and in rodents corticosterone. When released 
into circulation, glucocorticoids act on ubiquitously expressed glucocorticoid receptors in the 
CNS and peripheral tissues.  The receptors are intracellular and exist as homodimers in 
complexes with a number of heat shock proteins.  Activation of the glucocorticoid receptor 
by its ligand results in a conformational change, which in turn leads to translocation of the 
receptor to the nucleus, where it binds and activates the transcription of target genes which 
contain specific glucocorticoid response elements in the promoter regions (Smith and Vale, 
2006).  This results in a number of metabolic, cardiovascular and immune changes (Smith 
and Vale, 2006).  
As well as in response to stress stimuli, ACTH release follows a diurnal circadian rhythm, 
with maximum concentration seen early in the morning descending to minimum 
concentration at midnight (Weitzman et al., 1971). The effects of glucocorticoids are 
therefore either permissive (basal), or stimulating (stress induced) (Dallman et al., 1989; De 
Kloet et al., 1998; Ratka et al., 1989).  The permissive actions of glucocorticoids are 
mediated through the mineralocorticoid receptor, which binds glucocorticoids with a higher 
affinity than that of the glucocorticoid receptor and is selectively expressed in a tissue 
dependent manner within the brain (Reul and de Kloet, 1985, 1986).  During stress when 
concentration of glucocorticoids is higher, the mineralocorticoid receptor becomes fully 
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saturated and glucocorticoids bind the glucocorticoid receptor (Reul and de Kloet, 1985; 
Smith and Vale, 2006).  Overall, glucocorticoids act to increase blood glucose concentration 
through gluconeogenesis and metabolism of carbohydrates, proteins and lipids, and to 
dampen inflammatory and immune responses. 
The duration and intensity of the stress response is regulated by several different 
mechanisms. In a typical negative feedback loop, glucocorticoids inhibit the HPA axis at both 
the hypothalamic and pituitary level. Hence, when a high concentration of circulating 
glucocorticoids is present, ACTH release is inhibited, and when plasma glucocorticoid 
concentration is low, ACTH release increases.  Glucocorticoid receptors are ubiquitously 
expressed but particularly abundant in the PVN, where glucocorticoids negatively regulate 
expression of HPA specific genes, decreasing CRF release (Smith and Vale, 2006). In 
pituitary corticotrophs, glucocorticoids cause transcriptional repression of the POMC gene, 
reducing synthesis of ACTH (Sapolsky et al., 2000). There is also evidence to suggest that 
the HPA axis is regulated by CRF binding proteins.  Recombinant CRF binding protein 
(CRF-BP) diminishes CRF-induced ACTH release from cultured anterior pituitary cells 
(Westphal and Seasholtz, 2006).   
 
1.2 The Adrenal Gland 
1.2.1 Adrenal Morphology 
The adrenal glands lie on top of the kidneys and are each composed of two separate glands: 
the outer cortex and inner medulla (Ayres et al., 1960) (Fig. 1.2.1).  The medulla secretes 
catecholamines in response to the sympathetic nervous system under conditions of stress 
(Hillarp and Nilson, 1954).  Unlike the medulla, the adrenal cortex is essential for life.  Its 
primary role is to secrete steroids, which are synthesised in three morphologically distinct 
zones: mineralocorticoids such as aldosterone in the zona glomerulosa (ZG), glucocorticoids 
such as cortisol (corticosterone in rodents) in the zona fasciculata (ZF) and in humans and 
higher primates, adrenal androgens in the zona reticularis (ZR) (Ayres et al., 1960; Giroud et 
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al., 1956). Arnold et al. first described the three major zones in 1866.  Each zone can be 
easily distinguished on conventional staining by cell size and morphology, particularly 
between the ZG and ZF.  In rats, a fracture plane exists between the ZG and ZF making 
mechanical separation of the zones easy, suggesting discontinuity between the zones (Miller 
and Auchus, 2011; Vinson, 2003).     
The zones can also be distinguished by the spatially specific expression of steroidogenic 
cytochrome p450 (CYP) enzymes involved in the final steps of steroid synthesis. In rodents 
and humans, CYP11B2 encoding aldosterone synthase (Curnow et al., 1991) is selectively 
expressed in the ZG, preventing aldosterone production from the other zones, and CYP11B1 
encoding 11β-hydroxylase, is selectively expressed in the ZF (and the ZR in humans and 
higher primates) where it catalyses the final step of cortisol or corticosterone production 
(Domalik et al., 1991; Nishimoto et al., 2010; Ogishima et al., 1992). In rats specifically, the 
outer region of the ZF contains functionally undifferentiated cells which express neither 
enzyme, referred to as the ‘undifferentiated zone’ (not shown) (Mitani et al., 1994).  Unlike 
rodents which produce corticosterone, the major glucocorticoid in humans is cortisol, due to 
the expression of CYP17A1 in the ZF and ZR, which catalyses the 17α-hydroxylation and 17, 
20 lyase reactions and is not expressed in rodents (Sasano et al., 1989). 
Finally the zones are functionally responsive to different stimuli.  Whereas CYP11B2 
expression and aldosterone production increases in the ZG following stimulation by 
potassium or angiotensin II, CYP11B1 expression and cortisol/corticosterone synthesis are 
increased by ACTH stimulation. 
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Figure 1. 2: The human adrenal gland 
Illustration showing the adrenal gland and individual zones of the adrenal cortex. 
(Yates et al., 2013) 
 
1.2.2 Adrenal Steroidogenesis 
Adrenal steroidogenesis depends on the delivery of cholesterol to mitochondria and its 
catalysis by type 2 3β-hydroxysteroid dehydrogenases (3β-HSD) and p450 cytochrome 
(CYP) steroidogenic enzymes.  The human adrenal cortex produces mineralocorticoids, 
glucocorticoids and adrenal androgens in the ZG, ZF and ZR respectively, the products being 
dependent on the zone-specific expression profile of steroidogenic enzymes, and the 
stimulus. 
The initial substrate cholesterol is obtained from three sources:  de novo synthesis from 
acetate, high-density lipoproteins (HDLs) internalised from circulation by scavenger receptor 
B1, or LDLs internalised by LDL receptor-mediated endocytosis.  Humans source the 
majority of cholesterol from LDL proteins, whereas rodents use HDL (Miller, 2013).   
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Once internalised, LDL containing endosomes fuse with lysosomes where the LDL is 
degraded to cholesterol ester.  The cholesterol ester is de-esterified to its ‘free’ form by 
liposomal acid lipase (LAL), then released from the endosome, in part by the binding to 
cholesterol transport proteins Niemann Pick type C proteins 1 and 2.  Free cholesterol is 
targeted to the mitochondria for steroidogenesis, and excess cholesterol is converted back to 
its ester form by ACAT for storage in lipid droplets.  Cholesterol is released from storage by 
HSL (Fig 1.3).   
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Figure 1. 3: Cholesterol transfer.   
Cholesterol is sourced predominantly from low-density lipoproteins (LDL) in humans 
that are internalised from the circulation by receptor-mediated endocytosis via the LDL 
receptor.  LDL undergoes proteolysis in the endosome to cholesterol ester (ChE), and is 
de-esterified to free cholesterol (Ch) by liposomal acid lipase (LAL).  Niemann Pick type 
C proteins 1 and 2 (NPC1&2) are involved in the exit of Ch from the endosome. Free Ch 
is either targeted to mitochondria by STARD enzymes or stored in lipid droplets. Re-
esterification is the domain of acyl-coenzymes-A-cholesterol-acyl-transferase, whereas 
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hormone sensitive neutral lipase (HSL) de-esterifies. Ch is transferred from the outer 
(OMM) to the inner mitochondrial membrane (IMM) where it is converted to 
pregnenolone (Pg). Pregnenolone is translocated to the ER and processed by CYP21A2 
and 3β-HSD enzymes but the final steps of steroidogenesis occur back in the 
mitochondria, where the differential expression of CYP enzymes determines the steroid 
produced. (Androgens not shown) 
 
Although the exact mechanism is unclear, the most recent literature suggests cholesterol is 
targeted to the mitochondria by members of the START-domain (StAR-D) family of 
proteins, which bind cholesterol and are activated by sterol regulatory element binding 
protein (SREBP) transcription factors. StarD3, 4 and 5, bind cholesterol and facilitate its non-
vesicular transport through the cytoplasm to the outer mitochondrial membrane (Miller, 2013; 
Rodriguez-Agudo et al., 2008), where StAR  and StarD6 mediate transfer to the inner 
mitochondrial membrane (Bose et al., 2008). 
StAR is a 37kDa protein, with an N-terminal mitochondrial leader sequence that is cleaved to 
a 30kDa form following entry into the mitochondria.   Although both 37kDa and 30kDa 
forms are active in vitro, the activity of StAR is proportional to the time spent on the OMM 
(Arakane et al., 1996; Bose et al., 2002). 
To accept one molecule of cholesterol, StAR must undergo a pH dependent conformational 
change as the binding pocket is blocked by hydrogen bonds.  It does this through binding 
with charged phospholipid molecules in the OMM (Baker et al., 2005; Bose et al., 1999) 
On the outer mitochondrial membrane, StAR forms part of a 140-200kDa major complex that 
contributes to cholesterol internalisation, including translocator protein (TSPO), voltage-
dependent anion channel (VDAC1), adenine nucleotide transporter (ANT), diazepam-binding 
inhibitor (acyl-coA-binding domain 1 ACBD1), TSPO-associated protein-1 (PRAX-1) and 
PKA regulatory subunit RIα-associated protein 7 (PAP7) (Miller, 2013).  The most explored 
protein is TSPO, a 5 transmembrane domain protein that binds cholesterol and functions as a 
cholesterol channel (Hauet et al., 2005; Joseph-Liauzun et al., 1998; Korkhov et al., 2010; 
Liu et al., 2006).  Knockdown (KD)  of this gene in rat testicular leydig tumour (R2C) cells 
reduces cholesterol transport and steroidogenesis (Papadopoulos et al., 1997).  
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Once cholesterol has been transferred to the inner mitochondrial membrane, it is converted 
into steroids through sequential catalysis by enzymes belonging to two families; the 
cytochrome p450 (CYP) hydroxylases and the 3βHSDs.   
As illustrated in figure 1.4, three major pathways of steroidogenesis exist in the adrenal 
cortex producing mineralcorticoids, glucocorticoids and adrenal androgens in the ZG, ZF and 
ZR respectively.  The different end products of each zone are the result of selective 
expression of steroidogenic enzymes and associated factors. 
The first and only rate-limiting step, common to all three zones, involves the conversion of 
hydrophobic cholesterol to hydrophilic 21-carbon pregnenolone by side chain cleavage 
enzyme (CYP11A1) encoded by CYP11A1. Pregnenolone is then translocated to the 
endoplasmic reticulum for further catalysis by CYP17A1, 3βHSD and CYP21A2. 
In the ZG, CYP17A1 is not expressed, hence pregnenolone undergoes sequential activities of 
3βHSD and CYP21A2 to produce progesterone and 11-deoxycorticosterone. 11-
deoxycorticosterone is transferred to the mitochondrion for the final step in steroid synthesis, 
where CYP11B2 catalyses the 11β-hydroxylation, 18-hydroxylation and 18-methyl oxidation 
to aldosterone. Expression of CYP11B2 is restricted to the ZG preventing aldosterone 
production in the other zones, and absence of CYP17A1 expression prevents cortisol or 
androgen synthesis.   
In the ZF, pregnenolone undergoes 17α-hydroxylation by CYP17A1 prior to 3βHSD and 
CYP21A2 catalysis, producing 11-deoxycortisol instead of deoxycorticosterone, thereby 
allowing for cortisol production rather than corticosterone.  11-deoxycortisol is translocated 
back to the mitochondrion where it undergoes 11β-hydroxylation by CYP11B1 to form 
cortisol. 
Similar to the ZF, the ZR expresses CYP17A1 which catalyses the 17α-hydroxylation of 
pregnenolone. Unlike the ZF, the ZR has high levels of cytochrome b5, which enables 
CYP17A1a to catalyse a further 17, 20 lyase reaction.  High expression of cytochrome b5 
coupled with low expression of CYP21A2 and CYP11B1 in the ZR favours androgen 
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production and diminishes cortisol production. The 17, 20 lyase activity of CYP17A1 
converts 17-hydroxypregnenolone to dehydroepiandrosterone (DHEA), the major adrenal 
androgen. A small fraction of DHEA is converted to androsteonedione, and a subset of this is 
converted to testosterone by 17βHSD5, however this pathway is unfavoured as the expression 
of HSD3B1 (encoding 3βHSD) is low in the ZR whereas the expression of CYP17A1 is high  
(Miller and Auchus, 2011).   
Differences in adrenal steroidogenesis are evident between species, for example, rodents do 
not express CYP17A1, hence the major glucocorticoid is corticosterone, and androgens are 
not produced. 
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Figure 1. 4: Human adrenal steroidogenesis.  
Summary of enzymatic reactions that lead to the synthesis of adrenal steroids.  Green 
text depicts steroids synthesised in the ZG, red the ZF and blue the ZR.  Expression of 
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steroidogenic enzymes is zone dependent: green boxes depict the ZG, red the ZF and 
blue the ZR.   
The steroidogenic CYP enzymes require co-factors for their activity.  Mitochondrial type 1 
CYP enzymes receive electrons from nicotinamide adenine dinucleotide phosphate 
(NADPH), which is supplied by ferredoxin, which in turn is reduced by ferredoxin reductase 
(Miller, 2005). Type 2 CYP enzymes that reside in the endoplasmic reticulum (ER) receive 
electrons from 2-flavin P450 oxidoreductase (Miller, 2005). 
The initiation of steroidogenesis is triggered by several different stimuli resulting in 
appropriate steroid synthesis.  ACTH is the only regulator of glucocorticoid synthesis, and 
forms part of the hypothalamic-pituitary-axis. ACTH and potassium can stimulate the 
synthesis of aldosterone, however aldosterone production is primarily governed by 
angiotensin II (AngII) via the renin-angiotensin-aldosterone system (RAAS) (Yates et al., 
2013).  
Briefly, the RAAS plays an important role in inducing vasoconstriction when sodium levels 
fall or hemorrhage occurs (Collier et al., 1973; Scornik and Paladini, 1964).  Renin is a 
proteolytic enzyme that is synthesised in the kidney and is stimulated by a number of factors 
including the sympathetic nervous system, catecholamines, decreased renal perfusion 
pressure and reduced sodium delivery to the distal tubule (Johnson and Davis, 1973; Tobian 
et al., 1959; Yates et al., 2013). On stimulation, renin is released into circulation and cleaves 
angiotensinogen to angiotensin I (Miller, 1981).  Subsequently, angiotensin I is hydrolysed to 
AngII by angiotensin-converting enzyme (ACE) on pulmonary and renal endothelium, 
inducing vasoconstriction of arteriolar smooth muscle (Oparil et al., 1970). In addition, AngII 
stimulates the release of catecholamines and aldosterone into circulation.   
AngII stimulates aldosterone production in the ZG by activating the AT1 G-protein coupled 
receptor, stimulating inositol 1,4,5-triphosphate (ins(1,4,5)P3) and 1,2,-diacylglycerol (DAG) 
signalling, associated with an influx of calcium to the cytoplasm and increased protein kinase 
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C activity.  These events ultimately lead to aldosterone production, thought to be due to 
activation of trascription factors that target CYP11B2.  
The exact mechanism governing androgen production in the adrenal is not clear.   
 
1.3 Adrenal Insufficiency 
Adrenal insufficiency was originally described by Thomas Addison in 1855, who recognised 
a syndrome of hyperpigmentation and wasting due to adrenal failure.  The condition is found 
in multiple disorders, and presents with relatively unspecific symptoms which can delay 
diagnosis (Arlt and Allolio, 2003).  
Acute adrenal insufficiency usually presents with severe hypotension or hypovolaemic shock 
with abdominal pain, nausea and fever and, in children, hypoglycaemic seizures (Arlt and 
Allolio, 2003).  Patients with chronic adrenal insufficiency usually present with fatigue, lack 
of energy and muscle strength and irritability (Arlt and Allolio, 2003).  
There are two main types of adrenal insufficiency (AI): primary AI, caused by damage to the 
adrenal gland and secondary AI, caused by interference at the pituitary level or hypothalamic 
level (Reddy, 2011).   
Patients with primary adrenal insufficiency are deficient in glucocorticoids. 
Mineralocorticoid and adrenal androgen deficiency varies between conditions.  Symptoms 
associated with glucocorticoid deficiency include weight loss, anorexia (or failure to thrive in 
children), nausea and muscle/joint pain (Arlt and Allolio, 2003). The most obvious clinical 
feature is hyperpigmentation, which is absent from secondary adrenal insufficiency  (Reddy, 
2011).  Low levels of cortisol decrease negative feedback to the hypothalamus leading to 
high levels of ACTH, which activate MC1R receptors involved in pigmentation.  Cortisol 
deficiency also causes a decrease in cardiac output and vascular tone which is exacerbated by  
mineralocorticoid deficiency  (Reddy, 2011). This is because the permissive actions of 
cortisol are mediated through the mineralocorticoid receptor, 
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Mineralocorticoid deficiency causes dehydration and hypovolaemia leading to low blood 
pressure and postural hypotension (Arlt and Allolio, 2003).  Some patients also have 
hyponatraemia, hyperkalaemia and salt craving (Kong and Jeffcoate, 1994; Nerup, 1974).  
DHEA deficiency in women causes loss of axillary and pubic hair, dry skin and loss of libido 
(Arlt and Allolio, 2003). 
Patients with secondary AI have symptoms of cortisol deficiency with no symptoms of 
mineralocorticoid deficiency such as salt wasting or hyperkalaemia  (Reddy, 2011). The 
causes of secondary AI affect ACTH secretion from the pituitary, hence mineralocorticoid 
function is not impaired (Reddy, 2011).  Secondary AI can be grouped into isolated ACTH 
deficiency or combined pituitary hormone deficiency (pan-hypopituitarism). Isolated ACTH 
deficiency is most frequently caused by iatrogenic AI, the most common form of AI, where 
chronic glucocorticoid therapy suppresses the HPA axis.  Other causes of isolated ACTH 
deficiency include autoimmune hypophysitis and defects in the pro-opiomelanocortin 
(POMC) cleavage enzyme which yields ACTH (Nussey et al., 1993). Combined pituitary 
hormone deficiency is caused by tumours of the pituitary, surgery or radiotherapy, infectious 
diseases and mutations in genes encoding pituitary transcription factors such as HESX1, 
SOX3 and TPIT (Kelberman et al., 2009). 
 
The most common form of primary adrenal insufficiency in developing countries accounting 
for 80-90% patients is autoimmune adrenalitis (Addison’s), either isolated or as part of an 
autoimmune polyendocrine syndrome (APS) (Betterle et al., 2002; Neufeld et al., 1981).  
APS type 1 (APS1) is characterised by adrenal insufficiency, hypoparathyroidism and 
chronic mucocutaneous candidiasis and develops in childhood to early adulthood (Ahonen et 
al., 1990; Betterle et al., 2002).   Some cases also have childhood alopecia, chronic active 
hepatitis, malabsorption and the autoimmune diseases found in APS type 2. APS type 2, the 
most common form typically affecting middle-aged females, consists of adrenal insufficiency 
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and autoimmune thyroid disease, and in some cases the addition of other autoimmune 
disorders such as diabetes mellitus (Arlt and Allolio, 2003).   
Other causes of primary adrenal insufficiency include tuberculous adrenalitis, which is a 
common cause in developing countries (Soule, 1999).  Adrenal insufficiency can also occur 
through haemorrhage or adrenal infiltration, however this is rare (Arlt and Allolio, 2003). 
A number of genetic disorders are associated with primary adrenal insufficiency.  Mutations 
in the ABCD1 gene encoding for peroxisomal adrenoleukodystrophy protein cause X-linked 
adrenoleukodystrophy, characterised by neurological impairment in addition to adrenal 
insufficiency (Moser, 1997). Mutations in ABCD1 lead to a build-up of very long fatty acids 
and the demyelination of white matter (Moser, 1997).  The disease has two forms: either 
rapid progression developing in early childhood or slow progression developing in early 
adulthood (Arlt and Allolio, 2003). 
Congenital adrenal hyperplasia (CAH) is a group of monogenetic disorders, caused by 
mutations in the genes encoding the steroidogenic CYP enzymes and their co-factors (Krone 
et al., 2007; Miller, 1991; White and Speiser, 2000). The most common form is 21-
hydroxylase deficiency which presents at in the neonatal period.  
Although most conditions of primary adrenal insufficiency comprise combined 
glucocorticoid and mineralocorticoid deficiency, some genetic disorders result in 
glucocorticoid deficiency alone. These include ACTH insensitivity syndromes familial 
glucocorticoid deficiency type 1-4, which presents between neonatal and early childhood 
periods and triple A syndrome, which presents in the first two decades of life (Clark and 
Weber, 1998).   
A number of conditions of primary adrenal insufficiency have been associated with a 
pathogenesis involving oxidative stress.  These include Triple A syndrome, X-linked 
adrenoleukodystrophy and more recently, familial glucocorticoid deficiency.  It is becoming 
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increasing clear that oxidative stress is a disease mechanism for some forms of adrenal 
insufficiency, and that the adrenal cortex is particularly sensitive to oxidative pressure.  
 
1.4 Familial Glucocorticoid Deficiency 
Familial glucocorticoid deficiency (OMIM 202200) (FGD) is a rare, autosomal recessive 
disorder characterised by isolated glucocorticoid deficiency and resistance of the adrenal 
cortex to ACTH (Clark and Weber, 1998). The syndrome was first described by Shepard et 
al. (1959) as ‘Familial Addison’s disease’, based on post-mortem analysis and clinical study 
of two sisters.  Both were described to have hyperpigmentation, weakness and convulsions.  
Clinical study showed glucocorticoid deficiency with normal aldosterone levels, and selective 
damage to the ZF and ZR in the adrenal cortex. In the 1970’s, further reports of patients with 
isolated glucocorticoid deficiency surfaced prompting the search for genetic causes (Spark 
and Etzkorn, 1977; Thistlethwaite et al., 1975; Thistlethwaite et al., 1974).  If untreated, the 
disease can be fatal due to severe hypoglycaemia (Clark and Weber, 1998). 
 
1.4.1 FGD aetiology 
Following Shepard and colleague’s discovery a number of FGD cases were reported and the 
search for potential causes began. After the cloning of the ACTH Receptor (melanocortin 
receptor; MC2R), Clark et al. found the first mutation and went on to show that 25% of FGD 
cohorts had mutations in MC2R (Clark et al., 1993; Huebner et al., 1999). In 2005, a further 
20% cases were found to have mutations in the Melanocortin Receptor Accessory Protein 
(MRAP) (Metherell et al., 2005).  In 2009, a few patients were shown to have mutations in 
STAR (Baker et al., 2006; Metherell et al., 2009). In 2011, a few patients within the 
genetically isolated Irish traveller community were found to have mutations in Mini 
Chromosome Maintenance protein 4 (MCM4) (Hughes et al., 2012). Most recently, 10% 
cases were found to have mutations in nicotinamide nucleotide transhydrogenase 
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(NNT)(Meimaridou et al., 2012b).   Approximately 40% of cases remain with unknown 
aetiology. 
 
Figure 1. 5: FGD aetiology.  Pie chart showing known causes of FGD.  
 
1.4.2 Clinical features of FGD 
Patients with FGD can present within the neonatal period, infancy or early childhood, 
depending on the severity of their condition.  All symptoms are characteristic of 
hypocortisolaemia and elevated ACTH levels (Chan et al., 2008). 
Patients who present in the neonatal period tend to have severe hypoglycaemia, which often 
improves after more frequent feeding.  These patients tend to have excessive skin 
pigmentation, and are sometimes jaundiced.   Patients that are not diagnosed in the neonatal 
period tend to present over the next few years of life with recurrent hypoglycaemic episodes 
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and/or convulsions, skin pigmentation or poor recovery from infective episodes (Chan et al., 
2008).   
If left untreated, recurrent hypoglycaemic episodes may incur long-term neurological damage 
ranging from learning difficulties to spastic quadriplegia (Chan et al., 2008; Modan-Moses et 
al., 2006), but coupled with frequent infection can ultimately result in death.  Correct 
diagnosis early in life is therefore crucial to prevent the pathological sequelae, however 
diagnosis can be missed, for example during acute illness (Habeb et al., 2013) or mistaken for 
Addison’s disease because of subtle derangements of the renin-angiotensin axis. 
FGD is confirmed biochemically by low plasma cortisol levels, with elevated ACTH levels 
but normal levels of aldosterone, renin and electrolytes.  ACTH levels, measured by RIA or 
IRMA, are often above 1000pg/ml, normal range <50 and <80pg/ml respectively (Chan et al., 
2008; Clark and Weber, 1998). Cortisol levels are usually extremely low and sometimes 
undetectable. Further testing may include an ACTH stimulation test (Synacthen=1-24 
ACTH), in which a normal response is a peak plasma cortisol level of over 550nmol/l.  
FGD is commonly mistaken for Addison’s disease (AD) (ICD10 E27.1), in which patients 
have deficiencies of both glucocorticoids and mineralocorticoids.  Mineralocorticoid levels 
can indeed be low at presentation which can lead to the misdiagnosis as Addison’s (Clark et 
al., 2001; Clark and Weber, 1998).  The low mineralocorticoids are often due to the child 
being ill or in shock, and should be checked after the child is stabilised to determine whether 
they are truly mineralocorticoid deficient.  
One study suggested this phenotype might manifest in patients with particularly severe 
mutations in MC2R (Lin et al., 2007), in particular frameshift mutations whereby receptor 
function is completely ablated, whereas the majority of MC2R mutations are missense and 
leave some degree of receptor function (Chung et al., 2008).  However, a review of patients 
with such MC2R mutations showed no clinically significant mineralocorticoid deficiency 
(Chan et al., 2009a). Furthermore one report that investigated a cohort of autoantibody–
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negative Addison’s patients for mutations in genes known to cause FGD, showed that FGD is 
not underdiagnosed in the AD population (Dias et al., 2010). 
The absence of mineralocorticoid deficiency distinguishes FGD from other conditions of 
primary adrenal insufficiency many of which have additional features (Chan et al., 2008). 
These additional features and the relevant tests are listed in table 1.1.  
Symptoms Associated condition Investigations 
Progressive neurological 
manifestations 
X-adrenoleukodystrophy, 
triple-A syndrome 
-Very-long-chain fatty acid 
measurement 
-Sequencing of AAAS and 
ABCD1 genes 
Ambiguous genitalia Congenital adrenal 
hyperplasia 
17-hydroxyprogesterone, 
monitoring of blood pressure 
Hypogonadism, delayed 
puberty 
Adrenal hypoplasia 
congenita  
Sequencing of DAX1 and  
SF1 genes 
Alacrima/achalasia   Triple A syndrome Schirmer test of tear 
production together with a 
barium swallow 
Dysmorphic features,  
skeletal abnormalities 
Intrauterine growth 
restriction, metaphyseal 
dysplasia, adrenal hypoplasia 
congenita, and genital 
anomalies (IMAGe) 
syndrome 
-Ultrasound of renal tract 
-X-ray (skeletal survey) 
 -Sequencing of CDKN1C 
gene  
Other autoimmune 
deficiencies 
Polyglandular autoimmune 
syndromes 
Adrenal antibodies 
Table 1.  1: Clinical features absent from FGD.  
FGD can be distinguished from other forms of adrenal insufficiency by the absence of 
the listed symptoms. These symptoms are associated with other conditions and should 
be investigated using the tests listed. (Table based on Chan et al. (2008)) 
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Imaging of adrenals by MRI or CT scan can also distinguish FGD from other conditions of 
primary adrenal insufficiency, as FGD patients have relative small adrenal glands, whereas 
conditions such as adrenal tuberculosis and CAH have enlarged adrenals due to calcification 
and cholesterol build up respectively (Chan et al., 2008; Clark and Weber, 1998). Post 
mortem histological analyses of adrenals from affected individuals with FGD have 
disorganised glomerulosa cells and absent fasciculata and/or reticularis cells (Clark and 
Weber, 1998).  The disorganisation of the ZG in these patients may explain the subtle 
changes in mineralocorticoids sometimes seen in FGD patients. Subtle changes to aldosterone 
levels might be expected given that MC2R is expressed throughout the developing and adult 
adrenal cortex, including the ZG, and reports suggest ACTH stimulation can increase 
aldosterone synthesis (Arvat et al., 2000; Davidai et al., 1984; Reincke et al., 1998; Spark 
and Etzkorn, 1977; Xia and Wikberg, 1996). However, aldosterone synthesis is primarily 
governed by the RAAS system, which would presumably prevent significant changes to 
aldosterone production. 
A common phenotypic feature of FGD is hyperpigmentation, which either presents at birth or 
develops at a later stage.  Hyperpigmentation is caused by elevated levels of ACTH over-
stimulating MC1R receptors, which are responsible for the production of eumelanin pigment.  
Genetic variants in the MC1R gene are found in 80% individuals with red hair and pale skin 
(Valverde et al., 1995).  In an interesting case report, one patient with FGD was reported to 
have an MC2R mutation but no hyperpigmentation (Turan et al., 2012). Sequencing of the 
MC1R gene in this patient revealed a homozygous inactivating mutation previously 
associated with red hair and fair skin, explaining the discrepancy (Turan et al., 2012).   
Another feature observed in FGD patients is the absence of adrenarche, the production of 
adrenal androgens during puberty, through the action of ACTH on MC2R receptors 
expressed in the ZR (Weber et al., 1997).  Patients with FGD have delayed or sparse pubic 
hair development due to low adrenal androgen levels, but breast development and ovarian 
development are normal as are regular menses in women, as the hypothalamic-pituitary-
gonadal axis is not affected (Chan et al., 2008; Ishii et al., 2000). 
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FGD is easily treated with glucocorticoid replacement therapy in the form of oral 
hydrocortisone and long-term prognosis is good (Metherell et al., 2006). Doses are usually 
10–12 mg/m2/day in children and 20–30 mg/day in adults (Chan et al., 2008). 
 
1.4.3 Melanocortin Receptor family 
The first genetic cause of FGD was only identified following the cloning of the melanocortin 
receptors in 1992 by Mountjoy and colleagues (Cone et al., 1993; Mountjoy et al., 1992).  
The Melanocortin receptors (MCR) are a subfamily of class A GPCRs and are characterised 
by their short coding sequences and absence of certain commonly conserved GPCR motifs. 
The receptors have typical GPCR topology with 7 α-helix transmembrane domains (TMD), 
three intracellular and three extracellular loops (Cooray and Clark, 2011), and are 
distinguished by short N- and C-terminal ends.  MCR activity is mediated by adenylyl 
cyclase which induces cAMP signalling (Cooray and Clark, 2011). 
The melanocortin receptors respond to ligands synthesized from the 231 amino-acid pro-
opiomelanocortin precursor peptide (POMC), which is synthesised in the pituitary following 
CRF receptor activation from CRF secreting hypothalamic neurons.  The enzyme is cleaved 
into a number of different products depending on tissue specific expression of prohormone 
convertase (PC) enzymes (Fig. 1.6).   
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Figure 1. 6: POMC cleavage.  
POMC is cleaved by prohormone convertases 1 and 2 (PC1 and PC2) in the pituitary 
gland to yield N-terminal peptide (NT), melanocyte stimulating hormone (MSH), 
corticotrophin-like intermediate peptide (CLIP), joining peptide (JP), 
adrenocorticotrophin (ACTH), Lipotrophin (LPH) and β-endorphin (β-endo) Adapted 
from (Raffin-Sanson et al., 2003) and (Metherell et al., 2006).   
 
In corticotroph cells PC1 expression leads to cleavage of POMC into ACTH as well as other 
peptides.  In melanotroph cells, these derivatives are further cleaved to peptides including α-, 
β- and γ-melanocyte stimulating hormone (MSH) (Raffin-Sanson et al., 2003).   
The ligand specificity for the melanocortin receptors is outlined in table 1.2.  It is interesting 
to note, that whereas MC1,3,4,5R respond to multiple POMC derivatives, MC2R responds 
only to ACTH (Cone et al., 1993). 
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Receptor  Ligand Specificity  
MC1R  α-MSH> ACTH> γ-MSH  
MC2R  ACTH  
MC3R  γ-MSH >ACTH >α-MSH  
MC4R  α-MSH> ACTH> γ-MSH  
MC5R  α-MSH> ACTH> γ-MSH  
Table 1.  2: Melanocortin receptors have varying ligand specificity.   
MC1R, MC3R, MC4R and MC5R are all responsive to α-MSH, γ-MSH and ACTH.  
MC2R has one ligand which is ACTH (Metherell et al., 2006).   
 
The melanocortin receptors have a broad range of functions which are all important 
physiological processes. MC1R controls skin pigmentation (Valverde et al., 1995), MC2R is 
vital for HPA axis regulation of steroidogenesis, MC3R and MC4R are involved in appetite 
regulation and energy homeostasis (Butler et al., 2000; Chen et al., 2000; Marsh et al., 1999) 
and MC5R is thought to be involved in exocrine function (Chagnon et al., 1997; Labbé et al., 
1994; Ogawa et al., 2004). 
 
1.4.4 Melanocortin 2 Receptor 
The MC2R gene is located to chromosome 18p11.2 and is expressed as a 297 amino acid 
protein, making it the smallest member of the melanocortin receptor family.  It is unique 
amongst the melanocortin receptors in that it responds only to one ligand, ACTH, and is often 
referred to as the ACTH receptor.   
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Like the other MCRs, MC2R has typical GPCR topology, as detailed above.  The 
extracellular N-terminus is involved in membrane transport, as substitution of this segment 
for the corresponding MC4R segment reduces cell surface expression (Fridmanis et al., 
2010).  The transmembrane domains (TM) contain binding sites for ACTH. Specifically, 
TM2, 3 and 6 contain binding sites analogous to other MCRs, but TM4, 5 and 7 contain 
unique binding sites for ACTH which determines the receptors selectivity for ACTH as a 
ligand (Chen et al., 2007; Fridmanis et al., 2010). TM3 and 4 were also reported to be 
involved in intracellular retention (Fridmanis et al., 2010). Hirsch et al reported that loss of 
the C-terminus can impair cell surface expression and cAMP response.  
 
1.4.5 MC2R life cycle 
When activated, MC2R associates with heterotrimeric G proteins and catalyses the exchange 
of GDP for GTP on the alpha subunit (Gαs), which results in the dissociation of the alpha unit 
from the beta and gamma (Clark et al., 2003; Ritter and Hall, 2009).  The alpha unit binds to 
and activates adenylyl cyclase which generates cAMP, leading to an increase in Protein 
Kinase A (PKA) activity.  PKA increases the transcription of steroidogenic genes and 
increases cholesterol import (Chan et al., 2011).  ACTH stimulation also upregulates the 
transcription of MC2R, increasing the amount of MC2R at the cell surface and prolonging 
signalling, hence the receptor is positively regulated by its ligand (Hofland et al., 2012). 
Following ACTH stimulation, desensitisation of the receptor occurs at a fast pace, with 60% 
of MC2R desensitised within 30 minutes (Baig et al., 2001; Clark et al., 2003). Baig et al. 
(2001) showed that PKA mediates desensitisation as the PKA inhibitor H89, used at 
concentrations specific to PKA, resulted in a complete loss of desensitisation for 30 to 60 
minutes after a second ACTH stimulation. Site directed mutagenesis of a PKA 
phosphorylation site in MC2R (serine 208) resulted in a loss of desensitisation compared to 
wildtype MC2R when expressed in mouse Y6 adrenocortical cells. 
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Following desensitisation, MC2R is internalised by the clathrin dependent mechanism. Baig 
et al. (2002) showed that internalisation of MC2R in Y1 cells is halted when cells are treated 
with concanavalin A or hypertonic sucrose, which inhibit clathrin-mediated endocytosis.  
Clark and colleagues also confirmed that MC2R is not internalised through the caveolae 
mechanism because inhibitors filipin and nystatin had no effect on internalisation.  Kilianova 
et al (2006) also confirmed these results using immunofluorescence on M3 cells, showing 
that β-arrestin-2-GFP colocalises with myc-hMC2R in endocytic compartments following 
incubation with ACTH.  hMC2R did not colocalise with caveolin-1 with or without ACTH 
incubation (Kilianova et al., 2006).  
 
1.4.6 MC2R expression 
MC2R is predominantly expressed in the adrenal cortex where it mediates cAMP signalling 
leading to steroidogenesis.  It is expressed in all three zones, however ACTH acts 
predominantly on the ZF (Mountjoy et al., 1992).  Gorrigan et al. showed through in situ 
hybridisation that in the rat adrenal, MC2R expression is high in the ZF, following a gradient 
reduction towards the medulla. The highest expression was seen in the inner undifferentiated 
zone of adrenal cortex, a region between the ZG and ZF which is deficient of CYP11B1 
expression, and is thought to contain stem cells involved in adrenal cell differentiation and 
maintenance (Mitani et al., 2003; Wright and Voncina, 1977). 
Outside of the adrenal, MC2R is expressed at low levels in the skin, lymphocytes, and 
adipose tissue (Andersen et al., 2005; Boston, 1999; Mountjoy et al., 1992; Slominski et al., 
1996).  Though the role of MC2R in these tissues is not completely understood, in 
adipocytes, MC2R as well as MC5R, have been shown to be involved in lipolytic actions of 
ACTH and α-MSH (Boston, 1999). Furthermore, studies have reported the involvement of 
MC2R and MC5R signalling in the inhibition of leptin production, a satiety hormone (Maffei 
et al., 1995; Norman et al., 2003; Zhang et al., 1994). The expression of MC2R in the 
undifferentiated zone of the adrenal cortex suggests a role for ACTH in zonal development 
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(Gorrigan et al., 2011).  It is important to note that port-mortem analysis of adrenals taken 
from patients with FGD show a disorganised ZG with loss of the ZF and ZR (Clark and 
Weber, 1998). 
During development, MC2R is widely expressed, with particularly high expression in the 
adrenal gland.  High expression is also seen in the developing lung, where the production of 
glucocorticoids modulates maturation (Simard et al., 2010), and in the testes, where it 
regulates steroidogenesis (O'Shaughnessy et al., 2003).   
 
1.4.7 Mc2r-/-  knockout mice 
The Mc2r
-/-
 mouse was characterised in 2007 by Chida and colleagues (Chida et al., 2007).  
In some regards, it shares a similar phenotype to that of FGD patients with elevated ACTH 
levels, almost undetectable glucocorticoid levels and loss of ZF with relative preservation of 
ZG.  Unlike FGD patients, there was no increase in longitudinal growth and the mice had 
aldosterone deficiency similarly to Pomc
-/-
 mice.  Furthermore, Mc2r
-/-
 mice showed low 
expression of CYP11B2.  This might suggest that ACTH has a more prominent role in the ZG 
function and development in mice compared to that in humans (Coll et al., 2006; Karpac et 
al., 2005).  It also shows that the mouse model does not fully recapitulate the human 
condition. 
 
1.4.8 Familial Glucocorticoid Deficiency (FGD) 1 : mutations in MC2R  
Early reports predicted that the cause of FGD may be defects in the ACTH receptor MC2R.  
It wasn’t until the receptor was cloned, that Clark and colleagues (1993) identified the first 
inactivating MC2R mutation in a patient with FGD, which was a homozygous base change 
causing amino acid substitution p.S74I. Since then, more than 40 pathogenic mutations have 
been reported, and mutations in MC2R are found in 25% of the FGD cohort (Fig 1.7) (Clark 
et al., 2009; Clark et al., 2005). The other 75% of patients remained with unknown aetiology, 
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showing FGD is a genetically heterogeneous condition (Weber and Clark, 1994). Mutations 
in MC2R are classed as FGD type 1 (FGD1). 
The majority of MC2R mutations are missense mutations that render the receptor incapable of 
trafficking to the cell surface; however some are trafficking competent and affect ligand 
binding (Chung et al., 2008).  The pathogenetic mechanism underlying FGD therefore lies in 
the inability for ACTH to promote downstream cAMP signalling (Chung et al., 2008).  For 
this reason, FGD is sometimes referred to as ‘the hereditary unresponsiveness or resistance to 
ACTH’ (Clark et al., 2009). 
 
 
 
Figure 1. 7.  MC2R mutations 
The majority of MC2R mutations are missense mutations, affecting trafficking of the 
receptor to the cell surface.  (Chung et al., 2008) Blue, single nucleotide polymorphism 
(SNP); Green, nonsense mutation; Orange missense mutation. 
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Homozygous nonsense mutations in MC2R are rare which suggests the mutations might 
present a different phenotype than FGD, or that such mutations lead to reduced survival 
during foetal development (Clark et al., 2009).  However, nonsense mutations have been 
reported and suggested to cause a more severe phenotype including derangements to the 
RAAS axis (Lin et al., 2007). A second study clinically reviewed a separate group of FGD 
patients with nonsense MC2R mutations and discounted these findings showing the 
derangements were mild and not associated with clinically significant mineralocorticoid 
deficiency that would require long-term mineralocorticoid replacement (Chan et al., 2009a).  
Gain-of-function MC2R mutations are even rarer.  One patient has been reported with such a 
mutation resulting in cyclical Cushing’s syndrome (Swords et al., 2002).  Another patient 
with the same gain-in-function mutation also had a loss-in-function MC2R mutation.  
Because the loss-of-function mutation rendered the receptor trafficking-incompetent, the 
gain-of-function was void, and the patient presented with FGD (Chan et al., 2009a). 
Generally the genotype-phenotype correlation of FGD1 patients is poor and one genotype 
may show highly variable levels of ACTH resistance and cortisol production in different 
individuals (Elias et al., 1999).  However, a specific clinical feature of FGD type 1 is tall 
stature, the mechanism for which is not fully understood.  With the growth hormone-insulin-
like growth factor (IGF-1) axis unchanged (Elias et al., 2000), it has been suggested that tall 
stature is due to excessive ACTH acting on melanocortin receptors expressed in bone, 
increasing intracellular free Ca2
+
 in resting chondrocytes causing chondrocyte terminal 
differentiation (Elias et al., 2000; Evans et al., 2004; Imamine et al., 2005). Increased growth 
rate can be attenuated in patients following hydrocortisone treatment (Chan et al., 2008; 
Clark and Weber, 1998). 
 
1.4.9 Expression of MC2R in heterogeneous cells lines 
Studies attempting to characterise MC2R have been hindered by the apparent inability to 
functionally express MC2R at the cell surface in heterologous cell lines.  MC2R is retained in 
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the ER when expressed in heterologous cells, and a functional receptor that is ACTH 
responsive is only attainable in cell lines that endogenously express MC2R such as 
adrenocortical cells.  Functional expression of MC2R was possible in Y6 and OS3 cell lines 
(Schimmer et al., 1995), which lack endogenous MC2R, but possess all the other machinery 
necessary for the expression of a functional MC2R. This enabled researchers to characterise a 
number of MC2R mutations associated with FGD, without interference of endogenous 
receptors (Elias et al., 1999).  Y6 and OS3 cell lines are derived from the mouse Y1 adrenal 
cell line, and hence, it was suggested that an adrenal specific factor, was necessary for cell 
surface expression of MC2R (Noon et al., 2002). 
 
1.4.10 Discovery of melanocortin receptor 2 accessory protein (MRAP)  
Given that 75% FGD cases had unknown aetiology, the theory that an adrenal specific factor 
was required for MC2R cell surface expression, suggested a potential candidate gene for 
FGD.  In search of this gene, Metherell et al. (2005) carried out a whole genome scan by 
single nucleotide polymorphism (SNP) array in one consanguineous family. Homozygosity 
mapping revealed a locus on chromosome 21q22.1.  Analysing the tissue distribution of 
genes in this region identified one gene, C21orf61 that was expressed in the adrenal but not 
brain or liver.  Further analysis of the tissue distribution by RT-PCR showed it was highly 
expressed in the adrenal cortex, with lower expression levels in the brain, thyroid, ovary, 
testis and breast.  Sequencing the index patient revealed a homozygous splice site mutation, 
and screening probands from over 100 patients identified 26 affected individuals with 
mutations, accounting for 20% of the FGD cohort. 
The gene identified encoded a small protein named ‘fat-associated low-molecular weight 
protein’ (FALP), originally described by Xu et al.  (2002) as a protein that was upregulated 
on differentiation of mouse 3T3-L1 cells into adipocytes; however the function was mainly 
unknown.  It was hypothesised that this protein was the adrenal specific factor required to 
traffic MC2R to the cell surface. 
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Functional analysis of the gene resulted in its renaming to Melanocortin 2 Receptor Accessory 
Protein (MRAP). MRAP was shown to co-immunoprecipitate with MC2R indicating the two 
formed a complex. When expressed in heterologous chinese hamster ovary (CHO) cells, 
epitope-tagged mouse MRAP localised to the ER and plasma membrane.  Expression of 
epitope-tagged mouse MC2R alone, showed localisation to the ER.  However, co-expression 
of MRAP with MC2R in these cells led to a proportion of the MC2R pool shifting 
localisation to the plasma membrane, co-localising with MRAP. These immunocytological 
studies have been confirmed using human MRAP (Sebag and Hinkle, 2007; Webb et al., 
2009).  Furthermore, co-transfection of MRAP with MC2R in heterologous SK-N-SH cells 
led to ACTH-responsiveness, which was absent when MC2R was transfected alone.  
Other studies have since shown endogenous MRAP and MC2R in mouse Y1 cells co-localise 
at the cell surface, and produce a cAMP response when stimulated with ACTH, which is 
significantly reduced following knockdown of MRAP with small interfering RNA (siRNA) 
(Cooray et al., 2008).  The cAMP response can be rescued following transfection of siRNA 
resistant human MRAP.  Analysing cell lysates by immunoblotting for MC2R showed that 
MC2R migrates as different species depending on the cotransfection of MRAP.  The authors 
suggest that MRAP may promote some post-translational modifications to increase 
trafficking of MC2R (Sebag and Hinkle, 2007).  Interestingly, glycosylation of MC2R 
promotes cell surface expression (Roy et al., 2010). 
MRAP follows a similar expression pattern to MC2R in the foetal and adult adrenal cortex, 
with highest expression in the undifferentiated zone, and high expression also observed in the 
ZF (Gorrigan et al., 2011).  The mRNA expression, like MC2R, is upregulated by ACTH in a 
pulsatile manner, suggesting the expression of steroidogenic enzymes depends on the level of 
MC2R at the cell surface (Hofland et al., 2012; Spiga et al., 2011; Xing et al., 2010). 
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1.4.11 MRAP structure and topology 
Human MRAP is a 6 exon gene localised to chromosome 21q22.1. Alternative splicing of the 
gene yields two MRAP isoforms: MRAPα, encoded by exons 3 to 5, and MRAPβ, encoded by 
exons 3, 4 and 6, expressed as 172 and 102 amino acid proteins respectively (Fig. 1.8).  
Studies into the expression of MRAP in the adrenal gland, have not observed mRNA 
transcripts that include the first two exons (Webb and Clark, 2010).  MRAP is a single TMD 
protein with a highly conserved N-terminus and TMD and divergent C-terminus which is 
evident between α and β isoforms (Webb and Clark, 2010).  
 
 
Figure 1. 8: MRAP splicing.   
Alternative splicing of the MRAP leads to two isoforms of the gene: MRAPα (encoded 
by exons 3-5) and MRAPβ (encoded by exons 3, 4 and 6) respectively.  In addition, 
MRAP has a homologue gene called MRAP2 which has 39% sequence identity (not 
shown). 
Generally, MRAP is not particularly conserved amongst species; human and mouse MRAP 
share 63% homology with sequence variation occurring at the C-terminus.  An ortholog of 
MRAPα is detectable in zebrafish, but there is no ortholog in Fugu or Tetraodon (Klovins et 
al., 2004), indicating MRAP may not have been needed for MC2R cell surface expression in 
these species, or that MRAP2, a homologous gene to MRAP, took on this role.  There is also 
no expression data to suggest the MRAPβ isoform is expressed outside of primates  (Webb 
and Clark, 2010).  
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Western blot analysis of endogenous mouse MRAP (mMRAP) revealed a 32kDa band, much 
heavier than its predicted weight of 14.1kDa.  In two separate studies investigating both 
endogenous and epitope-tagged MRAP, immunoprecipitation and mass spectrometry 
confirmed that MRAP is able to form a SDS-resistant homodimer (Cooray et al., 2008; Sebag 
and Hinkle, 2007). Moreover, prediction tools suggested MRAP orientated with its N-
terminus extracellular to the plasma membrane.  However, immunofluorescent staining of 
non-permeabilised Y1 cells endogenously expressing Mrap with both N- and C-terminal 
mMRAP antibodies detected both termini at the cell surface, suggesting dual topology (Sebag 
and Hinkle, 2007).  Further investigation by Sebag and Hinkle (2007) using 
coimmunoprecipitation and glycosylation analysis showed that mMRAP exists as an 
antiparallel homodimer, a unique dual topology previously undocumented for single TMD 
proteins (Sebag and Hinkle, 2007). 
The proteomic domains involved in MRAP function have been explored in multiple studies.  
After it was confirmed that MRAP and MC2R formed a complex (Cooray et al., 2008; 
Metherell et al., 2005; Sebag and Hinkle, 2007), Webb et al. (2009) used a number of MRAP 
truncation constructs to investigate the functional domains of human MRAP, and showed 
using co-immunoprecipitation that a region between residues 36 and 61, corresponding to the 
TMD, was required for interaction with MC2R. In agreement, Sebag and Hinkle (2007) also 
showed, using mMRAP, that substituting the TMD with the corresponding region of 
RAMP3, an accessory protein to the odorant receptors, prevented MC2R trafficking.  
mMRAP was however able to form a homodimer indicating this region was not required for 
dimerisation of mMRAP. 
Sebag and Hinkle (2007) used biomolecular fluorescence complementation to show mMRAP 
could form an antiparallel homodimer at the ER and plasma membrane, and that parallel 
homodimers were not apparent.  Deleting residues 31-37 of the N-terminus, proximal to the 
TMD forced mMRAP into a Nexo/Ccyto topology suggesting the region was needed for 
antiparallel topology.  Deletion of this positively charged region also prevented dimerisation.  
Interestingly, inserting this region into RAMP3, which has single Nexo/Ccyto topology, forced 
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RAMP3 into dual topology, as detected by ELISA. MC2R was retained at the ER when the 
dimerisation domain was deleted showing mMRAP needs to be a dimer to traffic MC2R. 
The N-terminus of MRAP has been shown to have different roles in human and mice.  In 
humans, deletion of the N-terminus, specifically between residues 9-24, a tyrosine rich 
region, prevents MC2R trafficking to the cell surface (Fig. 1.9) (Webb et al., 2009). 
However, deletion of the N-terminus of mMRAP does not affect trafficking. It does however 
abolish ACTH responsiveness, suggesting that mMRAP has two roles in MC2R function: 
trafficking and signalling.  Narrowing this region, mutation of residues 18-21 within the N-
terminus, the LDYI motif, resulted in no measurable ACTH response.  Sebag et al went on to 
show that these residues are involved in MC2R binding of ACTH. 
The unconserved C-terminus of MRAP is not essential to its function, as its deletion does not 
prevent MC2R function.    The C-terminus has been suggested to have a regulatory role in 
MC2R function, based on observations made in several studies.   The length of the C-
terminus seems to be a key factor, for example cell surface expression and ACTH 
responsiveness of MC2R in transfected 293/FRT cells were higher in cells co-expressing the 
shorter 102aa MRAPβ than 172aa MRAPα, and more MRAPβ was localised to the plasma 
membrane than MRAPα (Roy et al., 2007). Similarly, deletion of the C-terminus of human 
MRAP increases cell surface expression of MC2R (Webb et al., 2009).  For mouse Mrap, 
deletion of the C-terminus did not affect cell surface expression.  It did however, attenuate 
ACTH responsiveness but did not completely abolish the cAMP response (Sebag and Hinkle, 
2007). 
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Figure 1. 9: MC2R trafficking by MRAP 
Illustration showing MC2R cell surface expression is facilitated by MRAP. The MRAP 
antiparallel homodimer binds to MC2R in the ER through its TMD, and transports the 
receptor to the cell surface where it is able to respond to ACTH.  It is essential that 
MRAP forms an antiparallel homodimer to be capable of transporting MC2R. For 
human MRAP, trafficking is also dependent on the N-terminus whereas the C-terminal 
region has a regulatory role, its length influencing the percentage of MC2R at the cell 
surface.  In mice, the N-terminus is essential for ACTH responsiveness and the C-
terminus regulates the intensity of the response. ER; Endoplasmic reticulum (Based on 
Webb et al. 2009). 
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1.4.12 MRAP2 
A homologue of MRAP named MRAP2 exists which was identified shortly after the 
discovery of MRAP (Chan et al., 2009b; Metherell et al., 2005).  MRAP2 shares 39% 
sequence identity with MRAP at the N-terminus, and is expressed as a 205aa single 
transmembrane domain protein.   
Compared to MRAP which has a broad expression pattern, in humans MRAP2 is expressed 
exclusively in the adrenal and brain, particularly the hypothalamus (Chan et al., 2009b).  This 
differs in lower vertebrates such as zebrafish where MRAP2 is more ubiquitous (Agulleiro et 
al., 2010). The conservation of MRAP2 is higher than MRAP in vertebrates, suggesting 
MRAP2 is the ancestral gene (Webb and Clark, 2010). MRAP2 expression is relatively low in 
the adult adrenal compared to MRAP, but high in the foetal adrenal suggesting a role in 
adrenal development (Gorrigan et al., 2011). 
MRAP2 has been functionally characterised and shown to have similar function to MRAP.  It 
is expressed at the plasma membrane and endoplasmic reticulum (ER), mirroring the 
subcellular localisation of MRAP, and is capable of forming homodimers as well as 
heterodimers with MRAP, both of which are thought to be anti-parallel (Chan et al., 2009b; 
Sebag and Hinkle, 2009b, 2010). It is also capable of trafficking MC2R to the cell surface in 
heterologous cells to the same degree as MRAP, and enables the receptor to respond to 
ACTH.   
There are however, differences between the proteins.  Firstly, deglycosylation of MRAP2 
abolishes the ability for MC2R to respond to ACTH, indicating the separate roles of MRAP2 
in trafficking and signalling are dependent on glycosylation whereas glycosylation does not 
affect the functioning of MRAP.   
Secondly, the MC2R-MRAP2 complex requires 1000X ACTH concentration to elicit the 
same cAMP response as MC2R-MRAP following ACTH stimulation (Gorrigan et al., 2011).  
These levels are supraphysiological, indicating the MC2R-MRAP2 complex has low affinity 
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for ACTH binding (Gorrigan et al., 2011; Sebag and Hinkle, 2009b). Interestingly, MRAP2 
does not have the LDYI domain of MRAP, shown to be involved in ACTH binding and 
response (Sebag and Hinkle, 2009).  Insertion of this motif into MRAP2 increases the ACTH 
response of MC2R to levels that are seen with MRAP. 
The role of MRAP2 in the adrenal is not fully understood.  It has been suggested that MRAP2 
negatively regulates MC2R function, by competing with MRAP for binding of the receptor 
(Sebag and Hinkle, 2010).  In this study, changing the ratio of MRAP/MRAP2 in cells 
cotransfected with MC2R shifted the cAMP dose response curve further right when MRAP2 
concentration was increased.  However, this phenomenon has not been observed in other 
studies, which suggest addition of MRAP2 has an additive effect to MRAP/MC2R complex 
cAMP generation (Agulleiro et al., 2010) or no effect at all (Gorrigan et al., 2011). 
 
1.4.13 MRAP and MRAP2 extra adrenal functions 
The tissue expression profiles of MRAP and MRAP2 are broader than that of MC2R, 
suggesting the proteins have additional non-adrenal functions independent of MC2R 
(Metherell et al., 2005).   Indeed, MRAP and MRAP2 have been demonstrated to interact 
with all 5 MCRs by co-immunoprecipitation (Chan et al., 2009b).  Apart from MC2R, which 
requires an accessory protein, the other members of the melanocortin receptor family are 
capable of cell surface expression in heterologous cell lines.  
In keeping with this, co-transfection of MC1R with human MRAP or MRAP2, does not 
affect cell surface expression or responsiveness of the receptor (Chan et al., 2009b; Sebag 
and Hinkle, 2010). Similarly, MC3R cell surface expression is not affected by co-transfection 
of MRAP or MRAP2, however one study found MC3R signalling was reduced in presence of 
MRAP2 (Chan et al., 2009b), supporting the dual functions of MRAPs (Novoselova et al., 
2013). 
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In contrast to these receptors, MC5R cell surface expression and signalling have been found 
to be negatively regulated by MRAP and MRAP2 (Chan et al., 2009b; Sebag and Hinkle, 
2009a, 2010). The effect of the MRAPs on MC4R is not clear, as there are mixed reports of 
no effect and negative regulation of the receptor MRAP2 (Chan et al., 2009b; Sebag and 
Hinkle, 2009a, 2010).   It is of value to note that these studies used different techniques to 
measure receptor responsiveness.   
The significance of these interactions is relatively unexplored.  MC3R is expressed in the 
arcuate nucleus and ventromedial nucleus of the hypothalamus, and is involved in energy 
metabolism.  MC3R mutations are also associated with obesity (Feng et al., 2005).  MC4R is 
expressed in the PVN of the hypothalamus and nuclear accumbens and is involved in appetite 
regulation. Consequently, knockout mice are obese and mutations in MC4R cause obesity in 
early childhood (Lee et al., 2008; Vaisse et al., 1998; Yeo et al., 1998).  MC4R in part 
mediates the stress response, however bar one case there are no reports of MRAP mutations 
causing obesity (Rumie et al., 2007). On the other hand, MRAP2 is highly expressed in the 
hypothalamus, and fittingly, a recent study has reported that Mrap2
-/-
 mice are obese (Asai et 
al., 2013). Given that no MRAP2 mutations are associated with derangements to the HPA 
axis, the above studies suggest MRAP2 has a role independent of adult adrenal function.  In 
support of this notion, whereas MC2R and MRAP are transcriptionally upregulated by ACTH, 
MRAP2 is unaffected (Hofland et al., 2012) and to date, there are no mutations in MRAP2 
associated with adrenal insufficiency. 
 
1.4.14 Familial Glucocorticoid Deficiency (FGD) type 2: MRAP mutations  
Mutations in MRAP account for 20% of the FGD cohort.  Since the initial discovery of 
MRAP, further mutations have been described by other groups (Akın et al., 2010; Jain et al., 
2011; Modan-Moses et al., 2006; Rumie et al., 2007). The majority of these mutations are 
nonsense or splice site mutations, therefore extremely deleterious to protein function and 
hence, patients with FGD2 typically present earlier with a more severe phenotype compared 
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to FGD1 patients, who typically have missense mutations (Chung et al., 2010; Chung et al., 
2008).  Despite earlier presentation, baseline levels of cortisol and ACTH do not differ 
between FGD1 and 2 patients (Chung et al., 2010). 
Two missense mutations in MRAP have been described, which give rise to a milder 
phenotype with later onset (Hughes et al., 2010). Most MRAP mutations, excluding these two 
missense mutations, result in truncation of the transmembrane domain, which is involved in 
MC2R interaction, and therefore trafficking to the cell surface (Meimaridou et al., 2012a).  
As a result, MC2R is retained at the ER. 
 
1.4.15 Familial Glucocorticoid Deficiency (FGD) type 3/Non-classical LCAH: 
Mutations in STAR 
A genome-wide linkage study using microsatellite markers previously linked a locus on 
chromosome 8 (8q12-1-21-2) to FGD in 3 families with unknown aetiology (Génin et al., 
2002; Metherell et al., 2009).  With no obvious candidate gene, SNP array genotyping of 1 of 
the 3 families was carried out in order to narrow the region, however the region was in fact 
expanded, revealing STAR as a putative candidate gene for FGD.  Mutations in STAR are a 
known cause of lipoid congenital adrenal hyperplasia (LCAH), a disease characterised by 
severe adrenal and gonadal insufficiency. However, mutations retaining a certain degree of 
functionality of the gene present a milder phenotype with late onset, classed as non-classical 
LCAH (OMIM #201710). In some cases where salt loss is minimal, the phenotype is 
indistinguishable from FGD, and therefore also classed as FGD3 (OMIM %609197 
GCCCD3). 
Classical LCAH is characterised by very low levels of steroids including cortisol and 
aldosterone, with elevated basal levels of plasma ACTH and renin.  Patients have grossly 
enlarged adrenals due to the build-up of cholesterol in lipid droplets, and are hyperpigmented 
because of excess ACTH (Miller, 1997).  Presentation usually occurs a few months into life, 
with no salt loss crisis at birth because aldosterone is synthesised at low levels in the foetal 
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adrenal  (Miller, 2013).  Because of the absence of testosterone production during gestation, 
androgenisation does not occur in 46XY karyotypes leading to female external genitalia, but 
female internal reproductive organs do not develop because sertoli cells function normally 
expressing anti-mullerian hormone (Miller, 2013).  46XX individuals might have normal 
puberty with breast development and cyclic vaginal bleeding due to the low levels of 
oestrogen that is synthesised through a StAR-independent mechanism, but have 
hypergonadotropic hypogonadism leading to anovulatory cycles and build-up of cholesterol 
causing damage to the ovaries (Bose et al., 1997; Fujieda et al., 1997).  
The development of LCAH has been described in a ‘2-hit model’, where the diminished 
activity of StAR leads to steroid deficiency evoking increased ACTH and gonadotropin levels 
to compensate, which increases cholesterol uptake and synthesis.  Cholesterol build-up leads 
to mitochondrial damage which further incurs damage to the steroidogenic capacity of the 
cell (Bose et al., 1996; Miller, 1995). 
Over 40 mutations in STAR have been described that are most frequently in the C-terminal 
regions between exons 5 and 7 (Miller and Auchus, 2011). Most mutations result in a 
complete loss of function, however the patients described by Metherell et al. (2009) to have 
isolated glucocorticoid deficiency had mutations p.R188C and p.R192C, which retain 20% 
StAR activity (Baker et al., 2006).  The absence of mineralocorticoid deficiency may have 
resulted from the low production rate of aldosterone compared to cortisol, hence the ZG 
would remain relatively undamaged.  The patients had normal pubertal development 
corresponding to their genetic karyotype and 46XX individuals had normal menstrual cycles. 
There were however additional features compared to classical FGD, for example some 
patients had hypospadias and affected individuals exhibited varying degrees of fertility 
(Metherell et al., 2009). 
A similar phenomenon is seen with mutations in the CYP11A1 gene. Mutations in CYP11A1 
that ablate all CYP11A1 activity cause a phenotype clinically indistinguishable from LCAH 
(Miller, 2013). However, mild mutations in this gene cause milder phenotype, similarly to 
mild mutations in STAR (Parajes et al., 2011).  Although STAR mutation leads to a more 
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enlarged adrenal than CYP11A1 deficiency, which can be diagnostic, the only dependable 
method of distinguishing between CYP11A1 and STAR mutations is genetic sequencing 
(Gucev et al., 2013). 
 
1.4.16 MCM4 mutations in the Irish traveller population 
FGD is common amongst the Irish traveller community, a highly consanguineous genetically 
isolated population.  Patients have a variant form of FGD with additional phenotypic 
characteristics including short stature, increased chromosomal breakage and natural killer 
(NK) cell deficiency. In addition the cortisol deficiency is mild compared to other forms of 
FGD.  In 2012, after ruling out all known causes of FGD, Hughes et al. (2012) carried out 
SNP array and microsatellite genotyping of 7 individuals from 3 families in order to unveil 
the genetic cause of these pathologies.  SNP array genotyping identified three regions of 
homozygosity shared by 5 of the affected patients on chromosome 4 and 8.  Exome capture 
and resequencing of these regions in one affected patient identified a homozygous splice site 
mutation c.71-1insG in mini-chromosome maintenance-deficient protein 4 (MCM4), which 
segregated with the disease.  
In a parallel study, another group used similar methodology to assess a separate group of 10 
affected children with the same phenotype of NK cell deficiency, DNA breakage and FGD, 
and likewise identified MCM4 as a candidate gene (Casey et al., 2012). 
MCM4 is a DNA helicase, part of the MCM2-7 complex involved in DNA replication.  The 
single nucleotide change prior to exon 2 shifted the consensus splice site upstream, resulting 
in the insertion of a base into the coding region and a frameshift, leading to a downstream 
premature stop codon and predicting a severely truncated protein.  Immunoblotting lysates 
from control and patient lymphocytes with MCM4 antibody showed that MCM4 migrated as 
2 main species in control cells, but the heavier species representing full length MCM4 was 
absent from affected patients.  The smaller species of MCM4 corresponded to the size of the 
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protein produced by translation from the third in-frame methionine. The smaller isoform was 
not detected with an N-terminal antibody, consistent with the N-terminus being absent. 
In addition to these findings, immunohistological analysis of adrenals from MCM4 mutant 
mice showed abnormal morphology, with atypical spindle-shaped non-steroidogenic cells.   
Given that Mcm4
-/-
 mice are embryonic lethal, Hughes et al. (2012) concluded that the 
relatively mild phenotype of these patients was due to the remaining translation of the smaller 
isoform of MCM4 rescuing patients from a lethal phenotype.  The shorter isoform maintains 
the highly conserved C-terminal domains required for MCM4 function, but lacks the 
relatively poorly conserved N-terminus involved in protein kinase regulation of cell cycle 
progression (Sheu and Stillman, 2010).  MCM4 mutations in the Irish traveller population 
account for 1% of the FGD cohort. (Hughes et al., 2012)  
 
1.4.17 FGD4: Mutations in NNT 
In a search for further causes of FGD, Metherell et al. carried out SNP array genotyping 
using the GeneChip Human Mapping 10K array Xba142 (Affymetrix) in nine probands with 
unknown aetiology. Linkage to a locus on chromosome 5 was identified in three 
consanguineous families (Meimaridou et al., 2012a). Targeted exome sequencing of the 
proband from one kindred identified a homozygous mutation, p.V533A, in nicotinamide 
nucleotide transhydrogenase (NNT) which was heterozygous in the parents and absent in 
controls.  Homozygous novel variants were also discovered in the other two probands with 
chromosome 5 linkage. 
Sequencing a further 100 FGD patients of unknown aetiology revealed a total of 23 
homozygous or compound heterozygous mutations in 16 kindreds, accounting for 10% of the 
FGD cohort (Fig. 1.10). The mutations spanned the 22 exons of NNT, and ranged from 
missense and nonsense mutations, to splice site mutations and even abolition of the initial 
methionine (Fig. 1.10).  
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Figure 1. 10: Mutations in NNT.  
Illustration showing gene structure of NNT and mutations described to date. NNT exons 
are represented by black boxes, with homozygous mutations in white lettering and 
compound heterozygous mutations in black lettering.  Mutations are presented at the 
protein level or cDNA level (denoted by ‘c.’). To date, a total of 23 mutations in 16 
families have been described.   
NNT is a highly conserved proton translocating dehydrogenase localised to the inner 
mitochondrial membrane, where it catalyses the interconversion of NADP
+
 and NAPDH by 
the reversible reaction NADH + NADP
+
 <--> NADPH + NAD
+
.  Under normal physiological 
conditions and an electrochemical gradient favouring NADPH production, NNT supplies the 
mitochondria with high concentrations of NAPDH, which is required for the glutathione and 
thioredoxin systems (Fig. 1.11).  
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Figure 1. 11: NNT is a mitochondrial dehydrogenase.   
NNT supplies glutathione and thioredoxin systems with NADPH which reduces GR and 
TXNRD2, which in turn reduce GPX and PRDX respectively.  NNT, nicotinamide 
nucleotide transhydrogenase; GR, glutathione reductase; TXNRD2, thioredoxin 
reductase 2; Trx2 thioredoxin 2; GPX, glutathione peroxidase (1 or 4); PRDX, 
peroxiredoxin (3 or 5). 
 
NADPH is utilised by glutathione reductase to  regenerate reduced glutathione (GSSG) from 
glutathione (GSH) (Rydström, 2006).  Glutathione is a potent antioxidant that can reduce 
disulphides, but it also acts as a cosubstrate in reduction of toxic hydrogen peroxide by the 
glutathione peroxidases, as described in section 1.7.4.  NADPH is also required by 
thioredoxin reductase 2, the mitochondrial enzyme that reduces thioredoxin, which acts as 
cosubstrate for peroxiredoxin 3 and 5 which also reduce hydrogen peroxide.  Finally NADPH 
is used by the ferredoxin reductase electron donor system to supply ferredoxin and in turn 
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mitochondrial steroidogenic CYP enzymes.  It therefore clear that mutations in NNT have the 
potential to impair mitochondrial function through several mechanisms.  
Previous studies have illustrated the antioxidant role of NNT, for example Caenorhabditis 
elegans lacking nnt-1, are more susceptible to oxidative stress because of a lower GSH/GSSG 
ratio (Arkblad et al., 2005). Furthermore, human phaeochromocytoma (PC12) cells with 
knockdown of NNT exhibited lower cellular NADPH and GSH levels (relative to GSSG) and 
increased H2O2 levels (Yin et al., 2012b). 
Investigation into the disease mechanism revealed that NNT is widely expressed in humans 
with high expression in the adrenal, heart, kidney, thyroid and adipose tissues, in agreement 
with previous studies in mice/rats (Dezso et al., 2008; Meimaridou et al., 2012b; Su et al., 
2002; Walker et al., 2004). Knockdown of NNT in human adrenocortical carcinoma (H295R) 
cells increased levels of reactive oxygen species (ROS) and markers of apoptosis, and 
lowered the GSH/GSSG ratio, indicating an impaired redox potential (Meimaridou et al., 
2012b).  A sub-strain of C57BL6/J mice carrying a spontaneous 5 exon deletion in Nnt had 
slightly disorganised cells within the ZF with higher levels of apoptosis, and lower basal and 
stimulated corticosterone levels (Meimaridou et al., 2012b). These mice have previously been 
demonstrated to have impaired insulin secretion and glucose intolerance due to increased 
oxidative stress in pancreatic β-cells (Toye et al., 2005). 
The above data indicated a novel disease mechanism for FGD, associated with increased 
levels of oxidative stress.   
 
1.5 Triple A syndrome 
Triple A syndrome (OMIM#231550) was initially discovered by Allgrove et al. (1978) who 
reported two pairs of siblings with a combination of adrenal insufficiency, achalasia of the 
cardia and alacrima (Clark and Weber, 1998). These three features characterise the disorder, 
as well as the progression of highly variable neurological defects in 60% of cases (Clark and 
64 
 
Weber, 1998).  The phenotype of Triple A syndrome is highly variable even within one 
family, with a low correlation of genotype to phenotype (Prpic et al., 2003). Patients often 
present with only one or two of these symptoms, the rest developing over time, and therefore 
should be suspected on the presence of any symptom (Metherell et al., 2006). The earliest 
symptom to present is usually alacrima, followed by achalasia, which can be easily 
overlooked on diagnosis (Clark and Weber, 1998).  These usually precede adrenal 
insufficiency which develops at a later stage, suggesting progressive destruction of the gland 
(Clark and Weber, 1998; Huebner et al., 1999). Hypoglycaemia and hyperpigmentation 
usually manifest in the first decade of life (Clark and Weber, 1998). Biochemically, 90% 
patients have isolated glucocorticoid deficiency, but 10% also develop mineralocorticoid 
deficiency most likely due to destruction of the adrenal cortex (Metherell et al., 2006).  Post 
mortem analysis of patient adrenals revealed atrophy of the ZF. Apart from glucocorticoid 
replacement, there is currently no treatment for the disease other than symptom relief. 
Following linkage of the disease to chromosome 12q13 (Weber et al., 1996), it was 
demonstrated the 90% of patients with Triple A syndrome possess mutations in the AAAS 
gene (Clark and Weber, 1998). AAAS encodes a 60kDa WD-repeat protein which forms part 
of the nuclear pore complex (NPC), called alacrima-achalasia-adrenal insufficiency 
neurological disorder (ALADIN). 
ALADIN is widely expressed with particularly high expression in the adrenal cortex and 
brain (Cho et al., 2009; Huebner et al., 2002; Metherell et al., 2006; Storr et al., 2005).  It is 
localised to the cytoplasmic side of the NPC, and AAAS mutations usually result in incorrect 
subcellular localisation of the protein, but do not affect the structure of the NPC, indicating 
targeting of ALADIN to the NPC is key to its function (Cronshaw and Matunis, 2003; 
Krumbholz et al., 2006).  
The exact function of ALADIN at the NPC is not known.  Over the past decade, the 
pathogenesis of Triple A syndrome has been explored and found to be associated with 
oxidative stress, which may reflect the progressive nature of the disease.  Using a bacterial-2-
hybrid assay Storr et al. showed that ALADIN interacted with ferritin heavy chain protein 
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(FTH1), which has a DNA-protective role in the nucleus (Storr et al., 2009).  FTH1 was not 
detected in nuclear fractions taken from patient fibroblasts, nor by confocal microscopy when 
transfected alone in these cells.  Only on cotransfection with AAAS was FTH1 detected at the 
nucleus, suggesting ALADIN has a role in nuclear translocation of FTH1.   Apoptosis in 
neuronal cells induced by hydrogen peroxide was reduced by transfection of AAAS and/or 
FTH1, suggesting nuclear import of FTH1 by ALADIN is crucial to the DNA-protective role 
of FTH1, preventing oxidative stress at/in the nucleus.  
Other studies have also implicated oxidative stress in the pathogenesis of triple A syndrome. 
Patient fibroblasts have increased susceptibility to oxidative stress and have higher basal 
levels of ROS (Hirano et al., 2006; Kind et al., 2010; Kiriyama et al., 2008).  Fibroblast cell 
survival is reduced following depletion of antioxidant glutathione with L-buthionine-(S,R)-
sulfoximine (BSO) compared to wildtype cells (Hirano et al., 2006).  These cells fail to 
import DNA repair protein aprataxin (APTX) and DNA ligase I.  Transfection of these latter 
two proteins into patient fibroblasts attenuated the toxic effects of BSO, suggesting these 
effects were the consequence of failed nuclear import of antioxidant proteins (Hirano et al., 
2006). 
Despite the above insights into ALADIN function, the disease mechanism for Triple A 
remains to be understood.  Using patient fibroblast models does not consider the tissue 
specific nature of the disease.  Unfortunately, the Aaas
-/-
 mouse model does not recapitulate 
the human phenotype, showing no histological abnormalities compared to wildtype, and only 
mild neurological disturbances (Huebner et al., 2006). 
Taking this into consideration, Prasad et al. (2013) generated a human in vitro model with 
shRNA knockdown of AAAS in human adrenocortical and neuronal cells to better understand 
the disease mechanisms underlying Triple A syndrome.  Cell viability was significantly 
reduced in AAAS knockdown cells compared to wildtype, which could be rescued with the 
antioxidant N-acetylcysteine. Cell viability in neuronal cells was not affected by AAAS 
knockdown, but AAAS knockdown did increase the sensitivity of these cells to induced 
oxidative stress. Both adrenal and neuronal AAAS deficient cell lines had a reduced 
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GSH/GSSG ratio indicating cellular toxicity.  Crucially, in adrenal cells AAAS knockdown 
lowered cortisol production, due to reduced transcription of STAR and protein expression of 
steroidogenic enzyme CYP11B1, which catalyses the final step of cortisol production. The 
reduction in cortisol could be partly rescued by treatment of cells with N-acetylcysteine.  
These data give further evidence that oxidative stress is involved in the pathogenesis of Triple 
A which subsequently impairs steroidogenesis, but further investigations are required to fully 
understand the function of ALADIN. 
 
1.6 X-Linked Adrenoleukodystrophy 
X-linked adrenoleukodystrophy (X-ALD) (OMIM #300100) is a rare genetic disorder 
characterised by the build-up of very long chain fatty acids (VLCFA) leading to progressive 
demyelination in the central nervous system, axonopathy in the spinal cord, and adrenal 
insufficiency (Galea et al., 2012).  There are two phenotypes of the disorder: 
adrenomyeloneuropathy (AMN), and cerebral demyelinating X-ALD (cerebral-ALD) (Kemp 
et al., 2012). 
 
AMN is the most common form of X-ALD, and is characterised by peripheral neuropathy 
and non-inflammatory distal axonopathy in the spinal cord leading to progressive spastic 
paraplegia (Galea et al., 2012; Kemp et al., 2012).  This form of the disease has late onset, 
manifesting between the ages of 20 to 30 in the hemizygous males and (Chaudhry et al., 
1996) and between 50 to 60 years in 65% of heterozygous females (Kemp et al., 2012).  In 
males, 20%, cases with AMN develop cerebral demyelination that becomes inflammatory 
(van Geel et al., 2001). 
 
The celebral-ALD form of X-ALD has a more severe prognosis.  It presents earlier in life, in 
childhood or adolescence, and is characterised by rapidly progressive inflammatory 
demyelination in the central nervous system leading to severe neurological and cognitive 
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disabilities (Kemp et al., 2012). Within two to five years after symptoms appear, the patient 
reaches a vegetative state which is terminal (Kemp et al., 2012). 
 
Another defining feature of X-ALD is adrenal insufficiency, which can present before any 
neuropathological symptoms (Kemp et al., 2012). Adrenal insufficiency occurs in two thirds 
of AMN cases, and 1% of heterozygous females. In addition to adrenal insufficiency, adult 
males sometimes develop testicular insufficiency (Kemp et al., 2012). 
 
X-ALD is caused by mutations in the ABCD1 gene on Xq28, which encodes ATP binding 
cassette (ABC) transporter, adrenoleukodystrophy protein (ALDP/ABCD1).  ALDP is a 
subclass D, membrane-bound ABC transporter that catalyses the transport of metabolites, 
such as VLCFAs, into the peroxisome in exchange for ATP, where they undergo β-oxidation. 
Absence of this protein leads to the build-up of VLCFAs and reduced β-oxidation of 
VLCFAs in the peroxisome (Kemp and Wanders, 2010).   
 
In humans ABCD1 is ubiquitously expressed with particularly high expression in the pituitary 
and adrenal glands, testis, liver, kidney, digestive tract, heart, skeletal muscle and skin 
(Höftberger et al., 2007). Within the adrenal cortex, ABCD1 is expressed in the ZF and ZR, 
where cortisol is produced (Höftberger et al., 2007). 
 
The disease mechanism for X-ALD is not completely understood, but is thought to be due to 
the build-up of VLCFAs.  The accumulation of VLCFAs is the earliest biochemical 
abnormality observed in tissues taken from X-ALD patients (Theda et al., 1992).  Children 
with cerebral-ALD, have higher accumulations of VLCFAs in white matter than AMN, 
indicating the severity of the condition is proportional to the accumulation of VLCFAs 
(Asheuer et al., 2005).   
 
The Abcd1
-/-
 mouse model displays elevated levels of VLCFA particularly in the nervous 
system and adrenal gland early in life, but no signs of cerebral demyelination until 6 months 
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(Forss-Petter et al., 1997; Kobayashi et al., 1997; Lu et al., 1997). From 16 months the mice 
develop axonopathy leading to neuronal damage and locomotor alterations by 20-22 months 
of age (Pujol et al., 2004; Pujol et al., 2002). The mouse model therefore recapitulates the 
human disease progression of AMN (Galea et al., 2012; Pujol et al., 2002), however, mice do 
not develop hypocortisolism (Lu et al., 2007). 
 
The consequences of VLCFA accumulation have been explored to better understand the 
pathogenesis of X-ALD. Evidence from both human and mouse models suggest that 
oxidative stress plays a crucial role in disease development.  Post mortem analysis of X-ALD 
brains show higher levels of markers of oxidative stress, such as increased nitrotyrosylated 
proteins, NOS2, lipid peroxides within neuropathological inflammatory lesions of cerebral-
ALD, as well as up-regulation of the mitochondrial antioxidant SOD2 (Powers et al., 2005). 
Human X-ALD fibroblasts with VLCFA excess have increased levels of ROS, reduced GSH 
and reduced mitochondrial membrane potential (Fourcade et al., 2008; Fourcade et al., 2010).  
Abcd1
-/-
 mice have elevated levels of MnSOD which is induced by oxidative stress in the 
cerebellum, liver, kidney and adrenal cortex (Powers et al., 2005). 
 
Although the precise mechanism is not clear, it is thought that accumulation of VLCFAs 
causes oxidative stress by impairing energy balance and inducing inflammation, which 
cumulatively and synergistically lead to oligodendrite and axonal death.   
 
Evidence suggests a certain degree of cross-talk between peroxisomes and mitochondria, so 
ROS generated in peroxisomes can disrupt mitochondrial redox status and cause 
mitochondrial fragmentation (Ivashchenko et al., 2011).  Oxidative stress impairs the activity 
not only of mitochondrial antioxidant enzymes, exacerbating the oxidative damage, but also 
enzymes involved in glycolysis and the TCA cycle, as observed in the spinal cord of Abcd1
-/-
 
mice (Galino et al., 2011).  Mice consequently have diminished ATP and NADH levels 
coupled with reduced GSH levels in spinal cords (Galino et al., 2011). Diminished ATP 
production is highly damaging to axonal function, which requires high levels of energy, and 
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hence may lead to degeneration (Ferrer, 2009; Galea et al., 2012).  Mitochondria may also 
undergo oxidative damage directly from VLCFAs, as Abcd1
-/-
 mice have enlarged 
mitochondria in the spinal cord due to lipid accumulation. 
 
 
1.7 Overview of Antioxidant mechanisms in Oxidative stress 
1.7.1 Reactive Oxygen Species 
Reactive oxygen species (ROS) are molecules or free radicals with one unpaired electron that 
are highly reactive and cause oxidative damage to DNA, lipids and proteins when levels are 
not maintained at a steady-state.  Indeed, a basal level of ROS is required for some signalling 
cascades, for example H2O2 acts as a secondary messenger in growth factor signalling (Rhee 
et al., 2012). However, if ROS exceeds normal levels, cells undergo ‘oxidative stress’, in 
which vulnerable proteins undergo structural alterations that alter their function, DNA 
undergoes fragmentation, and lipid peroxidation destabilises membranes, ultimately inducing 
cell death.  Hence, cells have an army of antioxidant defence proteins that ensure ROS levels 
are appropriately maintained. 
Different forms of ROS exist, which include the superoxide anion (O
-
2), hydrogen peroxide 
(H2O2), hydroxyl radical (HO
•
), peroxyl radical (RO
•
2), alkosyl radical (RO
•
), hydroperoxyl 
radical (HO
•
2), hypochlorous acid (HOCl), hypobromous acid (HOBr), and singlet oxygen 
(O2) (Galea et al., 2012). Superoxide anion is the predominant form of ROS and a precursor 
to most other ROS (Galea et al., 2012). 
 
1.7.2 Sources of ROS 
ROS is generated from multiple sources including uncoupled nitric oxide synthase, NADPH 
oxidase subtypes (NOX), which generate superoxide, and H2O2 is also produced directly by 
xanthine oxidase and NOX4 (Lubos et al., 2011).  The main source of cellular ROS comes 
from mitochondria, the energy houses of our cells. As a result, many disorders associated 
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with oxidative stress are also associated with mitochondrial dysfunction, including 
neurodegenerative disorders (Barnham et al., 2004), diabetes (Kaneto et al., 2005), 
cardiovascular diseases (Sheeran et al., 2010) and aging (Mattson and Magnus, 2006; 
Navarro and Boveris, 2007). Sources of mitochondrial ROS include complexes I and III of 
the electron transport chain that leak electrons which can be transferred to molecular oxygen 
forming the superoxide anion (Galea et al., 2012),  and in steroidogenic cells, the 
steroidogenic CYP enzyme donor system is inefficiently coupled leading to electron leakage 
and superoxide production (Lubos et al., 2011).                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
1.7.3 Antioxidant defence 
Humans have evolved multiple antioxidant systems to counteract ROS production.  The 
primary line of defence is the superoxide dismutase (SOD) enzymes, which convert 
superoxide anions to H2O2.  There are 3 forms of this enzyme which are localised to different 
cellular compartments: cytosolic copper-zinc SOD (CuZn-SOD; encoded by SOD1), 
extracellular SOD (SOD3), and mitochondrial manganese SOD (MnSOD).  The 
mitochondrial MnSOD (encoded by SOD2) is most critical for survival, and depletion can 
lead to neonatal lethality (Galea et al., 2012).  SOD2 is transcriptionally upregulated by 
oxidative stress. 
The production of H2O2 by SOD is simply an intermediate step, as hydrogen peroxide can 
also be detrimental. Unlike superoxide, H2O2 can diffuse across lipid membranes and it has a 
longer half-life than superoxide (Lubos et al., 2011).  It can also react with Fe
2+
 to form the 
hydroxyl radical (HO
•
), which is highly damaging to cells (Lubos et al., 2011).  
The reduction of H2O2 to water is catalysed by three enzyme families: the glutathione 
peroxidases (GPXs), peroxiredoxins (PRDXs) and catalase (CAT).  The GPX and PRDX 
families share a thioredoxin fold, but differ in their catalytic mechanisms and electron donors.  
Both families have multiple isoforms that vary in tissue specific expression patterns and 
cellular compartment.  The majority of these isozymes are cytosolic but GPX1, GPX4, 
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PRDX3 and PRDX5 also reside in mitochondria. However, PRDX3 is the only thiol 
peroxidase to be specifically localised to mitochondria. GPX1 and PRDX5 also reside in 
peroxisomal compartments to complement catalase activity, and GPX3 and PRDX4 are 
secretory proteins. Although relatively little is known about GPX7 and 8, these enzymes have 
been demonstrated to be ER bound (Brigelius-Flohé and Maiorino, 2013). 
There are 8 glutathione peroxidases (GPXs) that depend on glutathione as a co-factor, 5 of 
which are selenium-containing proteins with a selenocysteine residue at the active site, 
enabling extremely high reactivity with H2O2.   Six peroxiredoxins exist that use a redox 
active cysteine at the active site, ultimately resulting in a lower rate constant than GPXs. 
However, in comparison to GPXs, PRDXs have a higher affinity for H2O2 (Km <20µM) , and 
are highly abundant enzymes accounting for 1% of soluble protein (Chae et al., 1999; Rhee et 
al., 2001; Wood et al., 2003b). PRDXs are therefore efficient in reducing low levels of H2O2. 
PRDXs use thioredoxins as electron donors, which are the either type 1 cytosolic, type 2 
mitochondrial or type 3 testes specific isoforms (Hanschmann et al., 2013).  
Catalase is specifically localised to peroxisomes in mammals where it removes H2O2 
produced during α-oxidation of fatty acids (Rhee et al., 2005b).  Catalase acts as a dismutase 
converting two H2O2 molecules to one H2O and one O2 molecule, hence the requirement of 
two H2O2 molecules at the active site means catalase requires a high H2O2 concentration to be 
active and therefore has a low affinity for H2O2 (Rhee et al., 2005b).  Once active, catalase 
achieves high rates of reaction, and is therefore considered to have an important role when 
H2O2 levels are high.  The different catalytic mechanisms and tissue/compartment specific 
expression of these enzymes provide beneficial antioxidant defence in different 
circumstances.   
 
1.7.4 Mitochondrial mechanisms of antioxidant defence 
Mitochondria have a stringent antioxidant defence system that is coupled to the TCA cycle, 
regulating the ROS output from energy metabolism.  Antioxidant enzymes of mitochondria 
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rely principally on NADPH as an electron donor, which is generated by NADP
+
-dependent 
isocitrate dehydrogenase (IDH2) during oxidative phosphorylation, malate dehydrogenase 
during the TCA cycle or nicotinamide nucleotide transhydrogenase (NNT) (Yin et al., 
2012a).  NNT accounts for approximately 50% of the mitochondrial NADPH pool under 
physiological conditions (Rydström, 2006).   
NADPH sits at the top of an electron donor chain involving glutathione and thioredoxin 2 
dependent antioxidant systems (Fig. 1.12).   NADPH reduces glutathione reductase, an 
enzyme that subsequently reduces protein thiol glutathione. As previously mentioned, 
reduced glutathione (GSH) is a highly abundant non-enzymatic antioxidant present both in 
mitochondria and the cytosol, present in millimolar concentrations (up to 10mM) 
(Chakravarthi et al., 2006). It directly reduces ROS and other targets such as vitamin C, the 
second most abundant non-enzymatic antioxidant in most species (Sies et al., 1992).  A lower 
ratio of reduced to oxidised glutathione is associated with reduced cell viability (Deneke and 
Fanburg, 1989).  Hence, glutathione acts as a redox buffer for the cell, maintaining a reducing 
environment. Glutathione also acts as a co-factor for antioxidant glutathione peroxidases, 
glutathione transferases, sulfiredoxins as well as peroxiredoxins (Marí et al., 2009; Rhee and 
Woo, 2011; Yin et al., 2012a).  The main mitochondrial glutathione peroxidases are GPX1, 
which is also cytosolic and ubiquitously expressed, and mitochondrial specific GPX4, which 
is predominantly expressed in the testes. 
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Figure 1. 12: Mitochondrial ROS production and antioxidant defence.   
Illustration showing ROS is generated from electron transport chain complexes I and 
III and may cause oxidative damage to cellular components.  Mitochondria have two 
antioxidant systems: Glutathione and thioredoxin 2.  The electron donor system for 
both antioxidant systems starts with NAPDH, which is generated from NNT.  NNT 
converts NADP
+
 generated from the TCA and oxidative phosphorylation to NADPH, 
coupling the activity of antioxidants with energy demand.  Electrons are passed from 
NADPH to antioxidants including glutathione peroxidase and peroxiredoxin 3, which 
reduce H2O2 to water. GSR, glutathione reductase; GSH, glutathione; TXNRD2, 
thioredoxin reductase 2; TXN2, thioredoxin 2; GLRX2, glutaredoxin 2; MnSOD, 
manganese SOD. (Image by Prasad et al. unpublished) 
NADPH is also an electron donor to the mitochondrial specific isoforms of the thioredoxin 
family of antioxidants (Fig. 1.12).  NADPH is a cofactor for selenoprotein thioredoxin 
reductase 2 (TXNRD2), which reduces thioredoxin 2, which in turn reduces mitochondrial 
peroxiredoxins PRDX3 and PRDX5.  Thioredoxins, like glutathione, are potent redox-active 
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thiols themselves that scavenges ROS and are upregulated by oxidative stress (Galea et al., 
2012). PRDX3 has been reported to consume 90% of ROS generated in the mitochondrion 
(Cox et al., 2010). In addition to reduction by thioredoxin 2, PRDX3 can be reduced by 
glutaredoxin 2, a mitochondrial specific GSH dependent enzyme (Hanschmann et al., 2013). 
 
1.8 Oxidative stress in the Adrenal Gland  
In steroidogenic cells, the cytochrome P450 (CYP) enzyme family serves as an additional 
source of oxidative by products.  As previously mentioned, the steroidogenic enzymes require 
electron donors for enzymatic activity.  Mitochondrial type 1 CYP enzymes receive electrons 
from NADPH, which are transferred to ferredoxin reductase, then to ferredoxin and finally to 
the CYP enzyme (Miller, 2005).  ER bound CYP enzymes receive electrons from 2-flavin 
P450 oxidoreductase (Miller, 2005). 
The process of electron transfer is not efficiently coupled, so that electrons leak and react 
with O2 to form superoxide. In particular, the final step of cortisol production catalysed by 
CYP11B1 leaks 40% of its electron flow to ROS, a much higher proportion than that of 
CYP11A1 (Hanukoglu, 2006; Rapoport et al., 1995). This may explain why glucocorticoids 
suffer greater depletion than mineralocorticoids in conditions of adrenal insufficiency 
associated with oxidative stress. 
Antioxidant enzymes are highly expressed in the adrenal cortex compared to other tissues and 
have higher activity, possibly as a compensatory mechanism (Azhar et al., 1995; Hanukoglu, 
2006). Moreover, a study by Azhar et al.  (1995) showed vitamin C was 6-fold higher in the 
adrenal than in the ovary and 15-fold higher than in the liver.  Levels of vitamin E and 
glutathione were also higher in steroidogenic tissues and antioxidant enzymes CuZn SOD, 
MnSOD and GPX had high expression and activity in these tissues, with particularly high 
levels in the ZF and ZR of the adrenal cortex.  Furthermore, selenium (Se) levels, which 
determine GPX activity, have been shown to be preferentially retained in the adrenal and 
testes following Se deprivation in rats (Behne and Höfer-Bosse, 1984). 
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Although other antioxidant enzymes such as catalase are capable of detoxifying hydrogen 
peroxide, a study by Dorval et al. (2003) showed that the glutathione redox system was more 
efficient that catalase in protecting interrenal cells, the fish equivalent of adrenocortical cells, 
of trout from oxidative stress. Other studies have shown that catalase activity and expression 
levels are relatively low in the adrenal compared to other antioxidants (Azhar et al., 1995). 
In vitro studies on mouse, rat and human leydig tumour cells have shown that administration 
of oxidative stress in the form of H2O2 impairs steroidogenesis (Shi et al., 2010; Tsai et al., 
2003), which may explain the necessity for tight redox control within steroidogenic tissues.  
Similarly another source of oxidative stress, the pesticide endosulfan, reduces cortisol 
secretion in trout interrenal cells (Dorval et al., 2003). 
Two potential mechanisms for this ROS-induced impairment of steroidogenesis are proposed. 
The first is the suppression of StAR protein functionality.  Supporting evidence for this 
includes functional studies on rat testicular leydig MA-10 cells showing that  StAR protein is 
reduced following exposure to H2O2 (Diemer et al., 2003). Similarly, a study by Shi et al. 
(2010) illustrated that perfluorododecanoic acid (PFDoA), an inhibitor of steroidogenesis that 
increases ROS, acts by reducing expression of StAR in mouse and rat leydig cells.  In this 
study the effects of PFDoA on steroidogenesis and ROS were rescued with a superoxide 
dismutase analog.  Furthermore, Jin et al. (2011) showed that 3 week exposure to pro-oxidant 
cypermethrin causes a decrease in the expression of cholesterol transport and steroid 
synthesis proteins including StAR.  These studies suggest that ROS affects cholesterol 
transport into mitochondria, an essential step in steroidogenesis. Although these studies 
examine testicular steroidogenesis, the effect of ROS on StAR in adrenocortical cells may be 
similar. Furthermore, it has been demonstrated that StAR proteins may preferentially traffic 
peroxidised cholesterol in steroidogenic tissues which could result in damage and dysfunction 
selectively targeted to mitochondria (Korytowski et al., 2013; Korytowski et al., 2010). 
Alternatively, it has been suggested that ROS affects the activity of steroidogenic enzymes 
directly.  A study by Chanoine (2001) et al. demonstrated that Se deficient AN4Rppc7 
adrenal cells with minimal GPX1 activity exhibited a marked decrease in corticosterone, 
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aldosterone and progesterone production after cAMP stimulation compared to Se adequate 
cells, and StAR mRNA remained unchanged.  The authors suggest that GPX1 deficiency 
impairs steroidogenesis by a mechanism independent of mitochondrial cholesterol import, 
whereby increased hydrogen peroxide levels affect the activity of one or more CYP enzymes.  
Similarly, Hornsby et al. (1980) showed that cortisol production in bovine adrenocortical 
cells was decreased in culture because CYP11B1 activity was compromised by lipid 
peroxidation.   
 
1.9 Aims 
Given that 40% of FGD cases have unknown aetiology, the overall aim of this research was 
to find candidate genes/proteins that might be novel causes of FGD.   
The project was split into two approaches:  
1) Proteomic arm:  
To search for novel interacting partners of MC2R and MRAP using a tandem affinity 
purification approach, to disclose interacting proteins that, when defective, might 
influence MC2R or MRAP function.  
A better understanding of MC2R function may give further insight into the 
pathogenesis of FGD, and lead to potential candidate genes for FGD. This could 
reveal proteins that are embryonic lethal when defective and would therefore not be 
identified by the genetic approach.  
 
2) Genomic arm: 
To investigate the aetiology of one patient with FGD, with a region of linkage on 
chromosome 3p26-21.   
Candidate genes would be based on previous causes of FGD, for example genes 
involved in GPCR lifecycle, steroidogenesis or oxidative and replicative stress 
pathways.   
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The proband and kindred would be sequenced for mutations in such genes, and 
disease segregation would be checked.  This could reveal genes that are causal for 
FGD but do not interact with MC2R/MRAP.  
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Chapter 2: Materials and Methods 
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2.1  Cell Culture 
2.1.1  Maintenance 
The following cell lines were used for this project: 
H295R: Human Adrenal carcinoma cells 
HEK293T: Human Embryonic Kidney cells 
 
H295R cells were obtained from Ian Mason, University of Edinburgh and HEK293T from the 
European Collection of Cell Cultures (ECACC) at the Health Protection Agency (HPA; 
Salisbury). 
All cell lines were incubated at 37
o
C in a humidifier with 5% carbon dioxide.  Medium was 
changed every 2-3 days, until the cells reached the desired confluency, upon which cells 
would be passaged and seeded into new tissue culture flasks or suitable dishes for 
experiments. 
Cell lines were grown in the media as specified below: 
H295R 
Dulbecco’s Modified Eagles Medium (DMEM) with L-glutamine and Ham’s F-12 medium 
(1:1) (Gibco) 
2.5% NU serum (BD Biosciences) 
Penicillin (0.5u/ml) (Sigma-Aldrich) 
Streptomycin (0.5u/ml) (Sigma-Aldrich) 
1% ITS+ Premix (6.25µg/ml Insulin, 6.25µg/ml Transferrin, and 6.25ng/ml Selenous Acid) 
(BD Biosciences) 
 
HEK293 
DMEM (Sigma-Aldrich) 
10% heat-inactivated Foetal Calf Serum (FCS) (Invitrogen) 
Penicillin (0.5u/ml) (Sigma-Aldrich) 
Streptomycin (0.5u/ml) (Sigma-Aldrich) 
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2.1.2 Passaging of cells 
Materials 
Phosphate Buffered Saline (PBS) (Sigma-Aldrich) 
Trypsin/ Ethylenediaminetetraacetic acid (EDTA) (TE) (Sigma-Aldrich) 
Cell culture media (section 2.1.1.) 
 
Method 
All reagents were warmed to 37°C before use. For a standard T75 flask, culture media was 
removed and cells were washed in 10 ml PBS.  To detach cells from the flask, cells were 
incubated in 3ml TE.  After 2-3 minutes of incubation at 37°C, cells would lift from the 
surface.  7ml fresh media was added to neutralise the trypsin and the suspension was 
centrifuged at 200g for 1 minute to pellet the cells. Cells were resuspended in fresh media 
and plated at the density desired.   
 
2.1.3 Freezing and Storage 
Materials 
Dimethyl Sulfoxide (DMSO) 
Heat-inactivated FCS 
 
Method 
Confluent T75 flasks were trypsinised (as above), transferred to 15ml tubes and centrifuged 
at 200g for 3 minutes to pellet.  Media was removed and the pellet was resuspended in a 
solution of 10% DMSO and 90% FCS. Cell suspensions were transferred to 1ml cryotubes 
and frozen at -80°C overnight. For long term storage, tubes were moved to a liquid nitrogen 
tank. 
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2.1.4 Thawing Cells 
Materials 
PBS (Sigma-Aldrich) 
Cell culture media (section 2.1.1) 
 
Method 
Cryotubes containing frozen cells were incubated in the 37°C incubator until thawed.  
Thawed solutions were centrifuged for 2 minutes at 200g to pellet the cells.  Pellets were 
washed with 10ml PBS and centrifuged for 2 minutes at 200g, then resuspended in 12ml 
fresh media and transferred to new T75 flasks. 
 
 
2.1.5 Cell Counting 
Materials 
Neuberg Haemocytometer 
 
Methods 
Cells were trypsinised according to section 2.1.2 and transferred to a 15ml tube.  50µl of the 
cell suspension was pipetted into a haemocytometer channel (Fig. 2.1). Cells were counted in 
all four red corners of one grid using a Leica DMIL light microscope with 10x objective. If 
the number of cells exceeded 500, the cells were diluted further.  If the number of cells was 
fewer than 200, the four red corners in the second grid were also counted.  The concentration 
of cells and volume of the suspension needed to acquire the desired cell density were 
determined using the following calculations: 
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Number of cells counted/number red corners counted= number of cells/100nl 
Number of cells/100nl x 10
4
 = Number of cells/ml (y) 
Number of cells required/ y = volume (ml) of cell suspension to seed 
 
 
 
Figure 2.  1: Haemocytometer Grid 
The calculated volume of cells was transferred to each well, and media was added to cover 
cells. 
 
2.1.6 Transient Transfections 
For transient transfection of plasmid DNA, lipid based methods were used. Cells were 
transfected at 80-90% confluency and DNA concentration per transfection was kept constant. 
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2.1.6.1 Transient Transfection with Lipofectamine and Plus Reagent 
Materials 
Lipofectamine (Invitrogen) 
Plus Reagent (Invitrogen) 
Opti-MEM (Serum and antibiotic free medium) (Invitrogen) 
2x Cell culture media (section 2.1.1.) 
 
Method 
For a standard 6-well plate, 1µg plasmid DNA was diluted in 100µl Opti-MEM with 8µl Plus 
reagent, mixed gently by pipetting and incubated at room temperature for 20 minutes. 
Meanwhile, a master mix of Opti-MEM (100µl/well) and Lipofectamine (4µl/well) was 
prepared.  After incubation, the lipofectamine/Opti-MEM solution was mixed slowly with the 
DNA/Plus reagent solution, and incubated for a further 20 minutes at room temperature.  
Media was removed from wells and replaced with 800µl serum-free Opti-MEM.  The 212µl 
DNA/Plus/Lipofectamine solutions were added to wells, and cells were incubated for 3 hours 
at 37°C with 5% CO2. After 3 hours, 1ml 2x media was added to each well to given a final 
concentration of 1x. 
Transfections were scaled up and down as follows: 
 
Culture 
Vessel 
Opti-MEM 
(µl) 
DNA Plus reagent 
(µl) 
Lipofectamine 
(µl) 
Opti-
MEM(µl) 
12 well plate 
+ cover slips 
50 200ng 4 2 50 
6 well plate 100 1µg 8 4 100 
10cm
2
 dish 250 8µg 20 10 250 
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2.1.6.2. Transient Transfection with Lipofectamine-2000 
Materials 
Lipofectamine-2000 (Invitrogen) 
Opti-MEM (Invitrogen) 
1x Cell culture media (section 2.1.1.) 
 
Method 
For a standard 6-well plate, 2µg plasmid DNA was diluted in 100µl Opti-MEM, mixed gently 
by pipetting and incubated at room temperature for 10 minutes. During incubation, a master 
mix of Opti-MEM (100µl/well) and Lipofectamine-2000 (10µl/well) was prepared.  The 
lipofectamine 2000/Opti-MEM solution was mixed slowly with the DNA/Opti-MEM 
solution, and incubated a further 20 minutes at room temperature.  
Media was removed from wells and replaced with 800µl fresh cell culture media.  The 
solutions of DNA/Lipofectamine 2000 were added to wells, and cells were incubated 
overnight at 37°C with 5% CO2. Media was replaced the following morning. For 
transfections of GPX1 HEK293 cell culture media was supplemented with 1% ITS+ premix 
containing selenous acid to ensure selenocysteine incorporation. 
Transfection reagents were scaled up or down, depending upon the culture vessel, as follows: 
Culture 
Vessel 
Opti-MEM 
(µl) 
DNA (µg) Lipofectamine 
2000 (µl) 
Opti-MEM 
(µl) 
6 well plate 100 2 10 100 
T25 flask 250 8 15 250 
T75 flask 1500 24 40 1500 
 
 
 
85 
 
2.1.7 Lentiviral transduction 
2.1.7.1 Generating stable cell lines 
Materials 
pGIPZ lentiviral vector 
Packaging vectors p8.74 (Gag/Po1) and pMDG (VSV-4) 
Transfection reagents 
Cell culture media 
 
Method 
Stable knockdown cell lines were generated using lentiviral transduction. HEK293 cells were 
used as a packaging cell line in which shRNA plasmids targeting GPX1 and/or PRDX3 (Open 
Biosystems RHS4531-NM_000581 and RHS 54531-EG10935) with an additional GFP tag 
were transiently transfected.  On day 0, HEK293 cells were plated at a density of 7 x 10
5
 per 
well and were transfected 6 hours later with pGIPZshRNA-GFP vectors, packaging vectors 
p8.74 (Gag/Po1) and pMDG (VSV-4) in a 5:4:3 ratio respectively, according to the 
transfection protocol in section 2.1.6.  On day 1, media was changed to that of the target cell 
line H295R.  On Day 2, 48hrs post transfection, media containing viral particles was 
collected and concentrated 2x by centrifugation overnight at 5000g and 4°C.  On day 3, 
media containing viral particles was transferred to target H295R cells.  HEK293 cells were 
allowed to grow further and additional viral media was collected and transferred on day 4 to 
double dose target cells.  H295R cells were grown for 4 days before GFP-positive cells were 
visualised on a fluorescent microscope.  Selective pressure (puromycin 4µg/ml) was applied 
7 days post transduction. 
 
2.1.7.2 shRNA sequences 
Small hairpin shRNA constructs were purchased from Open Biosystems.  The pGIPZ 
lentiviral vector contains a microRNA-adapted shRNA expressed as human microRNA-30 
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primary transcript (miR-30). The hairpin has a 22 nucleotide dsRNA stem and a 19 
nucleotide miR-30 loop, which greatly increases Drosha and Dicer processing compared to 
previous shRNA designs, leading to increased shRNA production and greater knockdown of 
target genes (Silva et al., 2005). 
Multiple shRNA sequences were available targetting different regions of the genes.  The 
sequences of shRNA are details below: 
Gene ID Targetted exon Antisense sequence Catalogue 
number 
GPX1 07 2 ACATCGTTGCGACACACCG V3LHS_394707 
09 2 TTCTCGATAAGTAGTACCT V3LHS_394709 
10 2 TCCAGGCAACATCGTTGCG V3LHS_394710 
PRDX3 1 5 AGTCTGACAAGAGTGCGAT V2LHS_84099 
2 4 TTCTGTAGGACACACAAAG V2LHS_84094 
3 4 AGCTTTGTCACTAAAAGCA V3LHS_384405 
4 3’UTR TGCCTTCTACAAATAACCA V3LHS_412107 
5 6 TGATCGTAGGAGAATCCGG V3LHS_384402 
6 4 TCTGTAGGACACACAAAGG V3LHS_384404 
Table 2.  1: shRNA sequences 
 
2.1.8 Puromycin Kill Curve 
Materials 
Cell culture media 
Puromycin (1mg/ml) (Sigma-Aldrich) 
 
Method 
Lentiviral pGIPZ vectors contain resistance genes to puromycin, allowing for selection of 
cells expressing shRNA.  A series of doses were tested ranging from 0 to 10µg/ml, which 
was diluted in cell culture media.  H295R cells were seeded in triplicate at a density of 
20,000 per well in a 24 well plate, and left to adhere overnight, and were 10% confluent on 
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day 1.  Media was removed from cells and replaced with puromycin containing media, with 
doses applied, and replenished every 2 days.  The minimum concentration of puromycin to 
cause massive cell death in 3-4 days and to have killed all cells by 7 days was chosen for 
future selection.  
 
2.2 cDNA synthesis  
2.2.1 RNA extraction from cells 
Materials 
RNeasy mini kit (QIAGEN) 
β-Mercaptoethanol (β-ME) (Sigma-Aldrich) 
Ethanol (70%) (Fisher-scientific, UK) 
 
Method 
For RNA extraction, cells were washed with cold PBS and lysed directly from plates using 
350µl buffer RLT (lysis buffer) with β-ME, a reducing agent. Cells were homogenised by 
passing lysate at least 5 times through a blunt 20-gauge needle fitted to an RNase-free 
syringe.  RNA was purified according to the QIAGEN RNeasy mini kit protocol. Briefly, to 
each 350µl lysate, one volume of 70% Ethanol was mixed in by pipetting, and the solution 
was transferred to an RNeasy spin column over a 2 ml collection tube. Lysates were 
centrifuged at 9000g for 15 seconds through the column. Then, with the through-flow 
discarded, the column was washed with 700µl buffer RW1. Through flow was again 
discarded, and the column was washed with 500µl buffer RPE, centrifuged at 9000g for 15 
seconds. This step was repeated with a centrifugation time of 2 minutes. The column was 
then transferred to a clean collection tube, and RNA was eluted with 30µl RNase-free water 
by centrifugation at 9000g for 1 minute. The RNA yield was quantified using the Nanodrop 
ND-1000 spectrophotometer measuring absorbance at 260nm. Purity of DNA was 
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determined by the OD260/OD280 ratio, which should be approximately 1.8 for DNA and 2.0 
for RNA. A lower ratio can signify protein or phenol contamination. 
 
2.2.2 DNase Treatment 
Materials 
Deoxyribonuclease 1 (DNase1) 10,000u/ml (Sigma-Aldrich)  
DNase Turbo buffer (Ambion) 
RNase inhibitor (40u/µl) (Rnasin, Promega) 
RNase free water (Sigma-Aldrich) 
 
Method 
RNA from either cell lysates or the human RNA tissue panel was subjected to DNase 
treatment to cleave and remove genomic DNA.  Each reaction mixture contained 1µg RNA, 
5µl DNase Turbo buffer, 0.5µl RNase inhibitor (preventing RNA degradation) and 1µl 
DNase, made up to a volume of 50 µl with RNase free water. Reactions were incubated at 
37
o
C for 15 minutes and then transferred to ice.  RNA was purified and precipitated as 
detailed below. 
 
2.2.3 Phenol extraction and RNA Precipitation 
Materials 
Phenol pH 7.8 (Sigma-Aldrich) 
100% Ethanol (Fisher-scientific, UK) 
pH5.3 3M sodium acetate (BDH Chemicals) 
5mg/ml glycogen (Ambion) 
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Method 
Phenol is an organic solvent which can be used to remove protein contaminants from nucleic 
acids.  Samples were vortexed with an equal volume of pH 7.8 phenol (under a hood), then 
spun at 14,000rpm for 1.5 minutes to separate the layers.  The top aqueous layer containing 
purified RNA was transferred to a new tube and precipitated by ethanol precipitation.  To 
each RNA sample, a mixture of 5µl 3M sodium acetate pH5.3 (0.1x volume of RNA), 4µl 
5mg/ml glycogen and 125 µl absolute ethanol (2.5x volume of RNA) was added and the 
samples were incubated at -80
o
C overnight. 
Precipitated RNA was collected by centrifugation at 14,000rpm at 4
o
C for 10 minutes and the 
supernatant removed. The pellet was washed with 70% ethanol for a further 5 minutes at 
14,000rpm and the supernatant was removed. 
The RNA pellet was resuspended in 12.5µl RNase free water. If the sample was not used 
immediately, it was stored at -80°C. 
 
2.2.4 Reverse Transcription 
Materials 
5x MMLV RT-buffer (Promega) 
DTT 0.1M (Sigma-Aldrich) 
dATP, dTTP, dCTP, dGTP (dNTPs) (10mM) (Promega) 
RNase inhibitor (40u/µl) (Promega) 
MMLV RT-enzyme (200u/µl) (Promega) 
Random primers (hexadeoxynucleotides) (500µg/ml) (Promega) 
 
Method 
To each 12.5µl RNA sample, 0.25µl random primers were added. The mixture was heated for 
10 minutes at 80
O
C, and then returned to ice.  A 1µl aliquot was taken as a pre-reverse 
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transcription negative control which should not contain cDNA or genomic DNA if DNase 
treatment was successful. 
For reverse transcription, 4µl 5x MMLV RT-buffer, 2µl DTT 0.1M, 1µl dNTPs, 0.5 µl 
RNase inhibitor, and 1µl MMLV RT-enzyme were added to each RNA/primer mix and 
incubated for 2 hour at 37
O
C. Following reverse transcription, cDNA samples were diluted 
2x and stored at -20
o
C. 
cDNA samples and pre-RT negative controls were amplified by PCR (section 2.2.4) with 
GAPDH primers (section 2.7.3.) to confirm successful reverse transcription. The PCR 
product amplified from cDNA should be approximately 200 base pairs. Presence of a higher 
molecular weight band would suggest genomic DNA contamination. 
 
2.3  Polymerase Chain Reaction (PCR) and DNA sequencing 
2.3.1 Standard PCR 
Materials 
10 x Standard Taq polymerase Buffer (10 mM Tris-HCl, 50 mM KCl, 1.5 mM MgCl2, pH8.3)  
dATP, dTTP, dCTP, dGTP (dNTPs) (10mM) (Promega) 
Forward and Reverse Primers (10mM) (see section 2.7.3 for specific primers used in 
amplifications) 
Taq  polymerase (5000u/ml) (NEB) 
Template DNA (100ng) 
Nuclease-free H2O (Sigma-Aldrich) 
 
Method 
PCR thermal cycling can amplify specific regions of genes of interest. The technique 
involves a series of temperature steps that are repeated: Denaturation of DNA at 95⁰C to 
separate the double helix, annealing at 50-60
o
C to bind sequence specific primers to the 
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template strand, and elongation of complementary strands by DNA polymerase in a 5’ to 3’ 
direction at 72
o
C. The newly synthesised DNA is used as a template in a subsequent cycle, 
leading to exponential amplification following repeated cycles. The annealing temperature 
employed is dependent on the melting temperature of the specific primers. 
Unless specified, PCR reactions were set up to a volume of 25µl as follows: 
 25 µl reaction: 50 µl reaction: 
10 x Standard PCR Buffer 2.5 µl 5 µl 
dNTPs (10mM) 0.5 µl 1 µl 
TAQ Polymerase 5000u/ml 0.125 µl 0.25 µl 
Forward Primer (10mM) 0.5 µl 1 µl 
Reverse Primer (10mM) 0.5 µl 1 µl 
DNA (100ng) 200ng 
Nuclease free H2O To 25 µl To 50 µl 
 
Typically, samples underwent PCR cycling in a touchdown program, detailed below: 
Touchdown PCR Cycles: 
Step Temperature 
(
O
C) 
Time (Minutes)  
Denaturation 95 5 1 cycle 
Denaturation 95 0.5  
10 cycles Annealing * 0.5 
Extension 72 1/kb 
Denaturation 95 0.5  
20 cycles Annealing ** 0.5 
Extension 72 1/kb 
Extension 72 5  1 cycle 
Dependent on the melting temperature of the primers. * 65 to 55°C (‘Touch55’) or 60 to 
50°C (‘Touch50’); **55°C (‘Touch55’) or 50°C (‘Touch50’) 
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2.3.2 Gel Electrophoresis 
Materials 
Agarose (electrophoresis grade) (Sigma-Aldrich) 
10,000x Gel Red (Biotium) 
6x Loading Dye (MBI Fermentas) 
DNA Ladder (Generuler DNA ladder mix (100-10,000bp 0.5 mg DNA/ml) (MBI Fermentas) 
1x TAE Buffer (40mM Tris-acetate, 2mM disodium ethylenediaminetetraacetate 
(Na2EDTA), 
pH 8.3) (National Diagnostics) 
 
Method 
Successful PCR amplification was assessed by agarose gel electrophoresis.  DNA samples 
were loaded into the wells of an agarose gel and an electrical current was applied. Negatively 
charged DNA molecules migrate through the gel to the anode. The speed of migration 
depends on size, as larger molecules incur more resistance passing through the porous 
agarose and migrate more slowly. The size of a PCR product can be estimated by comparison 
with a DNA ladder containing fragments of known size, run in an adjacent lane. 
For a 1% agarose gel, 1g of agarose was mixed with 100ml 1x TAE buffer in a conical flask 
or bottle. Agarose was dissolved by heating the mixture in a microwave for a few minutes.  
The solution was cooled until there was no visible steam and 10 µl Gel red was added 
(10,000x). The mixture was poured into a plastic cast with combs inserted to produce the 
wells.  When the gel had set, the combs were removed and it was transferred to a tank. TAE 
was poured into the tank to cover the gel. 
Blue loading dye was added to each PCR sample in a 1:5 ratio. 7µl DNA ladder was loaded 
into the first well of each row as a size standard for the other wells.  PCR samples were 
loaded into adjacent wells. 
The gel was subjected to a directional electric field with a voltage of 100V for 40 minutes 
until the blue loading dye had reached 1cm from the end of the gel.  Samples were visualised 
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by UV detection using a Kodak Electrophoresis and Documentation analysis system UV 
transilluminator (Uvitec) 
 
2.3.3 Gel Extraction 
Materials 
QIAquick Gel extraction Kit, (QIAGEN) 
Isopropanol (100%) (Fisher-scientific, UK) 
Nuclease-free water (Sigma-Aldrich) 
 
Methods 
To purify DNA from an agarose gel, the bands were visualised under UV light, cut out with a 
clean blade and transferred to a 1.5ml tube.  The weight of the gel slice was determined, and 
3 volumes of Buffer QG were added to 1 volume of the gel.  The mixture was incubated at 
50°C for 10 minutes to dissolve the gel, vortexing intermittently. One gel volume of 100% 
isopropanol was added and mixed to precipitate the DNA. The sample was then transferred to 
the QIAquick column and centrifuged for 1 minute at top speed to bind the DNA to the silica 
membrane. Through-flow was discarded and the column was washed with 500µl Buffer QG 
and centrifuged for 1 minute to remove further agarose. Through-flow was removed and 
another wash step followed. 750 µl Buffer PE was applied to the column and centrifuged for 
1 minute to remove salt. Through-flow was discarded and the column was centrifuged for an 
additional minute to remove traces of Buffer PE.  The column was placed in a clean 
collection tube, and DNA was eluted with 25µl nuclease free water, centrifuging for 1 minute 
at top speed. DNA concentration in ng/ml was determined using a Nanodrop ND-1000, 
measuring absorbance at 260nm (using Beer’s Law). The purity of the DNA was determined 
by calculating the ratio of absorbance at 260nm and A280nm.  A ratio of ~1.8 was considered 
to be pure DNA.  Samples were stored at -20°C. 
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2.3.4 Real time quantitative PCR 
Materials 
2x SYBR green master mix (KAPA) (SYBR® Green I Dye, AmpliTaq Gold® DNA 
Polymerase, 
dNTPs with dUTP, and optimized buffer components) 
R-ox dye (Passive Reference) 
Nuclease-free water 
 
Methods 
mRNA expression levels were quantified by real time PCR (qRT) using SYBR green 1 
fluorescent dye and the Promega MX4000 thermal cycler.  Sybr green 1 dye increases its 
fluorescence when bound to double stranded DNA.  The amount of fluorescence is therefore 
directly proportional to the concentration of amplified template.   
 
Figure 2.  2: Amplification plot 
(Applied Biosystems technical manual 4309155) 
The emission intensity of fluorescence during the PCR reaction is plotted against cycle 
number to produce a sigmoidal amplification plot.  It is the density at the threshold cycle 
(CT), which is used to calculate the starting concentration of template. This is defined as the 
cycle at which there is the first significant increase in fluorescence over that of baseline, and 
is at the start of the exponential phase of the reaction.  
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The data can be analysed in two ways: either by absolute quantification or relative 
quantification.  Absolute quantification quantifies unknowns by extrapolating from a standard 
curve of known quantities.  Relative quantification quantifies changes in expression in a 
given sample compared to a reference sample for example an untreated control. 
Sybr green fluorescence is normalised to that of a passive reference dye, ‘ROXlow’, which 
does not intercalate with DNA and increase its fluorescence during the PCR reaction. This is 
used as an internal reference and to correct for inter-well fluorescent fluctuations. 
Each reaction contained the following reagents: 
Component Volume (µl) 
KAPA SYBR® FAST qPCR Master Mix 
(2X) Universal 
5 
Forward Primer (10 µM)  0.1 
Reverse Primer (10 µM)  0.1 
Template DNA (variable concentration) 2 
ROXLow 0.2 
H2O 2.6 
 
Reactions were run in duplicate in a 96-well plate, including a non-template control to check 
for contamination. Plates were centrifuged at 1500g to remove bubbles and ensure the 
reaction mixture was at the bottom of the wells.   
Data was analysed using the absolute quantification method.  The Ct value of the unknown 
was quantified absolutely by interpolating the quantity from a standard curve, whose 
quantities were pre-determined spectrophotometrically.  
Standard curves were created using serial dilutions of a known concentration of DNA for the 
gene of interest, and for GAPDH, a house keeping gene. Standard curves with a gradient of -
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3.3±0.3 were considered acceptable, which is the number of cycles expected between each 
standard with a serial dilution of 1 in 10.  The r
2
 value of the curve was required to be >0.97, 
which indicates the relationship between the Ct and the concentration of DNA, and should be 
linear (1).  The concentration of the gene of interest was normalised to GAPDH concentration 
for each sample.   
The dissociation curve, which shows the melting temperature (Tm) of PCR products, was 
used to check nonspecific amplification or contamination.  Amplification of specific PCR 
products should show a single peak at a temperature corresponding to the amplification 
product’s Tm.  The non-template control should only show a peak at a temperature 
corresponding to the Tm of primer dimers, typically much lower than a specific amplification 
product. 
The following cycles were used for all reactions: 
Temperature 
(
O
C) 
Time (Minutes: seconds) Cycles 
95 3:00 1 
95 00:03  
40 60 00:20 
68 00:01 
95 1:00  
1 60 00:30 
68 00:30 
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2.3.5 DNA sequencing 
Materials 
Big Dye 3.1 cycle sequencing kit (Applied Biosystems, UK) 
 
Method 
Sequencing of PCR products or cloned constructs was performed by the Genome centre 
(Barts and the London, Queen Mary, University of London).  The centre used BigDye 3.1 
chemistry to sequence samples, which is a form of Sanger sequencing based on the dideoxy-
mediated chain termination method (Sanger et al., 1977). The sequencing results were 
analysed on BioEdit software (Hall, 1999). 
 
2.3.6 Whole exome sequencing 
Materials 
Agilent V4 (51mbp) exome enrichment kit 
Illumina HiSeq2000 
 
Methods 
5µg of high quality genomic DNA with an OD260/OD280 of >1.8 was required for enrichment 
using the Agilent V4 (51Mbp) exome enrichment microarray.  The enrichment and exome 
sequencing was performed by Otogenetics. Briefly, DNA was fragmented and a library was 
created using standard techniques including end repair, A-tailing and paired adaptor ligation. 
DNA was hybridised to the array, washed to remove un-tethered strands, and then enriched, 
eluted and amplified.  The enriched DNA was subjected to massively parallel sequencing on 
the Illumina HiSeq 2000. 
Nucleotide level variation was analysed using DNAnexus online software 
(https://www.dnanexus.com/).  A filtration strategy was employed to minimise the number of 
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variants for analysis (Fig. 2.3), removing variants that were heterozygous and known SNPs, 
selecting variants that were non-synonymous coding, splice site mutations, insertions or 
deletions (indels) with a coverage of >20.  Variants were checked against the Ensembl SNP 
database, release 54.  The remaining variants were assessed for FGD candidate genes 
prioritising those that would have a role in oxidative stress. 
 
 
Figure 2.  3: Whole exome sequencing filtration strategy 
Variants were filtered to remove heterozygous variants, known documented SNPs, 
variants with  coverage less than 20 and synonymous variants.  Non-synonymous coding 
region, splice site and indel variants were selected for analysis.  It was hypothesised that 
candidate genes would have a role in oxidative stress. 
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2.3.7 Primer sequences for cloning, PCR, RT-PCR and sequencing 
 
Description FP(a) RP(b)  
Incorporate BamH1 and 
EcoR1 sites to MC2R for 
CTAP vector 
CTAGTGGGCGGATC
CATGAAGCACATTA
TCAACTCGTAT 
CTAGTGGAATTCCC
AGTACCTGCTGCAG
AAG 
Cloning 
TAP-tag 
vectors  
Incorporate BamH1 and 
EcoR1 sites to MC2R for 
NTAP vector 
CTAGTGGGATCCCA
TGAAGCACATTATC
AACTCGTATG 
CTAGTGGAATTCCT
ACCAGTACCTGCTG
CAGAAG 
Incorporate BamH1 and 
EcoR1 sites to MRAP for 
CTAP vector 
CTAGTGGGCGGATC
CATGGCCAACGGG
ACCAAC 
CTAGTGGAATTCGC
TCTGCAATTGAGAG
GTC 
Incorporate BamH1 and 
EcoR1 sites to MRAP for 
NTAP vector 
CTAGTGGGATCCCA
TGGCCAACGGGACC
AACGC 
CTAGTGGAATTCTC
AGCTCTGCAATTGA
GAGGTC 
GPX1 from initial 
methionine to exon 1 and 2 
junction 
ATGTGTGCTGCTCS
GCYAGCG 
CTTGGCGTTCTCCT
GATGCCCAAA 
Fusion PCR 
GPX1 from exon 1 and 2 
junction to end of 3’UTR 
TTTGGGCATCAGGA
GAACGCCAA 
TTCTGCTGACACCC
GGCACTT 
GPX1 from initial 
methionine to p.129 (start of 
R130-L133del) 
ATGTGTGCTGCTCS
GCYAGCG 
CTGGGAGCTGGCAG
GAAGGCGAA 
GPX1 from p.134 (end of 
R130-L133del) to end of 
3'UTR 
TTTGGGCATCAGGA
GAACGCCAAG 
TTCTGCTGACACCC
GGCACTT 
GPX1  incorporation of 
BamH1 at 5' and HindIII at 
3' 
CGGATCCATGTGTG
CTGCTCGGCCAGCG 
GATAAGCTTTTCTG
CTGACACCCGGCAC
TTTAT 
Cloning 
GPX1 for 
pCMV-
tag3B 
vector 
Correct unknown SNP at 
position 110 (p.Gly110Cys) 
in GPX1-pGEM-Te vector 
to wild type sequence  
GCTCCCTGCGGGGC
AAGGTACTACT 
AGTAGTACCTTGCC
CCGCAGGGAGC Site 
directed 
mutagenesis 
GPX1 correcting frameshift 
in GPX1-FLAG vector 
TTGCGGCCGCGGTG
AATTCGATTAT 
ATAATCGAATTCAC
CGCGGCCGCAA 
Real time PCR primers for 
GPX1 
TGCGGGGCAAGGT
ACTACTT 
ATGAGCTTGGGGTC
GGTCAT Real time 
PCR Real time PCR primers for 
GAPDH 
TGCACCACCAACTG
CTTAG 
GAACATCATCCCTG
CATCC 
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Real time PCR primers for 
PRDX3 
CGAGACTACGGTGT
GCTGTT 
AGAATCCGGTGTCC
AGTTCG 
Real time PCR primers for 
STAR 
GACATTCAAGCTGT
GCGCTG 
TGTAGAGAGTCTCT
TCTAGCCGAG 
Real time PCR primers for 
GPX2 
TGAGGCACAACCAC
CCGGGA 
TCCACCCCCAGGAC
GGACAT 
Real time PCR primers for 
GPX3 
ACGAGTACGGAGC
CCTCACCA 
TGGTTGCAGGGAAA
GCCCAGA 
Real time PCR primers for 
GPX4 
TCCGCCAAGGACAT
CGACGG 
GGGAAGGCCAGGA
TCCGCAA  
Real time PCR primers for 
NNT 
 GGGTCATGTCATTA
GAGG 
CAGTATCCCTGTGA
GACC 
T3 
GCAATTAACCCTCA
CTAAAGG 
CCTTTAGTGAGGGT
TAATTGC 
Sequencing 
primers 
T7 
TAATACGACTCACT
ATAGGG 
CCCTATAGTGAGTC
GTATTA 
SP6 
ATTTAGGTGACACT
ATAG 
CTATAGTGTCACCT
AAAT 
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2.4 Cloning 
2.4.1 Cloning TAP-tag vectors 
Materials 
pcDNA3.1+MC2R (cDNA.org) 
p3xFLAG-CMV14-MRAP (backbone Sigma-Aldrich) 
InterPlay mammalian TAP vectors pCTAP and pNTAP 
 
Method 
MC2R and MRAP inserts were amplified by PCR from pcDNA3.1+MC2R and p3xFLAG-
CMV-14-MRAP (MRAP-FLAG) (appendix 7.1), using the standard reaction mix (section 
2.3.1) and the following cycles:  
Step Temperature (
O
C) Time (Minutes) Cycles 
Denaturation 94 5 1  
Denaturation 94 0.5  
30  Annealing 64 0.5 
Extension 72 1 
Extension 72 5  1  
 
Primers incorporating BamH1 and EcoR1 sites were used to amplify genes for subsequent 
cloning into pCTAP and pNTAP (pTAP) vectors (section 2.3.7).  Amplified fragments and 
the pTAP vectors were digested using BamH1 and EcoR1 for 2 hours in a 40 µl reaction 
mixture, and treated with Antarctic phosphatase to prevent religation (section 2.4.7).  
Digested products were visualised by gel electrophoresis, gel extracted and purified using the 
QIAGEN gel extraction kit (sections 2.3.2. and 2.3.3). Inserts were ligated into the pTAP 
vectors at BamH1 and EcoR1 sites using T4 ligase (Promega) at 4
 O
C (section 2.4.4). 
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After which, ligation reactions were transformed into JM109 competent cells and grown on 
LB agar plates with 50µg/ml kanamycin (section 2.4.6).  Plasmid DNA was purified from 
transformation clones and screened for inclusion of the insert by digesting with BamH1 and 
EcoR1 (section 2.4.3). 
 
2.4.2 Cloning GPX1 vectors 
Materials 
pGEM-T easy (pGEM-Te) (Promega)  
p3xFLAG-CMV10 (Sigma-Aldrich) 
pCMV-tag3B (Agilent) 
 
Method 
Wild type and R130-L133del GPX1 were cloned into p3xFLAG-CMV10 and pCMV-tag3B 
mammalian expression vectors (appendix 7.1).  GPX1 was amplified from HEK293 cDNA 
using a two-step fusion PCR method, due to difficulties in amplifying the full transcript.  The 
fused fragments were ligated into pGEM-Te using conventional a/t cloning, before transfer to 
p3xFLAG-CMV and pCMV-tag3B.  Cloning was confirmed by DNA sequencing using 
sequencing primers details in section 2.3.7. 
 
2.4.2.1 Sub-cloning into pGEM-Te vector 
Materials 
5x OneTaq GC reaction buffer (NEB) 
dNTPs (10mM) (Promega) 
Forward and Reverse Primers (10mM) 
OneTaq polymerase (5000u/ml) (NEB) 
Nuclease free water (Sigma-Aldrich) 
pGEM-Te vector (Promega) 
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Method 
Wild-type and R130-L133del GPX1 were amplified from HEK293 cDNA in a two-step 
overlap PCR method in which two fragments were amplified separately in an initial PCR, 
then fused in a subsequent PCR reaction.  For both wild-type and R130-L133del GPX1, 
cDNA was amplified from the first initiating methionine to the end of the 3’ untranslated 
region (3’UTR), in order to include the SECIS element required for translation of 
selenoproteins.  
Primers were designed to amplify exon 1 and 2 of GPX1 separately using exon junction 
spanning primers (Fig. 2.4.) (section 2.3.7) in a 50µl PCR reaction mix described below and 
the touch 55 program described in section 2.3.1. The exon 1 fragment was 69% GC-rich, 
hence a commercially optimised PCR reaction buffer was used for initial amplification of the 
two fragments. 
 
Figure 2.  4: Fusion PCR 
Illustration showing primer pairs used to amplify wild-type and R130-L133del GPX1 
using two-step fusion PCR method.  In the first step, exon 1 and 2 of wild-type GPX1 
were amplified separately using primers pairs 1 and 2. R130-L133del GPX1 was 
amplified in two segments before and after the deletion, using primer pairs 3 and 4.  In 
the second step fragments were fused using primer pair 5. 
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Reaction: 
 
 
5x OneTaq GC reaction buffer 10µl 
10mM dNTP 1µl 
10µm FP 1µl 
10µm RP 1µl 
OneTaq polymerase 0.25µl 
Template DNA 200ng 
Nuclease-free water To 50µl 
 
The amplified products were analysed by gel electrophoresis (section 2.3.2) and bands were 
gel extracted (section 2.3.3), then mixed in equal concentration by vortexing in nuclease free 
water.  The cDNA mix was amplified using the standard touch 55 program and a 50µl 
reaction mix with standard Taq polymerase (section 2.3.1). The standard Taq polymerase 
amplifies DNA to include dA overhangs which is a requirement for subcloning into the 
pGEM-Te vector. Amplification fused the two fragments into one 824bp product, which was 
confirmed by gel electrophoresis (section 2.3.2).  
The 824bp fragment was gel extracted and subsequently subcloned into the pGEM-Te vector 
which is initially a linear vector with T-overhangs (appendix 7.1).  Sequencing revealed an 
unknown SNP at position 110 (p.Gly110Cys) which was rectified by site directed 
mutagenesis (section 2.4.9) in order to establish a wild-type construct. 
The mutant R130-L133del GPX1 transcript was amplified from the wild-type pGEM-Te-
GPX1 construct through similar methodology.  Two fragments were amplified using primers 
spanning either side of the 12 base pair deletion (Fig. 2.4.2.1) (section 2.3.7) using a touch 55 
program and standard Taq 50µl reaction mix (section 2.3.1).  The PCR products were 
analysed by gel electrophoresis and gel extracted, then fused in a second PCR reaction with 
the same reaction conditions (Fig. 2.4.2.1).   
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Full length fragments were ligated into the pGEM-Te vector using 2x rapid lipase buffer 
(section 2.4.4), transformed into JM109 E.coli competent cells and colonies were screened 
for presence of the insert by digesting with Not1 (section 2.4.3) 
 
2.4.2.2  Cloning into pCMV-FLAG GPX1 
To generate FLAG-tagged GPX1, pGEM-Te vectors containing wild-type and R130-L133del 
GPX1 and p3xFLAG-CMV10 were digested with Not1 for 2hr at 37°C (section 2.4.3) and the 
linearised p3xFLAG-CMV10 vector was treated with Antarctic phosphatase.  Digested 
products were subjected to gel electrophoresis, purification, ligation and transformation as 
above.  Sequencing the construct revealed a frameshift which was corrected by site directed 
mutagenesis according to section 2.4.9 using primers detailed in section 2.3.7. 
 
2.4.2.3 Cloning pCMV-tag3B GPX1 
To generate myc-tagged wild type and R130-L133del GPX1, primers were designed to 
introduce BamH1 and HindIII restriction sites 5’ and 3’ to GPX1, to enable direct cloning 
into pCMV-tag3B (primers detailed in section 2.3.7).  PCR was used to amplify fragments 
from wild type and R130-L133del pGEM-Te-GPX1 vectors using a touch 55 program and 
the following reaction mixture: 
Component  
5x Q5 reaction buffer  10µl 
10mM dNTP  1µl 
10µM FP 2.5ng 
10µM RP 2.5ng 
Q5 HF Hot start polymerase (2000U/ml) 0.5 
Template DNA 200ng 
Nuclease-free water To 50µl 
 
106 
 
PCR products were visualised by gel electrophoresis and gel extracted for purification.  The 
purified products were digested with BamH1 and HindIII for 1 hr at 37°C (section 2.4.3), in 
addition to the pCMV-tag3b vector. The linearised vector was treated with Antarctic 
phosphatase (section 2.4.3). 
As above, digested products were checked by gel electrophoresis and purified.  The purified 
products were ligated as described in section 2.4.4 with 2x Quick buffer and Quick ligase 
(NEB).  Ligations were transformed into JM109 competent cells, grown overnight and 
plasmid DNA was purified.  Plasmid DNA was digested with BamH1 and HindIII to check 
for insert release. 
 
2.4.3 Restriction Digest 
Materials 
Restriction endonucleases (Promega) 
100x Bovine Serum Albumin (BSA) (Promega) 
10x Buffer (dependent on the optimal buffer for each enzyme/enzyme combination) (NEB) 
Antarctic Phosphatase (5000u/ml) (NEB) 
1x Antarctic Phosphatase buffer (NEB) 
 
Methods 
Restriction endonucleases were used to digest inserts and vectors in order to prepare insert 
sticky ends and linearise vectors before ligation.  Restriction digests were also used at the end 
of the cloning process to screen transformed colonies for release of an insert.  Colonies 
displaying drop out of the correct size fragment on digestion were sent for Sanger sequencing 
to confirm the insert was in frame with the correct orientation.   
DNA was digested using appropriate restriction enzymes for 2 hours unless otherwise stated, 
in a 10µl reaction mixture for checking insert release, and 40 µl reaction mixture for 
digesting inserts and vectors before ligation as indicated below:   
107 
 
 Screening colonies for insert Preparing insert and vector 
for ligation 
DNA Template 100ng 1 µg 
100x BSA 0.1 µl 0.4 µl 
10x Buffer 1-4 (NEB Biolabs) 1 µl 4 µl 
Enzyme 1 (NEB Biolabs) 1 µl 1 µl 
Enzyme 2 (NEB Biolabs) 1 µl 1 µl 
ddH2O to a total volume of To 10 µl To 40µl 
 
Digested products were analysed by gel electrophoresis.  If preparing DNA for ligation, an 
additional step was required before gel electrophoresis. Reaction mixtures containing 
linearised vectors were treated with Antarctic phosphatase to dephosphorylate the 5’ end 
preventing religation of the empty vector. 1µl Antarctic phosphatase and 10x Antarctic 
phosphatase buffer were added to these reaction mixtures by pipetting, and samples were 
incubated for a further 30 min at 37°C, then heated to 65°C to deactivate the enzyme.  After 
gel electrophoresis digested inserts and vectors were gel extracted and purified (sections 2.2.6 
and 2.2.7) for ligation.  
 
2.4.4 Ligation 
Materials 
Vectors 
Control insert DNA (4ng/µl) (Promega) 
T4 DNA ligase 100u (Weiss units) (Promega) 
Either T4 DNA 10x DNA ligase buffer  (Promega), 2x rapid ligase buffer (Promega) or 2x 
Quick ligase buffer (NEB) 
Nuclease free water (Sigma-Aldrich) 
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Method 
The concentration of insert required for ligation was calculated using the following equation: 
 ng vector x kb insert)/kb vector x insert: vector ratio = ng insert 
Various insert to vector ratios were used to increase the likelihood of successful ligation. 
Ligation reaction mixes were prepared as follows: 
 Sample 
reaction 
Positive control No insert 
control 
No ligase 
control 
2X Rapid Ligation 
Buffer,2 x Quick buffer 
or 10x ligation buffer  
5µl/5µl/1µl 5µl/5µl/1µl 5µl/5µl/1µl 5µl/5µl/1µl 
 Vector 1µl 1µl 1µl 1µl 
PCR product Xµl - - - 
Control Insert DNA - 2 µl - - 
T4 DNA Ligase 
(400,000u/ml) or Q5 
ligase 
 
1µl 1µl 1µl - 
Deionised water to a 
final volume of 
10µl 10µl 10µl 10µl 
 
A Promega control insert DNA was used as a positive control to give an indication of the 
number of colonies expected after transformation for a successful ligation, and a no insert, 
negative control was used as a background check to assess background due to religation of 
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linear vectors, which should produce few colonies after transformation.  The no ligase control 
gives an indication of the number of background colonies due to uncut vector and should also 
produce few colonies  
Tubes were briefly centrifuged, and reactions were incubated overnight at 4
o
C when utilising 
10x ligation buffer, for three hours at room temperature when using 2x rapid ligation buffer 
or 10 minutes at room temperature when using 2x Quick ligase buffer. 
 
2.4.5 Preparation of LB agar plates 
Materials 
LB broth 
Agar (Sigma-Aldrich) 
Antibiotic (Sigma-Aldrich) 
X-Gal (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (Promega) 
0.1 M Isopropylβ-D-1-thiogalactopyranoside (IPTG) (Promega) 
 
Method 
10g LB broth and 7.5g agar were dissolved in 500ml water, autoclaved to sterilise and cooled 
to approximately 37°C.  Once cooled, antibiotic was added to the solution at a concentration 
of 100µg/ml for ampicillin or 30µg/ml for kanamycin, and the solution was poured into 
10cm
2
 plates under sterile conditions. Plates were left to set at room temperature, and stored 
at 4°C.  
For plates being used to grow competent cells transformed with pGEM-Te vectors, 20µl X-
Gal and 20µl IPTG were poured onto plates and spread using a sterile Pasteur pipette.  The 
pGEM-Te vector contains a segment of the LacZ gene that encodes the N-terminal fragment 
of β-galactosidase which converts X-Gal to a blue product.  The gene segment is located in 
the multiple cloning site, hence ligation of DNA into the vector disrupts the gene preventing 
β-galactosidase activity, resulting in no blue product.  Based on this principle, colonies can be 
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screened by colour, where white colonies contain the DNA insert, and blue colonies do not 
because they maintain β-galactosidase activity. 
 
2.4.6 Transformation 
Materials 
JM109 E.coli highly competent cells (Promega) 
LB Broth (Sigma-Aldrich) 
 
Method 
JM109 highly competent cells (>10
8
 cfu/µl) were defrosted on ice and gently mixed by 
flicking the side of the tube.  In a 1.5ml tube, 50µl competent cells were mixed with 10µl 
plasmid DNA and incubated on ice for 20 minutes. The cells were then heat shocked in a 
42
o
C water bath for 45 seconds, to uptake the DNA, and returned to ice for 2 minutes.  950 µl 
LB broth was added to the cells, which were then shaken at 230rpm for 1.5 hours at 37
o
C.   
The cells were pelleted by centrifugation at 4000g for 5 minutes and supernatant was 
removed. Cells were resuspended in 200µl LB broth and spread over an agar plate containing 
the appropriate antibiotic with a sterilised glass rod. The plate was incubated at 37
o
C 
overnight to grow colonies. 
Individual colonies were picked using a sterile pipette tip, and transferred to a 50ml tube 
containing 10ml LB Broth with the appropriate antibiotic.  For pGEM-Te cloning, colonies 
that were white in colour were selected to be grown, and blue colonies were disregarded. 
Cells were grown for 16 hours in a shaking incubator (37
o
C), then centrifuged at 4000g for 
20 minutes to collect the pellet and supernatant was discarded. Plasmid DNA was extracted 
and purified according to section 2.4.3. 
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2.4.7 Plasmid Purification 
Materials 
QIAGEN Miniprep kit 
 
Methods 
Cell pellets were resuspended in 250µl cold buffer P1 and transferred to a 1.5ml tube.  Cells 
were lysed in 250µl alkaline buffer p2, mixing by inversion. 350µl acidic buffer N3 was 
added and mixed to neutralise the solution.  Samples were then centrifuged for 10 minutes at 
13,000rpm and supernatant was collected and transferred to a QIAprep spin column, which 
was centrifuged for one minute to bind DNA to the silica membrane.  Through-flow was 
discarded and the 750µl buffer PE was added to wash the column of endonucleases and salt, 
again spinning for one minute.  Through-flow was again discarded and the column was 
transferred to a clean 1.5ml collection tube.  DNA was eluted in 30µl nuclease free water by 
centrifuging at 13,000rpm for one minute. For purification of larger plasmid preps, the 
QIAGEN Plasmid Midiprep kit was used according to manufacturer’s instructions. 
 
2.4.8 Glycerol stocks 
Materials 
100% glycerol (Sigma-Aldrich) 
LB broth (Sigma-Aldrich) 
 
Method 
A 700µl suspension of transformed JM109 cells was pipetted into a sterile 1.5ml tube.  300µl 
of 100% glycerol was added and mixed, and stocks were stored at -70°C. 
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2.4.9 Site directed mutagenesis 
Materials 
QuikChange XL Site-Directed Mutagenesis Kit (Promega): 
10 x Reaction buffer (Promega) 
dNTP mix (Promega) 
PfuTurbo DNA polymerase (2.5U/µl) (Promega) 
Dpn1 (10U/µl) (Promega) 
Primers 
Nuclease free water (Sigma-Aldrich)   
 
Method 
An unknown SNP at position 110 (p.Gly110Cys) was identified in the wild type GPX1-
pGEM-te construct, and a frameshift was apparent in GPX1-FLAG vectors.  In order to 
correct sequence anomalies, site directed mutagenesis (SDM) was employed.  The 
QuikChange® II XL Site-Directed Mutagenesis Kit was used to change the cysteine residue 
to a glycine, using two complementary primers containing the mutation desired flanked by 
unmodified sequence complementary to the wild type sequence (section 2.3.7).  Similarly the 
frameshift was corrected by SDM. The primers were required to be 25-45bp in length with a 
Tm >78°C. The following reaction was prepared: 
Component  
10 x reaction buffer 5µl 
dNTP mix 1µl 
FP 125ng 
RP 125ng 
Template DNA 50ng 
Nuclease-free water To 50µl 
Add last: PfuTurbo DNA polymerase 
(2.5U/µl) 
1µl 
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The following cycles were used for site directed mutagenesis: 
Temperature (°C) Time (Minutes) Cycles 
95 1  1 
95 0.5 18 
62 1 
68 1/kb 
68 5 1 
 
Following amplification, the reaction mix was incubated on ice for 2 minutes, and then 1µl 
restriction endonuclease Dpn1 was added to the reaction and mixed by pipetting.  The 
reaction was incubated at 37°C for 2 h to digest parental DNA.  The digested DNA was 
transformed into NEB 5-alpha Competent E.coli (high efficiency), grown and purified as 
described below.  To check for release of the insert, plasmid DNA was digested with Not1 
restriction endonuclease as described in section 2.4.3. 
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2.4.10 Transformation using NEB 5-alpha Competent E.coli (high efficiency) cells 
Materials 
NEB 5-alpha Competent E.coli (NEB) 
SOC medium (NEB) 
 
Method 
Tubes containing 50µl NEB 5-alpha Competent E.coli cells were thawed on ice for 10 
minutes. 5µl of Dpn1-digested DNA reaction was added to the competent cells and gently 
mixed by flicking the tube.  The mixture was incubated on ice for 30 minutes, then heat 
shocked at exactly 42°C for 30s using a water bath, and returned to ice for 5 min.  950µl SOC 
medium was pipetted into the mixture and incubated at 37°C for 60 min at 250rpm. 
Following incubation transformation reaction mixtures were centrifuged at 1000g for 10 min. 
800µl supernatant was aspirated and discarded. The cell pellet was resuspended in the 
remaining supernatant and 100µl was transferred to LB agar plates containing 100µg/ml 
ampicillin. 
Plates were incubated overnight at 37°C, after which colonies were picked and cultured in 
10ml LB broth overnight at 37°C with 230rpm shaking.  The cultured cells were centrifuged 
for 20 minutes at 4000g to form a pellet, then purified according to section 2.4.7. 
 
2.5 Protein Analysis and Protein-Protein interaction protocols 
2.5.1 Protein extraction for Western blotting 
 
Materials 
RIPA buffer (Sigma-Aldrich) 
complete, Mini, EDTA-free Protease Inhibitor Cocktail Tablets (Roche)  
2x Laemmli buffer (Sigma-Aldrich) 
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Methods 
To prepare lysates, media was removed by pipetting and cells were washed 3x in cold PBS.  
For a 6 well plate, cells were lysed in 200µl RIPA buffer (containing protease inhibitor), 
scraped off the plate, and transferred to 1.5ml tubes.  Tubes were left on ice for 30 minutes, 
then centrifuged at 13,000rpm for 12 min at 4
o
C to pellet cell debris.  Supernatant was 
collected and added to an equal volume of 2x Laemmli buffer, containing SDS and β-ME, 
then boiled for 10 minutes to denature proteins prior to gel loading 
 
2.5.2 Bradford Protein Assay 
Materials 
Protein Assay Dye (Coomassie Brilliant Blue G-250) (5x)(Biorad) 
Phosphate Buffered Saline (PBS) (Sigma-Aldrich) 
Bovine serum albumin (BSA) (Sigma-Aldrich) 
 
Method 
The Bradford protein assay was used to determine protein concentration of cell lysates.  The 
assay is based on the maximum absorbance shift from 465nm to 595nm of Coomassie 
Brilliant Blue G-250 when bound to a protein. Serial dilutions of BSA ranging from 0 to 
1mg/ml in concentration were used as protein standards. The protein assay dye was diluted 1 
in 5 with PBS prior to the assay.  10 µl of standard or test sample were added in triplicate to 
each well of a 96-well plate, plus 200µl protein assay dye.  The samples were left to incubate 
at room temperature for 5 minutes, then absorbance was read using a standard plate reader. A 
standard curve was produced by plotting OD595 against concentration of the BSA standard, 
and the protein concentration of each sample was determined by extrapolating from the linear 
equation. 
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2.5.3 Western blotting 
Materials 
Kaleidoscope prestained Protein Marker (Biorad) 
50x 3-(N-morpholino)propanesulfonic acid (MOPS) running buffer (50 mM MOPS, 50 mM 
Tris Base, 0.1% SDS, 1 mM EDTA, pH 7.7) 
SDS PAGE precast NuPage BisTris gels (4-12%, 10% or 12%) (Invitrogen) 
 
Methods 
A pre-cast gel was briefly rinsed with distilled water and inserted into the gel tank. The tank 
was filled with 1x MOPS buffer to cover the gel, and the comb removed. The protein ladder 
was loaded into the first well of the gel (10µl for 10 well gel, 8 µl for 15 well gel). Samples 
prepared in 2x Laemmli buffer (section 2.5.1) were centrifuged for 1 minute at 13,000g and 
loaded into adjacent wells, typically between 20 and 30µl depending on the protein content of 
the lysate. The gel was run for 30 minutes at 70V and an hour at 160V. 
 
2.5.4 Semi-dry Transfer of Proteins from Gel to Membrane 
Materials 
0.1µm pore nitrocellulose membrane 
1x Transfer Buffer (0.9% glycine (w/v), 0.242% Tris (w/v), 20% Methanol (v/v)) 
Extra thick filter paper (Biorad) 
Trans-Blot SD semi-dry transfer cell (Bio-Rad) 
 
Methods 
A square segment of nitrocellulose membrane was cut to the dimensions of the gel using the 
extra thick filter paper as a template. The membrane was soaked in transfer buffer for 10 
minutes prior to the transfer procedure. A sandwich of filter paper-membrane-gel-filter paper 
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was assembled in the transfer cell (Fig. 2.5).  First, filter paper was briefly soaked in transfer 
buffer and placed on the transfer cell, pressed with a roller to remove excess buffer. Next the 
membrane was placed on top of the filter paper, and then the gel was soaked and placed on 
top of the membrane. Bubbles were removed by gently pressing the gel from the centre to the 
corners. Finally, the second filter paper was soaked and placed on top of the gel.  The 
sandwich was pressed again with the roller to remove excess buffer.  The transfer cell was set 
to 15V for 40 minutes for one blot or 50 minutes for two blots. 
 
 
Figure 2.  5: Semi-dry Transfer.   
Illustration showing assembly of filter paper, nitrocellulose membrane and 
polyacrylamide gel on the transfer cell.  
 
After transfer, the gel was discarded and the membrane was subjected to Ponceau-S staining 
to determine efficiency of the transfer. 
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2.5.5 Ponceau-S staining  
Materials 
Ponceau-S (0.2% Ponceau-S and 1% Acetic acid) (Sigma-Aldrich) 
Washing buffer (1x PBS + 0.1% (v/v) Tween20) (PBS-Tw) (Sigma-Aldrich) 
 
Method 
Ponceau-S is a dye that reversibly stains protein bands without any adverse effects on the 
proteins.  Staining membranes with Ponceau-S reveals any regions where the transfer has 
failed (seen as bubbles) as well as the amount of protein loaded per lane, and the efficiency of 
the transfer.  Membranes were placed in small containers, covered with Ponceau-S and left on 
a shaker for two minutes.  Ponceau-S was removed and the membrane was washed with PBS-
Tw.  After one wash, protein bands became visible. Ponceau-S staining was then removed 
with further washes in PBS-Tw. 
 
2.5.6 Immunoblotting 
Materials 
Blocking buffer (5% non-fat dried powdered milk (Asda) in PBS-Tw (0.1%)) 
Primary antibody  
HRP conjugated Secondary antibody (Odyssey) 
Washing buffer (0.1% PBS-Tw) 
 
Method 
A blocking buffer was prepared by dissolving 5% powdered milk in PBS-Tw and mixing by 
inversion. Nitrocellulose membranes were transferred to 50ml tubes with 10ml blocking 
buffer for one hour, to prevent non-specific binding of the antibody. Tubes were rotated on a 
roller.  After blocking, membranes were incubated in milk containing relevant dilutions of 
primary antibodies overnight at 4°C.   
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The following day, membranes were subjected to 3x 10 minutes washes in PBS-Tw, 
incubated in milk containing fluorophore-conjugated secondary antibodies (goat rabbit 800 
1:5000, goat mouse 680 1:20,000) for 1 hour and wash steps were repeated.  Bands were 
detected using an Odyssey scanner at wavelengths 800 and 680. 
 
2.5.7 Antibodies for Western blotting 
 
 
Antigen/ 
Fluorophore Species Company Dilution 
1° β-actin Mouse monoclonal Sigma-Aldrich 1 in 10,000 
1° SOD2 Rabbit polyclonal Abcam 1 in 5000 
1° NRF2 Rabbit polyclonal Abcam 1 in 1000 
1° GPX1 Rabbit polyclonal Abcam  1 in 1000 
1° FLAG Mouse monoclonal Sigma-Aldrich  1 in 2000 
1° PRDX3  Rabbit polyclonal Proteintech  1 in 500 
1° PRDX-SO2/3 Rabbit polyclonal Abcam  1 in 2000 
1° 
Calmodulin 
binding protein Rabbit polyclonal Millipore  1 in 500 
1° GAPDH Rabbit polyclonal Abcam 1 in 5000 
1° PARP Rabbit polyclonal 
Cell Signalling 
Technology  1 in 1000 
1° StAR Mouse monoclonal Abcam  1 in 500 
1° Myc Rabbit monoclonal Sigma-Aldrich  1 in 1000 
1° p38-MAPK Rabbit polyclonal 
Cell Signalling 
Technology 1 in 1000 
1° ph-p38MAPK Mouse monoclonal 
Cell Signalling 
Technology  1 in 2000 
2° IRDye®680LT Goat anti-mouse Li-cor 1 in 20,000 
2° IRDye®800CW Goat anti-rabbit Li-cor 1 in 5000 
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2.5.8 Deglycosylation 
Materials 
N-Glycosidase F (PNGase F) (500,000 U/ml) (NEB) 
Buffer G7 (NEB) 
 
Method 
Hek293 cells were transfected with MRAP-CTAP, MRAP-NTAP or empty vector in 6 well 
plates and lysed as above (2.5.1). 10µl of lysate was subjected to digestion by PNGase in the 
following reaction mix: 
Component  
Protein lysate 10µl  
PNGase F 1µl  
Buffer  G7 10x 1.5µl 
Lysis buffer to a total volume of 15 µl 
 
Reactions were mixed, briefly centrifuged and incubated at 37°C for 2 hr.  The samples were 
then analysed by Western blot according to section 2.5.3. 
 
2.5.9 Tandem affinity purification (TAP) 
Materials 
InterPlay mammalian TAP system (Agilent): 
Streptavidin binding buffer (SBB) 
Streptavidin elution buffer (SEB) 
Calmodulin binding buffer (CBB) 
EDTA 0.5M 
14.4M β-ME 
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Method 
Tandem affinity purification is an immunoprecipitation technique that utilises a double 
epitope-tag to isolate proteins in two successive purification steps.   
For TAP, 1 x 10
8
 HEK293 and H295R cells (8 x 10cm
2
 plates) were transfected with TAP-
tagged MC2R, MRAP, NTAP-MEF2 (myocyte enhancer factor-2) as a positive control or 
empty vector as a negative control (section 2.1.6.1).  After 48h, cells were harvested using 
400µl/10cm
2 
plate of the lysis buffer provided supplemented with protease inhibitors, and 
transferred to 1.5ml tubes on ice (section 2.5.1).  A 20µl aliquot of lysate was stored at -80°C 
to use as an input during Western blot analysis.   
Prior to purification steps 500 µl/sample of the streptavidin resin slurry was centrifuged at 
1500g for 5 minutes and the supernatant comprising an ethanol storage buffer was removed 
by pipetting.  The streptavidin resin was washed twice in 1ml SBB and after each wash the 
resin was centrifuged for 5 minutes at 1500g.   After wash steps, streptavidin resin was 
resuspended in a small volume of SBB to cover the resin and transferred to 15ml tubes.  
Lysate pooled from 10cm
2 
dishes was transferred to the streptavidin resin and topped up with 
500µl SBB. A further 40µl 0.5M EDTA and 7µl 14.4M β-ME were added per ml lysate and 
samples were placed on a rotator overnight at 4°C.   
Following overnight incubation the resin was centrifuged at 1500g for 5 min and an 80µl 
aliquot of supernatant was separated and stored at -80°C for Western blot analysis to 
determine the amount of target protein that did not bind the resin.  The remaining supernatant 
was aspirated and the resin was washed three times with 1ml SBB for 20min on a rotator at 
4°C. On the final wash step, supernatant was removed and 1 ml SEB was added to the 
streptavidin resin to elute associated proteins.  Samples were placed on a rotator for 1h 15min 
at 4°C. 
The resin was collected by centrifugation at 1500g for 5 min and supernatant containing 
eluted proteins was transferred to 250µl calmodulin resin in a 15ml tube, which had been pre-
washed three times in CBB.  A 20µl aliquot was taken at this stage for Western blot analysis, 
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which would show the amount of target protein recovered by the first purification step. 4ml 
CBB with 20 µl streptavidin supernatant supplement were added to each sample and rotated 
at 4°C overnight.  
Following the second overnight incubation, samples were centrifuged at 1500g for 5 minutes 
to collect the resin.  The resin was washed 3 times in 1ml CBB and on the last wash 
supernatant was removed leaving enough to cover the beads. An equal volume of Laemmli 
buffer was added and samples were boiled to detach and denature proteins bound to the 
calmodulin resin. 
The efficiency of the double purification was analysed by Western blot, using aliquots taken 
from each step of the purification.  The intensity of the bands and level of background gave 
an indication of the success of the purification. 
 
2.5.10 Coomassie Blue staining  
Materials 
Coomassie Brilliant Blue G-250 Colloidal concentrate (Sigma-Aldrich)  
Methanol (Fisher-scientific) 
Acetic acid (Sigma-Aldrich) 
 
 
Method  
Coomassie brilliant blue is a triphenylmethane dye that stains proteins in polyacrylamide 
gels. Lysates containing TAP-tagged MC2R or MRAP isolated by tandem affinity 
purification were run on a 4-12% Bis-Tris 1D SDS-PAGE gradient gel.  The gel was fixed in 
a solution containing 7% acetic acid and 40% methanol, then stained with a solution of 
Coomassie Blue (colloidal concentrate with deionised water (1:4)) and 20% methanol 
overnight.  After bands became visible, the gel was destained with 25% methanol and 7% 
acetic acid for 5 minutes, and then 25% methanol and 2% acetic acid for a minimum of 10 
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minutes until the bands appeared in good contrast against the background.  The gel was 
stored in deionised water. Chosen bands were excised and analysed by mass spectrometry at 
KCL Proteomics Facility, Institute of Psychiatry. 
 
2.5.11 Mass spectrometry 
Method 
Coomassie Blue stained SDS-PAGE containing lysates purified by TAP were analysed by 
mass spectrometry at KCL Proteomics Facility, Institute of Psychiatry, using their optimised 
protocol: 
In-gel reduction, alkylation and digestion with trypsin were performed prior to subsequent 
analysis by mass spectrometry. Cysteine residues were reduced with dithiothreitol and 
derivatised by treatment with iodoacetamide to form stable carbamidomethyl derivatives. 
Trypsin digestion was carried out overnight at room temperature after initial incubation at 
37
o
C for 2 hours.  
Peptides were extracted from the gel pieces by a series of acetonitrile and aqueous washes. 
The extract was pooled with the initial supernatant and lyophilised. Each sample was then 
resuspended in 23L of 50mM ammonium bicarbonate and analysed by LC/MS/MS. 
Chromatographic separations were performed using an Ultimate LC system (Dionex, UK). 
Peptides were resolved by reversed phase chromatography on a 75 m C18 PepMap column 
using a three step linear gradient of acetonitrile in 0.05% formic acid. The gradient was 
delivered to elute the peptides at a flow rate of 200nL/min over 30 min. The eluate was 
ionised by electrospray ionisation using a Z-spray source fitted to a QTof-micro (Waters 
Corp.) operating under MassLynx v4.0. The instrument was run in automated data-dependent 
switching mode, selecting precursor ions based on their intensity for sequencing by collision-
induced fragmentation. The MS/MS analyses were conducted using collision energy profiles 
that were chosen based on the mass-to-charge ratio (m/z) and the charge state of the peptide. 
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Acquisition parameters were optimised for high coverage and full characterisation, which 
included a reduced ion exclusion time for MS/MS from 2 min to 20 sec to promote re-
sequencing of peptides. 
The mass spectral data was processed into peak lists using ProteinLynx Global Server v2.2.5 
with the following parameters: 
 
MS survey – No background subtraction, SG smoothing 2 iterations 3 channels, peaks 
centroided (top 80%) no de-isotoping. 
 
MS/MS – No background subtraction, SG smoothing 2 iterations 4 channels, peak 
centroiding (top 80%) no de-isotoping. 
 
The peak lists was searched against the Swiss Prot and r2 sequence specific databases using 
Mascot software v2.2 (http://www.matrixscience.com) using the following parameter 
specifications: 
 
Precursor ion mass tolerance 1.2 Da 
Fragment ion mass tolerance 0.6 Da 
Tryptic digest with up to three missed cleavages 
Variable modifications: Acetyl (Protein N-term), Carbamidomethylation (C), Gly->pyro-glu 
(N-term Q), Oxidation (M) and Phosphorylation (S, T &Y). 
 
Database generated files were uploaded into Scaffold 3 software 
(www.proteomesoftware.com) to align samples for easier interpretation.  Protein 
identifications were automatically accepted if they contained at least two unique peptide 
assignments and were established at 100% identification probability by the Protein Prophet 
algorithm (Nesvizhskii, et al., 2003). Mass spectra for all other protein identifications were 
manually validated according to accepted procedures. 
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2.6 Imaging of cells 
2.6.1 Immunocytochemistry 
 
Materials 
 
4’,’6-diamido-2-phenylindole stain (DAPI) (Sigma-Aldrich) 
Primary and secondary antibodies (Section 2.6.2) 
3.7% paraformaldehyde (Sigma-Aldrich) 
0.025% Triton X-100 (Sigma-Aldrich) 
PBS (Sigma-Aldrich) 
0.1% (v/v) Triton-100 in PBS (PBS-Tr) (Sigma-Aldrich) 
Blocking buffer (3% (w/v) Bovine Serum Albumin (BSA), 10% Normal Goat serum (NGS) 
in 0.1% PBS-Tr) 
Fluorescent Mounting Media (Dako) 
 
Methods 
HEK293 cells were transfected with appropriate vectors in 12 well plates containing 10mm 
cover slips. Cells were transfected at 50% confluence, and cultured until 60-70% confluent in 
order to distinguish and analyse single cells by microscopy.  Media was then discarded and 
cells were washed twice with PBS. To fix, cells were incubated in 3.7% paraformaldehyde 
for 10 minutes, followed by a 2 minute wash in PBS.  Cell were permeabilised with 0.025% 
TritonX-100 in PBS for 10 minutes, and then blocked in 3% BSA and 10% NGS in 0.1% 
PBS-Tr for an hour.  After blocking cells were stained with appropriate primary antibodies in 
blocking buffer for 1.5 hours, washed twice in PBS for 10 minutes,  incubated with species 
specific cy2 or cy3 conjugated secondary antibodies in blocking buffer for 1.5 hour, and 
washed again three times in PBS for 10 minutes.  Cells were briefly incubated with 2g/ml 
DAPI (1 minute) to stain nuclei, and washed again for 10 minutes in PBS. Cover slips were 
removed with forceps and mounted onto 1mm thick clear slides using one drop of fluorescent 
mounting media.  Slides were stored at 4°C in the dark.  Immunostained cells were visualised 
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on the Zeiss LSM510 laser scanning confocal microscope. Images were taken using a 63x 
objective.  
 
2.6.2 Antibodies for immunocytochemistry 
 
Antigen/Fluorophore Species Company Dilution 
1° 
Calmodulin binding 
protein Rabbit polyclonal Millipore 1 in 100 
1° FLAG Mouse monoclonal Sigma-Aldrich 1 in 500 
1° HA Mouse monoclonal Sigma-Aldrich 1 in 500 
2° AF488-Green Donkey Mouse  Invitrogen 1 in 1000 
2° AF546-Red Donkey Rabbit Invitrogen 1 in 5000 
2° AF488-Green Goat anti-mouse Invitrogen 1 in 1000 
2° AF568-Red Goat anti-rabbit Invitrogen 1 in 1000 
 
2.6.3 Confocal microscopy 
Fluorescent and RBG colour imaging was performed on the Zeiss LSM 510 inverted confocal 
laser scanning microscope (Carl Zeiss Ltd, UK).  Objectives used were either 10x, 20x, 40x 
or 63x. The pinhole was set to 1 Airy unit, with Cy2 green fluorophore detected by the 
458nm Argon laser, Cy3 red fluorophore detected by the 543 HeNe laser and blue 
wavelengths such as that emitted by DAPI detected by the 405nm Diode laser.  Images were 
acquired at 1024x1024 pixels, averaging 8, bit data depth 16.  Image processing was 
performed using Zen lite software (Carl Zeiss Ltd, UK).   
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2.7 Functional assays 
2.7.1 Cycloheximide treatment to assay half-life of proteins 
Materials 
Cell culture media 
ITS premix (BD biosciences) 
Cycloheximide (CHX) 50mg/ml (Sigma-Aldrich) 
MG132 10mM (Sigma-Aldrich) 
Dimethyl sulfoxide (DMSO) (Sigma-Aldrich) 
Method 
The half-life of a protein can be assayed using CHX, a eukaryotic protein synthesis inhibitor, 
to determine the degree of degradation of a protein. CHX blocks translation of mRNA on 80S 
ribosomes in the cytosol.  MG132 is a 26S-proteosome inhibitor, preventing degradation of 
ubiquitin-conjugated proteins.  
HEK293 cells were seeded in 12-well plates and grown overnight to a confluency of 70%.  In 
initial experiments, cells were transfected with 1µg R130-L133del-FLAG or 25ng WT-
FLAG, and DNA concentration was kept constant using an empty vector. Untransfected cells 
were used as a negative control.  24h after transfection, cells were treated either 25 µg/ml 
cycloheximide, 25µM MG132, both or DMSO as a vehicle control for 4h.  CHX, MG132 and 
DMSO were diluted in DMEM cell culture media supplemented with 1% ITS premix but no 
serum.  Following treatment, media was removed and cells were washed with cold PBS, then 
lysed for Western blot analysis using FLAG antibody (Sigma-Aldrich) and GAPDH as a 
loading control. 
In later experiments, cells were transfected with 10ng WT-FLAG to gain similar protein 
levels to R130-L133del-FLAG.  Cells were treated with 50µg/ml CHX, 25µM MG132 or 
both for 10h and lysed at 1, 2, 5, and 10h after treatment.  Lysates were analysed by Western 
blot analysis using antibodies to FLAG and GAPDH as a loading control to normalise data. 
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In order to calculate half-life, the percentage of protein remaining (Y) was plotted again time 
(X) for WT and R130-L133del.  GraphPad Prism 4 software was used to create a nonlinear 
regression model with an exponential curve to fit data, with the equation: 
Y=Y0e
-KX
 
Y0= Value of Y at time 0 
K= Rate constant 
X= Time 
The half-life was calculated using the equation ln(2)/K. 
 
2.7.2 cAMP luciferase assay 
Materials 
Dual-luciferase reporter system (Promega): 
Luciferase assay buffer II 
Luciferase assay substrate (lyophilized) 
Stop & Glo® Buffer 
50x Stop & Glo® Substrate 
5x Passive lysis buffer 
pRL-CMV Renilla luciferase plasmid 
α-GSU-846 plasmid 
 
Method 
cAMP production was measured using the Promega Dual-Luciferase Reporter assay system 
in which the activities of Firefly (Photinus pyralis) and Renilla (Renilla reniformis) 
luciferases are measured sequentially from a single sample. To measure the cAMP response 
to ACTH in the presence of TAP-tagged MC2R or MRAP, MC2R and MRAP constructs were 
co-transfected with an ‘experimental’ α GSU-846 luciferase reporter, containing a luciferase 
driven by the cAMP responsive promoter α GSU-846, and a ‘control’ reporter pRL-CMV 
Renilla luciferase plasmid, driven by the CMV immediate-early enhancer/promoter.  The two 
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luciferases respond to different substrates, hence the Firefly reaction can be quenched whilst 
simultaneously initiating the Renilla reaction. 
The following bioluminescent reactions are catalysed by Firefly and Renilla luciferases: 
 
Beetle Luciferin + ATP + O2   Oxyluciferin + AMP + PPi + CO2 + light 
 
Coelenterazine +O2    Coelenteramide + CO2 + light 
 
HEK293 cells were seeded in 6-well plates and grown overnight to 80% confluency.  Cells 
were transfected with either 1µg MC2R-TAP with 1µg MRAP-FLAG, MRAP-TAP or empty 
vector, 1µg MRAP-TAP with 1µg HA-MC2R, or 2µg empty vector alone.  All cells were 
transfected with 900ng α GSU-846 and 100ng pRL-CMV luciferase reporter plasmids.  48h 
after transfection, cells were stimulated for 6h with ACTH ranging from 10
-6
 to 10
-11
M 
concentration.  
Following stimulation, media was removed and cells were washed twice in PBS.  Cells were 
harvested in 100µl 1x passive lysis buffer which promotes rapid lysis, left on a rocker for 10 
minutes at 4°C, then transferred to a 1.5ml tubes and incubated on ice for 30 minutes.  Tubes 
were centrifuged at 13,000rpm for 2 minutes to pellet cell debris. 
Before starting the assay, Luciferase assay reagent II (LAR II) was prepared by resuspending 
the lyophilized luciferase assay substrate in 10ml of luciferase assay buffer II. Both reagents 
were warmed to room temperature before use. For Stop & Glo® reagents, 1 volume of 50x 
Stop & Glo® substrate was added to 50 volumes of Stop & Glo® Buffer in a glass tube.  
25µl of the cell lysate supernatant was transferred to a white-walled 96-well plate and 
inserted into the BMG Labtech Omega luminometer to measure luciferase activities.  The 
BMG Labtech Omega luminometer was programmed to inject 80µl of LARII into each well, 
Firefly 
luciferase 
Renilla 
luciferase 
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followed by 80µl Stop & Glo® reagent.  The reaction was initiated by the addition of LARII 
following which luminescence from the Firefly luciferase activity is quantified.  The reaction 
is then quenched by adding Stop & Glo® which simultaneously initiates Renilla luciferase 
activity leading to luminescent signal which is subsequently measured. 
Data obtained from the illuminator is analysed by dividing the Firefly luciferase activity 
values by those obtained by Renilla luciferase.  Luciferase activity is proportional to cAMP 
production, because cAMP activates protein kinase A (PKA) which phosphorylates cAMP 
response element binding protein (CREB) which is expressed by the α GSU-846 construct.  
CREB binds co-activators and in turn recruits RNA polymerase II to the αGSU promoter 
initiating transcription of the luciferase.   
Hence, Firefly luciferase is activated on ACTH stimulation due to cAMP generation, whereas 
the Renilla luciferase activity acts as an internal control.  
 
2.7.3 Glutathione Peroxidase (GPX) assay 
GPX activity was measured using continuous spectrophotometric rate determination, based 
on a coupled assay of NADPH oxidation, (Sigma-Aldrich protocol EC 1.11.1.9). As GPX1 
detoxifies hydrogen peroxide, glutathione is oxidised (Fig. 1.5.4.). In a second reaction, 
glutathione reductase uses NADPH to return glutathione to its reduced state.  Oxidation of 
NADPH to NADP
+
 results in a decreased absorbance at 340nm.  This decrease is inversely 
proportional to the level of GPX activity. 
As all GPXs will detoxify hydrogen peroxide, it is not possible to differentiate between 
different GPX activities in this assay.  One would only be able to discriminate between GPX4 
and total GPX activity, by using a phospholipid hydroperoxide. 
 
 
 
131 
 
2.7.3.1 In house assay GPX assay 
Materials 
Sodium Phosphate (Sigma-Aldrich) 
Dithiothreitol (DTT) (Sigma-Aldrich) 
Sodium Azide (Sigma-Aldrich) 
Reduced Glutathione (Sigma-Aldrich) 
Β-Nicotinamide dinucleotide 2-phosphate reduced tetrasodium salt (NADPH) (Sigma-
Aldrich) 
GPX1 enzyme from bovine erythrocytes (lyophilised powder >300u/mg) (Sigma-Aldrich) 
30% Hydrogen peroxide (Sigma-Aldrich) 
Deionised water (Sigma-Aldrich) 
 
Method 
Cells were grown in 6 well plates to 90% confluency.  To harvest, cells were scraped off 
plates using a rubber police man, with 10mM sodium phosphate with 1mM DTT buffer pH7 
at 4
o
C, and were homogenised using a sonicator.  The homogenised lysate was centrifuged at 
10,000g for 15 minutes at 4
o
C to pellet the cell debris and supernatant was transferred to 
1.5ml tubes and kept on ice. 
The following cocktail was prepared and equilibrated to 25
o
C: 
Cocktail components  
50mM Sodium Phosphate Buffer with 
0.4mM EDTA, 1mM Sodium Azide pH7 
9.2ml  
100u/ml Glutathione Reductase 0.1ml 
200mM Reduced Glutathione (GSH) 0.05ml 
NADPH 1mg 
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150µl cocktail and 25µl homogenised lysate were pipetted into the wells of a 96-well plate.  
As a positive control, purified GPX1 enzyme from bovine erythrocytes was diluted in sample 
buffer at concentrations ranging from 0.5 to 5u/ml to acquire a standard curve.  For a negative 
control, sample buffer with no cell lysate was used to calculate background activity. 
Absorbance at 340nm (A340nm) was monitored using a thermostatted spectrophotometer 
until it reached a steady state.  Following equilibration, 25µl 0.042% hydrogen peroxide was 
added to each well using a multichannel pipette and A340nm was recorded immediately for 5 
minutes at 30 second time intervals. 
To calculate units per ml of enzyme in the samples, the maximum ΔA340nm was determined 
for both test and blank samples and entered into the following equation: 
Units/ml enzyme = (A340nm/min Test - A340nm/min Blank)(2)(0.2)(df)/ (6.22) (0.025) 
Where 2 = 2 μmoles of GSH produced per μmole of β-NADPH oxidized, 0.2 = Total volume 
(in millilitres) of assay, df = Dilution factor, 6.22 = Millimolar extinction coefficient of ß-
NADPH at 340 nm and 0.025 = Volume (in millilitres) of enzyme used 
The units/ml GPX1 were measured relative to protein concentration, calculated using the 
Bradford assay. 
 
2.7.3.2 Commercial Assay 
Materials 
Glutathione peroxidase assay kit (Abcam): 
GPX Assay buffer 
Cumene hydroperoxide 
Glutathione 
GPX1 positive control 
NADPH 
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Method 
Cells were grown in T25 flasks to 90% confluency, and scraped off in 300µl cold assay 
buffer supplemented with protease inhibitors.  For the commercial assay standards were 
prepared before the assay by diluting NADPH to a range of concentrations between 0.1 to 
1mM. 100µl of NADPH standards were plated in duplicate in a clear 96 well plate and 
A340nm was measured using a thermostatic spectrophotometer. A standard curve was 
generated by plotting A340nm against NADPH concentration.  
After the standard curve had been generated, test wells were prepared.  50µl of each lysate, 
GPX1 positive control and assay buffer (background control) were added in duplicate to the 
wells of a 96-well plate. 
The following reaction mixture was prepared for each test reaction: 
Assay Buffer    33 μl 
40 mM NADPH solution  3 μl 
GR solution    2 μl 
GSH solution    2 μl 
 
40µl reaction mixture was added to each test well and incubated for 20 minutes to deplete 
GSSG in samples.  10µl cumene hydroperoxide solution was added samples to start the 
reaction, and A340nm was measured for 10 minutes with readings taken at 30 second 
intervals. The total change in A340nm within the linear range was calculated for each sample, 
and the NADPH standard curve was used to extrapolate the concentration of NADPH in the 
sample.  The GPX activity then was calculated using the following calculation: 
GPX Activity = B / T1 – T2 x V  x Sample Dilution = nmol/min/ml = mU/ml 
Where B is the NADPH amount that was decreased between T1 and T2 (in nmol), T1 is the 
time of first reading (A1) (in min), T2 is the time of second reading (A2) (in min) and V is 
the pre-treated sample volume added into the reaction well (in ml). 
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The units/ml GPX1 were estimated relative to protein concentration, calculated using the 
Bradford assay. 
One unit is defined as the amount of enzyme that will cause the oxidation of 1.0 μmol of 
NADPH to NADP+ under the assay kit condition per minute at 25°C. 
 
2.7.4 MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) assay 
Materials 
CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (Promega) 
MTS/PMS solution 
30% Hydrogen peroxide 
 
Method 
Cell viability was determined using the CellTiter 96® AQueous Non-Radioactive Cell 
Proliferation Assay (Promega), a colorimetric assay based on the conversion of MTS (an 
electron coupling reagent) into formazan, catalysed by dehydrogenase enzymes found in 
metabolically active cells. Conversion of MTS into formazan results in an increase in 
absorbance at 490nm (A490nm). 
Cells were seeded in triplicate in a 96 well plate at a density of 5000 cells and allowed to 
grow for 24 hours before treatment with 100µM H2O2 for a further 24 hours.  On the morning 
of the assay, a further subset of cells were seeded at densities of 0 to 30,000 cells per well in 
triplicate to create a standard curve which was used as a positive control.  Cells were allowed 
an hour to adhere, then media was removed from all wells and replaced with 100µl fresh 
media and 20µl MTS/PMS solution.   After 2 hours incubation at 37°C in darkness, 
absorbance at 490nm was measured using the Wallac spectrophotometer.   The number of 
metabolically active cells in test wells could be calculated using the linear equation of the 
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standard curve.  Alternatively, the A490nm of samples could be compared directly, which 
was directly proportional to the number of metabolically activity cells. 
 
2.7.5  GSH assay 
Materials 
Menadione 40µM 
Total Lysis buffer 
Oxidised Lysis buffer 
Luciferin generation reagent 
Luciferin detection reagent 
 
Method 
Glutathione is potent and abundant antioxidant that reduces toxic ROS.  It acts as an electron 
donor, which on reducing disulfide bonds between proteins becomes oxidised (GSSG). The 
ratio of reduced to oxidised glutathione (GSH/GSSG) is therefore an indicator of cell toxicity. 
The GSH/GSSG-Glo assay is a luciferase based assay with an output measure of 
luminescence.  The assay principle is that the conversion of Luciferin-NT to Luciferin by 
glutathione-s-transferase, is dependent on GSH.  This reaction is coupled to a Firefly 
luciferase reaction producing light, hence GSH is proportional to luminescence.   
Samples are plated twice for two separate treatments.  In one subset, all glutathione is 
converted to the reduced form GSH by a reducing agent, to calculate total glutathione. In the 
second subset, a reagent is used to block all reduced GSH.  Remaining GSSG is then 
converted to GSH by the reducing agent and luminescence is quantified.  From measuring the 
total and oxidised glutathione, the GSH/GSSG ratio can be calculated using the following 
calculation: 
(Net total glutathione RLU- Net GSSG RLU)/(Net GSSG/2) 
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10,000 cells seeded in duplicate in a 96 well plate with white walls, to protect from inter-well 
cross-talk. Cells were seeded in duplicate twice for separate total and oxidised glutathione 
measurements, and were grown for 48 hours in normal media.  For a positive control, a 
subset of cells were treated with 40µM menadione, a synthetic compound which increases 
levels of GSSG, for 1 hour prior to lysis (Sun et al., 1997). 
Buffers for the assay were made a maximum of 30 minutes before use as follows: 
Volume per reaction (96-well plate): 
 Total Lysis Buffer 
(µl) 
Oxidised Lysis Buffer 
(µl) 
Luciferin-NT 1 1 
Passive Lysis Buffer 
5x 
10 10 
NEM, 25mM - 0.5 
Water 39 38.5 
Total volume: 50 50 
 
Luciferin Generation Reagent (µl) 
100mM DTT 1.25 
Glutathione-S-Transferase 3 
Glutathione Reaction Buffer 45.75 
Total volume 50 
 
One subset of cells was lysed in 50µl total lysis reagent and the other in 50µl oxidised lysis 
reagent.  As a background control, 50µl total lysis buffer was added to one well with no cells. 
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The plate was shaken gently for 5 minutes at room temperature. Luciferin generation buffer 
was added to all wells, shaken briefly, and incubated at room temperature in the dark for 30 
minutes.  Finally, 100µl luciferin detection buffer was added to wells, shaken briefly and 
incubated for 15 minutes in the dark.  Luminescence was then read using the BMG Labtech 
OMEGA machine. 
 
2.7.6 Enzymatic immunoassay 
Materials 
Cortisol Assay (Parameter): 
Wash buffer 
Stop Solution 
Calibrator Diluent RD5-43 
Colour reagent A 
Colour reagent B 
Primary antibody solution 
Conjugate 
 
Methods 
Cortisol levels were measured using an enzymatic immunoassay, which is a competitive 
binding technique.  Lysates are incubated with mouse-monoclonal antibody to cortisol and 
horse radish peroxidase (HRP)-conjugated cortisol, hence endogenous cortisol in the lysate 
must compete with HRP-conjugated cortisol for binding sites of the antibody.  The incubation 
occurs in a goat anti-mouse coated microplate, to which the mouse monoclonal antibody 
becomes bound.  Wash steps remove unbound sample and a substrate solution is added to 
determine bound enzyme activity which is measured by an increase in absorbance at 450nm.  
The absorbance at 450nm is inversely proportional to the concentration of endogenous 
cortisol in the lysate. 
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To measure cortisol levels, 800,000 cells were plated in 6 well plates and grown for 48 hours.    
Media was removed and replaced with serum free media either with no additives or 
containing 100µM H2O2 or 10
-5
M forskolin.  Cells were incubated for 6h, after which media 
was removed and stored in 1.5ml tubes at -80°C. Cells were lysed and subjected to Bradford 
assay for protein quantification.   
Prior to the cortisol assay, samples were diluted 10-fold in calibrator diluent RD5-43 reagent. 
All assay reagents were warmed to room temperature before use.  20ml wash buffer 
concentrate was diluted in deionised water to prepare 500ml of wash buffer.  The substrate 
solution was made 15 minutes prior to the assay procedure by mixing equal volumes of 
colour reagents A and B, enough for 200µl per well.  The cortisol standard was reconstituted 
in 1ml deionised water to form a stock solution of 100ng/ml concentration and allowed to 
stand for 15 minutes.    A standard curve was generated by making serial dilutions of the 
stock and was used within 1h of preparation. 
To begin the assay, 150µl calibrator diluent RD5-43 was added into non-specific binding 
(NSB) wells and 100µl into zero standard wells (blank), standard wells and sample wells of 
the microplate. 100µl standard or sample was added to appropriate wells in duplicate.  50µl 
of cortisol conjugate was added to all wells, producing a red colour.   A further 50µl primary 
antibody solution was added to all wells except NSB wells, changing the colour of wells to 
violet.  The plate was incubated in the dark for 2h at room temperature on a shaker.   
Following incubation wells were washed with 400µl wash buffer four times, each time 
aspirating and after the final step blotting against paper towel.  200µl substrate solution was 
added to each well and incubated a further 30 minutes at room temperature in darkness, the 
50µl stop solution was added changing the colour from blue to yellow.  The optical density of 
each well was measured within 30 minutes of adding the Stop Solution with a wavelength set 
at 450nm.  The reading was corrected by subtracting readings at 570nm. 
For data analysis, the optical density was plotted against cortisol concentration and a standard 
curve was generated using the mean of each standard.  The sample values were obtained by 
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extrapolating from the standard curve and multiplying by the dilution factor.  All values were 
normalised to protein concentration. 
 
2.8 in vivo techniques  
2.8.1 Mouse lines 
Adrenals from GPX1
-/-
 mice of a mixed genetic background were obtained as a kind gift of 
Xingen Lei from Cornell University. 
 
2.8.2 Paraffin Embedding 
Materials 
4% paraformaldehyde (Sigma-Aldrich) 
Ethanol (Fisher-scientific) 
Xylene (Fisher-scientific) 
Paraffin wax 
 
Method 
Adrenal glands from WT and GPX1
-/-
 KO mice were fixed in 4% paraformaldehyde and 
stored in PBS at 4
o
C overnight.  Adrenals were incubated in increasing concentrations of 
ethanol (50-100%) for 1 hr intervals, and then xylene for 1-2 minutes, to dehydrate the tissue.  
Following dehydration adrenals were embedded in paraffin wax by incubating for 6 hours at 
56
o
C, and allowed to cool to room temperature in plastic moulds. 
 
2.8.3 Sectioning  
Materials 
3-triethoxysilylpropylamine (TESPA) (VWR) 
Superfrost Plus slides (VWR) 
140 
 
Method 
8µm cross sections were cut using a microtome (Leitz 1512) and mounted onto TESPA 
treated 1mm thick superfrost plus slides. TESPA leaves the slide with a coating of positively 
charged ions, creating an adhesive surface for the section to bind.  A few drops of distilled 
water were placed on the slide and the paraffin section was laid on top.  A gentle heat was 
applied to soften the wax and remove crinkles. Water was aspirated by pipetting, leaving the 
section adhered to the slide surface. Slides were left to dry at 37
o
C overnight. 
 
2.8.4 Deparaffinisation 
Materials 
Ethanol (Fisher-scientific) 
Xylene (Fisher-scientific) 
 
Method 
Before staining, sections were deparaffinised and rehydrated.  Paraffin is insoluble and would 
inhibit staining if not removed. Sections were deparaffinised in a series of 10 minute 
incubations through the following solutions: 3x Xylene, 2x 100% EtOH, 1x 90% EtOH, 
1x70% EtOH, 1x 50% EtOH and 2x H2O.  
 
2.8.5 Haematoxylin and Eosin (H&E) staining 
Materials 
Haematoxylin (Lamb Laboratories) 
Acid alcohol (75% EtOH, 0.04% HCL) (Sigma-Aldrich) 
Ammonia solution (0.084% ammonium hydroxide) (Sigma-Aldrich) 
Eosin (Lamb Laboratories) 
EtOH (Fisher-scientific) 
Xylene (Fisher-scientific) 
DPX Fluorescent mounting media (Lamb Laboratories) 
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Method 
For H&E staining, slides were incubated in Haematoxylin dye for 2 minutes, washed for 2 
minutes in running water, dipped 10 times in Acid Alcohol, washed, dipped 10 times in 
ammonia solution and left under running water for 5 minutes. Then, slides were dipped 10 
times in 80% EtOH, 15 seconds in Eosin dye, 20 times in 90% ETOH, 100% EtOH and 
incubated twice for 3 minutes in Xylene.  Cover slips were mounted with DPX mounting 
media, and slides were visualised with the confocal laser scanning microscope (Carl Zeiss 
Ltd, UK).  
 
2.8.6 Immunofluorescent staining of adrenal sections 
Materials 
0.5M Sodium Citrate 
normal goat serum 
PBS-Tr 
Antibodies 
DAPI 
 
Method 
For immunofluorescence, slides were boiled in 0.5M Sodium Citrate (BDH Chemicals) for 
antigen masking, blocked in 10% normal goat serum for 1 hour to reduce non-specific 
binding of secondary antibodies. Slides were then incubated in PBS-Tr (0.1%) with 
antibodies to side chain cleavage, cleaved caspase-3 or inner zone antigen (IZA-1) overnight 
(section 2.8.6).  The following day, slides were washed in PBS triton three times, and 
incubated in secondary antibodies, goat anti-mouse Alexa Fluor 488 and goat anti-rabbit 
Alexa Fluor 568 (section 2.8.6) in PBS-Tr for 2 hours.  Slides were washed 3 times in PBS-
Tr for 10 minutes and treated with DAPI for one minute and washed once more.  Cover slips 
were mounted with glycerol in PBS (1 in 5). Slides were visualised using the confocal laser 
scanning microscope (Carl Zeiss Ltd, UK). 
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2.8.7 Antibodies for immunostaining 
Ab Antigen/ Fluorophore Species Company Dilution 
1° SCC Rabbit polyclonal Millipore 1 in 1000 
1° IZA-1 
Mouse 
monoclonal 
Kind gift of 
Professor 
Gavin Vinson, 
QMUL 1 in 10 
1° Cleaved Caspase-3 Rabbit polyclonal Santa-cruz 1 in 1000 
2° AF488-Green Goat anti-mouse Invitrogen  1 in 1000 
2° AF568-Red Goat anti-rabbit Invitrogen 1 in 1000 
 
2.8.8 Radioimmunoassay 
Materials 
Steroid Diluent 
corticosterone_125I 
Corticosterone antibody 
Precipitant Solution 
 
Method 
Corticosterone measurements were made using a radioimmunoassay which was performed by 
collaborators Xingen Lei and colleagues, Cornell University.  The principle of the 
radioimmunoassay is similar to the enzymatic immunoassay used to measure cortisol, where 
a radioactive label is used instead of a colorimetric signal.  Samples containing corticosterone 
are incubated with a known concentration of radioactive-labelled corticosterone and antibody 
to corticosterone, so that endogenous corticosterone from samples has to compete with the 
radioactive labelled form for binding of the antibody.  After incubation the unbound proteins 
are removed and the radioactivity is measured, which is inversely proportional to 
corticosterone levels.   
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All reagents were brought to room temperature before the procedure.  Serums from WT and 
GPX1
-/-
 mice were diluted 1 in 200 with Steroid Diluent before addition to assay tubes.  
300µl Steroid Diluent was added to NSB tubes and 100µl to zero standard tubes. 100µl each 
standard and 100µl diluted serum samples were added to appropriate tubes in duplicate.   
200µl corticosterone_125I was added to all tubes and 200µl anti-corticosterone was added to 
the zero standard tubes to stop the assay. The zero standard tube (B0) would have 100% 
binding of corticosterone_125I.  Tubes were incubated for 2h at room temperature, after 
which 500 µl Precipitant Solution was added to all tubes and vortexed thoroughly.  Tubes 
were then centrifuged at 1000g for 15 min, and supernatant was aspirated removing unbound 
sample.  
The precipitate was counted on a gamma counter.  To calculate corticosterone levels the 
following calculation was made: 
% B/Bo (percentage bound) = mc(sample)- mc(NSB) / mc(zero standard)-mc(NSB) x 
100 
Mc=mean counts 
 
The standard curve was plotted with percent bound versus the concentration of corticosterone 
from which the concentration of corticosterone in samples was extrapolated. 
 
2.9 Statistical Analysis 
Statistical analysis was performed on PRISM4 software and significance was determined by 
the student’s t-test.  Experiments that were analysed with statistics were performed in 
duplicate or triplicate and represent 3 independent experiments.  Error bars represent the 
standard deviation of the mean taken from individual experiments.  A p value under 0.05 was 
taken as statistically significant. 
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Chapter 3: Tandem Affinity Purification to identify 
interacting proteins of MC2R and MRAP in human 
adrenocortical cells 
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3.1 Introduction 
In 2005, Metherell et al. identified MRAP as a causal gene for FGD, accounting for 20% of 
the patient cohort. Investigation into the role of MRAP revealed that the protein co-localised 
with MC2R at the ER and cell surface membrane, and co-IP showed the two proteins form a 
complex that was functionally receptive to ACTH when co-transfected into heterologous 
chinese hampster ovary (CHO) or neuroblastoma ‘SK-N-SH’ cells. 
Like MC2R, some other GPCRs require accessory factors for trafficking for example a 
Drosophila cyclophilin gene NinaA is implicated in the transportation of RH1, the 
predominant rhodopsin, to rhabdomeres where it functions in phototransduction (Colley et 
al., 1991). In the absence of NinaA, RH1 accumulates in the ER and is eventually degraded, 
and hence, NinaA mutants have low levels of rhodopsin (Cooray et al., 2009). Other 
examples include the receptor activity-modifying proteins (RAMPs) which are required for 
expression of calcitonin and calcitonin-like receptors at the cell surface, and the receptor 
expression-enhancing proteins (REEPS) which are thought to be involved in the folding and 
trafficking of odorant receptors (Cooray et al., 2009); (Hay et al., 2006; McLatchie et al., 
1998; Saito et al., 2004; Webb et al., 2009). 
Interacting accessory factors can aid different aspects of the receptor cell cycle, for example 
correct folding, docking, ligand specificity, anchoring/stabilisation and endocytosis. It is 
therefore possible that in addition to MRAP there are other, unknown, interacting partners of 
MC2R which regulate its function. 
Given that approximately 50% drugs target GPCRs, gaining understanding of their 
interacting partners could provide valuable information (Daulat et al., 2007; Participants, 
2004). Likewise, revealing further players in MC2R regulation could pinpoint genes involved 
in the pathogenesis of FGD. I therefore hypothesised that MC2R and MRAP are only two 
parts of an interacting complex of proteins that are necessary for the correct functioning and 
signalling of MC2R.  In order to disclose potential interacting partners of MRAP and/or 
MC2R, a proteomic approach was employed. 
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Techniques that decipher protein interactions include the yeast 2 hybrid assay, and more 
recently tandem affinity purification (TAP). Currently, TAP is the most efficient technique 
for bait protein purification because of its quick, simple, generic protocol and flexibility 
meaning it can be used for any organism and a multitude of applications. Coupled with other 
techniques it has proven to be more informative than previous methods (Xu et al., 2010).   
 
3.1.2 Tandem Affinity Purification 
Tandem Affinity purification was initially developed by Rigaut and colleagues of the 
European Molecular Biology Laboratory, Germany
 
(Rigaut et al., 1999).  Previous protein 
purification techniques, including the Yeast 2 Hybrid screen (Y2H), have been limited by 
high levels of false positives and negatives as well as a lack of information regarding 
stoichiometry.  The flexibility of such techniques was poor, with only a certain set of 
conditions testable (Puig et al., 2001). Generating a generic protein purification technique to 
isolate protein complexes had not been possible due to the variability of protein properties.  
To resolve this Rigaut et al. chose to tag target proteins with peptides or protein domains so 
that a standardised purification strategy could be employed for all proteins, based on the tag.  
To retain protein complex integrity and to eliminate false positives such as non-physiological 
complexes, the tagged target protein would have to be expressed as close as possible to native 
levels.  This meant a high affinity tag would be needed for purification and hence a double 
tag was developed.  
The Tandem Affinity Purification tag (TAP-tag) forms the basis of the TAP method.  Various 
different tags now exist, but the first tag developed consisted of calmodulin binding peptide 
(CBP), a tobacco etch virus (TEV) cleavage site and protein A (from Staphylococcus aureus, 
containing two IgG binding domains) at the C-terminus, or the same proteins in reverse at the 
N-terminus (Fig. 3.1).  These tags were chosen over others because they purified the highest 
percentage of target protein from cell extracts (Rigaut et al., 1999).  
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C terminus tag: 
 
N terminus tag 
 
Figure 3.  1: Original tandem affinity purification tag 
Illustration showing the first tandem affinity purification tag designed by Rigaut et al., 
with protein A and calmodulin binding peptide tags at either the C (upper panel) or N 
(lower panel) terminus.  The Prot A and CBP tags are separated by a TEV cleavage site. 
After the first purification step with IgG matrix the ProtA tag is cleaved with TEV 
protease.  Therefore, the CBP tag is always closest to the inserted gene. (Based on Puig 
et al. (2001) 
To summarise, the method consists of fusing the target protein to the affinity tags, 
introducing the construct into the host cell, maintaining native expression levels, and then 
recovering the target protein and its interactants via two purification steps (Fig. 3.2) (Rigaut 
et al., 1999). In the first purification step, lysates are passed through an IgG matrix for which 
the Protein A has a high affinity.  The target and associated proteins are captured by the IgG 
matrix and washed before being eluted.  Protein A can only be detached from the IgG matrix 
under denaturing conditions.  To overcome this, Rigaut et al. designed the TAP-tag to have a 
TEV protease recognition site between ProtA and CBP, enabling the target protein and its 
associated factors to be released by adding TEV protease (Rigaut et al., 1999).  In the second 
purification step, the eluate is incubated with calmodulin beads in the presence of calcium, 
and then eluted with EGTA in gentle conditions. However, EGTA can affect the stability of 
some proteins (Rigaut et al., 1999), a factor that has been overcome in later developments of 
the tag.  
 
TARGET PROTEIN CBP TEV ProtA 
TARGET PROTEIN CBP TEV ProtA 
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Figure 3.  2: Tandem Affinity Purification, an Overview 
Based on Xu. et al. (2010) 
Following two step purification, proteins recovered can be analysed in different ways. One 
can either simply identify interactants, or examine the structure or activity of the complex.  
To identify protein complex components, the purified material can be fractionated, for 
example by centrifugation and gel filtration, for further enrichment and to separate complexes 
by organelle/compartment.  This is an optional step however stoichiometry cannot be 
determined without fractionation (Puig et al., 2001).  Samples are loaded on to a gradient 
polyacrylamide SDS gel which denatures the proteins and separates them by mass.  The 
bands can be visualised by coomassie blue or silver staining and cut from the gel for protein 
identification via mass spectrometry (Puig et al., 2001).  Alternatively, if the structure is to be 
investigated, purified proteins are concentrated and then examined by electron microscopy.  
Finally, because tandem affinity purification is such a gentle technique, the activity of the 
intact protein complex can be tested by suitable assays (Puig et al., 2001). 
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3.1.3 Yeast-2-hybrid Assay 
The yeast two hybrid screen also caters for high throughput screening and, to its merit, was 
the starting point for interactome mapping. In contrast to TAP, it has the advantage of 
detecting less stable interactions that are less likely to be picked up by TAP (Gingras et al., 
2007).  It is based on the activation of a reporter gene, for example LacZ, which is activated 
when a bait protein of interest interacts with a prey protein.  In one strain, a bait protein is 
fused to a binding domain of a transcriptional activator for a region upstream of the gene. In a 
second, a prey protein is fused to an activating domain of a transcriptional activator.  When 
strains are mated, the reporter gene can only be activated when the binding and activating 
domains are within close proximity.  Therefore the gene is only activated if an interaction has 
taken place (Johnsson and Varshavsky, 1994).  Despite discovering a multitude of 
interactions, this technique fails to give consistent data and is riddled with false positives and 
negatives.  Numerous low and high throughput studies do not show overlap, to a greater 
extent than TAP (Parrish et al., 2006).  Other factors also bring fault, such as the fact that 
only isolated domains of proteins, and not the full length are used for bait and prey, which 
could cause false negatives (Daulat et al., 2007). Testing mammalian proteins that usually 
succumb to post translation modifications is not possible in yeast and could miss interactions 
(Johnsson and Varshavsky, 1994).  Finally, and quite simply, the technique is a lot more time 
consuming than TAP. 
Conventional Y2H systems are not ideal for studying the interaction of membrane bound 
proteins since they rely on transcription factor activation and must therefore be performed in 
the nucleus. Previously this has been circumvented by studying the interaction of a portion of 
the membrane protein that is not embedded in the membrane, such as its N- or C- terminus, 
that can be relocalised to the nucleus. Such studies may not accurately reflect the situation in 
living cells because the conformation of the protein may be altered and interactions with 
other membrane proteins may be missed in the nucleus. Several variations on the Y2H 
strategy have been developed to overcome these problems including the Ras recruitment 
system and the Cytotrap assay. However a particularly efficient variation that overcomes 
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these difficulties is the split ubiquitin MbY2H assay. This is based on split-ubiquitin 
technique (Johnsson and Varshavsky, 1994) in which the reassociation of N- and C-terminal 
halves of ubiquitin allows the release of reporter gene(s). This system allows the screening of 
both full-length integral membrane and membrane-associated proteins, the interactions occur 
in their natural environment and post-translational modifications such as glycosylation and 
disulphide bonds are preserved. Several different groups have successfully applied this 
technique to detect protein-protein interactions in a wide range of organisms (Thaminy et al., 
2003; Wang et al., 2003; Wang et al., 2004) 
 
3.2 Aims 
The aim of this section was to identify novel interacting partners of MC2R and MRAP, in 
order to unveil proteins potentially involved in the pathogenesis of FGD.  To overcome the 
limitations of the yeast two hybrid system, the tandem affinity purification technique was 
employed to isolate interacting proteins. Before performing purification steps, TAP-tagged 
proteins of interest would be cloned and their functional expression validated.  The double 
purification technique would be carried out on lysates from cultured H295R adrenocortical 
carcinoma cells (H295R) transfected with target genes, and purified complexes would be 
detected by mass spectrometry. 
 
3.3 Results 
3.3.1 Construction of TAP-tag vectors 
For the purposes of this project I employed the Stratagene Interplay Mammalian TAP system 
in which target protein is fused to streptavidin binding peptide (SBP) and calmodulin binding 
peptide (CBP) tags.  The SBP tag is a 38aa synthetic sequence obtained from a random 
peptide library with an affinity of ~2 x10
-9
M for the streptavidin resin. The tag is eluted from 
the resin with biotin.  The 26aa CBP tag is derived from the C-terminus of muscle myosin 
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light-chain kinase, and in the presence of calcium, has an affinity of ~1x10
-9
M for the 
calmodulin resin.  The tagged protein is eluted by removing calcium with a chelating agent. 
Unlike previous TAP methods, the Stratagene Interplay system does not require protease 
digestion to cleave tags for elution.  Furthermore, the TAP expression vectors contain a 
human cytomegalovirus (CMV) promoter which drives the insert expression in most 
mammalian cell lines. 
MC2R and MRAP were cloned both into the N-terminal (NTAP) and C-terminal (CTAP) 
TAP-tag vectors.  For NTAP the SBP and CBP tags were 5’ to the gene and for CTAP 3’ to 
the gene (Fig. 3.3A-B). As described in section 2.4.1, cDNA protein coding regions for 
MC2R and MRAP were amplified from pcDNA3.1+ and p3xFLAG-CMV14-vectors 
containing the genes previously constructed in our laboratory, with primers containing 
BamH1 and EcoR1 restriction sites (Fig 3.3C).  Purified PCR fragments were digested with 
BamH1 and EcoR1, and ligated into the vectors, then transformed into bacterial cells for 
amplification. Clones positive for the TAP vector were selected with 50µg/ml kanamycin, 
and extracted plasmid DNA was digested with BamH1 and EcoR1 to check for the release of 
the insert (Fig. 3.3D).   Plasmid DNA from selected clones expressing the insert was 
sequenced using T3 and T7 sequencing primers to confirm the insert was in frame and had no 
sequence anomalies. More details are found in section 2.4.1. 
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Figure 3.  3 Cloning TAP-Tag constructs 
A. Schematic diagram of MC2R and MRAP TAP-tag constructs. The TAP-tag, 
consisting of streptavidin binding peptide and calmodulin binding peptide, was 5’ in 
NTAP constructs and 3’ in CTAP constructs. MC2R and MRAP were cloned into vectors 
through conventional cloning strategies. B. Amino acid sequences for SBP and CBP tags, 
38 and 26 residues in length respectively. C. PCR amplification of MC2R and MRAP 
cDNA from pcDNA3.1+–MC2R and MRAP-FLAG constructs. D. Restriction digests of 
plasmid DNA extracted from transformed clones, screening for release of MC2R (i.) or 
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MRAP (ii.) insert from the CTAP vector. Image representative for CTAP and NTAP 
clones. 
 
3.3.2 Validation of TAP-tag vectors 
3.3.2.1 Expression levels 
To determine protein expression of NTAP and CTAP tagged MC2R and MRAP, constructs 
were transiently transfected into HEK293 cells seeded in 6-well plates and grown for 24 
hours, then lysed for protein extraction.  In adjacent wells, empty CTAP vector was 
transfected as a negative control and NTAP-MEF2 (myocyte enhancer factor-2) as a positive 
control for protein detection.  Cell lysates were subjected to Western blot analysis detecting 
TAP-tagged proteins using a calmodulin binding peptide antibody (anti-CBP) at a dilution of 
1:500 (Millipore). 
Endogenous MRAPα has a predicted MW of 19kDa.  It has previously been demonstrated 
that C-terminal tagged MRAP-FLAG, with a predicted MW of 24kDa, migrates as several 
bands between 16-32kDa on SDS-PAGE (Webb et al., 2009).  These bands are thought to be 
products of glycosylation, post-translation modifications and/or cleavage products. Indeed 
MRAP has one glycosylation site situated at the N-terminus (Sebag and Hinkle, 2007). 
MC2R has a predicted MW of 33kDa but has previously been shown to migrate as a smear 
(Webb et al., 2009).  The NTAP affinity tag will add 8kDa so the expected sizes of MC2R 
and MRAP constructs would be 41kDa and 27kDa respectively.  The CTAP affinity tag will 
add 9kDa hence the expected sizes of MC2R and MRAP constructs would be 42kDa and 
28kDa respectively. 
In agreement with previous reports neither MC2R-NTAP nor -CTAP presented a clear 
banding pattern on Western blot but migrated as a smear, typical of many GPCRs (Fig. 3.4A)   
(Webb et al., 2009).   Similarly MRAP-CTAP showed a banding pattern consistent with 
Webb et al., whereby several protein species are resolved believed to be post-translationally 
modified possibly by glycosylation.  In contrast the N-terminal tagged NTAP-MRAP 
presented a distinct single band at the predicted size of the monomer (approx. 27kDa) (Fig. 
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3.4A).  It is therefore possible the N-terminal tag in NTAP-MRAP interferes with post-
translational modifications.   
 
Figure 3.  4: Validating protein expression of TAP-tag vectors:  
(A) Western blot showing expression of transfected TAP-tag constructs in HEK293 
cells, blotting with anti-CBP antibody. MC2R-CTAP (representative for NTAP-MC2R) 
migrates as a smear (Vertical bar). NTAP-MRAP migrates as one 27kDa band (white 
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arrow head) whereas MRAP-CTAP migrates as three species (red arrow heads). NTAP-
MEF2a was used as a positive control, detected at 62kDa (green arrow head). Unlabelled 
bands are non-specific.  (B) Western blot analysis of transfected cells treated with 
PNGaseF to remove glycosylation. Left panel shows treatment of MRAP-CTAP 
transfected cells with PNGaseF resulted in the addition of a lower molecular weight 
band (green arrow head) and the removal of the higher MW band, suggesting removal 
of glycosylation (red arrow heads represent higher MW bands).  Treatment of NTAP-
MRAP transfected cells with PNGaseF did not change the size of the protein suggesting 
it had no post-translational modification (white arrows heads). MRAP-FLAG was 
subjected to equivalent treatment as a positive control (right panel) where the two 
higher MW, glycosylated species disappear on PNGaseF treatment (red arrow heads 
represent MRAP-FLAG).  
 
To determine whether MRAP-CTAP and NTAP-MRAP were glycosylated, HEK293 cells 
were transfected with one or the other construct and lysates were digested with Peptide-N-
Glycosidase F (PNGaseF) or left untreated (Fig. 3.4B left panel).  PNGaseF is an 
endoglycosidase that cleaves N-terminal linked oligosaccharides, removing glycosylation. As 
a positive control, a subset of cells were transfected with MRAP-FLAG, an N-terminally 
tagged construct which is known to be glycosylated, and lysates treated similarly (Fig. 3.4B 
right panel). The MW of MRAP recombinant proteins was determined by Western blot 
analysis, running lysates on a 4-12% SDS-PAGE gel and detecting with anti-CBP antibody. 
As a negative control, lysates from untransfected cells were run in parallel.   
Figure 3.4B shows that treatment with PNGaseF resulted in a reduction in the intensity of the 
highest molecular mass band believed to be MRAP-CTAP and the addition of a lower 
molecular weight band, suggesting that MRAP-CTAP is glycosylated.  The molecular weight 
of NTAP-MRAP did not decrease following PNGaseF treatment, consistent with the theory 
that the TAP-tag had hindered post-translational glycosylation of NTAP-MRAP.   
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The above experiments suggest both NTAP-MRAP and MRAP-CTAP constructs express 
proteins at the correct predicted MW, but the N-terminal tag may interfere with 
glycosylation.  The expression of MC2R in both NTAP (not shown) and CTAP vectors was 
not clearly detected by Western blot, a common issue encountered when immunoblotting 
GPCRs, however, other methods such as immunocytology and activity assays can be used to 
determine their expression and functionality as detailed below. 
 
3.3.2.2 Subcellular localisation 
In order to check TAP-tagged MC2R was expressed at the cell surface, NTAP-MC2R or 
MC2R-CTAP constructs were co-transfected with MRAP-FLAG into HEK293 cells and 
analysed by immunocytochemistry.  MRAP-FLAG was previously constructed in our 
laboratory by directional cloning of MRAPα cDNA into the HindIII and EcoR1 restriction 
sites of the p3xFLAGCMV-14 expression vector (Sigma, Poole, UK) (Chan et al., 2009b). 
HEK293 cells have no endogenous MC2R or MRAP but have been shown to express all the 
other proteins required for a fully functional MC2R (Rached et al., 2005). HEK293 cells were 
chosen over an adrenocortical cell line, such as H295R, as they are easier to transfect, 
achieving 80-90% transfection efficiency. 
 
12 well plates containing coverslips were seeded with HEK293 cells and grown to 50% 
confluency, then transfected according to section 2.1.6.1 with either single constructs or co-
transfected with MRAP and MC2R constructs in various combinations to assess protein 
function (Fig. 3.5).  Cells were fixed and either permeabilised by the addition of Triton or 
untreated, then stained with anti-CBP, anti-FLAG, and fluorescently labelled secondary 
antibodies. Nuclei were stained with DAPI, and coverslips were mounted to slides.  
When transfected alone MRAP-TAP constructs were retained intracellularly (Fig. 3.5 B-C) 
similar to the localisation seen with the MRAP-FLAG construct previously investigated in 
our laboratory (Fig. 3.5A).  
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Co-transfection of HA-MC2R and MRAP-CTAP or HA-MC2R and NTAP-MRAP showed 
localisation of both proteins to the perinuclear region and cell surface in permeabilised cells 
(Fig. 3.5F) (NTAP-MRAP not shown) with good cell surface expression of MC2R in 
unpermeabilised cells (D-E), suggesting both MRAP-TAP constructs were capable of 
trafficking MC2R to the cell surface. 
  
Figure 3.  5: Subcellular localisation of TAP-tagged MRAP proteins.  
Subcellular localisation was determined by immunofluorescent staining of HEK293 cells 
transfected with MRAP-FLAG (A), NTAP-MRAP (B), MRAP-CTAP (C), HA-MC2R in 
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combination with NTAP-MRAP (non-permeabilised) (D), HA-MC2R in combination 
with MRAP-CTAP (non-permeabilised) (E), HA-MC2R in  combination with MRAP-
CTAP (permeabilised) (F) or empty vector alone (G).  Cells were fixed, permeabilised 
(unless stated), and stained with anti-HA, anti-FLAG or anti-CBP antibodies and 
viewed by confocal microscopy.  NTAP-MRAP (B) and MRAP-CTAP (C) had similar 
subcellular localisation to MRAP-FLAG (A) when transfected alone.  In non-
permeabilised cells, HA-MC2R (green) localised to the cell surface when cotransfected 
with NTAP-MRAP (D) or MRAP-CTAP (red) (E).  In permeabilised cells, proteins 
colocalised to the cell surface and perinuclear area (F), (representative of HA-MC2R + 
NTAP-MRAP).  CBP antibody staining of cells transfected with empty TAP-tag vectors 
were used as negative controls (F). 
 
MC2R-TAP constructs were also retained intracellularly when transfected alone, similar to 
the localisation seen with the HA-MC2R construct previously investigated in our laboratory 
(Fig. 3.6A).  
Co-transfection of NTAP-MC2R with MRAP-FLAG saw a substantial amount of the NTAP-
MC2R pool shift to the cell surface, the rest remaining intracellularly in a pattern consistent 
with endoplasmic reticulum staining, however markers were not used (Fig. 3.6D).  These data 
suggest that NTAP-MC2R is capable of trafficking to the cell surface without interference 
from the double tag. 
When MC2R-CTAP was cotransfected with MRAP-FLAG, it was expressed intracellularly, 
but cell surface expression was not apparent (Fig. 3.6E). This could be because the C-
terminus of MC2R and hence the tag itself is intracellular.    
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Figure 3.  6: Subcellular localisation of TAP-tagged MC2R proteins. 
Subcellular localisation was determined by immunofluorescent staining of HEK293 cells 
transfected with HA-MC2R (A), NTAP-MC2R (B), MC2R-CTAP (C), NTAP-MC2R 
with MRAP-FLAG (D), MC2R-CTAP with MRAP-FLAG (E) or empty vector alone 
(F).  Cells were fixed, permeabilised (unless stated), and stained with anti-HA, anti-
FLAG or anti-CBP antibodies and viewed by confocal microscopy.  NTAP-MC2R (B) 
and MC2R-CTAP (C) had similar subcellular localisation to HA-MC2R (A) when 
transfected alone.  When co-transfected with MRAP-FLAG, NTAP-MC2R was 
localised to the cell surface and perinuclear area (D), whereas MC2R-CTAP in 
combination with MRAP-FLAG was detected intracellularly (E).  CBP antibody 
staining or cells transfected with empty TAP-tag vectors were used as negative controls 
(F). 
 
These data confirms that NTAP-MC2R and MC2R-CTAP constructs express the protein, 
which had not been clearly detected by Western blot.  Overall the localisation of TAP-tag 
160 
 
proteins mirror that of HA-MC2R and MRAP-FLAG proteins, used in previous studies (Chan 
et al., 2009b; Metherell et al., 2005; Webb et al., 2009) which suggests that the proteins are 
localising correctly. However, it was unclear whether MC2R-CTAP was able to reach the cell 
surface when co-transfected with MRAP-FLAG.  I further investigated the functionality of 
these proteins in the following section. 
 
3.3.2.3 Functional cell surface expression and ACTH Response 
Functional studies into MC2R and MRAP function suggest that MRAP interacts with MC2R 
through its TMD, and a 15aa tyrosine rich region in the N-terminus of MRAP can influence 
MC2R trafficking. This region has been suggested to either play a role in stabilising the 
MRAP/MC2R interaction or interact with another protein that regulates MRAP/MC2R cell 
surface expression (Webb et al., 2009). Increasing the length of the C-terminus of MRAP 
reduces the amount of MC2R that reaches the cell surface and hence the ACTH 
responsiveness of the cells.  Therefore, it was necessary to check whether the presence of the 
9kDa TAP-tag added to MRAP and MC2R would influence the ACTH responsiveness of the 
receptor.   
As previously described, when ACTH binds to and activates MC2R, a series of downstream 
signalling events occur including the generation of cAMP, which through a number of routes, 
stimulates the induction of cortisol genesis. cAMP activates PKA, which phosphorylates and 
activates StAR protein in the acute phase of ACTH stimulation. In the later stages of ACTH 
stimulation cAMP also activates the transcriptional upregulation of steroidogenic genes 
through binding to cAMP response element binding proteins (CREB).  
To measure ACTH responsiveness of cells transfected with NTAP or CTAP-tagged MC2R 
and MRAP, a dual reporter cAMP luciferase assay was employed, which is described in 
detail in section 2.7.2. HEK293 cells containing no endogenous MC2R or MRAP were 
seeded in 6 well plates and grown for 24h. As a positive control, HA-MC2R and MRAP-
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FLAG vectors were used, which when co-transfected have previously been demonstrated to 
elicit a cAMP response (Chung et al., 2008; Webb et al., 2009).  
 
To test the functionality of NTAP-MC2R (Fig. 3.7A) cells were cotransfected with NTAP-
MC2R and either MRAP-FLAG, NTAP-MRAP or for a negative control empty vector. In all 
wells, equal concentration of α-GSU and Renilla were transfected. 48h after transfection, 
cells were stimulated with doses of ACTH ranging from 10
-6
 to 10
-11
M in order to create dose 
response curves. Cells were stimulated for 6h, then lysed and the luminescence was read on a 
luminometer in duplicate. The experiment was duplicated with CTAP constructs (Fig. 3.7B). 
Dose response curves were generated and EC50 measurements for each transfection using 
Prism (Prism Software Corp.). The EC50 or the half maximal effective concentration is 
defined as the concentration of ACTH when 50% of its maximal effect is observed.   
162 
 
 
Figure 3.  7: TAP-tag constructs express functional proteins. 
Graph showing dose response curves for TAP-tagged MC2R and MRAP normalised to 
100% HA-MC2R and MRAP-FLAG. HEK293 cells were transfected with MC2R-
NTAP/CTAP in combination with MRAP-FLAG, NTAP-MRAP/CTAP or empty vector 
and reciprocally MRAP-CTAP was also transfected with HA-MC2R.  All cells were co-
transfected with α-GSU and Renilla, and stimulated with ACTH (1-39) for 6h.  As 
negative controls, single construct or empty vectors were transfected alone. Luciferase 
activity was assessed as the relative light units (RLU) of reporter α-GSU Firefly 
luciferase relative to internal control Renilla.  Both NTAP- (A) and -CTAP (B) MC2R 
and MRAP proteins elicited a cAMP response that was ACTH dose dependent, 
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indicating the constructs expressed functional proteins that were able to interact, traffic 
to the cell surface and signal.  
The cAMP response elicited by co-transfecting NTAP-MC2R with NTAP-MRAP (EC50 1.98 
x 10
-7
M) was similar to that of HA-MC2R and MRAP-FLAG (EC50 1.17 x 10
-7
M), 
suggesting NTAP-MRAP is able to bind and traffic NTAP-MC2R to the cell surface and 
facilitate its response to ACTH (Fig. 3.7A). In cells co-transfected with NTAP-MC2R with 
MRAP-FLAG there was a higher cAMP response and the dose response curve shifted to the 
left (EC50 4.00 x 10
-9
M). 
Similarly, co-transfection of MC2R-CTAP and MRAP-CTAP also elicited a cAMP response 
curve compared to negative controls (Fig. 3.7B).  However, cAMP response was reduced by 
addition of the CTAP tag.  The combination of HA-MC2R and MRAP-FLAG produced the 
highest cAMP response (EC50 2.97 x 10
-10
M), followed by MC2R-CTAP and MRAP-FLAG 
(EC50 4.81 x 10
-4
M) and MC2R-CTAP and MRAP-CTAP elicited the lowest response (EC50 
3.98 x 10
-2
M).   
These data suggest that both MC2R and MRAP are hindered by the CTAP-tag, to a greater 
degree than NTAP.  As mentioned above, the increased length of the C-terminus of MRAP 
can decrease cell surface expression, and hence an extra length of the CTAP tag may have 
this effect. For MC2R, the extension of the C-terminus has been reported to have differing 
effects, for example, Fridmanis et al. (2010) found fusion of eGFP to the C-terminus 
decreased receptor activity, whereas Noon et al. (2002) found no effect.  
To summarise, in cells co-transfected with TAP-tag MC2R and MRAP, ACTH stimulated a 
cAMP response in a concentration dependent manner, suggesting the proteins are functional.    
Based on these data, tandem affinity purification was attempted with these constructs. 
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3.3.3 Tandem Affinity Purification 
After verifying that NTAP- and -CTAP constructs expressed functional proteins, the 
constructs were used to express target proteins for tandem affinity purification. 
Constructs were transfected in both HEK293 cells, detailed above, and also H295R human 
adrenocortical cells, as I hypothesized that some interacting partners of MC2R/MRAP might 
be adrenal specific like MC2R. 
For both cell lines, cells were seeded at a density of 1x10
8
 cells and transfected with either 
NTAP-MC2R, NTAP-MRAP or empty NTAP vector as a negative control. After 48h lysates 
were collected and subjected to the double purification steps detailed in section 2.5.9. Briefly, 
lysates were incubated with beads coated in a streptavidin resin overnight, then washed and 
eluted and transferred to beads coated in calmodulin resin and incubated a further 24h. The 
purified lysate bound to the calmodulin resin was washed and then detached from the beads 
with Laemmli buffer containing β-ME and SDS. The experiment was repeated with CTAP 
constructs. 
The efficiency of purification was analysed by Western blot, using aliquots taken from each 
step of the purification process.  The transfection efficiency for H295R cells is relatively low, 
and this is reflected in the poor detection of NTAP-MC2R/MRAP in transfected H295R cells 
with anti-CBP antibody (Fig. 3.8Ai). Similarly, the CTAP proteins were not detected in 
transfected H295R lysates (Fig. 3.8Bi). 
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Figure 3.  8: Tandem Affinity Purification of MC2R and MRAP 
Proteins captured by TAP from HEK293 and H295R cells transfected with (A) empty 
NTAP vector,  NTAP-MRAP or NTAP-MC2R, or (B) empty CTAP vector, MRAP-
CTAP or MC2R-CTAP.  Images show Western blot analysis of lysates from protein 
inputs (i), proteins eluted from streptavidin beads (ii), proteins remaining on the 
streptavidin beads after elution (iii), and proteins detached from calmodulin beads after 
elution with Laemmli buffer (iv), immunoblotted with CBP antibody. NTAP-MRAP 
was detected in both HEK293 (white arrows) and H295R lysates (black arrows) 
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following affinity purification (Aiv).  An additional higher molecular weight band (red 
arrow) was observed in HEK293 lysates following the first purification step (Aii). 
MRAP-CTAP and MC2R-CTAP were detected in HEK293 lysates following 
purification (white arrows depict MRAP-CTAP, black lines depict MC2R-CTAP), but 
not in H295R lysates (Biv). Failure to detect MRAP-CTAP or MC2R-CTAP in H295Rs 
could be due to low expression levels.  A considerable amount of protein was left on 
streptavidin beads following the first purification step which could decrease total yield 
(Aiii & Biii).  
 
In HEK293 cells, NTAP-MRAP was readily detectable at 27kDa from input lysates (Fig. 
3.8Ai white arrow), but the anti-CBP antibody detected a lot of background from nonspecific 
proteins. MRAP-CTAP was not detected in HEK293 inputs due to high background and 
possibly low expression levels (Fig. 3.8Bi). 
Following elution from streptavidin resin, immunoblotting with anti-CBP antibody showed 
the first purification step had eradicated most non-specific bands. In HEK293 cells, NTAP-
MRAP was detected as a doublet (Fig. 3.8Aii white arrows) after this first elution and 
MRAP-CTAP as three species (Fig. 3.8Bii white arrows) confirming our findings in section 
3.3.2. As previously mentioned, MRAP has previously been demonstrated to migrate as 
multiple species, which have described to be products of glycosylation, post-translational 
modifications and/or cleavage products (Metherell et al., 2005; Webb et al., 2009). 
In H295R cells, NTAP-MRAP was not detected from input lysates using anti-CBP, only after 
purification with the streptavidin resin, which revealed a 27kDa band (Fig. 3.8Aii black 
arrow) and a slower migrating band (Fig. 3.8 Aii red arrow), possibly the SDS resistant 
homodimer previously described (Cooray et al., 2008).  MRAP-CTAP was not detected in 
H295R lysates after this purification step (Fig. 3.8Bii). 
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Western blot analysis of streptavidin coated beads resuspended in Laemmli buffer showed 
that a lot of protein remained on the beads following the elution step, suggesting some 
inefficiency in the protocol/purification process (Fig. 3.8Aiii and Biii white arrows). 
Following purification with calmodulin resin, Western blot analysis showed the higher 
molecular weight species of NTAP-MRAP in H295R cells was absent, suggesting the band 
was not specific to MRAP (Fig. 3.8Aiv).  The lighter species of the doublet in HEK293 cells 
was also absent and hence may also have been non-specific (Fig. 3.8Aiv). The other 
possibility is that the washes were too stringent, removing interactors.  
NTAP-MC2R was not detected with anti-CBP antibody for either cell line after two-step 
TAP (Fig. 3.8Aiv).  It is well documented that GPCRs do not form a clear banding pattern, 
and often migrate as a smear  (Webb et al., 2009). However, one would expect to see a 
banding pattern after double purification, as seen for MC2R-CTAP in HEK293 cells (Fig. 
3.8Biv black lines).  Furthermore, after 2-step purification, neither MC2R-CTAP nor MRAP-
CTAP was detected in H295R lysates using anti-CBP antibody (Fig. 3.8Biv).  
All lysates from transfected H295R cells were run on 4-12% SDS-PAGE in parallel with 
lysates from cells transfected with empty vectors. The gel was then fixed and stained with 
Coomassie blue to make proteins visible. The resultant banding patterns were compared to 
select protein bands to send for mass spectrometric (MS) analysis (Fig. 3.9A). For gel A the 
NTAP vector lane and NTAP-MC2R lanes showed very similar banding patterns in keeping 
with the suspicion that the NTAP-MC2R purification had failed. For this reason no bands 
were sent for analysis from NTAP-MC2R. Bands EM1_1, EM1_2, EM1_3 and EM1_4 from 
the NTAP-MRAP purification, that differed from the vector alone lane, were submitted for 
MS. For gel B bands EM2_1, EM2_2, EM2_3, EM2_7, EM2_8, EM2_9, EM2_10 that 
differed from the control lane were submitted for MS (Fig. 3.9B). We speculated that bands 
EM2_7, EM2_8 and EM2_9 might harbour MRAP.  Bands EM2_4, EM2_5 and EM2_6, that 
presented similar banding patterns across all three lanes, were also sent for MS in the 
anticipation of finding MC2R somewhere within the smears for EM2_5 and EM2_6 with the 
expectation it would be absent in EM2_4. 
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For detection of interacting partners, gel slices were digested and analysed by mass 
spectrometry which was carried out by the KCL proteomics facility (detailed methodology 
section 2.5.10).  The full list of proteins detected from bands labelled in figure 3.9 is shown 
in table 3.1.   
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Figure 3.  9: Coomassie blue staining of affinity purified lysates 
Affinity purified protein complexes from H295R cells transfected with either empty 
vector, MC2R or MRAP flanked by N-terminal (A) or C-terminal (B) TAP-tag were 
separated on a 4-12% 1D SDS-PAGE and detected by Coomassie Blue staining of the 
gel.  Purified extracts from cells transfected with empty TAP-tag vector were ran in 
parallel as a negative control.  Bands that were present in either MC2R or MRAP lanes 
but absent from the empty vector purification were considered for LC/MS/ analysis. 
The bands labelled were excised for digestion and LC/MS/MS analysis. 
 
3.3.4 Identification of interacting partners by mass spectrometry 
 
Band 
ID. Protein I.D. Species 
Uni-prot 
Access. 
No. 
MW 
(Da) pI 
No. 
Pep. 
No. 
Uniq. 
% 
Cov. 
EM1_1 
  
  
  
  
Serum albumin Bovine P02769  69248 5.82 4 2 4% 
GTPase-activating-
like protein IQGAP2 Human Q13576  180465 5.47 8 1 1% 
GTPase-activating-
like protein IQGAP1 Human P46940  189134 6.08 7 1 1% 
Ig kappa chain C 
region Human P01834  11602 5.58 2 1 13% 
Lysozyme C Human P61626  16526 9.38 2 1 8% 
EM1_2 
  
Serum albumin Bovine P02769  69248 5.82 9 4 8% 
Heat shock protein 
HSP 90-beta Human Q4R4T5  83185 4.97 7 3 6% 
EM1_3 
60kDa heat shock 
protein,  Human P10809  61016 5.7 3 2 4% 
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mitochondrial 
       
  
  
Tryptophanase E.coli P0A853  52740 5.88 3 2 5% 
NADPH: 
adrenodoxin 
oxidoreductase, 
mitochondrial Human P22570  53803 8.72 3 2 4% 
EM1_4 
  
  
Serum albumin Bovine P02769  69248 5.82 7 6 12% 
Purine nucleoside 
phosphorylase deoD-
type E.coli Q0T8S9  25919 5.42 4 2 10% 
Streptavidin 
S.avidi
ni P22629  18822 7.93 2 2 16% 
EM2_1 
  
  
  
  
Myosin-9  Human P35579  226392 5.5 221 102 45% 
Myosin-10 Human P35580  228858 5.44 63 26 20% 
Clathrin heavy chain 
1 Human Q00610  191493 5.48 10 8 8% 
Myosin-14 Human Q7Z406  227863 5.76 14 4 3% 
Ras GTPase-
activating-like 
protein IQGAP1 Human P46940  189134 6.08 2 1 2% 
EM2_2 
  
  
  
Myosin-9 Human P35579  226392 5.5 31 19 14% 
Myosin-10 Human P35580  228858 5.44 7 4 4% 
LIM and calponin 
homology domains-
containing protein 1 Human Q9UPQ0  121762 6.1 2 2 2% 
Protein AMBP Human P02760  38974 5.95 1 1 7% 
EM2_3 
  
Myosin-9 Human P35579  226392 5.5 15 10 8% 
Myosin-10 Human P35580  228858 5.44 3 2 2% 
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  Protein AMBP Human P02760  38974 5.95 3 1 7% 
EM2_4 
  
  
  
  
  
  
  
  
60 kDa heat shock 
protein, 
mitochondrial Human P10809  61016 5.7 12 8 23% 
Tubulin alpha-1B 
chain Human P68363  50120 4.94 3 2 8% 
Actin, cytoplasmic 2 Human P63261  41766 5.31 3 1 9% 
Actin, cytoplasmic 1 Human P60709  41710 5.29 3 1 5% 
Tubulin beta chain Human P07437  49639 4.78 3 1 3% 
Putative elongation 
factor 1-alpha-like 3  Human Q5VTE0  50153 9.15 2 1 2% 
Protein AMBP Human P02760  38974 5.95 2 1 7% 
Vimentin Human P08670  53619 5.06 2 1 3% 
Pyruvate kinase 
isozymes M1/M2 Human P14618  57900 7.96 1 1 3% 
EM2_5 
  
  
  
  
  
  
60 kDa heat shock 
protein, 
mitochondrial Human P10809  61016 5.7 17 8 21% 
Tubulin alpha-1B 
chain Human P68363  50120 4.94 4 3 12% 
Tubulin beta chain Human P07437  49639 4.78 4 2   
Vimentin Human P08670  53619 5.06 6 1 3% 
Pyruvate kinase 
isozymes M1/M2 Human P14618  57900 7.96 1 1 3% 
Putative elongation 
factor 1-alpha-like 3  Human Q5VTE0  50153 9.15 2 1 2% 
Methylcrotonyl-CoA 
carboxylase beta Human Q9HCC0  61294 7.57 1 1 3% 
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chain, mitochondrial 
EM2_6 
  
  
  
  
  
  
  
Actin, cytoplasmic 1 Human P60709  41710 5.29 13 9 31% 
Myosin-9 Human P35579  226392 5.5 10 6 5% 
Tubulin beta chain Human P07437  49639 4.78 5 5 17% 
Tubulin alpha-1B 
chain Human P68363  50120 4.94 4 3 12% 
Vimentin Human P08670  53619 5.06 4 3   
Myosin-10 Human P35580  228858 5.44 3 2 2% 
60 kDa heat shock 
protein, 
mitochondrial Human P10809  61016 5.7 2 1 4% 
Actin, cytoplasmic 2 Human P63261  41766 5.31 13 1 5% 
EM2_7 Actin, cytoplasmic 1 Human P60709  41710 5.29 15 10 34% 
EM2_8 
  
Actin, cytoplasmic 1 Human P60709  41710 5.29 7 6 25% 
Protein AMBP Human P02760  38974 5.95 3 1 7% 
EM2_9 
  
  
  
  
Actin, cytoplasmic 1 Human P60709  41710 5.29 83 22 67% 
Tropomodulin-3 Human Q9NYL9  39570 5.08 5 5 21% 
Myosin regulatory 
light chain 12B Human O14950  19767 4.71 6 3 34% 
Myosin-9 Human P35579  226392 5.5 2 2 1% 
Protein AMBP Human P02760  38974 5.95 1 1 7% 
EM2_10 
  
  
  
Tropomyosin alpha-
4 chain Human P67936  28504 4.67 45 23 79% 
Tropomyosin alpha-
3 chain Human P06753  32799 4.68 36 8 25% 
Actin, cytoplasmic 1 Human P60709  41710 5.29 5 4 16% 
Putative Human A6NL28  26253 4.47 8 3 20% 
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tropomyosin alpha-3 
chain-like protein 
  
  
  
Myosin-9 Human P35579  226392 5.5 2 2 2% 
40S ribosomal 
protein S3 Human P23396  26671 9.68 4 1 11% 
THO complex 
subunit 4 Human Q86V81  26872 11.2 1 1 7% 
Table 3.  1: LC/MS/MS analysis of 1D SDS gel bands EM1_1 – EM2_10 from a 
transfected H295R cells 
Rows highlighted in grey represent common false positives such as ribosomal proteins, 
heat shock proteins, cytoskeletal proteins or proteins that associate with the 
cytoskeleton.  Blue represents proteins frequently pulled out since they are interactors 
with the affinity tags. In the species column non-human contaminants are represented 
by red shading. Italicised proteins represent those present in empty vector preparations. 
Parameters analysed were peak intensity (pI), molecular weight (MW), number of 
peptides aligned (No. pep.), the number of peptides unique to protein of interest (no. 
uniq.) and percentage coverage (% cov.) 
Mass spectrometry identified heat shock proteins, ribosomal proteins and a large number of 
cytoskeletal proteins, often reported as false positives in TAP-tag studies, these are 
highlighted in grey in Table 3.1. Other proteins included those known to interact with the 
cytoskeleton, for example IQGAP1&2, tropomodulin-3, LIM and calponin homology 
domains-containing protein 1 and myosin which were also considered false positives.   
Although it is likely MRAP and MC2R interact with cytoskeletal proteins during trafficking, 
it is unlikely these proteins are specific to MC2R function. Furthermore, it is through 
elimination of common false positives that putative candidate proteins can be identified.  
Proteins detected from band 2_4 (Fig. 3.9) containing empty vector lysates included 
cytoskeletal and heat shock proteins, as well as mitochondrial pyruvate kinase.  
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Protein I.D. Uniprot Accession No. 
60 kDa heat shock protein, mitochondrial P10809  
Tubulin alpha-1B chain P68363  
Actin, cytoplasmic 2 P63261  
Actin, cytoplasmic 1 P60709  
Tubulin beta chain P07437  
Putative elongation factor 1-alpha-like 3  Q5VTE0  
Protein AMBP P02760  
Vimentin P08670  
Pyruvate kinase isozymes M1/M2 P14618  
Table 3.  2: False positives isolated by TAP 
Table listing proteins purified from cells transfected with empty TAP-tag vector.  
H295R cells transfected with empty vector alone were subjected to tandem affinity 
purification and MS analysis.  Proteins purified from empty vector preparations 
included cytoskeletal proteins, proteins that interacted with calmodulin binding peptide 
(protein AMBP), and mitochondrial pyruvate kinase. 
 
The bands EM2_5 and EM2_6 contained a similar list of proteins and crucially did not 
contain MC2R. Disappointingly MRAP was not identified in any of the MC2R-CTAP bands 
either.   A list of proteins detected from lysates transfected with CTAP is shown in table 3.2. 
For the purposes of establishing potential candidate proteins, all cytoskeletal, heat shock and 
ribosomal proteins and proteins detected in EC 2_4 were filtered out.  Proteins known to 
interact with CBP and SBP affinity tags were also eliminated, and finally any non-human 
contaminants were excluded.   
A list of the remaining proteins identified and their known functions is shown in Table 3.3. 
Importantly this list did not include the expected reciprocal positive interactors MC2R and 
MRAP themselves. As a crucial validation of the system we would expect the MRAP 
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constructs to pull out MC2R and vice versa. I hypothesised that the candidate protein would 
be involved in the life cycle of MC2R, which could include folding, dimerisation, trafficking, 
docking or endocytosis. To ascertain if this was likely for the candidates listed I searched for 
their functions in online databases. 
 
 
Protein I.D. Uniprot 
Accession No. 
Function 
MC2R-
CTAP 
Clathrin heavy chain 1 Q00610 Intracellular trafficking 
THO complex subunit 4 Q86V81 Nuclear chaperone 
MRAP-
CTAP 
Methylcrotonyl-CoA 
carboxylase beta chain, 
mitochondrial 
Q9HCC0 Leucine catabolism 
NTAP-
MRAP 
Lysozyme C P61626 Bacteriolysis 
NADPH:adrenodoxin 
oxidoreductase, 
mitochondrial 
P22570 
 
Electron transfer 
Table 3.  3: Candidate proteins following elimination of common contaminants 
MS data was filtered by eliminating common contaminants of TAP, and proteins that 
interacted with affinity tags, non human proteins, and proteins that were detected in 
lysates purified from cells transfected with empty vector. 
 
3.4. Discussion 
Proteomic techniques that reveal protein-protein interactions are important tools for 
understanding the organisation and mechanics of cellular processes.  Genetic approaches that 
produce gene and protein lists do not always provide enough insight into how these processes 
are conducted or managed.  
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This chapter aimed to use a proteomic technique to uncover interacting partners of MC2R 
and MRAP, which when dysfunctional, may contribute to the pathogenesis of FGD.  It was 
also important to increase our understanding of MC2R regulation, as until the discovery of 
MRAP it was not possible to express the fully functional receptor in heterologous cell lines.  
Other factors may exist that regulate MC2R lifecycle, and these may interact with MC2R or 
MRAP.  We therefore hypothesised that MC2R and MRAP were two parts of a greater 
complex. 
The tandem affinity purification (TAP) technique, followed by mass spectrometry (MS) was 
employed to uncover interacting partners because it offered several advantages over the 
traditional yeast two hybrid screen.  TAP allows for purification of protein complexes under 
native conditions and cellular compartment, a consideration required when investigating 
transmembrane proteins (Puig et al., 2001; Rigaut et al., 1999; Xu et al., 2010). It allows the 
full length protein to be expressed with post-translational modifications maintained, and has 
reduced background from contaminants compared to the Y2H (Daulat et al., 2007; Xu et al., 
2010).  
The Stratagene Interplay mammalian tandem affinity purification system is a commercial kit 
specifically developed to isolate interacting proteins from mammalian cells.  The double tag 
includes a 38aa streptavidin binding peptide with a high affinity to streptavidin which is 
eluted with biotin, and a 26aa calmodulin binding peptide tag that binds to calmodulin in the 
presence of calcium and is eluted with a chelating agent such as EGTA.  This system has 
been previous used to successfully isolate a number of proteins (Ahlstrom and Yu, 2009; 
Bradley et al., 2007; Chiu et al., 2006; Gallois-Montbrun et al., 2007; Griffin et al., 2007; 
Haag Breese et al., 2006; Hentschke et al., 2010; Juillard et al., 2009; Li et al., 2011; 
Medina-Palazon et al., 2007; Park et al., 2011; Wei et al., 2007; Wiederschain et al., 2007; 
Xie et al., 2009).  Compared to other TAP systems, its main advantage is the gentle elution 
conditions.  Fusion proteins can be eluted with small molecules under mild conditions (Li, 
2011) with no need to use protease cleavage enzymes to release protein complexes during the 
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first elution.  Protease cleavage usually results in a significant loss of yield, therefore 
dispensing with this step is a clear advantage (Li, 2011). 
MC2R and MRAP TAP-tag constructs were successfully cloned and expressed functional 
proteins, with correct subcellular localisation.  Staining patterns mirrored that of previous 
studies, however a future consideration would be to use compartmental markers to confirm 
this data. The Western blot banding pattern of NTAP-MRAP differed to that previously 
published for MRAP-FLAG, presenting as one band compared to the 3 bands ranging from 
16-32kDa observed when transfecting MRAP-FLAG into CHO cells (Webb et al., 2009).  In 
contrast, MRAP-CTAP shared a similar banding pattern to MRAP-FLAG, with three distinct 
bands absent from control lysates.  NTAP-MRAP was however expressed at the correct 
predicted MW (TAP-tag approximately 8kDa), and hence it was possible that the N-terminal 
TAP tag interfered with post-translational modifications.  MRAP is known to be glycosylated 
at the N-terminus (Sebag and Hinkle, 2007). Digesting with PNGaseF confirmed NTAP-
MRAP was not glycosylated, and in our initial cAMP assay, we found no major differences 
between NTAP-MC2R/NTAP-MRAP and HA-MC2R/MRAP-FLAG cAMP responses, 
however in order to determine statistical significance more experimental repeats would be 
required.  
Western blot analysis at each step of tandem affinity purification showed a marked reduction 
in background protein patterning and enhanced purification of target product.  The 
purification process therefore appeared to be efficient. However, a large amount of fusion 
protein was left bound to streptavidin beads following elution, a problem that has been 
encountered previously with elution from streptavidin with biotin (Li, 2011).  This would 
have decreased the final yield, and therefore this step requires further optimisation. 
It was hypothesised that candidate proteins acquired from the affinity purification and Mass 
Spectrometry (MS) would have a role in MC2R life cycle, for example folding, trafficking, 
docking or endocytosis.  MS analysis of TAP-tagged MRAP and MC2R transfected cell 
lysates extracted from coomassie blue stained gels identified a very small number of putative 
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interacting partners; however, most of these were not considered good candidate proteins for 
MC2R regulation. 
MS analysis identified cytoskeletal and scaffolding proteins as well as heat shock protein 60, 
all of which are abundant proteins and common false positives in the TAP technique (Gingras 
et al., 2007).  These were excluded these from the final list of candidate proteins because of 
this reason, however, many studies have implemented cytoskeletal proteins as regulators of 
steroidogenesis, and hence these proteins should not be completely overlooked.  In the 1960’s 
it was demonstrated that stimulating adrenocortical cells with ACTH resulted in a change in 
cell morphology, which was found to be due to paxillin (Han and Rubin, 1996; Vilgrain et 
al., 1998; Yasumura et al., 1966).  Many studies, the first by Crivello and Jefcoate (1978), 
have used inhibitors of cytoskeletal protein polymerisation to investigate the effects on 
steroidogenesis in adrenal cells.  Generally, inhibiting polymerisation prevents cAMP 
dependent steroidogenesis at the stage before delivery of cholesterol to the mitochondria 
(Sewer and Li, 2008).   
The final list of the candidate proteins remaining following the exclusion of common false 
positive such as those described above is given in table 3.2.  Of the 5 proteins listed, the most 
fitting candidate gene, based on the criteria detailed above, was clathrin heavy chain 1, which 
was isolated from lysates of H295R cells transfected with MC2R-CTAP, and excised from 
gel slice EM2_1.  It has previously been demonstrated by our own laboratory, that clathrin is 
implicated in the internalisation of MC2R (Baig et al., 2001; Baig et al., 2002). Baig et al. 
showed that internalisation of MC2R in Y1 cells is halted when cells are treated with 
concanavalin A or hypertonic sucrose, which inhibit clathrin-mediated endocytosis.  Baig and 
colleagues also confirmed that MC2R is not internalised through the caveolae mechanism 
because inhibitors filipin and nystatin had no effect on internalisation. Kilianova et al. (2006) 
also confirmed these results using immunofluorescence on M3 cells, showing that β-arrestin-
2-GFP colocalises with myc-hMC2R in endocytic compartments following incubation with 
ACTH.  hMC2R did not colocalise with caveolin-1 either with or without ACTH incubation. 
The detection of clathrin by affinity purification may suggest that MC2R and clathrin interact 
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directly, however this finding would need to be investigated by reciprocal 
immunoprecipitation in order to confirm an interaction.   
MC2R-CTAP also pulled out THO complex subunit 4 encoded by ALYREF, also named 
ALY, which is forms part of the THO/TREX complex.  The THO/TREX complex is involved 
in mRNA processing and export from the nucleus (Masuda et al., 2005; Umlauf et al., 2013).  
The complex associates with the splicing machinery, and along with UAP56, recruits mRNA 
export receptor NXF, which has been suggested to transport messenger ribonucleoprotein 
particles (mRNP) containing processed mRNA to the nuclear pore complex (NPC) where 
they are exported to the cytoplasm for translation on ribosomes (Umlauf et al., 2013).  As the 
THO complex is involved in mRNA processing, it is unlikely the THO complex interacts 
with MC2R at a protein level, suggesting this could be a false positive. However, it is 
interesting that conditions of adrenal insufficiency have been associated with defects in genes 
involved at a nuclear level, for example, 90% of patients with Triple A syndrome, a condition 
of adrenal insufficiency and neurological defects (described in section 1.5), have mutations in 
AAAS, a nuclear pore protein (Prasad et al., 2013; Storr et al., 2009). Furthermore, the 
genetically isolated Irish traveller community that harbour FGD, have mutations in MCM4, a 
DNA helicase involved in DNA replication (Hughes et al., 2012).  
A slightly unsuspected finding from the purification process was the detection of 
mitochondrial proteins from purified lysates of H295R cells transfected with NTAP-MRAP 
or MRAP-CTAP.  In NTAP-MRAP lysates, NADPH dependent adrenodoxin oxidoreductase 
(FDXR) was detected. Nuclear encoded FDXR is an important mitochondrial enzyme for 
multiple biological processes but is particularly important in the adrenal cortex for its role in 
steroid biosynthesis (Ewen et al., 2012).  FDXR receives electrons from NAPDH which it 
transfers to adrenodoxin which then reduces type 1 mitochondrial steroidogenic CYP 
enzymes, including CYP11A1, CYP11B1 and CYP11B2 (Sparkes et al., 1991). Deficiency 
of p450 oxidoreductase, an electron donor to type 2 ER-bound CYP enzymes is associated 
with congenital adrenal hyperplasia (Arlt et al., 2004; Flück and Miller, 2006; Flück et al., 
2008). In light of this finding, a co-immunoprecipitation of FDXR and MRAP was carried 
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out to confirm the interaction, however the FDXR did not immunoprecipitate with MRAP or 
vice versus (data not shown), suggesting the detection of FDXR by TAP-MS was a false 
positive, most likely due to high expression levels of the enzyme. 
In MRAP-CTAP lysates, the β-subunit of mitochondrial 3-Methylcrotonyl-CoA carboxylase 
2 (MCCC2) was co-purified, which is a biotin containing enzyme that catalyses the 
conversion of 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA (Gallardo et al., 2001).  
MCCC is from a family of biotin containing carboxylases including acetyl-Co-A carboxylase 
and pyruvate carboxylase, which catalyse one step in leucine catabolism ultimately leading to 
the production of acetyl-CoA which is used in the citric acid cycle (Chu and Cheng, 2007).  
Whereas the biotin containing alpha unit binds ATP and HCO3
-, the β-unit binds the acyl-
CoA substrate (Gallardo et al., 2001). Patients with mutations causing deficiency in either 
subunit have 3-Methylcrotonylglycinuria, in which acute metabolic decomposition leads to 
convulsions, coma or death typically at 6 months to 3 years of age (Gallardo et al., 2001; 
Holzinger et al., 2001) 
To our best knowledge, MRAP resides at the cell surface and intracellularly at the ER (Chung 
et al., 2008; Metherell et al., 2005). However, with no mitochondrial markers used in these 
studies, it is not yet been determined whether MRAP is also present in mitochondria. NTAP-
MRAP also pulled out lysozyme C, an enzyme that cleaves the  beta-(1,4)-glycosidic bond 
between N-acetylmuramic acid and N-acetylglucosamine in peptidoglycans in bacterial cell 
walls (Callewaert and Michiels, 2010), and therefore not a credible candidate protein for 
MRAP interaction. 
Overall, the TAP-tag technique identified mostly common false positives and poor candidate 
proteins.  Crucially, TAP-MS failed to detect MC2R and MRAP in H295R adrenocortical 
cell lysates, which would be present both as target proteins and as endogenous interactors.  
Furthermore, the potential interaction between MRAP and FDXR was found to be a false 
positive when validated. These data suggest the TAP-MS process was not efficient in 
identifying interactors of MC2R and MRAP and may indicate a need to optimise my protocol 
to gain a better yield and recovery of proteins. 
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Although assessing cAMP response by luciferase assay provided evidence to suggest TAP-
tagged MC2R and MRAP could interact, an important control that should be implemented in 
future before proceeding with ‘bait and prey’ experiments is to coimmunoprecipitate MC2R 
and MRAP, using the TAP technique, for example by pulling down with TAP-tagged MC2R 
and probing for FLAG tagged MRAP.  The lysates would be subjected to Western blot 
analysis to confirm the proteins interact, and the gel would be stained and subjected to MS 
analysis to confirm whether MS was sensitive enough to detect the isolated proteins. 
Several studies that employed the same Interplay Mammalian TAP system to isolate proteins 
have made interesting adjustments to the original protocol which may prove useful for future 
experiments.  Ahlstrom et al. (2009) used the Interplay Mammalian TAP system to 
successfully isolate and recover full length N-terminal tagged WNK4 from HEK293 cells and 
examine its kinase activity against OSR1 and SPAK.  The original protocol was adapted by 
introducing a high salt and detergent lysis buffer and increasing the number of wash steps 
following precipitation from the streptavidin resin (using the high salt buffer), in order to 
dissociate weakly interacting proteins. Comparing preparations separated on a silver stained 
SDS gel taken from the regular and HSD protocols showed a great reduction in background 
in HSD preparations.   
Although Ahlstrom et al. (2009) successfully purified their target protein WNK4, they were 
unable to identify a novel interacting partner by MS, a 40kDa protein kinase that copurified 
with WNK4 and was absent from empty vector preparations. Similarly to my results, mass 
spectrometry detected mostly highly abundant proteins such as tubulin and heat shock 
proteins.  Ahlstrom et al. used 1 x 10cm
2
 plate per transfection, whereas other studies made 
larger preparations from 10 x 15cm
2
 plates (Griffin et al., 2007; Xie et al., 2009), and 
successfully identified novel interacting partners.  In my protocol, I used 8 x 10cm
2
 dishes to 
purify extracts from cells.  Bearing in mind the purification of NTAP-MRAP was detected by 
Western blot, and MS did not detect known interacting partners, a problem with my protocol 
could be that MS is not sensitive enough to detect low abundance proteins. Therefore, a 
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future consideration would be to scale up my experiment. This may also increase the 
likelihood of detecting interacting partners. 
More recent studies implementing Interplay technology have used the latest version of the 
system, the Interplay ‘Adenoviral TAP system’ (InterPlay), which uses viral infection to 
increase transfection efficiency (Li, 2011).   This could be an important consideration for 
future attempts to find interacting partners of MC2R and MRAP as the H295R line used for 
this project has a low transfection efficiency.  Another advantage being the likelihood of 
gaining expression levels closer to physiological levels, which has been argued to reduce 
false positives and encourage only true interactions (Bradley et al., 2007; Chen et al., 2005; 
Li, 2011; Puig et al., 2001; Rigaut et al., 1999).   
Taking these options into account, there is potential to improve the quality of my data in 
future experiments.  However, the efficiency of the TAP-MS technique as a whole remains 
questionable considering the number of adjustments made by researchers to improve 
efficiency. Common adaptations to the original protocol include substituting the CBP tag, 
which has been reported to produce poor yield/recovery (Li, 2011) and bind endogenous 
calmodulin, interfering with binding of the CBP-tag to the calmodulin resin. Other 
adaptations include reducing tag size to prevent interference with protein complex formation 
or protein complex function (Xu et al., 2010), and introducing triple tags to increase yield (Li 
et al., 2011).  
Despite these many improvements false positives remain. TAP-MS has the ability to generate 
high-throughput data however studies do not show a great deal of overlap in the interactions 
reported. Two of the first high-throughput studies employing TAP-MS to map the multi-
protein complex networks of yeast Saccharomyces cerevisiae were deemed highly successful, 
allowing deep insight into the organisational network of proteins in yeast (Gavin et al., 2006; 
Gavin et al., 2002; Krogan et al., 2006). However, the two datasets showed high levels of 
noise from non-specific interactions and despite employing statistical algorithms and scoring 
systems there was very low overlap between the datasets (Collins et al., 2007; Xu et al., 
2010). 
184 
 
Further limitations of the TAP-MS technique include its unsuitability for detecting transient 
interactions.  This could introduce false negatives into the technique, which could explain 
why control proteins were not isolated for my experiments.  To rectify this, methods such as 
crossing linking could be used in future to stabilise interactions (Gingras et al., 2007).   
To conclude, other proteomic techniques have previously been used within our laboratory to 
find interacting partners of MC2R, including the yeast-2-hybrid and bacterial-2-hybrid 
screen, neither of which identified clear candidate proteins for investigation.  Although TAP-
MS has been associated with limitations which question its reliability, coupled with other 
techniques it has proved to be more informative than previous methods. My application of the 
TAP technique to search for novel candidates of MRAP and MC2R did not generate valuable 
data suggesting it could be optimised in future, for example by stably expressing TAP 
proteins and scaling up experiments to increase the overall yield and abundance of low level 
proteins for MS detection. Following these adjustments, it is possible the TAP-tag technique 
could disclose interesting proteins involved the MC2R lifecycle and potentially novel 
candidate genes for FGD. 
During  the proteomic arm of this project mutations in nicotinamide nucleotide 
transhydrogenase (NNT) were recognised as a novel cause of FGD and, further, a variant in 
another antioxidant gene glutathione peroxidase 1 (GPX1) was identified, the consequence of 
which was unclear. The remainder of my PhD focussed on the investigation of this variant as 
a possible cause of FGD.  
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Chapter 4: Investigation of GPX1 as a putative candidate 
gene for FGD 
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4.1 Background 
4.1.1 Identification of GPX1 as a putative candidate gene for FGD 
50% of FGD cases have mutations in genes in the ACTH signalling or steroidogenic 
pathway, namely MC2R, MRAP or STAR. The discovery of FGD-causing NNT mutations 
introduced a novel pathway into the pathogenesis of FGD suggesting adrenal steroidogenesis 
is affected by changes in antioxidant machinery.  For the second part of this project I 
undertook the functional characterisation of further candidate genes. 
As discussed in section 1.4.17, NNT is an inner mitochondrial membrane enzyme that 
supplies mitochondria with NADPH, required for regeneration of reduced glutathione, a 
potent antioxidant and co-substrate for multiple antioxidant enzymes.  Of the nine probands 
with unknown aetiology analysed by SNP array genotyping, three had chromosome 5 linkage 
(leading to the discovery of NNT mutations), and one had a large region of homozygosity on 
chromosome 3p26-21. Following the investigation of NNT, this latter region was re-examined 
for putative candidate genes. An antioxidant enzyme, glutathione peroxidase 1 (GPX1) was 
identified based on the known function of NNT.  
Sequencing the affected individual (#1; Fig. 4.1C arrowed) with chromosome 3 linkage 
revealed a twelve base pair in-frame deletion in exon 2 of GPX1; c.del388-399; p.Arg130-
Leu133del (p.R130-L133del) (Fig. 4.1A-B, E), which was heterozygous in the parents and 
the unaffected sibling (#2; Fig. 4.1C ).  This mutation was absent from SNP databases.  Post 
mortem analysis of the deceased 5 month old sibling (#3; Fig. 4.1C) revealed small adrenals 
with loss of the ZF, but it is unknown whether she carried the GPX1 mutation since DNA was 
unavailable for study.  Sequencing 100 FGD patients with unknown aetiology revealed three 
further heterozygous missense mutations: p.Ala132Thr, p.Ala140Ser and p.Leu168Gly in 
different individuals, but no other homozygous or compound heterozygous mutations were 
found. R130-L133del is at alpha helix-2, a stretch of sequence at the subunit interface of the 
tetrameric protein (Fig. 4.1D) so it is possible it affects oligomerisation.  
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Figure 4.  1: GPX1 mutation c.del388-399; p.Arg130-Leu133del in proband (arrowed) 
A.  Partial DNA sequence electropherograms for the affected patient and a wild-type 
control. The dashed line indicates the site of the homozygous in-frame deletion. B. 
Alignments of genomic DNA and corresponding protein sequences. C. Pedigree of the 
family with one affected individual with homozygosity on chromosome 3. 1=proband 
(depicted by arrow); 2= unaffected sibling; 3=deceased sibling with unknown genotype 
(denoted by ‘?’).  D. A ribbon diagram of the GPX1 monomer highlighting segment 
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p.Arg130-Leu133del in pink, which is at the start of a long loop responsible for 
oligomerisation of the protein. E. Location of p.Arg130-Leu133del in second exon of 
transcript 1 (upper panel) depicted by red box and heterozygous mutations depicted by 
grey boxes.  Transcript 2 in lower panel.  Start codons (ATG), the selenocysteine codon 
(Sec) and stop codons (TAG) are labelled accordingly. 
 
4.1.2 Clinical Phenotype 
The proband was diagnosed with familial glucocorticoid deficiency at 2 years of age after 
collapsing. His synacthen test revealed 248-331nmol/l cortisol (normal range >550nmol/l) 
and 145pg/ml ACTH (normal range <50pg/ml). Other biochemistry results showed low 
DHEAS, slightly high sex hormone-binding globulin, low free androgen index (FAI) and he 
was negative for adrenal antibodies.  He was also vitamin D deficient.  Other investigations 
have included an adrenal scan, which was normal, and genetic diagnostic tests which showed 
a 46XY karyotype and no mutations in MC2R, MRAP, STAR or NNT.   
The patient has a body mass index (BMI) of 17.9 and is tall at 1.77m final height, his father 
and mother at 1.7m and 1.68m respectively.  His parents are first cousins and both suffer 
dylipidemia.   The father experienced a heart attack at the age of 67.  The proband has one 
brother who has congenital deafness but no glucocorticoid deficiency and is of normal 
weight.  His sister died aged 5 months of adrenal insufficiency with hypoplasia of the ZF and 
ZR, but preservation of the ZG. 
The proband has previously undergone surgery for an inguinal hernia in 1983 and testicular 
torsion reduction in right testicle in 1988.  For FGD, the proband was treated with 
hydrocortisone as glucocorticoid replacement therapy, and the dose was reduced following an 
improvement in 2003. Treatment was stopped for 6 months between September 2011 and 
February 2012 due to nausea, and is now at 10mg in the morning.  
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4.1.3 GPX1 encodes Glutathione Peroxidase 1  
The glutathione peroxidases are a group of enzymes that use glutathione as an electron donor 
to reduce toxic hydrogen peroxide to water.  GPX1 was first discovered by Mills et al. in 
1957, in erythrocytes, where it was found to act to protect haemoglobin from oxidative 
damage.   
GPX1 is located on chromosome 3p21.3, and has two isoforms (Fig. 4.2). Isoform 1 is 
1146bp, 2 exon transcript, translated as a 203aa protein with a predicted molecular weight of 
22kDa.  The protein forms a tetramer with a predicted weight of approximately 85-93kDa 
(Awasthi et al., 1975). Isoform 2 is 1106bp transcript lacking an intron, which reads through 
into intron 1 to form a shorter coding region.  It has an additional stretch of coding sequence 
absent from the first transcript, which shifts the open reading frame resulting in a shorter C-
terminus but longer 3’ untranslated region (3’UTR).  This transcript is poorly documented in 
literature.  GPX1 also has a pseudogene on the X chromosome which is conserved back to the 
chimpanzee/human split.  The active site, surrounding residues and 3’UTR are homologous 
to functional GPX1, however, a premature stop codon is present at position 161 downstream 
of the active site.  Lack of EST data suggests the gene is not expressed (Mariotti et al., 2012). 
 
Figure 4.  2: GPX1 transcripts.   
Illustration showing two coding transcripts for GPX1. Transcript 1 has two exons and is 
1146bp in length. Transcript 2 has one exon and is 1106 in length. In transcript 2, the 
exon reads through into intron 1 up to the next TAG codon, and the rest of the 
transcript is untranslated. Intron depicted by single line and UTRs by double line. 
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4.1.4 GPX1 is a Selenoprotein 
A decade after its discovery, purification of GPX1 established it as a selenium (Se) 
containing enzyme, which was dependent on the trace element for peroxidase activity (Flohe, 
Rodtruck 1973). Mass spectrometric analysis revealed the presence of a selenocysteine 
residue in the middle of exon 1, sometimes referred to as the ‘21stamino acid’ (Kraus et al., 
1983). The selenocysteine residue (Sec) is similar to a cysteine with Se replacing the sulphur 
moiety in the amino acid side chain (Lubos et al., 2011). Sec, like Cys is redox active and 
forms the active site of the enzyme.  Both Sec and non-Sec containing glutathione 
peroxidases exist with the same catalytic function.  However, replacing the Sec in GPX1 with 
a Cys lowers the rate of catalysis by a few orders of magnitude (Rocher et al., 1992).  Sec is 
deprotonated at a normal physiological pH making it a stronger nucleophile, which could 
partly account for this difference (Lubos et al., 2011), and is also less sensitive to inactivation 
by hyperoxidation (Rocher et al., 1992).  
Se as a trace element is found in various chemical forms in the body but probably confers its 
main biological function through its incorporation into proteins as an amino acid (Lei et al., 
2007).  There are 25 selenoproteins in the human genome, (Kryukov et al., 2003; McCann 
and Ames, 2011). Most are enzymes that have significant roles in redox regulatory pathways 
and thyroid metabolism (McCann and Ames, 2011).   
Following the molecular cloning of GPX1 in mice, sequence analysis revealed the 
selenocysteine was encoded by a TGA opal stop codon in the middle of exon 1 (Chambers et 
al., 1986).  For the stop codon to be translated as a selenocysteine, a number of factors are 
required: 
The 3’UTR sequence is essential for the correct translation of the UGA codon (Berry et al., 
1991; Shen et al., 1993).  Deleting the 3’ UTR in thyroid selenoprotein 5’ deiodinase (5’DI) 
abolishes the enzymes activity, but does not alter the activity of the cysteine-mutant 5’DI 
(Berry et al., 1991).  The 3’ UTR sequence is not particularly conserved amongst 
selenoproteins or between species.  However, a stem-loop secondary structure named the 
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selenocysteine insertion element (SECIS), is highly conserved and required for 
selenocysteine incorporation (Shen et al., 1993).  Despite sequence differences, SECIS 
elements of GPX1, 5’DI and GPX4 can be interchanged without reducing selenocysteine 
incorporation (Berry et al., 1991; Weiss and Sunde, 1998). The sequence of the SECIS stem 
loop can be altered providing the secondary structure is maintained (Shen et al., 1995). Only 
a change to the conserved ‘AAR’ apical loop sequence would affect enzymatic activity 
without changing the secondary structure (Budiman et al., 2009; Shen et al., 1995). 
The role of the SECIS element is to recruit binding proteins that facilitate Sec incorporation 
(Fig. 4.3). These binding proteins include SECIS-binding peptide 2 (SBP2), which recruits 
elongation factor eEFSec and a specific tRNA
(Ser)Sec
 to the ribosome(Donovan et al., 2008) 
(Donovan 2009). Other binding proteins have also been discovered.  In a model proposed by 
Chavatte et al. (2005), after associating with the ribosome, SBP2 is exchanged for ribosomal 
L30, and a conformational change in the SECIS loop triggers the release of tRNA
(Ser)Sec
 and 
GTP hydrolysis.  Another binding factor involved  is nuclease sensitive element binding 
protein 1 which increases translation efficiency by stabilising the complex (Shen et al., 2006). 
The importance of selenoproteins as a whole is highlighted by studies examining defects in 
the selenocysteine incorporation machinery.  Mutations in the SBP2 gene in humans lead to a 
multisystem disorder, including azoospermia, impaired thyroid function, axial muscular 
dystrophy, increased susceptibility to ultraviolet radiation and enhanced insulin sensitivity 
(Schoenmakers et al., 2010) and tRNA
Sec[Ser] 
knockout mice are embryonic lethal (Bosl et al., 
1997). 
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Figure 4.  3: Selenocysteine incorporation  
Illustration of selenocysteine incorporation machinery.  The stem-loop SECIS element 
situated in the 3’ UTR, recruits binding proteins SBP2 and EFsec to facilitate 
incorporation of Sec at the ribosome.  After associating with the ribosome, L30 
competes with SBP2 for binding of SECIS, releasing the tRNA
[Ser]Sec
.  
 
4.1.5 GPX1 Catalytic Cycle 
The catalytic heart of GPX1 is not only comprised of the redox active Sec, as crystallography 
studies reveal the involvement of glutamine (Gln) and tryptophan (Trp) residues in substrate 
interaction (Epp et al., 1983) . This triad of residues is highly conserved amongst glutathione 
peroxidases and has been shown to be essential for catalytic function (Maiorino et al., 1998). 
An additional fourth residue, asparagine (Asn), is thought to form a tetrad with these residues 
based on molecular modelling and mutational analysis of D.melanogaster non-Sec GPX4 
(Toppo et al., 2009; Tosatto et al., 2008).   The conservation of these residues is illustrated in 
figure 4. 4, which shows an alignment of all 8 human GPXs. 
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Figure 4.  4: Multiple sequence alignment of human GPX1-8 
The GPX active site tetrad of residues includes Sec (U), glutamine (Q), tryptophan (W) 
and asparagine (N) depicted by boxes. Only GPX8 varies in substitution of glutamine 
(Q) for a serine (S). Consensus symbol ‘*’ indicates positions with a fully conserved 
residue; ‘:’ conservation between groups of strongly similar properties; and ‘.’ 
conservation between groups of weakly similar properties. Residues highlighted Red 
depict small and hydrophobic residues; blue acidic residues; magenta basic residues, 
green hydroxyl, sulfhydryl and amine residues; and grey unusual amino acids 
 
194 
 
GPX1 confers its catalytic action by a ‘ping-pong’ mechanism consisting of peroxidatic and 
reductive steps with an intermediate bond (Brigelius-Flohé and Maiorino, 2013).  As 
illustrated in figure 4.5, in step 1 when a hydroperoxide binds to the Sec active site it oxidises 
the selenol moiety (Se-H) to selenic acid (Se-OH) (Flohe et al., 1973). In the second step 
selenic acid is reduced by glutathione to form a glutathionylated selenol (Se-SG), releasing 
oxygen in the form of water.  In the third reaction Se-SG is reduced by a second glutathione 
molecule back to selenol (Se-H), producing oxidised glutathione (Brigelius-Flohé and 
Maiorino, 2013; Flohé et al., 2011; Lubos et al., 2011). Because the abundance of glutathione 
outweighs the concentration of hydroperoxides in the cell, saturation kinetics are never met 
(Brigelius-Flohé and Maiorino, 2013; Lubos et al., 2011).  The overall reaction is seen in 
figure 4.5B. 
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A. 
 
 
(1) GPX-Se- + H2O2    GPX-SeOH + OH
-
 
(2) GPX-SeO- + H+ + GSH  GPX-Se-SG +H2O2 
(3) GPX-Se-SG +GSH   GPX-Se- +H+ +GSSG  
 
B.     ROOH + 2GSH   ROH + GSSG +H2O  
(Brigelius-Flohé and Maiorino, 2013) 
Figure 4.  5: GPX1 catalytic cycle 
A. Diagram showing GPX1 catalytic cycle with corresponding equations for each step. 
B. Overall equation for GPX1 catalysis of H2O2 
 
4.1.6 GPX Enzyme family 
There are eight GPX genes (GPX1-8), five of which are selenoproteins (Kasaikina et al., 
2011).  GPX5, GPX7 and GPX8 instead have a cysteine residue at their active site (Brigelius-
Flohé and Maiorino, 2013; Ghyselinck and Dufaure, 1990). The enzyme family are thought 
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to have evolved in three distinct groups: GPX1/GPX2, which are enzymatically very similar 
but have different tissue expression (Chu et al., 1997), GPX3/GPX5/GPX6, the latter two 
formed by duplication of GPX3 and GPX4/GPX7/GPX8, with GPX4 as the ancestral gene 
which are all monomeric unlike the other GPXs which are tetrameric (Fig. 4.6) (Brigelius-
Flohé and Maiorino, 2013; Mariotti et al., 2012). The active site tetrad of residues is 
conserved between all mammalian GPXs except GPX8 in which one residue is substituted 
(Fig. 4.6) (Lubos et al., 2011; Tosatto et al., 2008). 
 
Figure 4.  6: Phylogenetic tree for human GPX family. 
 
GPX1 is widely expressed in all tissues, whereas the other genes are more tissue specific (Lei 
et al., 2007).  GPX2 is expressed exclusively in the gastrointestinal tract in rats but in humans 
also the liver and colon (Chu et al., 1997).  It is thought to be an extra source of antioxidant 
defense from gut derived pathogens and can be induced by NRF2, a transcription factor 
upregulated by oxidative stress (Banning et al., 2005).   GPX3 is expressed predominantly 
from the kidneys but is also secreted into extracellular fluid as a glycoprotein (Takahashi et 
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al., 1987; Yoshimura et al., 1991).  GPX4 is expressed in most tissues, however its activity is 
generally lower than GPX1, excluding the testes, where it is highly expressed. GPX5 is an 
epididymis-specific GPX found in humans, primates, pigs and rodents (Brigelius-Flohé and 
Maiorino, 2013) and it is thought to have a role in maintaining sperm integrity, as mating 
GPX5
-/-
 male mice with WT females increases the incidence of miscarriage (Chabory et al., 
2009). Relatively few details are known about the remaining GPXs, but GPX6 has been 
shown to be expressed in olfactory glands (Kryukov et al., 2003),  GPX7 in oesophageal 
epithelial cells (Peng et al., 2012) and GPX8 in the lung (Yamada et al., 2012). 
Most GPXs are cytosolic, but the isoforms do vary in cellular compartment.  GPX1 is 
predominantly cytosolic but also resides in  mitochondria and peroxisomes (Lubos et al., 
2011).  GPX4 can be alternatively spliced into cytosolic, mitochondrial (mtGPX4) and sperm 
nuclear (snGPX4) isoforms (Brigelius-Flohé et al., 1994). The mitochondrial isoform has 
been reported to have a structural function in midpiece of spermatozoa where it is 
enzymatically inactive (Ursini et al., 1999), and knockout of mtGPX4 renders mice infertile 
(Schneider et al., 2009). As the name suggests, snGPX4 resides in the nuclei of spermatozoa 
where it has been suggested to protect the structural integrity of sperm chromatin in 
conjunction with epididymis expressed GPX5 (Puglisi et al., 2012). GPX7 and 8 have been 
reported as ER residing proteins, specifically GPX7 in the lumen and GPX8 in the membrane 
(Nguyen et al., 2011) 
GPX4 is unique amongst the GPXs, in that it is the only enzyme capable of reducing complex 
phospholipid hydroperoxides and cholesterol hydroperoxides in membranes (Arai et al., 
1999).  One theory is that the peroxidatic moiety is more exposed in the monomer allowing 
increased accessibility by larger phospholipid substrates, although GPX7 and 8, which are 
also monomeric have only been reported to reduce H2O2 (Brigelius-Flohé and Maiorino, 
2013).  
 
 
198 
 
4.1.7 Regulation of GPX1 
4.1.7.1 Regulation of GPX1 by Selenium 
The principal regulator of GPX1 expression and activity is Se.  Se is required for tRNA
(Ser)Sec
  
synthesis, hence Se deficiency greatly diminishes GPX1 activity by halting the selenocysteine 
incorporation process at the translational level (section 4.1.4).  In addition, selenium 
deficiency reduces transcript stability as the TGA is then read as a stop codon leading to 
nonsense mediated decay.   Converting the Sec codon (TGA) to either a stop (TAA) or 
cysteine (TGC) will stop regulation by Se, as demonstrated in rat hepatocytes, and 
substituting Sec for a TAA stop codon decreases GPX1 mRNA levels, indicating possible 
nonsense mediated decay (Moriarty et al., 1998).  
The regulation of GPX1 mRNA levels by Se has been demonstrated both in vitro and in vivo 
(Baker et al., 1993; Bermano et al., 1996; Sun et al., 2000; Weiss Sachdev and Sunde, 2001).  
However, the mRNA stability of other selenoproteins is not as severely affected by Se 
depletion (Sunde et al., 2009), even when the selenoprotein is as likely a candidate to 
undergo nonsense mediated decay (Sunde et al., 2009). 
Se regulates each selenoprotein to a different degree, in a tissue dependent manner. For 
example, severe Se deficiency can result in a total loss of GPX1 mRNA expression and 
activity in rat liver. In contrast only 75% loss of GPX4 activity is seen with no changes to 
GPX4 mRNA expression (Bermano et al., 1995).  
The preferential protection of certain selenoproteins under Se deficiency has been reviewed 
by McCann and Ames (2011), who suggest that a hierarchy of selenoproteins exists, where 
those classed as ‘essential’ are more resistant to Se deficiency than those that classed as non-
essential.  A protein is essential if it is required for survival or reproduction, (its absence 
causing embryonic lethality or infertility in mice). Under this assumption, GPX4 is essential 
and GPX1 is not, which is reflected in their respective resistances to Se deficiency (McCann 
and Ames, 2011). 
199 
 
The mechanisms behind this preferential regulation at the translational level are not 
completely understood, however several studies suggest selenoproteins more resistant to Se 
deficiency have greater binding affinity to Sec incorporation machinery such as SBP2 (Low 
et al., 2000; Schoenmakers et al., 2010; Squires et al., 2007). In keeping with this, SBP2 is 
constrained to the nucleus under oxidative conditions, forcing selenoproteins in other cellular 
compartments to compete for its binding when there is limited availability (Papp et al., 2006). 
It has also been suggested that SECIS element variation is a contributing factor which alters 
translation efficiency (Latreche et al., 2009; Low et al., 2000; Squires et al., 2007).   Two 
types of SECIS elements exist the difference between the two lying in the positioning of the 
adenine-adenine-purine (AAR) motif, a highly conserved sequence in all SECIS elements 
(Budiman et al., 2009). Replacing the 3’ UTR of 5’DI1 with either the GPX1 or GPX4 3’ 
UTR alters translational efficiency under Se deprivation, with the GPX1 3’ UTR proving 
least efficient (Bermano et al., 1996).   
Another mechanism involves eIF4a3, a eukaryotic initiation factor released during Se 
deprivation.  eIF4a3 binds to type 1 SECIS elements, competing with SBP2 for binding 
thereby inhibiting translation (Budiman et al., 2009). Selenoproteins with type 1 SECIS 
elements include GPX1 and other selenoproteins at the bottom of the hierarchy (Budiman et 
al., 2009). 
Finally, a number of studies have indicated that regulation by Se is dependent on the 
methylation of the Sec tRNA
Sec[Ser]
. Selenoproteins such as GPX1 that are more sensitive to 
Se deprivation appear to require the Sec tRNA
Sec[Ser]
 to be methylated at position 34 (Um34) 
for successful Sec incorporation.  Methylation of Um34 is decreased by Se deprivation.  
Selenoproteins GPX1, GPX3, SelR and SelT were not detected in Sec tRNA
Sec[Ser] 
knockout 
mice engineered to express the unmethylated form (Carlson et al., 2005).  
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4.1.1.1 Se Independent Regulation of GPX1 
Non-Se regulators of GPX1 expression include adenosine and nucleolin. Adenosine is 
involved in numerous biological functions including the protection again 
ischemia/reperfusion injury and apoptosis (Lee and Emala, 2002).  In human primary 
pulmonary endothelial cells, adenosine treatment can regulate GPX1 by increasing mRNA 
stability and GPX activity, which could explain its protective role (Zhang et al., 2005). 
Similarly, nucleolin has been shown to bind the 3’ UTR of many selenoproteins including 
GPX1 to increase mRNA stability (Wu et al., 2000). Knockdown of nucleolin decreases 
protein levels of selenoproteins in a selective manor, where GPX1 is least affected (Miniard 
et al., 2010; Wu et al., 2000). 
GPX1 is also regulated at the transcriptional level, for example paraquat can stimulate GPX1 
promoter activity (de Haan et al., 1998).  The GPX1 promoter contains binding sites for many 
transcriptional regulators involved in the cellular response to oxidative stress including P53 
(Tan et al., 1999), NFκB and AP-1 (Zhou et al., 2001) and oxygen response elements (Cowan 
et al., 1993). P53, a tumour suppressor that is pro-apoptotic, surprisingly upregulates GPX1 
transcription, but may do this in the initial stages of activation before it induces ROS 
production (Tan et al., 1999). The pro-survival transcription factor NFκB, has been 
implicated in upregulation of GPX1 during oxidative stress.  Inhibitors of NFκB prevent the 
typical ROS induced increase in GPX1 expression in skeletal muscle cells, indicating NFκB 
mediates this response (Zhou et al., 2001). 
GPX1 can also undergo post-translational modifications that regulate its activity.  It is a 
substrate for c-Abl and Arg tyrosine kinases, which interact and phosphorylate GPX1 
increasing its activity.   Under lethal doses of hydrogen peroxide, c-Abl and Arg promote 
apoptosis, but the abundance of GPX1-kinase complexes is low.  Under lower doses, c-Abl 
and Arg activate GPX1 to protect against apoptosis.  c-Abl/Arg deficient cells treated with 
hydrogen peroxide have an increased apoptotic response, suggesting increased sensitivity to 
ROS in the absence of GPX1 activation by these kinases (Cao et al., 2003a).  
201 
 
4.1.8 Functional Role of GPX1: Protection Against Oxidative Stress  
Despite the abundance and distribution of GPX1, the knock-out (KO) mice are normal, viable 
and fertile with no histopathologies until 15 months of age (Esposito et al., 2000). For an 
enzyme that reduces hydrogen peroxide, it is also surprising that KO mice show no 
abnormalities when exposed to hyperbaric oxygen, a form of oxidative stress (Cheng et al., 
1997b).  It is possible that residual glutathione peroxidase activity is maintained by other 
members of the enzyme family, preventing lethality. 
However, a number of independent GPX1 KO mice lines have shown GPX1 to play a major 
role in protection against oxidative stress.  Studies indicate that GPX1 KO mice are more 
susceptible to hydrogen peroxide and paraquat induced lethality (Cheng et al., 1998; de Haan 
et al., 1998) and diquat-induced oxidative stress (Fu et al., 1999) when compared to wild-
type (WT) mice. In keeping with this, GPX1 overexpressing mice are more resistant to 
paraquat induced lethality (Cheng et al., 1998).   
Knockout mice are generally smaller and have increased levels of lipid peroxidation, 
mitochondrial hydrogen peroxide production, and a decreased mitochondrial control ratio 
(less ATP production) in the liver (Esposito et al., 2000; Esposito et al., 1999).  When 
injected with paraquat, KO mice have an increased NADPH/NADP ratio and higher levels of 
protein and lipid peroxidation compared to WT (Cheng et al., 1999). Therefore GPX1 
protects against oxidative stress by attenuating levels of oxidation and maintaining a balanced 
redox status. 
 
4.1.9 GPX1 Polymorphisms and Disease 
 GPX1 KO mice show no gross abnormalities, and no human mutations have been described 
to date however, variants in GPX1 have been implicated in the increased risk of various 
disease states in humans.  The deficiency of Se, considered a trace element, has health 
implications,  presumably due to loss of selenoprotein(s) activity.  Low Se dietary intake can 
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result in Keshan disease, a cardiomyopathy, or Keshan-Beck disease, an osteoarthropathy, 
both due to increased oxidative stress (Lei et al., 2009; Reeves et al., 1989; Wu and Xu, 
1987). 
The antioxidant effects of Se have been recognised for years and it is thought to have 
anticarcinogenic properties (Lei et al., 2007).  In fact, a clinical trial by Clark et al. (1996) 
showed daily supplementation with Se reduced mortality rates significantly (Clark et al., 
1996).  However, other studies such as the SELECT trial by Lippman et al. found Se had no 
beneficial effect on cancer risk (Lippman et al., 2009).   
The two most common sequence polymorphisms in GPX1 associated with increased 
susceptibility to disease are a proline to leucine substitution at position 198, and a variation in 
the number of alanine repeats (5 to 7) in exon 1 with five alanines found most commonly 
(Moscow et al., 1994; Shen et al., 1994). A high incidence of the P198L SNP has been 
identified in patients with lung cancer (Moscow et al., 1994), bladder cancer (Ichimura et al., 
2004) and colon cancer (Hu and Diamond, 2003). Furthermore, expression of GPX1 is 
decreased in breast and prostate cancer cell lines (Gladyshev et al., 1998; Hu and Diamond, 
2003) and in a liver cancer mouse model (Esworthy et al., 1995). 
The sequence polymorphisms described are known to affect enzyme activity. A recent study 
by Zhou et al. (2009) showed GPX1 with 5 alanines and a leucine at position 198 had 
significantly higher activity than other alleles when transiently transfected into Se treated 
MCF-7 cells which have low levels of GPX1.  However the authors only investigated the 
activities of 5 and 7 alanines in combination with proline or leucine residues and did not 
investigate the activity of a 6 alanine/leucine combination. Moreover, other studies have 
suggested the leucine allele at 198 gives lower GPX activity due to reduced responsiveness to 
Se (Hamanishi et al., 2004; Lei et al., 2009), and the number of alanines has no effect on 
activity (Moscow et al., 1994; Shen et al., 1994). 
Loss of heterozygosity at this locus is common in cancer (Hu and Diamond, 2003; Moscow et 
al., 1994).  It is therefore interesting that naked mole rats, that have a naturally occurring 
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mutation in GPX1 causing a premature stop codon and minimal expression, do not develop 
cancer and have an unusually long life span for rodents of 28 years (Kasaikina et al., 2011). 
In addition to cancer, GPX1 polymorphisms have been associated with increased 
susceptibility to cardiovascular disease, neurodegenerative diseases such as Parkinson’s 
(Damier et al., 1993), Alzheimer’s (Paz-y-Mino et al., 2010), osteoporosis (Mlakar et al., 
2010) and decreased activity has been associated with early onset type 1 diabetes mellitus 
(Dominguez et al., 1998).  
 
4.2 Aims 
The genomic arm of this project focused on the discovery of GPX1 as a novel candidate gene 
for FGD.  The aim of this chapter was to uncover the mechanism through which a mutation in 
GPX1 may cause FGD, and to investigate the role of GPX1 in the adrenal cortex by: 
(1) Functionally characterising R130-L133del in vitro 
(2) Analysing GPX1 expression levels in the adrenal cortex relative to other tissues by 
real time PCR  
(3) Knocking down GPX1 with shRNA in human adrenocortical cells and assessing 
cellular and steroidogenic function.  
(4) Assessing differences in adrenal morphology and corticosterone production in 
GPX1 KO mice compared to WT by immunohistology and radioimmunoassay 
 
 
4.3 Results 
4.3.1 Analysis of GPX -/- Mouse Adrenals 
GPX1 is one of the most abundant antioxidant enzymes in mammals and is ubiquitously 
expressed throughout the body. GPX1
-/-
 mice show no obvious phenotype and naked mole 
rats, which lack a functional GPX1, have no reported abnormalities. It was therefore 
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questionable whether GPX1 deficiency could be the cause of the adrenal phenotype in our 
patient.   In humans, post mortem histological analyses of adrenals from FGD patients show 
small adrenals, with disorganised glomerulosa cells and absent fasciculata and/or reticularis 
cells (Clark and Weber, 1998). An autopsy of the deceased 5 month old sibling of the 
proband (no 1 Fig. 4.1C) revealed small adrenals with loss of the ZF, but it is not known 
whether the individual carried the GPX1 mutation.  To address this question I employed a 
mouse model with loss of GPX1, to analyse adrenal gland histology for abnormalities.   
Adrenals from 4 month old WT and GPX1
-/-
 mice were obtained courtesy of Xingen Lei, 
Cornell University (Esworthy et al., 1997).  Mice were from a mixed genetic background.  
The adrenals from WT and GPX1
-/-
 were of similar size.  Adrenals were embedded in 
paraffin and sectioned into 8µm slices as described in section 2.8.3. 
Haematoxylin and eosin staining (H&E) was used to inspect gross adrenal morphology.  
GPX1
-/-
 mice showed normal adrenal morphology compared to WT mice (Fig. 4.7A).  
To check steroidogenic capacity cells were immunostained with side chain cleavage enzyme 
(CYP11A1) antibody. CYP11A1 converts cholesterol to pregnenolone in the first and only 
rate limiting step of steroidogenesis, and is therefore expressed in all steroid producing cells.  
Immunofluorescent analysis showed typical CYP11A1 staining in all adrenal cortex zones, 
for both WT and GPX1
-/-
 mice, suggesting loss of GPX1 does not affect adrenal morphology 
(Fig. 4.11B).  The intensity of CYP11A1 staining was not distinctly different.  Sections were 
counterstained with zonal marker inner-zone antigen 1 (IZA-1), a protein expressed only in 
the zona fasciculata and reticularis.  WT and GPX1
-/-
 mice both showed typical zonation with 
no abnormalities in the knockout (Fig. 4.7B). 
Loss of GPX1 in previous mouse studies has been associated with increased levels of 
apoptosis, and mice with a spontaneous NNT mutation show greater levels of cleaved 
caspase-3, a marker of apoptosis, in the ZF (Meimaridou et al., 2012b). We hypothesised that 
loss of GPX1 may present a similar phenotype.   Immunostaining WT and GPX1
-/-
 sections 
with cleaved caspase-3 antibody showed an unusual phenotype, with staining apparent 
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between steroidogenic cells possibly staining blood vessels (Fig. 4.7C).  This staining pattern 
was characteristic of capillary wall vascular endothelial cells that run through the adrenal 
cortex. The intensity of staining was much higher in the GPX1
-/-
 mice perhaps indicating 
higher levels of apoptosis in these cells. Unfortunately further analysis of GPX1
-/- 
mouse 
adrenals was not possible due to a lack of supply. 
NNT mutant mice also had significantly lower corticosterone levels than WT (Meimaridou et 
al., 2012b), consistent with FGD patients who present with low or undetectable levels of 
cortisol.  Therefore basal corticosterone levels were measured for 6 WT and GPX1
-/-
 mice by 
radioimmunoassay, which was performed by colleagues at Cornell University, US.  GPX1
 -/-
 
mice showed a trend towards lower basal corticosterone levels than WT (Fig. 4.7D), but the 
difference was not significant. Should further mice become available increasing the numbers 
assayed may enable significance of this difference to be established. 
To summarise, the adrenals of GPX
-/-
 mice had normal histology compared to WT, with no 
morphological and zonal differences or changes to CYP11A1 expression pattern.  The 
adrenals did however have increased cleaved caspase-3 staining in an unusual pattern that 
appeared vascular.  Measurement of basal corticosterone concentration showed a trend 
towards lower levels in GPX
-/-
 mice however there was no statistical significance. 
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Figure 4.  7: Analysis of adrenals from 4 month old WT and GPX1
-/-
 mice.   
A. H&E staining of wild-type (i and ii) and GPX1
-/-
 mice (iii and iv). Adrenals from 
GPX
-/-
 mice had grossly normal morphology . B. GPX1
-/-
 adrenals had normal zonation,  
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depicted by immunofluorescent staining for zonal markers CYP11A1 (ii and vi) and 
IZA-1 (iii and vii) which was similar to WT. C. Increased immunofluorescent staining 
with apoptotic marker cleaved caspase-3 showed staining characteristic of vascular 
endothelial cells in GPX1
-/-
 mice adrenal (iii and iv) which was absent from WT adrenals 
(i and ii)(n=2). D. Basal corticosterone levels in wild-type and GPX
-/-
 mice, measured by 
radio-immunoassay.  GPX
-/-
 mice had lower corticosterone levels but the difference did 
not reach statistical significance (n=6).  Abbreviations: ZG, Zona Glomerulosa; ZF, 
Zona Fasciculata; CYP11A1, p450 side chain cleavage enzyme; IZA-1, Inner Zone 
Antigen 1. 
 
4.3.2 Tissue Distribution of GPX1 Expression in Humans 
Expression levels of a gene can give an indication of tissue specific functional significance. 
To investigate GPX1 expression in the adrenal cortex relative to other tissues, tissue 
distribution of GPX1 mRNA was analysed using cDNA synthesised from a panel of human 
tissue RNA samples of trauma patients with no underlying health issues (Ambion).  Real time 
quantitative PCR using primers targeting GPX1 and GAPDH (section 2.3.7) was carried out 
on this panel. 
Data was analysed using the absolute quantification method.  The Ct value of the unknown 
was quantified absolutely by interpolating the quantity from a standard curve, whose 
quantities were pre-determined spectrophotometrically. Gene expression of the house keeping 
gene GADPH was used for normalisation.   
Analysing the mRNA expression of GPX1 relative to GAPDH in each tissue, showed GPX1 
was highest in the adrenal cortex, suggesting it has an important role there.  Following the 
adrenal, mRNA expression was highest in the spleen and adipose tissue (Fig. 4.8A).  
Comparing tissue distribution of NNT, a known FGD causing gene, did not show a similar 
expression pattern however both were highly expressed in adipose tissue with substantial 
expression of NNT in the adrenal (Fig. 4.8C).  
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Figure 4.  8: Quantitative Real time PCR analysis of GPX1 mRNA expression in 
humans 
Real time PCR analysis of mRNA expression of GPX1 (A), GPX4 (B) and NNT (C) 
normalised to GAPDH using cDNA derived from a panel of 20 human tissues. A. GPX1 
is highly expressed in the adrenal, spleen and adipose tissue. B. GPX4 is highly 
expressed in the testes, adipose tissue and adrenal.  C. NNT is highly expressed in 
adipose tissue, kidney and thyroid. D. Real time PCR analysis of relative mRNA 
expression of GPX1-4 in adrenal cortex, using adrenal cortex cDNA, normalised to 
GAPDH. GPX4 mRNA levels were significantly lower than GPX1 (***p<0.001) (A-C 
n=3 mean ± SD, D GPX1 and 4 n=3, GPX2 and 3 n=1).  
  
The second most abundant glutathione peroxidase in mammals is GPX4, which is also 
ubiquitously expressed, but predominantly in the testes where it has a role in 
spermatogenesis.  To determine whether GPX1 was the predominant glutathione peroxidase 
in the adrenal cortex, GPX4 mRNA expression was quantified by qRT-PCR in a subset of 
209 
 
tissues.  As predicted, GPX4 mRNA expression peaked in the testes, but was also high in 
adipose tissue and the adrenal cortex (Fig. 4.8C).  GPX1 mRNA expression was significantly 
higher than GPX4 expression in the adrenal cortex, suggesting it is the predominant GPX in 
this tissue.  Preliminary data (n=1) suggested GPX2 and 3 expression was much lower than 
that of GPX1 and 4 in the adrenal cortex, similar to most tissues (Fig. 4.8D). 
These data suggest GPX1 is highly expressed in the adrenal cortex compared to other tissues 
and is more highly expressed than GPX4 in the adrenal cortex.   
 
4.3.3 Generation of stable knockdown H295R cell lines using a lentiviral delivery 
system 
4.3.3.1 H295R Human Adrenal Carcinoma Cell line 
H295R cells were chosen as a human adrenal model because they express all of the necessary 
steroidogenic enzymes for glucocorticoid, mineralocorticoid and androgen steroid 
production, secreting 20 steroids in total, representing all three adrenal zones (Wang and 
Rainey, 2012).  The cell line is derived from an adrenocortical carcinoma belonging to a 48 
year old black female and was originally established as the NCI-H295 cell line (Wang and 
Rainey, 2012).   These cells are aneuploid hypertriploid with a modal chromosome number of 
62 (Wang and Rainey, 2012). The H295R cell line is a substrain developed for a lower 
doubling time and greater attachment.  H295Rs are supplemented with Nu serum or Ultra-G 
to increase growth rate, leading to a doubling time of 2 days (Wang and Rainey, 2012). For 
cell maintenance conditions see section 2.1.1.   
H295Rs are not responsive to ACTH due to low expression of MC2R, however these cells do 
respond to forskolin treatment, a cAMP pathway activator (Wang and Rainey, 2012). 
Forskolin can induce the production of cortisol, 11β-hydroxyandrostenedione, DHEA, 
DHEAS, corticosterone, 11-deoxycortisol and androstenedione (Wang and Rainey, 2012). 
Hence, the cell line makes a good model for steroid synthesis. 
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To investigate the role of GPX1 in the adrenal cortex, GPX1 expression was knocked down 
in human adrenocortical cells (H295R).  Poor transfection efficiency is a common difficulty 
associated with the H295R cell line when using traditional cationic lipid transfection 
methodology. Therefore, stable cell lines were generated using lentiviral transduction, using 
pGIPZ plasmids expressing shRNAs targeting one or more regions of the GPX1 gene.   
 
4.3.3.2 Optimisation of puromycin selection 
The pGIPZ shRNA lentiviral vectors used for stable KD cells lines contain not only the 
shRNA but also a puromycin resistance gene, making it possible to select cells which express 
the shRNA and a GFP tag allowing easy identification of transfected cells.  Before generating 
stable cell lines, the optimal concentration of selection antibiotic puromycin was determined 
by a kill curve. The kill curve was designed to quantify the minimum concentration of 
puromycin needed to cause significant cell death in 3-4 days and to have killed all cells by 
day 7.  H295R cells were seeded in triplicate in 24-well plates and subjected to doses of 
puromycin ranging from 0 to 10µg/ml.   
From observation it was evident that a dose above 2.5µg/ml was neccessary to cause cell 
death in 3 days (Fig. 4. 9).  Based on these data, selection was started at 4µg/ml, which could 
be increased to 5µg/ml if required.  The efficiency of the treatment was easily determined by 
visualising the cells under a fluorescent microscope, as the shRNA are expressed with a GFP 
tag. 
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Figure 4.  9: Puromycin Kill curve.  
Cells plated at a density of 20,000 were subjected to doses of puromycin ranging from 0 
to 10µg/ml.  Massive cell death was observed for doses of 5µg/ml and above, suggesting 
a dose between 2.5µg/ml and 5µg/ml was suitable for puromycin selection. Data is based 
on visual observation of cells treated in triplicate. 
 
4.3.3.3 Generating stable cell lines 
Three stable cell lines were created using lentiviral transduction (section 2.1.7.), each 
expressing different combinations of shRNAs targeting one or more regions of the GPX1 
gene. An additional ‘scrambled’ (SCR) cell line was created as a negative control, which 
stably expressed a shRNA targeting a nonspecific sequence.   
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The following combinations of shRNA were used to create the respective cell lines: 
Cell line: shRNA ID: 
KD-10 #10 
KD-0910 #09 and #10 
KD-070910 #07,  #09 and #10 
 (Sequences detailed in section 2.1.7.2) 
To determine knockdown efficiency, mRNA expression of GPX1 relative to GAPDH was 
measured by quantitative real time PCR (qRT) using primers specific to GPX1 and GAPDH. 
SCR and GPX1 knockdown (KD) cells, were seeded in 6 well plates and grown to 90% 
confluency, then lysed for RNA extraction and cDNA synthesis.  qRT-PCR showed that 
mRNA levels were reduced by approximately 50% in GPX1 KD cell lines compared to SCR, 
with the highest KD of 54% seen in KD-10 cells (Fig. 4.10Ai).   
shRNA sequences were chosen that were specific to GPX1, however mRNA levels of GPX4, 
the second most highly expressed GPX, were checked by qRT-PCR to confirm any 
experimental findings from functional assays were the result of GPX1 KD alone.  mRNA 
levels of GPX4 were unchanged in GPX1 KD cells compared to SCR (Fig. 4.10Aii).  This 
also suggests that GPX4 is not upregulated in absence of GPX1 expression.  The subsequent 
effect of mRNA KD on protein levels was determined by Western blot.  Cell lysates from 6 
well plates were collected and immunoblotted using anti-GPX1 and anti-actin antibodies.  
Western blot analysis showed an >80% decrease in GPX1 protein abundance in all three 
GPX1 KD cell lines compared to SCR with KD070910 cells showing the highest knockdown 
of 92% (Fig. 4.10B). 
These data show successful generation of GPX1 KD model in H295R cells with no 
compensatory increase in GPX4 mRNA expression. 
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Figure 4.  10:GPX1 knockdown in human adrenocortical carcinoma cells 
RNA and protein extracts were collected from cells harvested after stable transduction 
of shRNA and cDNA was generated. mRNA and protein knockdown were assessed 
relative to a scrambled negative control.  A. Knockdown validation by real time PCR 
analysis measuring GPX1 mRNA expression relative to GADPH (n=3 ± s.d.) B. 
Knockdown validation by Western blot and densitometric analysis of GPX1 protein 
levels relative to β-actin loading control (n=4 ± s.d.). C. Real-time PCR analysis of GPX4 
mRNA levels relative to GAPDH following GPX1 knock down (n=3 ± s.d.)  .    
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4.3.4 Total GPX activity in GPX1 Knockdown cells 
As described above, GPX1 is one of 8 glutathione peroxidases capable of reducing hydrogen 
peroxide in conjunction with several other antioxidant systems.  It is therefore uncertain 
whether loss of GPX1 alone would compromise antioxidant defense in the adrenal cortex.  To 
investigate the GPX1 contribution to total GPX activity in the adrenal, SCR and GPX1 KD 
cell lines were assessed for total GPX activity by an NADPH coupled assay system.   
The GPX assay is a commonly used technique based on the original method established by 
Paglia and Valentine (1967). The protocol can be used on homogenised tissue, plasma or cell 
lysates.  Details of the protocol used for this chapter are described in section 2.7.3.1.  All 
GPXs reduce hydrogen peroxide using glutathione as a co-substrate.  In a coupled reaction, 
glutathione reductase reduces oxidized glutathione simultaneously oxidizing NADPH to 
NADP
+
 (Fig. 4.11).  This replenishes the glutathione store, ready for GPX1 to recycle.  
NADPH absorbs UV light in its reduced form but not its oxidised form, hence the decrease in 
reduced NADPH levels following GPX activity is associated with a decrease in absorbance at 
340nm.  The assay is based on this inverse relationship between activity of GPX and levels of 
NADPH.   
To determine GPX activity, the absorbance of NADPH (A340nm) was plotted against time, 
with the rate of reaction equal to the maximum change in absorbance between two time 
points within linear regression (Vmax). The units of enzyme per milligram protein were 
calculated using the extinction coefficient of NADPH at 340nm (section 2.7.3.1).  Purified 
GPX enzyme was used as a positive control.   
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Figure 4.  11: Spectrophotometric NADPH-coupled GPX assay.   
GPXs reduce H2O2 simultaneously consuming glutathione (GSH) as an electron donor.  
Oxidised glutathione (GSSG) is reduced by glutathione reductase which uses NADPH as 
a donor.  The subsequent decrease in reduced NADPH, which absorbs light at 340nm, 
can be measured as an indicator of GPX activity. The higher the GPX activity, the more 
GSH oxidised leading to greater GR activity and increased oxidation of NADPH to 
NADP
+
.  GSH, reduced glutathione; H2O2, hydrogen peroxide; GPX, glutathione 
peroxidase; GSSG, oxidised glutathione; β-NADPH, β-nicotinamide adenine 
dinucleotide phosphate, reduced form; β-nicotinamide adenine dinucleotide phosphate, 
oxidised form. 
 
Different cell types have different levels of GPX activity (Sandström et al., 1987), therefore it 
is important to optimise the assay to ensure appropriate sensitivity.  High concentrations of 
reducing agents such as DTT can reduce GPX activity, and increasing pH will increase the 
spontaneous reaction between hydrogen peroxide and reduced glutathione.  Indeed, initial 
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assay test runs presented a high level of background activity in the blank sample, which 
contained only reagents from the cocktail and hydrogen peroxide. The assay cocktail was a 
sodium phosphate buffer containing all proteins needed for the enzymatic reaction including; 
NADPH, GSH and glutathione reductase, as well as sodium azide, to inhibit catalase activity.   
To find optimal assay conditions, three variables were investigated: concentration of H295R 
cell lysates, concentration of DTT, and pH.   
For a positive control in all conditions, purified glutathione peroxidase from bovine 
erythrocytes was used.  Figure 4.12A shows that in positive control samples (GPX1), a pH 
greater than 7 leads to a decreased rate of reaction (Vmax), and an increased rate of reaction in 
the blank (Fig. 4.12A), suggesting a spontaneous reaction between hydrogen peroxide and 
glutathione is occurring. Generally, a higher concentration of DTT (1mM), gave higher GPX 
activity for H295R lysates (Fig. 4.12A).  
In terms of assay sensitivity, the optimal cell density in 1mM DTT/sodium phosphate buffer 
appeared to be between variable, but concentration higher than 3.6 x 10
6
 lead to a reduced 
reaction rate. This trend was seen in lysates at pH6.5, 7 and 7.5 in 1mM DTT.  The highest 
detection of activity was in pH7.5 with 1mM DTT and 2.4 x 10
6 
cells, with the largest 
difference between the sample and the blank (Fig. 4.12B).  However, the rate of reaction in 
the blank sample at this pH was very high (Fig. 4.12A), with the linear phase of the reaction 
ending in one minute (not shown). With the reaction ending too quickly, it could be possible 
that data from the start of the reaction would be lost. 
Based on the above data, it was decided that the optimum conditions for the GPX assay were 
sodium phosphate buffer (pH 7.0) with 1mM DTT and lysate from 3.6 x10
6
 H295R cells.  
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Figure 4.  12: NADPH coupled assay for total GPX activity in GPX1 KD cells. 
Spectrophotometric enzymatic assay for total GPX activity following treatment with 
substrate H2O2. Cells harvested in sodium phosphate buffer were sonicated and protein 
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extracts mixed with GSH, NADPH, glutathione reductase and sodium azide. Reactions 
were started with the addition of H2O2 (0.042%). Rate of absorbance of NADPH at 
340nm over a 5 min period was determined and normalised to total protein 
concentration (mg) using a Bradford assay. A. Maximum rate of reaction (Vmax) for 
purified GPX1 (3u/ml) positive control and blank (no GPX/cell lysate) negative control 
samples in 8 different sodium phosphate buffers, calculated as the maximum change in 
absorbance/time (performed in duplicate). B. Total GPX activity per mg total protein 
for lysates of different cell densities in 8 different sodium phosphate buffers (performed 
in duplicate). Cell density indicated by colour: red, 1.2 x 10
6
 cells; yellow, 2.4 x 10
6
 cells; 
blue 3.6 x 10
6
 cells; purple, 8.8 x 10
6
 . C.  Percentage total GPX activity in GPX1-KD 
cells relative to in SCR control (normalised to total protein concentration). GPX activity 
was significantly lower in the knockdown cell line (**p<0.01; n=3 ± s.d.).  
 
Using the optimised conditions, lysates from SCR and KD10 cells were collected and assayed 
(section 2.7.3.1).  Data analysis showed 50% less GPX activity (u/ml) in the KD cell line 
calculated from the rate of absorbance over a 5 minute period following addition of H2O2 (Fig 
4.16C).  This suggests that GPX1 accounts for the remaining 50%, and is the predominant 
GPX in the adrenal cortex.  It also suggests that the other GPXs cannot compensate for loss 
of GPX1. Hence, a significant portion of antioxidant defense in the adrenal cortex would be 
lost with a non-functional GPX1.   
 
4.3.5 Effect of GPX1 knockdown on cell viability 
Evidence suggests GPX1 can modulate both cell proliferative and apoptotic pathways. A 
catalogue of studies investigating GPX1
-/-
 in vivo and in vitro, have shown that loss of GPX1 
increases apoptosis (de Haan et al., 2004; Faucher et al., 2005; Fu et al., 2001).  I therefore 
hypothesised that GPX1 KD would increase oxidative stress in the adrenal and could lead to 
increased apoptosis and hence a decrease in cell viability in H295R KD cell lines. 
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To test whether GPX1 KD has an effect on cell viability and proliferation, SCR and KD cells 
were plated at a density of 5000 cells per well, and grown for 24 hours, then subjected to 
100µM H2O2 and grown for a further 24 hours.  Cell proliferation was determined by 
spectrophotometric MTS assay (section 2.7.4), measuring the number of viable, metabolically 
active cells.   
The MTS assay showed no difference in the number of metabolically active cells between 
SCR and KD cell lines when untreated, however a marked decrease in viability was seen in 
KD cells when subjected to H2O2 treatment (Fig. 4.13A) suggesting that KD cells are more 
susceptible to cell death when exposed to oxidative stress. 
 
 
 
 
Figure 4.  13: Effect of GPX 
knockdown on cell viability 
Cell viability was determined by 
MTS assay measuring absorbance 
at 490nm. Scrambled and 
knockdown cells were either left 
untreated or treated with 100µM 
H2O2 for 24 hours (A) or 72 hours 
(B & C) before assaying. 
A. At 24 hours post treatment there were significantly less metabolically active KD 
cells than SCR (**p<0.01, n=6 ±s.d).  B.GPX1 knockdown cells grow at a similar 
rate to scrambled when untreated (n=3 ±s.d) C. Scrambled cells have a delayed 
response to hydrogen peroxide treatment compared to GPX1 knockdown cells (n=3 
±s.d) 
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To examine this effect further, 3000 cells were plated and grown for 24 hours, then treated 
with H2O2 for 72 hours, to observe a trend in cell viability. When untreated, SCR and KD 
cells grew at a similar rate (Fig. 4.13B). Differences were seen after H2O2 treatment, when 
the number of metabolically active KD cells dropped between 0 and 12 hours, and slowly 
recovered by 48 hours (Fig. 4.13C).  SCR cells also reacted to H2O2, but after 24 hours (Fig. 
4.13C). This delayed response could suggest SCR cells are better protected from hydrogen 
peroxide than the GPX1 KD cells.  
The decrease in viability could suggest an increase in apoptotic cell death.  To test whether 
GPX1 KD cells had higher levels of apoptosis, KD and SCR cells seeded in 6 well plates 
were subjected to acute oxidative stress in the form of 1mM H2O2 for 30 minutes and left to 
recover for 24 hours.  Cell lysates were assayed by Western blot for cleaved poly (ADP-
ribose) polymerase (PARP) protein, which is a marker of cell death by apoptosis.  
Basal untreated levels of cleaved PARP were significantly higher in KD cells compared to 
SCR.  When treated with H2O2, both SCR and KD cells showed a marked increase in cleaved 
PARP relative to actin (Fig. 4.14A-B).  The data suggests that absence of GPX1 may cause 
an increase in pro-apoptotic signaling under normal physiological conditions.  
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Figure 4.  14: Expression levels of markers of oxidative stress 
Scrambled and knockdown cells were either untreated or subjected to 1mM H2O2 for 30 
minutes and left to recover overnight. Lysates from scrambled and knockdown cells 
were immunoblotted with antibodies to cleaved-PARP (A), SOD2 (C), NRF2 (E) and 
protein levels were quantified relative to an internal control, β-actin, by densitometric 
analysis (B, D, F).  There were significantly higher basal levels of cleaved-PARP 
(**p<0.01) (A), but no significant differences in SOD2 (C) or NRF2 (E).   (n=3, mean 
±sd) 
To further investigate the effect of GPX1 KD on oxidative stress in adrenal cells, the protein 
levels of several antioxidants were determined by Western blot.  Increased levels of ROS 
may activate nuclear factor, erythroid 2-like 2 (NRF2), a redox sensitive transcription factor.  
NRF2 acts on antioxidant response elements in the promoters of many antioxidant genes to 
upregulate their transcription (Fig. 4.14), and inhibition of NRF2 can increase apoptosis in 
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lung cancer cell lines (Wang et al., 2008). Previous studies have shown that NRF2 protein 
levels are upregulated by oxidative stress (Purdom-Dickinson et al., 2007), however 
immunoblotting SCR and GPX1 KD lysates with NRF2 antibody did not show any consistent 
differences between the cell lines (Fig. 4.14E-F). Analysing protein levels does not however 
consider the level of NRF2 activity, which is dependent on subcellular localisation as 
described in figure 4.15. 
SOD2 is a potent antioxidant that converts superoxide radicals to H2O2 (Fig. 4.14) which 
goes on to be reduced by GPXs. It is therefore plausible, that loss of GPX1 activity would 
alter the balance of this reaction.  An imbalance of GPX1/SOD2 is seen in the aldosterone 
switch off phenomenon, where chronic ACTH stimulation results in increased SOD2 and 
decreased GPX1 mRNA levels, leading to higher levels of H2O2, and down regulation in 
CYP11B2 (Suwa et al., 2000). Levels of SOD2 were determined for SCR and KD cell lines 
by immunoblotting lysates with anti-SOD2 antibody. Levels of SOD2 were reduced by H2O2 
treatment in all cell lines, but there was no difference between SCR and KD cells (Fig. 
4.14C-D). 
To summarise, the data suggest no difference in cell viability between SCR and KD cells 
under normal conditions however a KD cells show greater vulnerability to H2O2 toxicity. 
GPX1 KD lysates had a higher concentration of cleaved-PARP, an apoptotic marker, 
however there was no compensatory increase in protein abundance of antioxidants NRF2 or 
SOD2, which are upregulated on oxidative stress. 
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Figure 4.  15: Illustration of Nrf2 activation by ROS.  
Under normal physiological conditions Nrf2 is bound to a repressor molecule KEAP1, 
however under increased oxidative stress Nrf2 dissociates from KEAP1 and translocates 
to the nucleus where it dimerises with other transcription factors such as small Maf.  
Nrf2 binds to antioxidant response elements (AREs) in the promoters of antioxidant 
genes and activates their transcription. Nrf2, nuclear factor, erythroid 2-like 2; Maf, 
small Maf; ARE, antioxidant response element; ROS, reactive oxygen species; O
•-
2, 
superoxide anion; H2O2, hydrogen peroxide; MnSOD, manganese SOD; KEAP1, Kelch-
like ECH-associated protein 1 Adapted from (Kensler et al., 2003; Kim and Vaziri, 
2010) 
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4.3.6 Assessing steroidogenic capacity in knockdown cells 
In vitro studies on human Leydig tumour cells have shown that H2O2 administration impairs 
steroidogenesis through reducing protein levels of StAR (Diemer et al., 2003; Shi et al., 
2010; Tsai et al., 2003).   For insight into a mechanism through which a mutation in GPX1 
causes FGD, the protein levels of StAR were checked in KD and SCR lysates by Western 
blot.  Cells were grown in 6 well plates, treated with 1mM H2O2 for 30 minutes and left to 
recover overnight, and lysates were immunoblotted with anti-StAR and anti-actin antibodies.   
StAR protein levels were significantly decreased in GPX1 KD cells both when untreated and 
when treated with H2O2 suggesting that absence of GPX1 affects StAR protein levels, 
potentially by increasing levels of H2O2 (Fig. 4.16A-B).  Quantifying mRNA expression of 
StAR by qRT showed no difference between SCR and KD cell lines, suggesting StAR levels 
were modulated by GPX1 post-transcriptionally (Fig. 4.16C). 
These data suggest a potential mechanism whereby absence of GPX1 reduces StAR protein 
abundance potentially through increasing levels of H2O2. 
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Figure 4.  16:GPX1 Knockdown cells have decreased StAR protein levels 
Scrambled and knockdown cells were treated with 1mM H2O2 for 30min and allowed to 
recover overnight.  A. Lysates were immunoblotted with anti-StAR antibody, anti-
GPX1 to illustrate GPX1 knockdown, and anti-actin as a loading control. StAR protein 
levels were significantly decreased in GPX1 knockdown cells either when treated with 
H2O2 or untreated (*p<0.05). B. Densitometric analysis of Western blot. (*p<0.05, n=3 ± 
SD) C. qRT PCR analysis of StAR mRNA expression in scrambled and knockdown cells 
showed no differences in expression. cDNA was generated from RNA extracts (n=3 
mean±sd) 
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4.3.7 Functional characterisation of GPX1 mutation 
This is the first description of a 12bp deletion in GPX1. I explored the effect of the deletion 
on expression and function of the enzyme, by overexpressing epitope tagged WT and R130-
L133del genes in HEK293 cells.  The expression, subcellular localisation and ability to 
oligomerise were tested. 
4.3.7.1 Cloning GPX1 constructs 
To investigate R130-L133del protein expression, WT and mutant GPX1 were cloned into 
p3XFLAG-CMV and pCMV-tag3B (Myc-tag) mammalian expression vectors.   
Following difficulties amplifying full length WT GPX1, the gene was amplified from 
HEK293 cDNA using a two-step overlap PCR method, where exon 1 and 2 were amplified 
separately using exon spanning primers, and then fused in a subsequent PCR reaction, 
illustrated in figure 4.17. Primers were designed to include the 3’ UTR, which contains the 
SECIS sequence vital for incorporation of the selenocysteine residue.  See detailed 
methodology in section 2.4.2. 
GPX1 was subcloned into pGEM-Te (Promega) by conventional a/t cloning strategies.  
Sequencing revealed an unknown SNP at position 110 (p.Gly110Cys) which was rectified by 
site directed mutagenesis in order to establish a WT construct.   
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Figure 4.  17: Cloning of WT and R130-L133del GPX1-FLAG constructs 
Wild-type and R130-L133del vectors were constructed by 2-step overlap PCR (A & B) 
and subcloned into pGEM-Te (C) vector then transferred to pCMV-3xFLAG and 
pCMV-tag3B).  A. WT gene was amplified in two sections: exon 1 and exon 2-3’ UTR, 
including SECIS element. B. Two amplified fragments fused in second PCR. The R130-
L133 deletion was created using the same strategy with primers bordering the deletion. 
C. Wild-type gene subcloned into pGEM-Te. Plasmid DNA was extracted from positive 
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clones and digested with Not1 restriction endonuclease to release GPX1 insert. Clones 
that released inserts were sequenced. 
R130-L133del was created by fusion PCR using the WT vector as a template. Initially two 
fragments were amplified either side of the deletion, which were fused in a second PCR and 
religated into PGEM-T easy vector.  
GPX1 WT and R130-L133del genes were subsequently cloned into p3xFLAG-CMV vector 
at Not1 sites and pCMV-tag3b at BamH1 and HindIII sites. Inserting fragments at Not1 sites 
led to a frameshift which was corrected by site directed mutagenesis (section 2.4.9). 
 
4.3.7.2 Expression of GPX1 constructs 
GPX1 p3xFLAG-CMV constructs (WT-FLAG and R130-L133del-FLAG) were tested for 
expression by Western blot analysis using FLAG antibody, 48h after transfection into 
HEK293 cells. Western blot analysis showed that the WT gene was expressed as a 25kDa 
protein, the predicted molecular weight of GPX1 plus the triple FLAG tag.  The R130-
L133del GPX1 was also expressed, however at a slightly lower molecular weight, consistent 
with 4aa deletion, and presenting a lower intensity band relative to the loading control 
GAPDH (4.18A).   
The expression of WT and R130-L133del genes was investigated over time.  HEK293 cells 
transfected with one or other vector were lysed at 6, 12, 24, 48 and 72 hours.  The abundance 
of the R130-L133del protein was lower than the WT throughout the time course (Fig. 4.18B). 
To compare the function of these proteins in future experiments, for example enzymatic 
activity, it would be necessary to gain similar protein levels.  In order to optimise a 
transfection protocol where this would be achieved, HEK293 cells were transfected with 
different quantities of the WT plasmid DNA to produce a similar intensity band as R130-
L133del at 24 hours.  These experiments showed that the input of WT plasmid had to be 
reduced 100x to gain similar protein levels to R130-L133del (Fig. 4.18.C-D). 
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To summarise, both WT-FLAG and R130-L133del-FLAG constructs express proteins, the 
latter detected at much lower abundance following transfection at the same DNA 
concentration. 
 
Figure 4.  18: Expression of WT-FLAG and R130-L133del-FLAG in HEK293 cells 
GPX1 wild-type and R130-L133del FLAG-tagged constructs were expressed in HEK293 
cells, and lysates were immunoblotted for anti-FLAG and anti-GADPH as a loading 
control. A. WT-FLAG is expressed at 25kDa. Lower protein levels were seen for R130-
L133del-FLAG at a slightly lower molecular weight. B. GPX1 protein expression over 
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time relative to GAPDH loading control.  Upper panel showing Western blot with 
FLAG and GAPDH antibodies. Lower panel showing densitometric analysis of GPX1 
protein levels relative to GADPH loading control, at time points 6, 12, 24, 48 and 72h C. 
Upper panel showing Western blot with GPX1 antibody of an assay to reduce the 
quantity of wild-type DNA transfected to gain similar expression levels to R130-
L133del-FLAG, lower panel GAPDH loading control.   (n=3, mean ±sd). D. 
Densitometric analysis of GPX1 relative to GAPDH loading control. 
 
4.3.7.3 Subcellular localisation of R130-L133del 
Following the discovery that R130-L133del protein is found at lower concentrations than 
WT, I explored whether the mutation altered the subcellular localisation of the protein.  
GPX1 is a predominantly cytosolic  enzyme but also resides in mitochondria and 
peroxisomes (Lubos et al., 2011).  HEK293 cells transfected with either WT or mutant vector 
and the mitochondrial fluorescent marker MitoDSred were stained with antibody to FLAG 
and cy-labelled secondary antibody, in addition to DAPI, which stains nuclei.   
Confocal analysis revealed the R130-L133del protein had similar staining patterns to wild-
type (Fig. 4.19), suggesting the mutation did not affect subcellular localisation.  For both WT 
and R130-L133del proteins mitochondrial staining was minimal.  This could be due to the 
low percentage of protein localised to this organelle.  
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Figure 4.  19: Subcellular localisation of R130-133Ldel-FLAG in HEK293 cells 
Images show expression of wild-type (A-C) and R130-133Ldel (D-F) FLAG-tagged 
vectors in fixed and permeabilised HEK293 cells.  Cells were stained with anti-FLAG 
antibody and Cy2 secondary antibody (green), cotransfected with fluorescent 
mitochondrial marker MitoDSred (red) and nuclei stained with DAPI (blue).   
 
4.3.7.4   Degradation of R130-L133del. 
The effect of the R130-L133del mutation on GPX1 is unknown, but the reduced protein 
abundance suggest that there is either translational repression or that the protein is 
inappropriately targetted for degradation. GPX1 fills the criteria for nonsense mediated decay 
because it has a UGA codon in the middle of an exon that is at least 50 bp away from the 
intron (Lubos et al., 2011; Silva and Romão, 2009).  However, the SECIS sequence in the 3’ 
UTR prevents nonsense mediated decay.  To assess the R130-L133del degradation, HEK293 
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cells in 12 well dishes were transfected with either WT or R130-L133del-FLAG, or an empty 
vector as a negative control.  Cells were grown overnight, then treated to compare the half-
life of the proteins with either protein synthesis inhibitor cycloheximide (CHX), to halt 
protein synthesis or MG132, a 26S proteasome inhibitor, to inhibit degradation.  As a vehicle 
control, cells were treated with DMSO.  After 4 hours treatment with 25µg/ml CHX a 
reduction in WT and R130-L133del protein abundance was seen (Fig. 4.20A), consistent with 
inhibition of protein synthesis.  Similarly treatment with 25µM MG132 clearly increased 
abundance of R130-L133del, consistent with blockade of the degradation pathway. 
To investigate further, the experiment was repeated with 100X less WT plasmid DNA to gain 
similar protein levels to R130-L133del before treatment.  A higher concentration of CHX was 
used to increase the effect seen, based on optimisation experiments using the WT protein 
(data not shown).  Cells were lysed at 1, 2, 5 and 10 hours after treatment and the percentage 
of GPX1 protein remaining was analysed by Western blot.  After CHX treatment, the 
abundance of both WT and R130-L133del diminished, but a significant decrease in protein 
abundance was only seen for R130-L133del suggesting levels were decreasing at a faster rate 
(Fig. 4.20C-D and I). In support of this there was virtually no R130-L133del protein in CHX 
treated cells after 10 hours (Fig. 4.20C). The half life, calculated from 0.69/K where K is the 
rate constant in Y= Y0e
-kx
, was far shorter for R130-L133del than WT, at 2.714 hours 
compared to 11.15 hours respectively.  However, there was no significant difference between 
the reduction in WT and R130-L133del by 10 hours (Fig. 4.20I).   
MG132 alone increased R130-L133del protein levels significantly compared to DMSO 
treatment (Fig. 4.20I-J), but reduced WT protein levels significantly, possibly due to the 
toxicity of MG132.  Why this should not affect the R130-L133del is not clear.  MG132 did 
increase the intensity of a band between 10 and 15kDa for R130-L133del, however 
expressing R130-L133del with a myc epitope tag did not produce a similar band, suggesting 
it was an artifact, perhaps a degradation product, of FLAG (Fig. 4.20B). 
To summarise R130-L133del had a shorter half-life than WT GPX1, and responded to 
MG132 treatment inhibiting the 26S proteasome, suggesting it was degraded at a faster rate.   
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CHX treatment significantly reduced R130-L133del protein abundance compared to DMSO 
treated cells, but had no significant effect on WT abundance. Despite this, there was no 
significant difference between WT and R130-L133del abundance after 10h CHX treatment. 
This may suggest R130-L133del undergoes some degree of degradation to exhibit a shorter 
half-life than WT, but the low abundance of R130-L133del seen upon transfection may also 
be due to poor translation. 
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Figure 4.  20: Degradation of R130-L133del-FLAG in HEK293 cells.  
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A. HEK293 cells transfected with 25ng WT or 2µg R130-L133del-FLAG treated for 4h 
with 25µg/ml CHX, 25µM MG132, both or DMSO as a vehicle control. An increase in 
R130-L133del protein levels is seen following treatment with MG132. B. Expression of 
WT and R130-L133del FLAG and MYC-tag vectors in HEK293 cells, lysates 
immunoblotted with anti-FLAG and anti-MYC.  C-J. Cells transfected with 1µg R130-
L133del-FLAG plasmid DNA and 10ng WT to gain similar protein concentration, were 
treated with 50µg/ml CHX, 25µM MG132, both, or DMSO as a vehicle control for 10 
hours. Lysates were collected at 0, 1, 2, 5 and 10 hours after treatment and 
immunoblotted with anti-FLAG antibody and anti-GAPDH antibody as a loading 
control (C, E, G, I). Protein concentration was quantified by densitometric analysis 
normalising to GAPDH intensity (D, F, J).  Images show protein abundance of WT and 
R130-L133del-FLAG over time following CHX (C&D), MG132 (E&F) and DMSO 
(G&H) treatment. The half-life of R130-L133del was 2.714h compared to 11.15h for 
WT.  A 12kDa band (indicated by arrow) was present for R130-L133del which 
increased in intensity after MG132 treatment (E), this is likely an artifact (see B).  At 10 
hours (I&J), protein concentration of R130-L133del was significantly lower with CHX 
treatment and significantly higher with MG132 treatment compared to DMSO treated 
cells, however there was no significant difference between R130-L133del and WT 
protein concentration (I&J). (n=3 ±sd *p<0.05, **p<0.01, ***p<0.001) 
 
4.3.7.5 Oligomerisation of GPX1  
R130-L133del is located in alpha helix-3 and the beginning of a region before β-strand 6 
which is associated with oligomerisation (Fig. 4.21).  This region shows structural variability 
which ultimately determines whether the GPX is a monomer like GPX4, a dimer like GPX5 
in plants or a tetramer like the majority of GPXs.    Within dimeric and tetrameric proteins 
this loop is conserved. It contains two flat regions allowing an interface for adjacent 
monomers, and also stabilises interactions with the other two monomers forming the 
tetramer.  Tetramerisation is primarily determined by the presence of the ‘PGGG’ motif 
236 
 
which is upstream of alpha helix-3, and forms a hairpin-like structure which through 
hydrophobic interactions and hydrogen bonds stabilises tetramer formation. 
The deletion R130-L133del, would effectively remove one loop of alpha-helix-3 and the first 
residue of the oligomerisation domain (Fig. 4.21). It is therefore unclear whether the mutation 
would affect oligomerisation.  To further investigate the effect of this mutation, I intended to 
perform co-immunoprecipitation of WT and R130-L133del proteins, by cloning the genes in 
both FLAG and myc tagged vectors.  Unfortunately, initial experiments to optimise 
coimmunoprecipitation with WT proteins, were not successful. In search of alternative 
methods, cells were transfected with WT- and R130-L133del-FLAG plasmids, lysed in a 
non-reducing sample buffer and immunoblotted with anti-FLAG and anti-GPX1 antibodies to 
detect native GPX1 complexes. 
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Figure 4.  21: Ribbon diagram of glutathione peroxidase 1.    
Positions 130-133, affected by R130-L133del, are in alpha-helix 3 and an adjacent 
oligomerisation domain, a region responsible for subunit interface. (i.) GPX1 tetramer 
with positions 130-133 depicted by pink circle.  (ii.-iii).  GPX1 dimer showing positions 
130-133 in pink, alpha-helix 3 in yellow and oligomerisation domain in blue with 
subunit interface indicated by an arrow.  Deletion R130-L133del removes one loop of 
the alpha helix (depicted in pink). Diagrams of GPX1 crystal structure obtained from 
Tetramer image obtained from protein data bank (Kavanagh et al.). Dimer illustrated 
using PyMol software. 
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GPX1 migrated as a smear, possibly due to posttranslational modifications or ubiquitination.  
Blotting with FLAG antibody showed the most striking bands were between 22kDa and 
25kDa, consistent with the monomer (Fig. 4.22A).  An additional band is seen between 75-
100kDa that may represent the tetramer, with a predicted molecular weight of 83-95kDa 
(Flohé et al., 1971).  This band is detected with both FLAG and GPX1 antibodies meaning it 
is specific for the FLAG-tagged GPX1 and is similar for both the WT and R130-L133del 
proteins, suggesting the R130-L133del protein is capable of forming a tetramer (Fig. 4.22B). 
Interestingly, with the GPX1 antibody alone a strong band is seen just below, which may 
represent the endogenous tetramer (Fig. 4.22B red arrow). In addition to these bands, a strong 
band is seen in both WT and R130-L133del channels between 50-75kDa, presumably a 
dimer, which may form before tetramerisation (Fig. 4.22B). 
To summarise, R130-L133del migrates in a similar pattern to WT GPX1, showing bands 
consistent with the predictive molecular weight of the tetramer. Hence, this data suggests 
R130-L133del is capable of oligomerisation. 
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Figure 4.  22: R130-133Ldel can form a tetramer when expressed in HEK293 cells. 
HEK293 cells were transfected with WT- or R130-L133del-FLAG tagged GPX1 vectors 
or an empty vector negative control. Lysates were collected in a non-reducing sample 
buffer and run on SDS-PAGE, then blotted with anti-FLAG and anti-GPX1 antibodies.  
A. Image showing FLAG detection only. Recombinant WT GPX1 is detected with 
strong bands between 22-25kDa, the monomer, and between 75-100kDa, potentially the 
tetramer (black arrows).  A strong band is also seen at approximately 50-60 kDa 
perhaps the dimer (black arrow). No bands were seen for the empty vector negative 
control.  B. Image shows co-staining with anti-FLAG in red and anti-GPX1 in green, 
with overlap in yellow. Overlap of FLAG and GPX1 detection confirms bands are 
specific for GPX1. A band that may correspond to the endogenous protein tetramer is 
depicted by the red arrow. 
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4.4 Discussion 
In the search for novel causes of FGD, a mutation in the antioxidant gene GPX1 was 
discovered in a FGD patient with unknown aetiology.   
4.4.1 GPX1
-/-
 Mouse Model
 
An autopsy on the 5 month old sibling of the affected individual revealed small adrenals with 
loss of the ZF and disorganised cells in the ZG. Adrenals from GPX1
-/-
 mice were analysed to 
check for a similar phenotype.  However, immunostaining with zonal markers IZA-1 and 
CYP11A1 showed no abnormalities in 4 month old GPX1 
-/-
 mouse adrenals compared to WT 
and GPX1
-/-
 cells had steroidogenic capacity.  The mice were however, relatively young, and 
it has been documented in past literature that GPX1
-/-
 mice do not show abnormalities until 
over a year of age (Esposito et al., 2000). H&E staining also confirmed normal morphology, 
in contrast to NNT deficient mice which have been previously noted to show a mild display of 
overcrowded and disorganised cells (Meimaridou et al., 2012b).   
Immunofluorescent staining for cleaved caspase-3, a marker of apoptosis, presented an 
unusual staining pattern in the GPX1 knockout mouse adrenal, characteristic of vascular 
endothelial cells.  Interestingly, GPX1
-/-
 mice have an impaired ability to promote 
angioneogenesis, and isolated endothelial progenitor cells from GPX1
-/-
 mice are more 
susceptible to hydrogen peroxide mediated apoptosis than WT cells (Galasso et al., 2006).  
GPX1 is known to protect against vascular endothelial dysfunction, characterised by 
increased levels of ROS reducing the bioavailability of nitric oxide (NO), which mediates 
vasorelaxation.  Agonists of NO that usually cause vasorelaxation, cause vasoconstriction in 
GPX1 deficient (+/-) mice, and these mice have increased structural abnormalities in 
myocardial vasculature (Forgione et al., 2002). Furthermore, the effect of angiotensin II, a 
ROS-inducing agent in vascular endothelial cells that leads to dysfunction, can be rescued by 
overexpression of GPX1, but augmented by GPX1 deficiency in mice (Chrissobolis et al., 
2008). It is interesting that angiotensin II acts on the zona glomerulosa in which most of the 
cleaved caspase-3 positive staining is seen. However, in order to confirm that the staining is 
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specific to vascular endothelial cells, counterstaining for endothelial cell marker PECAM-1 
would be needed.  By comparison, mice harbouring a natural loss of function mutation in 
antioxidant enzyme NNT elicit increased cleaved caspase-3 staining within the ZF cells of the 
adrenal cortex, from which corticosterone is secreted (Meimaridou et al., 2012b).  The effect 
of increased apoptosis in the vasculature supplying the adrenal is unknown.   
GPX1
-/-
 mice also showed a trend towards less corticosterone production, but this was not 
significant.  The mouse model does not therefore recapitulate the human condition but 
displays a milder phenotype.  This is similar to the situation seen with other knockout models 
used to study adrenal insufficiency syndromes, for example the AAAS
-/-
 knockout mouse, has 
no adrenal abnormalities (Huebner et al., 2006) and NNT knockout mice also show no major 
histopathologies (Meimaridou et al., 2012b). Although NNT knockout mice had a 50% 
reduction in corticosterone levels, these mice were ACTH responsive and had relatively high 
basal and stimulated corticosterone levels (Meimaridou et al., 2012b) in contrast to human 
FGD patients.  It is also worth noting that in our experiment corticosterone levels were high 
for unstimulated mice, suggesting the mice were stressed before the assay. 
4.4.2 Tissue Distribution of GPX1 
In humans, previous studies have shown GPX1 mRNA levels to be high in the liver, heart and 
kidney (Atanasova et al., 2006). The quantitative real time PCR data showed that GPX1 is 
ubiquitously expressed in human tissues, similar to the situation in marmoset and mouse 
tissues (Atanasova et al., 2006; Cheng et al., 1998).  My data revealed GPX1 expression to be 
highest in the adrenal cortex followed by spleen and adipose tissue.  It has been suggested 
that the adrenal cortex has a greater need for antioxidant defense than other tissues, due its 
additional sources of reactive oxygen species from steroid biosynthesis (Azhar et al., 1995). 
During steroidogenesis, electron transfer by CYP enzymes from the donor system is not 
completely coupled, leading to leakage of electrons and generation of ROS.  40% of electron 
flow from NADPH is lost to ROS in the hydroxylation of steroids by CYP11B1, which could 
explain why FGD patients with NNT mutations have isolated glucocorticoid deficiency 
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(Hanukoglu, 2006).   High GPX1 expression in the adrenal gland may act as a compensatory 
mechanism to tackle excess hydrogen peroxide generated by steroidogenesis. 
Compared to GPX1, GPX4 mRNA expression was also ubiquitous but generally lower in all 
tissues apart from the thyroid and testes.  Highest expression was seen in the testes, in 
accordance with previous data (Atanasova et al., 2006), as GPX4 is involved in 
spermatogenesis and acts as a structural component of the sperm midpiece (Imai and 
Nakagawa, 2003).  Following the testes, expression was highest in adipose tissue and the 
adrenal gland.   
Levels of GPX1 mRNA were significantly higher than GPX4 in the adrenal, suggesting 
GPX1 is the predominant form in this tissue. Initial tests (n=1), suggest that GPX2 and 3 are 
expressed at low levels in comparison to GPX1 and 4.  GPX2 is predominantly expressed in 
the gastrointestinal tract but also the liver (Chu et al., 1997; Wingler et al., 1999), whereas 
GPX3 is a glycoprotein expressed and secreted from the kidney (Avissar et al., 1994). 
Both GPX1 and 4 were highly expressed in the adrenal compared to other tissues.  Although 
GPX1 is considered to be the predominant GPX, GPX4 has been well characterised in the 
literature as an important antioxidant that protects membranes from oxidative damage.  
Unlike GPX1, GPX4 is a monomer with 3 alternative splicing forms: cytosolic, 
mitochondrial and sperm-nuclear (Maiorino et al., 2003).  GPX4
-/-
 mice are embryonic lethal, 
due to its unique ability to reduce complex membrane bound phospholipid and cholesterol 
hydroperoxides. Like GPX1, overexpression of GPX4 can protect against apoptosis (Nomura 
et al., 1999). Interestingly, although cGPX4 and mtGPX4 are ubiquitously expressed, 
mtGPX4 is predominantly expressed in the testes with limited expression elsewhere.  This 
suggests that GPX1 is the predominant mitochondrial form in other tissues (Brigelius-Flohé 
and Maiorino, 2013) 
The role of glutathione peroxidase in adipose tissue has been recently explored. Oxidative 
stress has been implicated in the pathogenesis of obesity-associated metabolic diseases.  
GPX1 overexpressing mice are insulin resistant with hyperinsulinaemia and hyperglycemia 
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(McClung et al., 2004), whereas GPX1
-/-
 mice have enhanced insulin sensitivity (Loh et al., 
2009). GPX1 can regulate insulin signalling through modulating H2O2 levels in pancreatic 
islets.  An increase in hydrogen peroxide in GPX1
-/-
 mice leads to the inactivation of redox 
sensitive PTEN, which is an inhibitor of insulin signalling.    Thus, loss of GPX1 increases 
insulin signalling by increasing hydrogen peroxide levels.  It is therefore surprising that 
GPX1 is highly expressed in adipose tissue. Interestingly, the affected FGD patient with the 
GPX1 mutation has been described as underweight. 
One should also consider, that the adrenal is surrounded by a layer of adipose tissue.  A study 
by Li et al. (2009), investigated whether adipocyte secretory products could influence 
adrenocortical steroidogenesis, and found in Y1 mouse adrenocortical cells, adiponectin 
reduced ACTH-stimulated secretion of corticosterone and changed the expression of 
steroidogenic genes (Li et al., 2009). This is interesting considering human hepatic mRNA 
expression of adiponectin receptors has been shown to correlate with mRNA expression of 
GPX1 (Carazo et al., 2011). 
4.4.3 GPX1 Knockdown Model in Human Adrenal H295R cells 
Given the high expression of GPX1 in the adrenal cortex, it was hypothesised that GPX1 has 
an essential role in the adrenal cortex in detoxifying ROS.  The effect of GPX1 knock down 
in human adrenocortical H295R cells was analysed to gain insight into its function in the 
adrenal.  Stable lentiviral transduction of shRNA was carried out to maximise KD of GPX1.  
Three stable cell lines were generated achieving 50% mRNA and 90% protein KD, with cell 
lines 10 and 7910 showing the highest KD. The total GPX activity was measured by an 
NADPH coupled spectrophotometric assay, to determine the percentage to which GPX1 
contributes in adrenocortical cells.  There are 8 glutathione peroxidases in mammals which 
all reduce hydrogen peroxide to water.  KD of GPX1 by shRNA lead to 50% loss of total 
GPX activity in the human adrenocortical cell line, suggesting GPX1 is the predominant form 
of GPX in the adrenal, accounting for a large degree of hydrogen peroxide detoxification.  
mRNA levels of GPX4 were unchanged by GPX1 KD, suggesting its expression is 
independent of GPX1 and not upregulated by absence of GPX1.  Similar findings are 
244 
 
reflected in other cell culture (Kelner et al., 1995; Lei et al., 1995), and mouse models (Cheng 
et al., 1997a; Cheng et al., 1997b).  GPX1 
-/-
 or overexpressing mice show no differences in 
GPX3 and 4 mRNA expression compared to WT (Cheng et al., 1997b).  Taken together, this 
data suggests that GPX1 is the predominant form of GPX in the adrenal cortex, and its loss is 
not compensated for by the other GPXs. 
GPX1 KD cells showed increased basal levels of cleaved PARP, a marker of apoptosis, and 
decreased cell viability when treated with hydrogen peroxide.  Similarly, many cell lines 
cultured from GPX1
-/-
 mice have increased susceptibility to ROS induced apoptosis, 
including astrocytes (Liddell et al., 2006b), embryonic fibroblasts (De Haan et al., 2003), 
hepatocytes (Fu et al., 1999; Fu et al., 2001) and at low oxidative conditions (6% O2) in 
myoblasts (Lee et al., 2006). GPX1
-/-
 mice injected with paraquat have increased mRNA 
levels of pro-apoptotic markers GADD45, Bax, Bcl-w, cMyc, and pro-caspase-3 and 
decreased levels of apoptosis inhibitor BCl-2 compared to WT (Cheng et al., 2003), and 
overexpressing GPX1 protects against these effects, for example in breast carcinoma cells 
(Gouaze et al., 2001).   
Despite significantly higher basal levels of cleaved PARP in GPX1 KD cells, there was no 
difference in viability seen between SCR and KD cells measured by MTS assay. This may 
suggest a subtle phenotype.  The level of cleaved PARP increased after acute oxidative stress 
in both SCR and KD cells, but there was no significant difference between the cell lines.  On 
the other hand, the MTS assay showed exposure to H2O2 significantly reduced viability in 
GPX1 KD cells compared to SCR.  This latter discrepancy could be due to different 
experimental conditions, as cleaved PARP was detected after acute stress (1mM H2O2) and a 
recovery period, whereas viability was measured after 24 hours in 100µM H2O2.   A 
difference in levels of cleaved-PARP after H2O2 was apparent between cell lines, but there 
was so significant difference.  An effect may have been seen with a lower dose of H2O2, to 
which SCR cells may have been more resistant. 
GPX1 has been repeatedly demonstrated to influence apoptotic pathways through modulating 
levels of hydrogen peroxide, predominantly to promote survival (Emerling et al., 2005; Li et 
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al., 2001; Taylor et al., 2004).  Furthermore, the antioxidant and anti-apoptotic effects of Se 
are mediated in part through GPX1 (Cheng et al., 2003; Kasaikina et al., 2011; Kayanoki et 
al., 1996; Kretz-Remy and Arrigo, 2001) . GPX1
-/-
 mice have over 50% less Se in the liver 
than WT, suggesting the remaining Se is used by GPX1 (Cheng et al., 1997a; Cheng et al., 
1997b). Paraquat induced liver aponecrosis is attenuated by Se injection in Se deficient WT 
mice to a greater degree than in Se deficient GPX1
-/-
 mice, presumably due to increased 
GPX1 activity (Cheng et al., 2003). 
Previous studies have demonstrated that excess ROS in different forms can impair 
steroidogenesis (Diemer et al., 2003; Dorval et al., 2003; Shi et al., 2010). Mechanisms for 
impairment include the suppression of StAR protein, which has been shown in Leydig cells 
following exposure to hydrogen peroxide or perfluorododecanoic acid (PFDoA) (Diemer et 
al., 2003; Shi et al., 2010);  and in mice after exposure to pro-oxidant cypermethrin (Jin et al., 
2011). However, the influence of ROS on StAR mRNA expression is not clear, as studies 
show opposing findings.  Another theory is that ROS affects steroidogenesis directly by 
influencing the activity of steroidogenic enzymes (Chanoine et al., 2001).  My data show a 
40% decrease in StAR protein abundance in GPX1 KD cells compared to SCR at baseline 
and 90% decrease when treated with hydrogen peroxide, with no changes to StAR mRNA 
expression, suggesting that StAR is inhibited post-transcriptionally. StAR is expressed in 
three forms: a 37kDa precursor, 32kDa intermediate and a mature 30kDa form.  The 37kDa 
form contains a mitochondrial targetting sequence that is proteolytically cleaved when it 
enters the mitochondrial matrix (Miller and Auchus, 2011).  The 37kDa is considered to be 
the active form of StAR, but the conversion of StAR to its intramitochondrial forms is the 
final step of cholesterol transfer process (Diemer et al., 2003).  Hence the finding of a 
decrease in the 30kDa form suggests that loss of GPX1 increases levels of ROS that inhibits 
cholesterol transport. 
GPX1 has already been linked to the regulation of steroidogenesis.  Adrenocortical cells 
deprived of Se with subsequently lower GPX1 expression levels have decreased steroid 
production after cAMP stimulation (Chanoine et al., 2001), suggesting GPX1 expression 
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influences steroid output. Azhar et al. (1995) also show that an age-associated decrease in 
corticosterone in rats is correlated with a decrease in mRNA and protein levels of several 
antioxidants, including GPX1.    
The above data may give insight into a potential disease mechanism whereby loss of GPX1 
function leads to increased levels of hydrogen peroxide, inhibiting StAR, resulting in reduced 
steroidogenesis.  Alternatively, I did not explore the possibility, that the disease mechanism 
could also act before steroidogenesis, affecting MC2R signalling directly.  A study by 
Wiseman et al. (2011), showed trout exposed to dietary selenomethionine (Se-Met) had 
greater plasma corticosterone levels with increased transcript levels of mc2r but not star, 
cyp11A1 or cyp11b1, which are usually up regulated on ACTH stimulation.  This suggests 
that the Se-Met dependent increase in plasma corticosterone was independent of ACTH, but 
acting on the MC2R signalling pathway (Wiseman et al., 2011). Furthermore, cadmium, a 
toxic ROS inducing endocrine disrupter, suppresses ACTH stimulated cortisol production by 
reducing MC2R, StAR and CYP11A1 transcript levels in trout. The inhibition of ACTH-
induced cortisol production was rescued by a cAMP analog, suggesting it exerted its effect 
upstream on MC2R signalling (Sandhu and Vijayan, 2011).  Therefore, it would be 
interesting to explore the effects of oxidative stress on MC2R signalling and its expression at 
the cell surface. 
4.4.4 Functional Characterisation of R130-L133del 
To further characterise a disease mechanism, it was necessary to functionally characterise the 
R130-L133del mutation in GPX1. Expressing the R130-L133del gene in mammalian 
HEK293 cells showed reduced protein levels compared to WT, which suggested the protein 
was being degraded.  In order to gain similar levels of the WT protein 24 hours after 
transfection, 100x less of the WT plasmid DNA was needed.  Treating transfected cells with 
cycloheximide showed that the R130-L133del protein had a shorter half-life than WT, and 
treatment with MG132 to inhibit the 26S proteasome increased R130-L133del protein levels. 
Furthermore, CHX treatment significantly reduced R130-L133del abundance by 10h 
compared to DMSO treated cells, but did not significantly reduce WT abundance. Despite 
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these findings, there was no significant difference between WT and R130-L133del protein 
abundance 10 hours after cycloheximide treatment.  It is therefore unclear whether the low 
protein levels of R130-L133del are due entirely to degradation, or whether other mechanisms 
such as poor translation may also contribute. 
The protein could be degraded for a number of reasons.  Even small changes to GPX1 
primary structure can change the functioning of this enzyme, for example the Pro198Leu 
mutation in exon 2 and a varying number of alanine repeats at the start of the protein, both 
affect enzymatic activity.  The R130-L133del mutation is on alpha-helix3 and a stretch of 
sequence responsible for subunit interface, so it was predicted to affect oligomerisation.  
However, Western blot analysis of lysates run in a non-reducing buffer showed high 
molecular weight bands between 75-100kDa for the R130-L133del that mirrored that of WT, 
suggesting it was able to form the tetramer, discounting this theory.   
Other possible reasons for degradation include changes to tertiary structure, for example the 
12 base pairs of R130-L133del sit between the Trp and Gln residues of the predicted tetrad 
that form the GPX1 active site hence the deletion would change the distance between these 
residues, which could affect the final tertiary structure of the protein, and the positioning of 
the tetrad residues in the active site (Fig. 4.23).  The region deleted also over crosses a c-
Abl/Arg tyrosine kinase phosphorylation site at positions 132-145 key to GPX activity.   
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Figure 4.  23: GPX1 monomer and catalytic tetrad. 
R130-L133del highlighted in pink, the catalytic tetrad residues Sec in red; glutamine, 
tryptophan and asparagine in orange; and region between catalytic tetrad residues 
altered in length by R130-L133del highlighted in white. The R130-L133del deletion 
would shift tryptophan and asparagine residues away from the active site, as indicated 
by the orange arrow. 
Alternatively R130-L133del protein abundance may be low due to poor translation.  GPX1 is 
already a likely candidate for nonsense mediated decay, and selenocysteine incorporation is 
an inefficient process.  Interestingly, naked mole rats have a naturally occurring premature 
stop gain mutation in GPX1 at the end of exon 2, which is only five codons premature of the 
existing TAG codon.  This mutation similarly results in a low protein levels when expressed 
in mammalian cells. Kasaikina et al. (2011), show that the enzymatic activity of the protein 
was unchanged compared to WT, however, mutating the selenocysteine to a cysteine at the 
active site, rescued protein levels. This suggests that the mutation affected selenocysteine 
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incorporation, leading to the reading of Sec as a stop, and subsequent nonsense mediated 
decay.  It would therefore be of great interest to see whether the R130-L133del has a similar 
effect on selenocysteine incorporation, which could lead to reduced translation and explain 
low protein levels.  
4. 4. 5 Conclusions 
The majority of mutations causing FGD are in genes involved in the ACTH signalling-
steroidogenic pathway.  The discovery of a FGD patient with a mutation in GPX1, and the 
previous findings of FGD causing NNT and TXNRD2 mutations, suggests that oxidative 
stress also plays a role in this disease pathogenesis.  Oxidative stress has also been implicated 
in the pathogenesis of Triple A syndrome, another adrenal insufficiency disorder, and 
adrenoleukodystrophy, which involves the build-up of very-long chain fatty acids.  The 
antioxidant genes causing these conditions are ubiquitously expressed, but impact specifically 
on the adrenal. The pathogenic mechanisms include peroxisomal dysfunction and a failure to 
import antioxidant DNA repair proteins.  Therefore, disruption to redox status in several 
different compartments can impair steroidogenesis in the adrenal cortex.  
 
Taken together, the data from this chapter suggests GPX1 has an important role in preventing 
oxidative stress in the adrenal cortex.  R130-133Ldel renders GPX1 a shorter half-life, 
resulting in low protein levels, however the percentage of protein remaining after CHX 
treatment was not significantly different to WT, suggesting translational inefficiency is also 
involved.  Low levels of GPX1 may cause FGD by increasing oxidative stress in the adrenal 
cortex, potentially by reducing StAR protein levels, inhibiting the first step of 
steroidogenesis.  However, overall analysis of GPX1
-/-
 adrenals and adrenocortical cells with 
GPX1 KD revealed a relatively mild phenotype, raising the question of causality in the 
patient and the possibility that the disease might be di- or oligogenic.  
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Chapter 5: Digenic inheritance of mutations in antioxidant 
pathway genes in the proband with Familial 
Glucocorticoid Deficiency 
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5.1 Background 
In the previous chapter, a mutation in GPX1 in a patient with FGD of unknown aetiology was 
investigated. GPX1 was a valid candidate gene because of the previous finding of mutations 
in antioxidant gene NNT causing FGD, however, investigation into the disease mechanism 
revealed that loss of GPX1 presents a mild phenotype in adrenocortical cells. Although GPX1 
knockdown cells had increased susceptibility to hydrogen peroxide induced cell death and 
lower protein levels of StAR, GPX1
-/-
 mice had relatively normal adrenal glands. At basal 
levels, GPX1 knockdown cells had increased levels of apoptosis, but there was no difference 
to viability in normal conditions, which could suggest the effect of loss of GPX1 is subtle. 
In addition to the above findings, sequencing 100 FGD patients of unknown aetiology did not 
reveal any homozygous or compound heterozygous mutations in GPX1, raising the 
possibility that GPX1 was not the causal gene in our proband.  Alternatively, it was worth 
considering that the disease in this proband was di- or oligogenic with GPX1 in addition to 
other genes, perhaps in the same pathway.  
5.2 Aims 
This chapter aimed to clarify whether GPX1 was the causal gene in the proband, or a second 
gene defect was present, by carrying out whole exome sequencing of the proband and his 
brother.  The function of the second candidate gene identified would be explored in the 
context of the human adrenal cortex by shRNA knockdown of the gene, alone and in 
combination with GPX1 in H295R human adrenocortical cells, gaining insight into a 
potential disease model of digenic inheritance. 
 
5.3 Whole exome sequencing  
5.3.1 An Introduction to Exome Sequencing 
Next generation sequencing is now an accessible and accurate way of discovering disease 
causing mutations behind Mendelian disorders, and has the potential to accelerate biological 
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and medical research (Shendure and Lieberman Aiden, 2012). Given that 85% of disease 
causing mutations in Mendelian disorders are in protein coding regions or canonical splice 
sites (Cooper et al. 1995) , which cumulatively comprise only 1% of the human genome, 
exome sequencing is an efficient and cost effective technique for revealing novel candidate 
genes and mutations.  Additionally, whole exome sequencing bypasses the need for linkage 
data and does not require large cohorts (Ng et al., 2010; Ng et al., 2009). 
Exome capture and targeted enrichment by hybridisation can be achieved with the use of 
programmable microarrays.  This method has been demonstrated in a proof-of-concept study 
by Ng et al. who used exome sequencing followed by a filtration strategy to accurately 
identify the known causal gene of Freeman-Sheldon syndrome (FSS) (Ng et al., 2009).  The 
authors also demonstrated the first successful application of exome sequencing to discover a 
causal gene for a Mendelian disorder of unknown aetiology, identifying DHODH as the 
causal gene for Miller’s syndrome.  Exome sequencing also has clinical implications as 
discussed by Choi et al. (2009) who illustrated the value of the technique in making an 
unanticipated genetic diagnosis of congenital chloride diarrhoea in a suspected Bartter 
syndrome patient. 
Several cycle-array sequencing technologies have been developed in the past decade 
including 454 pyrosequencing, AB SOLiD and the Illumina Genome Analyser (SOLEXA 
technology), which all have the same basic work-flow. A ‘shot gun’ DNA library (of the 
individual to be sequenced) is prepared by DNA fragmentation and common adaptor 
sequences with sticky ends are ligated in vitro.  Clonal ‘sequencing features’ or ‘amplicons’ 
are then generated in clusters by emulsion or bridge PCR (described below), attached to a 
substrate coated platform or micrometer sized beads. Clusters are then sequenced using 
alternating cycles of DNA synthesis catalysed by a polymerase or ligase and image 
acquisition of fluorescently labelled nucleotides  (Shendure, 2011). 
454 pyrosequencing uses emulsion PCR to generate amplicons bound to 28µm beads.  
Adaptor-flanked library fragments are amplified by PCR within a water-oil emulsion with the 
forward primer tethered to the bead.  The template concentration is low enough to ensure a 
253 
 
maximum of one library fragment per bead. Once the emulsion is broken, beads are washed 
with a denaturant to remove unbound DNA strands, and a universal sequencing primer is 
hybridised to the common adaptor on all fragments for enrichment by hybridisation. Beads 
are pre-incubated with Bst polymerase and single stranded binding protein and transferred to 
an array of pico-litre sized wells containing ATP sulfurylase and luciferase.  Sequencing 
involves the addition of one nucleotide per cycle, with incorporation leading to 
pyrophosphate release with subsequent ATP and luciferin production, generating light which 
is detected as a signal  (Ng et al., 2009; Shendure, 2011).  454 pyrosequencing enables read 
lengths of 400bp within one day, however it comes at a price, costing >1$ per megabase, 
greater than other technologies (Shendure and Lieberman Aiden, 2012). 
AB SOLiD technology also utilises emulsion PCR to enrich adaptor flanked sequence 
features, however beads are magnetic and 1µm in diameter. Once the emulsion is broken, the 
beads are washed and immobilised to a substrate coated planar platform.  For sequencing, a 
universal primer is hybridised to all adaptors, and at every cycle DNA ligase ligates one of a 
mixture of octamers to the sequence feature. Fluorescent labels within the octamer 
correspond to the base identity at the octamer centre. At the end of each cycle images are 
taken in four channels corresponding to each base fluorescent label, and the label is then 
chemically cleaved between base positions 5 and 6 in the octamer.  In the cycles that follow, 
octamers are ligated every 5 bases until the extended primer is denatured.  The process is then 
repeated with ligation of the sequencing primer at a different position (eg. +1 or-1) in the 
adaptor allowing sequencing of bases between those already sequenced  (Shendure, 2011). 
SOLiD technology is significantly cheaper than 454 pyrosequencing at <$0.10 per megabase 
but read length is a short as <200bp. 
For this project, I employed SOLEXA technology, also known as the Illumina genome 
analyser.   In contrast to the above techniques, amplified sequence features are generated by 
bridge PCR, in which forward and reverse primers are bound by linkers to a solid substrate 
platform resulting in clusters at specific locations on the surface. For sequencing, features are 
linearised to single strands and sequencing primers hybridise to the common adaptor regions, 
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then amplification occurs through Bst polymerase.  Sequencing involves the addition of four 
chemically modified nucleotides, which each possess a ‘reversible terminator’ cleavable 
moiety that only allows a single incorporation per cycle. Each type of nucleotide is labelled 
with a different fluorescent wavelength which is detected through four channels. After 
extension and image acquisition, the reversible terminator and fluorescent label are cleaved 
by denaturation with formaldehyde and the next cycle begins. The Illumina Genome analyser 
has 8 lanes on a single flow cell, which can be used to sequence 8 libraries at once  
(Shendure, 2011).  Similar to SOLiD technology, Illumina sequencing is <$0.10 per 
megabase, however reads are longer between 200-400bp. 
All the above sequencing technologies have the ability to generate millions of sequencing 
reads that can be enzymatically manipulated in vitro, which was not possible for Sanger 
sequencing. The disadvantages of next generation sequencing compared to Sanger 
sequencing is the lower accuracy and short read length, features that may be optimised in 
time  (Shendure, 2011).  
 
5.3.2 Whole exome sequencing of the proband 
To search for alternative candidate genes, next generation whole exome sequencing was 
employed, sequencing all protein coding regions in the proband and his brother.  For exome 
capture, 5µg genomic DNA was required to be fragmented and hybridised to the Agilent V4 
(51 Mbp) exome enrichment microarray and washed to remove un-tethered strands.  The 
targeted DNA was then enriched, eluted and amplified.  Massively parallel resequencing of 
the enriched DNA was employed using one lane of the Illumina HiSeq2000 platform with 
SOLEXA technology.   
For the proband a total of 49,087,900 reads, averaging 100bp in length, were mapped to the 
GRCh37/hg19 2009 human reference sequence, revealing 267,711 variants compared to 
wildtype, with an average coverage of 4.58.  A filtration strategy was employed to minimise 
the number of variants for analysis.  Typical of FGD, the inheritance pattern in this kindred 
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appeared to be autosomal recessive as both parents were unaffected and there was known 
consanguinity; hence, heterozygous variants were eliminated. FGD is a rare disorder and we 
hypothesized that, like all the mutations in NNT, the causal variant would be novel. We 
therefore searched for novel variants removing all common SNPs recorded in SNP databases. 
Synonymous coding variants were also removed, as were variants outside coding regions and 
splice sites. Variants with a coverage lower than 20 were excluded.  This gave a total of 80 
variants for analysis. 
Of the 80 variants, 72 were non-synonymous coding region missense mutations (appendix 
1.1), 5 were in-frame deletions (appendix 1.2), 1 was a frameshift mutation (appendix 1.3.), 
and 2 were stop gain mutations (appendix 1.4). Candidate genes were selected based on their 
known biological function. I hypothesised that the ‘second hit’ candidate gene would have a 
role in oxidative stress, similar to that of NNT or GPX1.  
Only one variant fulfilled this criteria, with a coverage of 20 reads, a stop gain mutation 
(c.C199T; pQ67X (CAG>TAG); chromosome 10: 120,933,975) in exon 1 of peroxiredoxin 3 
(PRDX3) (Fig. 5.1C).  PRDX3 is a strong candidate gene because of its role as an antioxidant 
enzyme. Like the glutathione peroxidases, peroxiredoxins catalyse the reduction of toxic 
hydrogen peroxidase to water (Fig. 5.1B).  PRDX3 is the mitochondrial isoform and a 2-
Cysteine (2-Cys) subtype, utilising 2 cysteine residues for catalysis; an N-terminal 
peroxidatic redox active cysteine which functions as the active site, and a C-terminal 
‘resolving’ cysteine (CysR) which reduces the oxidised Cysp on an adjacent subunit, a crucial 
part of the catalytic cycle. 
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Figure 5.  1: A homozygous mutation in PRDX3 
A.  Pedigree of the family with the affected proband, homozygous for GPX1 (red) and 
PRDX3 (blue) mutations, and the unaffected sibling heterozygous for the GPX1 
mutation but homozygous for the PRDX3 mutation. B. Partial DNA sequence 
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electropherogram for the affected patient and a wild-type control. C. Illustration of the 
NNT antioxidant pathway in mitochondria, with the candidate gene PRDX3 
emphasized.  Abbreviations include nicotinamide transhydrogenase (NNT), 
nicotinamide adenine dinucleotide phosphate (NAPD
+
/NADPH), glutathione reductase 
(GR), thioredoxin reductase 2 (TXNRD2), glutathione peroxidase (GPX) and 
peroxiredoxin 3 (PRDX3). D. Illustration of PRDX3 gene with c.C199T; p.Q67X 
mutation depicted by arrow and red box (introns not to scale). 
The mutation results in the substitution of a glutamine residue for an amber stop codon, 
leading to an early truncation at position 67 of a 256aa protein and the ablation of the CysR 
residue key to the enzyme’s function as a 2-Cys peroxiredoxin.  The Q67X mutation was 
confirmed by PCR and Sanger sequencing with primers targeting exon 1.  This variant was 
not present in SNP databases including dbSNP (www.ncbi.nlm.nih.gov/SNP/) and NHLBI 
GO-ESP (https://esp.gs.washington.edu/drupal/).  Sequencing the family revealed that the 
parents were heterozygous for the mutation (Fig. 5.1A), however the unaffected brother was 
homozygous for the defect, hence the variant did not segregate with the disease (Fig. 5.A). 
Sequencing 100 FGD patients with unknown aetiology revealed one more patient with a 
homozygous mutation in PRDX3, which was a missense mutation R214C.  No mutation in 
GPX1, NNT or TXNRD2 was discovered in this patient on sequencing and unfortunately it 
was not possible to check whether the variant segregated with the disease as the DNA of the 
family members was not available. It is unlikely this variant on its own is the cause of FGD 
and further investigation of gene variants in this patient is underway by whole exome 
sequencing (WES).  
The discovery of the PRDX3 mutation in the unaffected sibling raised a few questions.  It 
could suggest that mutations in GPX1 alone are in fact capable of causing FGD. However, 
the previous chapter illustrated that loss of function in GPX1 presents a subtle phenotype.  
We therefore hypothesised that mutation in GPX1 or PRDX3 alone is insufficient to cause 
FGD, but digenic inheritance of both mutations could tip the redox balance and present a 
similar phenotype to that of NNT mutations.   
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5.4 Generation of GPX1/PRDX3 knockdown cell lines by RNAi 
To investigate the possibility of digenic inheritance, single PRDX3, GPX1 and double 
PRDX3 and GPX1 knockdown H295R cell lines were generated by RNAi using lentiviral 
transduction of shRNA targeting these genes, similarly to section 4.3.3.3.  For GPX1 
knockdown, shRNA10 targeting exon 2 was used which previously generated an mRNA 
knockdown of 54% and protein knockdown of 91%.   
For PRDX3 knockdown, a selection of six shRNAs targeting exons 4-7 and the 3’ UTR 
(section 2.1.7.2, Open Biosystems) were tested for optimal knockdown. HEK293 cells grown 
on 6 well plates were transiently transfected with a 1µg of individual shRNA constructs or a 
scrambled (SCR) negative control shRNA using lipofectamine 2000 reagent and incubated 
for 48 hours before protein extraction. 
Western blot analysis of lysates using an antibody to PRDX3 and β-actin (section 2.5.7) as an 
loading control showed highest knockdown in cells transfected with either shRNA constructs 
3 or 6 which both target exon 4, reducing PRDX3 protein abundance by 59% and 67% 
respectively (Fig. 5.2A-B).  These shRNA constructs were selected to generate stable PRDX3 
knockdown (PRDX3-KD) in the H295R cells by lentiviral transduction (see section 2.1.7). 
Briefly, HEK293T packaging cells were transiently transfected with lentiviral shRNA 
constructs in a 5:4:3 ratio with p8.74 (Gag/Pol) and pMDG (VSV-G) packaging vectors.  
After 48 h of expression, supernatant containing viral particles was concentrated by 
centrifugation overnight and transferred to H295R target cells, which were incubated over a 4 
day period for transduction (section 2.1.7).  Cells that had incorporated the shRNA were 
screened for presence of a fluorescent GFP marker flanking the shRNA, and were selected 
with 4µg/ml puromycin over a two week time course, however little cell death was observed 
(section 2.7.3).  The dose was subsequently increased to 7.5µg/ml and cells were grown until 
all showed green fluorescence. Untransfected H295R cells were used as a negative control to 
check for autofluorescence. 
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Stable KD of PRDX3 and GPX1 was assessed by Western blotting for protein expression and 
qRT PCR for mRNA levels.  Stable KD and SCR negative control cells were grown on 6 well 
plates for 48 hours then lysed for analysis. 
Lysates were immunoblotted with antibody to PRDX3 or GPX1 and actin as an internal 
control.  Western blot analysis demonstrated a significant reduction in PRDX3 protein 
abundance by 84% in PRDX3 KD (PRDX3-KD) cells and 84% in double KD (double-KD) 
cells (Fig. 5.2 C&D). Interestingly, a significant reduction in PRDX3 protein levels was also 
observed in GPX1 KD (GPX1-KD) cells (38%) (Fig. 5.2 C&D).  GPX1 protein levels were 
reduced significantly by 75% and 54% in GPX1-KD and double-KD cells respectively, but 
there was no alteration to GPX1 protein levels in PRDX3-KD cells (Fig. 5.2C&E). 
qRT PCR analysis using primers for PRDX3 or GPX1 and GAPDH as a control, showed 
PRDX3 mRNA levels were significantly reduced by 68% in PRDX3-KD cells and 42% in 
double-KD cells (Fig. 5.2F). Unlike protein expression levels, PRDX3 mRNA levels were 
not significantly lower in GPX1-KD cells compared to SCR cells. 
GPX1 mRNA levels were significantly reduced by 61% in GPX1-KD, but did not reach 
statistical significance for double-KD cells (27%) (Fig. 5.2G).  Therefore, the main output 
measure used for this project was protein levels.  
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Figure 5.  2: Dual GPX1 and PRDX3 knockdown in H295R adrenocortical cells 
A. Western blot analysis of HEK293 cells transiently transfected with shRNA for 
PRDX3. A. Cells grown in 6-well plates were transfected with shRNA targeting exons 3-
7 and 3’UTR of PRDX3 or a SCR control shRNA. 48 hours after transfection, lysates 
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were immunoblotted with anti-PRDX3 and anti-β-actin. B. Densitometric analysis 
quantifying PRDX3 protein levels relative to β-actin loading control, showing shRNAs 3 
and 6 targeting exon 4 generate the highest knockdown (n=2). C-G. Validation of stable 
knockdown in H295R cells after transduction with lentiviral shRNA to PRDX3, GPX1, 
both, or a SCR negative control. Cells were grown in 6 well plates and harvested after 
48h. C&D. mRNA knockdown validation by real time PCR analysis measuring PRDX3 
(C) or GPX1 (D) expression relative to GADPH as a control (n=3±sd).  E. Western blot 
analysis of PRDX3 and GPX1 protein levels in knockdown cells. F&G. Densitometric 
analysis of PRDX3 (F) and GPX1 (G) protein levels relative to β-actin as a loading 
control (n=3±sd).  (*p<0.05, **p<0.01***p<0.001). 
 
5.5 Assessing GPX activity 
In the previous chapter, I demonstrated that GPX1 accounted for 50% of total GPX activity in 
H295R adrenocortical cells (section 4.3.4), suggesting other GPXs could not compensate for 
its loss. The effect of PRDX3 KD or double KD on GPX activity was explored, to see 
whether loss of this additional antioxidant capacity invoked compensatory glutathione 
peroxidase activity.  A similar experiment was performed as in section 4.3.4 with the addition 
of PRDX3-KD and double-KD cell lines, using a commercially available GPX assay kit. 
Lysate from 3 x 10
6
 stable KD and SCR H295R cells were collected in the assay buffer 
containing protein inhibitors and homogenised by sonication (section 2.7.3.2). The lysates 
were mixed with NADPH, GSH and GR and preincubated for 20 minutes at room 
temperature.  Following addition of substrate cumene hydroperoxide, absorbance at 340nm 
(indicative of NADPH concentration) was measured for 10 minutes and then rates determined 
(section 2.7.3.2).   
In agreement with findings from section 4.3.4, GPX1-KD cells had 50% less GPX activity 
compared to their SCR counterparts (Fig. 5.3).  PRDX3- KD alone had no effect on GPX 
activity. Double-KD cells had a 40% decrease in GPX activity compared to SCR cells, with 
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no significant difference in activity compared to GPX1-KD cells.  These data suggest the loss 
of both PRDX3 and GPX1 activity does not upregulate activity of the other glutathione 
peroxidases.  
In order to determine whether GPX1 KD influences PRDX function, a future direction would 
be to carry out a spectrophotometric assay measuring thioredoxin reductase activity, which 
would assess whether there is compensation by the thioredoxin/peroxidoxin antioxidant 
system. 
 
Figure 5.  3: NADPH coupled assay for total GPX activity in PRDX- KD, GPX1-KD and 
double-KD cells 
Spectrophotometric enzymatic assay for total GPX activity following treatment with 
substrate H2O2. Cells harvested in an assay buffer (Abcam) were sonicated and protein 
extracts mixed with GSH, NADPH and glutathione reductase. Reactions were started 
with the addition of cumene hydroperoxide. Rate of absorbance of NADPH at 340nm 
over a 10 min period was determined and normalised to protein concentration using a 
Bradford assay. A. Total GPX activity of lysates taken from SCR and knockdown cells. 
GPX activity was significantly lower in the GPX1-KD and double-KD cell lines 
263 
 
compared to SCR, with no significant difference between GPX1-KD and double-KD 
cells (n=3 ± s.d. **p<0.01).  
 
5.6 Assessing Cell viability 
The previous chapter found untreated GPX1-KD cells had significantly higher levels of an 
apoptosis marker, cleaved-PARP, when compared to cells expressing SCR shRNA, and the 
MTS assay showed GPX1-KD cells had no changes to cell viability under physiological 
conditions but had increased susceptibility to cell death following H2O2 treatment.   
PRDX3 has been similarly documented to influence cell death pathways, for example PRDX3 
KD by RNAi leaves Hela cells more susceptible to apoptosis induced by TNF-alpha or 
staurosporine (Chang et al., 2004). 
To investigate whether loss of function in both PRDX3 and GPX1 together presented a more 
severe phenotype than GPX1 KD alone, the MTS assay was repeated using the same 
experimental conditions (sections 4.3.5) with the addition of PRDX3-KD and double-KD cell 
lines.  Briefly, SCR and KD cells were seeded at a density of 5000 in triplicate, grown for 
24h then either subjected to 100µM H2O2 or left untreated for 24h.  The number of 
metabolically active, viable cells was determined by spectrophotometric MTS assay (section 
2.7.4). 
As demonstrated in the previous chapter, GPX1 KD had no effect on viability under basal 
conditions, but led to a significant decrease in cell viability when treated with H2O2 (Fig. 
5.4A).   This effect was also seen for PRDX3 KD, which did not affect cells under normal 
conditions but decreased viability after treatment. Crucially, double KD of GPX1 and PRDX3 
significantly reduced the number of metabolically active cells under normal conditions 
compared to the SCR control.    Hydrogen peroxide treatment significantly reduced cell 
viability in all three cell lines with the most dramatic effect seen in the double-KD cells, 
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however there was no significant difference between the single KD and the double KD cell 
line. 
The ratio of reduced to oxidised glutathione (GSH/GSSG) is often used as an indicator of cell 
toxicity.  Although GSH is used as a cosubstrate by GPXs, it is also a potent antioxidant 
itself, responsible for reducing protein thiols.  The ratio of GSH/GSSG is significantly 
reduced in human NNT KD cells, showing the cells are generally less healthy with increased 
antioxidant consumption (Meimaridou et al., 2012b).  The GSH/GSSG ratio in GPX1-KD, 
PRDX3-KD and double-KD cells was assessed to see whether loss of the two antioxidants 
increased cell toxicity.   
Cells were seeded in 96 well plates at a density of 10,000 and grown overnight.  Cells were 
lysed and the ratio of reduced to oxidised glutathione was determined using a luciferase based 
assay (section 2.7.5). There was no significant difference in GSH/GSSG between cell lines, 
suggesting the cells were not under oxidative stress (Fig. 5.4B).   
Together these results suggest that a significant decrease in viability is only seen under 
physiological conditions with double KD of GPX1 and PRDX3.  However, there was no 
significant difference in viability between double and single KD cells, suggesting double KD 
has no add-on effect.  The GSH/GSSG ratio was unaltered by KD of either gene, suggesting 
the cells did not have high levels of toxicity. 
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Figure 5.  4: Cell viability and toxicity in SCR and knockdown cells. 
A. Cell viability was determined by MTS assay measuring absorbance at 490nm. SCR 
and knockdown cells were either left untreated or treated with 100µM H2O2 for 24 
hours before assaying. A. At physiological levels only double knockdown of PRDX3 and 
GPX1 significantly reduced viability compared to SCR cells (p<0.05).  24h post 
treatment significantly less metabolically active cells were present for all three 
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knockdown cell lines compared to SCR (n=3 ±s.d *p<0.05, **p<0.01***p<0.001). B. 
GSH/GSSG ratio in SCR and knockdown cells.  Cells seeded at 10,000 and grown for 
24h were harvested and subjected to luciferase based assay to determine the ratio of 
GSH to GSSG.  Increased ROS levels induced by 40µM menadione to SCR cells 
reduced GSH/GSSG to 1.33 (n=1).  There was no significant difference in GSH/GSSG 
between cell lines (n=3 ±s.d *p<0.05, **p<0.01***p<0.001). 
 
5.7 Assessing the effects of GPX1 and PRDX3 knockdown on steroidogenesis 
In the previous chapter I demonstrated that GPX1 KD significantly reduced StAR protein 
levels.  GPX1 has previously been implicated in the regulation of steroidogenesis through 
modulation of ROS levels. A study by Kil et al. (2012) also suggests a crucial role for 
PRDX3 in adrenal steroidogenesis. In brief, Kil et al. showed that PRDX3 is highly 
expressed in the mouse adrenal and is readily hyperoxidised and deactivated by high levels of 
H2O2 produced by steroidogenesis particularly CYP11B1.  They demonstrate that 
inactivation of PRDX3 by H2O2 leads to the accumulation of H2O2, activation of p38MAPK, 
suppression of StAR and inhibition of steroidogenesis. The authors propose a model whereby 
PRDX3 inactivation acts as a feedback mechanism to inhibit further steroidogenesis 
following electron leakage from CYP11B1 activity. 
GPX1 has also been reported to influence p38MAPK phosphorylation as overexpression of 
GPX1 in mouse embryonic fibroblasts prevents phosphorylation under hypoxia (Emerling et 
al., 2005).  Although GPX1 is not inactivated in physiological conditions, it may inhibit 
steroidogenesis through a similar mechanism involving p38MAPK suppression of StAR 
synthesis.   
To explore the effects of loss of PRDX3, GPX1 or both on steroidogenesis in human cells, 
GPX1-KD, PRDX3-KD and double-KD cell lines were grown in 6-well plates for 24h, then 
either treated with 100µM H2O2 for 24 h or left untreated.  Lysates were immunoblotted with 
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antibodies to StAR relative to β-actin as an internal control and, in addition, with antibodies 
to phosphorylated p38MAPK (p-p38MAPK) relative to total p38MAPK. 
A general trend was apparent whereby levels of StAR were highest in SCR cells, followed by 
PRDX3-KD cells, then GPX1-KD cells and lowest in the double-KD cells (Fig. 5.5 A&B). 
There was however, no significant difference between GPX1-KD and SCR cells, conflicting 
with our previous finding in chapter 4.3.6.  There was also no statistical difference between 
SCR and double-KD cells however there was a significant difference between PRDX3-KD 
and SCR cells (p<0.05). More experimental repeats may be required in order to clarify 
whether the trend is real. 
Similarly, levels of p-p38MAPK followed a trend being lowest in SCR cells, and highest in 
GPX1-KD and double-KD cell lines (Fig. 5.5.C-D).  The only significant difference however 
was between SCR and PRDX3-KD cells.  We also measured cortisol levels by immunoassay 
but found no significant difference between cell lines (Fig. 5.5.E).  
To summarise, there was no significant difference in cortisol concentration between SCR and 
KD cell lines, but there was a trend towards decreased StAR and increased p-p38MAPK in 
the KD cells compared to SCR (Fig. 5.5).  The only significant difference seen was between 
PRDX3-KD and SCR cells.  More experimental repeats are required to clarify the trend. 
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Figure 5.  5: Effects of GPX1 and PRDX3 knockdown on steroidogenesis.                   
SCR and knockdown H295R cells were grown in 6 well plates for 24h and then either 
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subjected to 24h 100µM H2O2 or left untreated. A. Cell lysates immunoblotted with 
antibodies to StAR and also actin as a loading control. B. Densitometric analysis of the 
Western blots showing StAR protein levels significantly reduced in PRDX3-KD cells 
relative to SCR cells (untreated n=3±sd *p<0.05, H2O2 treated n=2).  C. Cell lysates 
immunoblotted with antibodies to phospho-p38MAPK (p-p38MAPK) relative and total 
p38MAPK (D). Densitometric analysis of Western blot showing p-p38MAPK 
significantly increased (*p<0.05) in PRDX3-KD cells compared to SCR cells. (n=3 ±sd) 
E. Cortisol levels in SCR and knockdown cell lines detected by ELISA.  Cells were 
either left untreated or subjected to 6h treatment with 10
-5
M forskolin or 100µM H2O2 
then lysed and assayed (n=5±sd). 
 
5.8 Discussion 
The pathogenesis of FGD has been recently associated with disease mechanisms involving 
ROS-induced suppression of steroidogenesis (Meimaridou et al., 2012b).  The identification 
of a rare GPX1 mutation in a FGD patient therefore provided a plausible candidate gene for 
investigation, however the effects of GPX1 KD in cultured adrenocortical cells were mild 
compared to previously published data on NNT KD in analogous cells.  NNT mutations 
account for 10% of the FGD cohort, but sequencing a further 100 FGD patients with 
unknown aetiology did not reveal any other GPX1 homozygous or compound heterozygous 
mutations. To ascertain whether another gene defect, either alone or in combination with the 
GPX defect, was causative for disease in this proband, whole exome sequencing (WES) was 
carried out in the proband and his brother.  
Using an Agilent V4 exome capture array and Illumina HiSeq2000 technology to sequence 
our samples, analysis of nucleotide level variation with a filtration strategy revealed a 
homozygous stop gain mutation in PRDX3, p.Q67X, with coverage of 20/20 reads.   
Peroxiredoxin 3 (PRDX3) is part of the peroxiredoxin family of antioxidant enzymes with 
multiple isoforms that are capable of reducing hydrogen peroxide, organic hydroperoxides 
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and peroxinitrates (Bryk et al., 2000), ultimately exhibiting the same function as the 
glutathione peroxidases.  The enzymes are highly abundant antioxidants forming 1% of all 
soluble cellular protein in mammals and are ubiquitously expressed (Chae et al., 1999). They 
are  present in all organisms, all organelles (Hanschmann et al., 2013) and are essential in the 
maintenance of a steady redox state. 
PRDX3 was selected as a candidate gene on the grounds of its antioxidant function, fulfilling 
my hypothesis that a second causal gene could have a role in oxidative stress. The mutation 
was predicted to cause loss-of function as the truncation removed most of the protein 
including key residues for enzymatic activity.  This gene defect would seem a highly 
plausible candidate for the phenotype on its own; however, Sanger sequencing of the kindred 
revealed the mutation did not segregate with the disease, as it was homozygous in the 
unaffected sibling. Hence PRDX3 mutations alone were not capable of causing FGD.  This 
raised the possibility that inheritance of both defects was necessary to cause FGD, or that the 
GPX1 defect alone was responsible for disease progression.   
Sanger sequencing a further 100 FGD patients of unknown aetiology revealed one further 
PRDX3 mutation, a missense variant R214C previously documented as a somatic mutation, 
however it was not possible to check segregation of the variant because DNA samples from 
family members were unavailable. It seems unlikely that this missense mutation would be 
causative in isolation when a more severe, truncation mutation in PRDX3 does not cause a 
phenotype in the unaffected brother, however the possibility of the variant affecting PRDX3 
function cannot be ruled out. 
Mammalian PRDXs can be grouped into 2-Cys (PRDX1-4), atypical 2-Cys (PRDX5) and 1-
Cys PRDXs (PRDX6) which vary in subcellular expression patterns and catalytic 
mechanism.   
Of the 2-Cys PRDXs, PRDX1 is predominantly cytosolic but also localised to the nucleus, 
peroxisomes and serum (Chang et al., 2005; Immenschuh et al., 2003); PRDX2 is present in 
the cytosol and the nucleus, but also associates with cell membranes (Cha et al., 2000);  
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PRDX3 is entirely mitochondrial in localisation (Cao et al., 2007; Watabe et al., 1997); and 
PRDX4 is localised to cytosol and ER and contains a leader sequence required for its role as 
secretory protein (Matsumoto et al., 1999; Okado-Matsumoto et al., 2000).  Atypical 2-Cys 
PRDX5 is the second mitochondrial PRDX and is also localised peroxisomes and the cytosol 
(Knoops et al., 1999). Finally, 1-Cys PRDX6 is localised to the cytosol, vesicles and 
lysosomes (Sorokina et al., 2009; Sorokina et al., 2011). 
All PRDXs have a conserved N-terminal redox active cysteine (CysP) which functions as the 
active site.  At this cysteine the peroxide is reduced, oxidising the active site to a sulfenic 
acid, producing water/alcohol as a by-product.  In 2-Cys PRDXs, the sulfenic acid moiety of 
the oxidised cysteine is ‘resolved’ by forming a disulfide bridge with a second conserved 
cysteine (CysR) at the C-terminus of an adjacent PRDX subunit, forming an anti-parallel 
homodimer.  The oxidised dimer is recycled back to its reduced form by thioredoxin.  
Oxidised thioredoxin is subsequently recycled by thioredoxin reductase using NADPH as 
illustrated in figure 5.1.  
Other conserved residues include an additional Arg residue 75 bp downstream of CysP which 
contributes to the active site which ensures stabilisation of the deprotonated thiol when the 
enzyme is in its fully folded (FF) state ready for peroxidation of the hydroperoxide (Hall et 
al., 2010; Karplus and Hall, 2007; Nelson et al., 2011). 
For atypical 2-Cys PRDXs, an unconserved C-terminal Cys residue is used to reduce the 
oxidised CysP, forming an intramolecular disulfide within a monomer.  With no resolving 
Cys, 1-Cys PRDX6 requires additional protein thiols such as GSH or ascorbic acid to 
complete catalysis (Hanschmann et al., 2013).   
PRDX3 is a 7 exon gene located on chromosome 10q25-q26  (Kim et al., 1988), expressed as 
a 259aa protein, which is longer than PRDX1 and 2 (199 residues) due to a mitochondrial 
targetting leader sequence.  In our proband, the stop gain mutation in PRDX3, p.Q67X, does 
not affect the N-terminal peroxidatic Cysp residue at position 45. It does however ablate the 
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C-terminal resolving CysR and the Arg residue at p75 downstream of CysP, which we predict 
would result in a loss-of-function.   
A loss-of-function mutation in PRDX3 may compromise mitochondrial antioxidant defense.  
Mitochondria generate high levels of oxidants associated with energy metabolism and have 
therefore evolved competent antioxidant defenses to cope with the high demand,  such as its 
own thioredoxin system and  a strong reducing environment (see section 1.7.4 for overview) 
(Yin et al., 2012a). The mitochondrial peroxidases include peroxiredoxin 3 and 5 of the 
thioredoxin system, and GPX1 and the mitochondrial form of GPX4 (mtGPX4) of the 
glutathione system. Peroxiredoxin 5 is predominantly involved in peroxinitrate reduction and 
is less efficient in reducing H2O2 than PRDX3 (Trujillo et al., 2007; Yin et al., 2012a) and 
Glutathione peroxidase 1 (GPX1) is predominantly cytosolic and is present in mitochondria 
at levels of < 0.7 µg in mice (the relative levels in humans mitochondrial fractions has not 
been reported) (Kil et al., 2012).  PRDX3 is an exclusively mitochondrial protein that has 
been reported to consume 90% of H2O2 generated in mitochondria (Yin et al., 2012a), 
suggesting it contributes significantly to mitochondrial antioxidant defense.  Therefore, the 
PRDX3 mutation in the proband may impact strongly on mitochondrial redox homeostasis. 
My findings from the previous chapter implied that loss of GPX1 alone did not present a 
severe phenotype, compared to that of NNT KD, suggesting GPX1 may not be the causative 
gene in this proband.  In this chapter, although the PRDX3 mutation did not segregate with 
the disease, I hypothesised that GPX1 and PRDX3 had an additive and dual role in 
mitochondrial redox homeostasis in adrenocortical cells.  I therefore investigated the concept 
of digenic inheritance by developing adrenocortical cells with targeted shRNA KD of either 
GPX1 and PRDX3 alone or in combination, to compare the effects of losing the function of 
either or both genes on steroidogenesis and viability, thereby aiming to clarify whether GPX1 
alone, or in combination with PRDX3 could be the causative genes in our proband. 
A marked loss of cell viability was seen in the GPX1 and PRDX3 double KD cells under 
physiological conditions. A significant loss of cell viability was not seen for either GPX1 or 
PRDX3 KD alone, unless cells were treated with hydrogen peroxide. When exposed to 
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increased ROS through hydrogen peroxide treatment, double-KD cells had the lowest 
viability with the highest statistical significance.  This data suggest that in isolation loss of 
GPX1 and PRDX3 decrease cell viability but a notable effect is only evident under 
physiological conditions when both are compromised. This cumulative effect on cell viability 
could contribute to a potential disease mechanism in the proband.  
A decrease in cell viability is most likely attributed to increased levels of mitochondrial and 
cytosolic H2O2. However, under physiological levels the ratio of GSH/GSSG was not altered 
in the double-KD cell line, which is a frequently used indicator of cell toxicity.  My data also 
show that there was no compensatory GPX activity (all glutathione peroxidases) in the 
PRDX3-KD cells, nor was there an upregulation in GPX1 mRNA or protein levels.  The 
double-KD cells, had statistically similar total GPX activity to GPX1-KD cells, indicating no 
compensatory upregulation of the other glutathione peroxidases, again suggesting the cells 
were not under particularly high oxidative pressure. Interestingly, a reduction in PRDX3 
protein levels was seen in GPX1-KD cells, however I did not complete the reciprocal 
experiment by measuring PRDX activity to investigate this result further, a direction that can 
be taken in future using a TXNRD assay. 
Studies have demonstrated that cell viability is dependent on GSH/GSSG (Muyderman et al., 
2007), and even depletion of mitochondrial GSH alone, which accounts for 15% of total 
GSH, can induce cell death (Shan et al., 1993).  The above data indicate that under 
physiological conditions, the overall redox state of the cell is not changed significantly. 
However, these experiments do not consider the possibility of local redox changes that are 
mitochondria specific, which should be addressed in future experiments. Another 
consideration is the influence of GPX1 activity on GSH levels, as it oxidises GSH as a co-
substrate.  In this regard, KD of GPX1 would mask decreases in GSH by alleviating the 
consumption of GSH.  This effect has been seen in cells cultured from GPX1
-/-
 mice, which 
have less/slower GSH depletion and lower GSSG levels than wildtype cells following 
treatment with diquat (Fu et al., 2001; Liddell et al., 2006b).  
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Both GPX1 and PRDX3 have been shown to modulate apoptosis through influencing cellular 
H2O2 levels. Cultured cells from GPX1
-/-
mice are more susceptible to pro-apoptotic stimuli 
for example hydrogen peroxide and paraquat (Cheng et al., 2003; De Haan et al., 2003; Fu et 
al., 1999; Fu et al., 2001; Liddell et al., 2006b).  Similarly, depletion of PRDX3 by RNA 
interference in cultured Hela cells rendered them more susceptible to apoptosis induced by 
TNF-alpha or staurosporine (Chang et al., 2004), and SH-SY5Y cells with KD of PRDX3 had 
higher levels of caspase-3 activity, protein carbonyls and apoptotic nuclei following MPP
+
 
exposure, a neurotoxic compound (De Simoni et al., 2008). Overexpressing PRDX3 protects 
cells from a number of apoptotic stimuli including TNFa (Chang et al., 2004), cadmium, 
hydrogen peroxide, paraquat (Chen et al., 2008) hypoxia, and anti-cancer drug Imexon (Nonn 
et al., 2003). 
To investigate the effects of GPX1 and PRDX3 combined KD on steroidogenesis, I employed 
similar methodology to Kil et al. (2012) who described an HPA-axis independent negative 
feedback loop whereby reversible inactivation of PRDX3 regulates adrenal steroidogenesis.  
When engaged in catalysis PRDXs can undergo hyperoxidation, forming either sulfinic acid 
(-SO2) or sulfonic acid (-SO3) at the Cysp, which are enzymatically inactive.  The level of 
sensitivity to H2O2 induced inactivation is high considering it is the substrate of PRDXs 
(Poole et al., 2011).   In 2-Cys PRDXs, the sulfinic acid moiety can be actively reduced back 
by sulfiredoxin (SRX) consuming ATP, Mg
2+
 and electrons from a thiol donor (Rhee et al., 
2005a).   
It is becoming increasingly evident that this process has a biological role and has evolved 
over time.  PRDX inactivation is rare in prokaryotes (Hall et al., 2009; Poole et al., 2011; 
Wood et al., 2003a) and eukaryotes PRDXs possess insertions of two conserved motifs 
(GGLG and YF) that are absent from more robust prokaryote isoforms (Wood et al., 2003a).  
The ‘floodgate’ hypothesis described by Wood et al 2003, implies that the abundance of 
PRDXs coupled with their sensitivity to hyperoxidation has evolved as a mechanism to keep 
basal H2O2 levels low, but allow localised peroxide production required for signal 
transduction (Poole et al., 2011; Wood et al., 2003a). 
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In the model described by Kil et al. (2012), the electron donor system supplying 
steroidogenic enzymes is leaky, leading to superoxide and subsequent H2O2 generation within 
the mitochondria. To compensate, high levels of PRDX3 are present in the mitochondria of 
the adrenal cortex.  Inactivation of PRDX3 is a consequence of steroidogenesis, but is 
counteracted by SRX reversing this process.  However, after long periods of steroidogenesis 
the level of excess H2O2 outweighs the capacity of SRX.  An overspill of H2O2 into the 
cytosol occurs, leading to phosphorylation of p38MAPK, which through an unknown 
mechanism, is associated with the reduced synthesis of StAR protein.  Reduced levels of 
StAR consequently downregulate steroidogenesis.  
PRDX3 is only hyperoxidised when it is in the catalytic cycle, hence the level of PRDX3 
inactivation is directly proportional to the level of H2O2 produced by steroidogenesis.  The 
authors detected from mouse adrenal tissue 10% of total PRDX3 in its sulfinic form, 
suggesting that levels of H2O2 are high enough in the adrenal cortex for PRDX3 to be 
constantly engaged in its catalytic cycle.   
In mice, the circadian oscillation of corticosterone production was accompanied by 
oscillations in H2O2, inactivated PRDX, SRX, phosphorylated p38 MAPK and StAR, which 
were all increased by ACTH stimulation.  SRX
SC
 mice with reduced SRX expression had 
reduced corticosterone production and although oscillations remained, the amplitude was 
reduced.  
Taken together, this study gave evidence of a critical role of PRDX3 reversible inactivation 
in an HPA axis independent negative feedback loop which can influence circadian rhythms of 
corticosteroid production (Kil et al., 2012).  On this basis, I investigated the effects of GPX 
and PRDX single or double KD on levels of StAR, corticosteroid production and the 
phosphorylation of p38-MAPK, to explore the effects on this proposed feedback system.   
A general trend was seen where levels of StAR protein were highest in the SCR control cell 
line, following PRDX3-KD cells, then GPX1-KD cells and lowest in the double-KD cell line.  
However, only the change in PRDX3-KD cells reached statistical significance.  This data was 
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not as convincing as the data for GPX1-KD cells in chapter 4, where statistical significance 
was reached.  Levels of phosphorylated p38MAPK were highest in GPX1-KD cells, then 
double-KD cells, PRDX3-KD cells and lowest in SCR cells.  Again, the only difference that 
reached statistical significance was between PRDX3-KD and SCR cells.  The corresponding 
basal cortisol levels were highest in SCR cells, and lowest in the double-KD cell line 
however there was no significant difference in these changes. 
The above data is preliminary, hence it is not possible to draw firm conclusions. A trend is 
seen whereby double KD has an additive effect in reducing both StAR and basal cortisol 
levels; however the changes were not significant.  More experimental repeats would be 
required in order to clarify.  Only PRDX3 KD resulted in a significant change in StAR and p-
p38 MAPK levels, reflecting the pathway proposed by Kil et al, and that PRDX3 is the most 
significant antioxidant peroxidase for the adrenal cortex.   
Different experimental approaches may also be necessary to clarify whether a trend is seen.  
For example, large concentrations of inactive StAR compared to newly synthesised active 
form may mask changes in StAR levels, as observed by Kil et al. (2012), who only noted an 
increase in StAR levels in mice following ACTH stimulation or p38MAPK inhibition after 
pre-treatment with DEX to deplete the inactive form.  Similarly an increase in StAR levels 
was seen in mouse Y-1 cells, which contain low levels of the inactive form, after p38MAPK 
inhibition. Therefore, a future experiment could be to treat H295R cells with DEX to deplete 
pre-existing StAR and then stimulate with forskolin, before lysing cells.  This may clarify 
whether there is a clear difference between cells lines. 
Despite these considerations, a very recent study by Kil et al. (2013) suggested that H295R 
and Y1 cell lines are not suitable as in vitro models for redox signaling  because expression 
levels of SRX and PRDX3 do not reflect in vivo levels, in either basal or ACTH stimulated 
states. Likewise, primary mouse adrenocortical cells are unsuitable because Srx levels 
increase, along with a decrease in levels of hyperoxidised PrxIII shortly after isolation.  This 
report raises concerns for our immediate study of redox homeostasis in H295R cells and may 
require us to move to novel models such as zebrafish in the future (section 6.2 and 6.3) 
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Although the results were not conclusive, previous studies have implicated both GPX1 and 
PRDX3 in the regulation of steroidogenesis.  Chanoine et al. (2001) implicated GPX1 in the 
regulation of steroidogenesis after demonstrating that Se deficient AN4Rppc7 adrenal cells 
with minimal GPX1 activity exhibited a marked decrease in corticosterone, aldosterone and 
progesterone after cAMP stimulation compared to Se adequate cells. Like PRDX3, GPX1 is 
also able to modulate p38MAPK activity by influencing hydrogen peroxide levels, as 
overexpression of GPX1 in mouse embryonic fibroblasts prevents p38MAPK 
phosphorylation under hypoxia (Emerling et al., 2005). My data also reveal that GPX1 is 
highly expressed in the human adrenal cortex compared to other tissues (Section 4.3.2) in 
agreement with previous studies (Azhar et al., 1995) suggesting it may have an important 
antioxidant role there. 
In comparison to GPX1, PRDX3 is more highly expressed in the adrenal cortex of mice (Kil 
et al., 2012). In mitochondrial fractions taken from the adrenal cortex of mice, PRDX3 
concentration was 10 times higher than GPX1, and 40 times higher than PRDX5, the only 
other mitochondrial PRDX.  ACTH stimulation increases levels of hyperoxidised PRDX3, 
which are associated with the ROS induced negative feedback of adrenal steroidogenesis as 
described above.  ACTH also induces translocation of SRX to the mitochondria which 
reverses PRDX3 inactivation, and SRX
sc
 mutant mice have reduced amplitude of the 
oscillations of corticosterone compared to WT (Kil et al., 2012).   
The mRNA and activity of mitochondrial antioxidant SOD2, which converts superoxide 
radicals to hydrogen peroxide, is also upregulated by ACTH stimulation (Goncharova et al., 
2006; Raza and Vinson, 2000)  and protein levels oscillate in correlation with the diurnal 
rhythm of cortisol, decreasing in parallel with cortisol with age.  In keeping with the model 
proposed by Kil et al. (2012), this could be another factor allowing accumulation of H2O2 
after cortisol production to halt further steroidogenesis. 
In comparison to SOD2 and PRDX3, GPX1 is not upregulated by ACTH and does not have 
circadian rhythms. Glutathione peroxidases require millimolar concentrations of H2O2 to be 
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inactivated, and therefore would not be involved in negative feedback loop similar to that 
involving PRDX3 inactivation (Lubos et al., 2011). 
Based on the literature described and the preliminary data collected in this chapter, PRDX3 
presents a stronger candidate gene for FGD, however only the GPX1 mutation segregated 
with the disease, as the unaffected brother was homozygous for the PRDX3 mutation too. 
Data from the cell viability assay, suggest GPX1 and PRDX3 KD have an additive effect in 
reducing cell viability, presumably by increasing ROS levels, which impair steroidogenesis.  
Given that GSH-GPX1 and TXN2-PRDX3 antioxidant systems work synergistically to 
detoxify the same target (Zhang et al., 2007), it is likely that loss of GPX1 and PRDX3 in our 
proband cumulatively contribute to increased oxidative stress in the adrenal cortex. 
Our group has recently described FGD cases with a loss of function TXNRD2 mutation 
(Prasad et al. unpublished).  As PRDX3 is reduced by thioredoxin 2 (TXN2) which is 
recycled by TXNRD2 (Fig. 5.35.3.2), it may be surprising that mutations in PRDX3 do not 
cause FGD.  However, TXNRD2 has multiple functions in addition to reducing PRDX3 for 
example it too has peroxidase activity (Björnstedt et al., 1995), it can reduce cytochrome C 
(Nalvarte et al., 2004) and reduce glutaredoxin 2 in the glutathione antioxidant system 
(Johansson et al., 2004). Mutations in NNT and TXNRD2 may cause FGD because these 
enzymes supply two antioxidant systems, whereas PRDX3 is involved in one, at the bottom 
of the electron chain.  
 
Taken together, although GPX1 and PRDX3 have the same function in reducing hydrogen 
peroxide, the enzymes may have different roles in steroidogenesis. Evidence suggests that the 
inactivation of PRDX3 is critical to steroidogenesis under normal physiological conditions, 
allowing accumulation of hydrogen peroxide for negative feedback.  GPX1 is likely to be the 
second most highly expressed peroxidase in adrenal mitochondria as mtGPX4 is mostly 
expressed in the testes with only low levels present in other tissues (Brigelius-Flohé and 
Maiorino, 2013). Hence it may be an advantage for GPX1 as the second most abundant 
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peroxidase to be independent of ACTH regulation, in order to allow the ACTH induced 
accumulation of H2O2 after PRDX3 inactivation.  Its resistance to hyperoxidation may also 
play a part, ensuring some residual peroxidase activity remains within mitochondria to limit 
oxidative damage.  Considering GPX1 is predominantly cytosolic, it may also minimise the 
extent of H2O2 overspill from the mitochondria to the cytosol, ensuring H2O2 signalling 
remains localised. Based on this speculative model, whereas PRDX3 has a regulatory role in 
steroidogenesis, GPX1 may have a protective role.   
With this in mind, I propose a multiple hit model whereby, an inactivating mutation in 
PRDX3 may reduce steroidogenic capacity by interfering with the internal feedback loop and 
increasing oxidative stress levels.  Despite this, negative feedback from the HPA axis would 
remain.  A mutation in GPX1 would further increase oxidative stress in the cytosol and 
mitochondria which would exacerbate steroidogenesis impairment and mitochondrial 
oxidative damage. 
In conclusion, multiple antioxidant systems exist to maintain a healthy redox balance. The 
glutathione peroxidases and peroxiredoxins work simultaneously to reduce hydrogen 
peroxide, preventing cellular damage.  I identified a patient with two homozygous mutations 
in the redox pathway. My data show that loss of function in PRDX3 alone is insufficient to 
cause adrenal failure and suggest that mutation in GPX1, either alone or in combination with 
PRDX3 mutation, may tip the redox balance and cause FGD. 
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Chapter 6:  Final Conclusions and Future Directions 
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6.1 Introduction 
FGD is an autosomal recessive disorder characterised by the resistance of the adrenal cortex 
to ACTH and subsequent isolated glucocorticoid deficiency.  FGD is a heterogeneous disease 
with 60% cases of known aetiology.  Causal genes include MC2R (Clark et al., 1993) and its 
accessory protein MRAP (Metherell et al., 2005) and STAR (Metherell et al., 2009) which 
constitute genes involved in ACTH signalling and steroidogenesis.  More recently mutations 
in genes outside this pathway have been described, including the DNA helicase MCM4 in the 
genetically isolated Irish traveller population (Hughes et al., 2012) and NNT, the 
mitochondrial antioxidant dehydrogenase, which accounts for 10% of affected patients 
(Meimaridou et al., 2012b).  
The aim of this thesis was to discover genes that might be responsible for the disease in some 
or all of the remaining 40% of patients with unknown aetiology, using both proteomic and 
genomic approaches. After the discovery of MRAP, it was suggested that other causal genes 
may also be associated with MC2R trafficking (Clark and Metherell, 2006; Génin et al., 
2002; Metherell et al., 2006). Therefore the proteomic side of this project aimed to find 
interacting partners of MC2R and/or MRAP in order to disclose FGD causal genes. This 
could reveal proteins that are embryonic lethal when defective and would therefore not be 
identified by the genetic approach. Such protein discovery might also broaden our 
understanding of MC2R regulation and MRAP function.  This approach identified 5 putative 
interactors of MC2R/MRAP the most promising of which was clathrin heavy chain 1.  
The genomic arm of this project aimed to investigate the cause of FGD in one affected 
individual with linkage to a region on chromosome 3.   Following the discovery of NNT as a 
causal gene, the region was examined for genes in the same antioxidant pathway and GPX1 
was identified.  GPX1 is an antioxidant enzyme that converts hydrogen peroxide to water.  
This arm of the project thereafter aimed to investigate GPX1 as a putative candidate gene for 
FGD by sequencing further individuals with unknown aetiology for GPX1 mutations and 
examining its role in the adrenal cortex through in vitro and in vivo models. This revealed 
GPX1 ablation to cause a mild phenotype and subsequent finding of a ‘second hit’ in this 
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patient in PRDX3 led to the investigation of gene knockdown for this enzyme too which 
revealed double knockdown of the two genes, but not single knockdowns, deleteriously 
affected human adrenocortical cell function. 
6.2 Summary of findings 
6.2.1 Proteomic Approach 
A tandem affinity purification technique was employed to isolate interacting partners of 
MC2R and MRAP in human adrenocortical carcinoma (H295R) cells.  Using the Interplay 
TAP mammalian system, N- and C-terminal MC2R and MRAP TAP-tag constructs were 
cloned, and MC2R-MRAP complexes possessing the double purification tag were capable of 
eliciting an ACTH response at the cell surface in HEK293 cells.    
Lysates from H295R cells transfected with TAP-tag constructs were purified in two steps 
utilising the two purification tags, and analysed by mass spectrometry.  The majority of 
proteins identified by mass spectrometry were highly abundant proteins such as cytoskeletal 
proteins.  Although proteins such as β-tubulin might make good candidates for MC2R 
trafficking, the high occurrence of this type of protein as false positives in other studies meant 
these proteins could not be considered as candidates. 
Following filtration of non-specific interactions five proteins remained, none of which were 
clear candidate proteins apart from clathrin which is involved in endocytosis of MC2R.  It has 
previously been established that MC2R is internalised from the cell surface through a 
clathrin-dependent mechanism (Baig et al., 2001; Baig et al., 2002), however my data suggest 
that MC2R and clathrin interact directly.  In order to confirm this result, reciprocal co-
immunoprecipitation would be required. 
Other proteins isolated using the TAP approach included a nuclear export protein, THO 
complex subunit 4, from MC2R-CTAP transfected cells.  FGD and Triple A syndrome, 
another condition of adrenal insufficiency, are both associated with mutations in genes 
involved at the nuclear level.  Mutations in MCM4, a DNA helicase, cause FGD in the Irish 
traveller community (Hughes et al., 2012) and mutations in AAAS, a nuclear pore complex 
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protein are found in 90% of triple-A patients (Clark and Weber, 1998). However, as MC2R 
resides at the ER or cell surface, it is likely that these interactions were non- specific/non-
physiological.   
Similarly, mitochondrial proteins FDXR and MCCC2 were isolated from NTAP-MRAP and 
MRAP-CTAP transfected cells respectively, but according to current literature, MRAP also 
resides at the ER and the cell surface (Metherell et al., 2005; Sebag and Hinkle, 2007; Webb 
et al., 2009), and there is no data to suggest MRAP is mitochondrial or that MRAP has a 
mitochondrial leader sequence. It is therefore unclear whether these interactions are real. 
Other proteomic techniques such as the yeast-2hybrid and bacterial-2-hybrid screens have 
been used by our laboratory to find interacting partners of MC2R, but have similarly failed to 
identify suitable candidate proteins.  Although some studies have successfully isolated 
interacting partners of given proteins using the Interplay mammalian system (Griffin et al., 
2007; Xie et al., 2009), others have failed to identify proteins that present clearly visible 
bands on a silver-stained SDS-PAGE (Ahlstrom and Yu, 2009), suggesting the problem is 
rooted in poor yield following purification preventing detection by MS.  Studies that have 
succeeded in identifying interacting partners have carried out transfections on a larger scale 
(Griffin et al., 2007; Xie et al., 2009), which would increase the final yield after purification 
but may also increase the abundance of non-specific proteins. Other studies have taken 
further steps to reduce background noise from false positives, for example the use of high salt 
detergent washes (Ahlstrom and Yu, 2009).  Furthermore, Interplay has developed a viral 
based delivery method for TAP-tagged genes to increase transfection efficiency, which would 
increase the recovery of target proteins and yield.   
I therefore concluded from this section that despite the advantages of the TAP-tag technique 
over previous proteomic approaches, such as a natural environment for TMD proteins and the 
use of full length proteins, limitations remained in the high level of false positives and 
negatives. Namely, the affinity purification of TAP-tagged MC2R did not pull out 
endogenous MRAP and vice versus, which are known interacting partners.  The technique 
would require further optimisation to increase yield and reduce background in order to find 
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interacting partners of MC2R and MRAP. It may be necessary to cotransfect TAP-tagged 
MC2R and MRAP to ensure cell surface expression of overexpressed MC2R, as correct 
subcellular localisation is key to the protein’s function. 
6.2.2 Genomic approach 
In the genomic approach, a region of linkage in an FGD patient with unknown aetiology was 
screened for potential candidate genes, and GPX1 was identified, based on the function and 
pathway of NNT (Fig.6.1).  Sequencing the gene revealed a homozygous in-frame 12bp 
deletion in exon 2; c.del388-399; p.R130-L133del, this was heterozygous in the parents and 
the unaffected sibling.  This is the first description of a human mutation in GPX1.  Clinically 
the proband was in his 30s, with a mild phenotype and no other medical conditions.  
The mutation was functionally characterised by overexpressing FLAG-tagged R130-L133del 
in mammalian HEK293 cells, and Western blotting with anti-FLAG antibody showed that 
R130-L133del was poorly expressed compared to the wild type.  Treatment of transfected 
cells with cycloheximide revealed R130-L133del had a shorter half-life than the wild type 
protein, and that treating transfected cells with MG132 to inhibit the 26S proteasome 
significantly increased R130-L133del levels, suggesting the protein is degraded.  
Furthermore, CHX significantly reduced R130-L133del abundance compared to DMSO 
treatment, but had no significant effect on WT transfected cells.  Despite this, there was no 
statistical difference between protein abundance of WT and R130-L133del proteins after 10h 
CHX treatment, suggesting other mechanisms such as poor translation are also involved. 
R130-L133del is on alpha-helix 3 and the oligomerisation domain of GPX1 (Fig. 4.9), a 
region responsible for subunit interface, hence it was originally hypothesised that the 
mutation would affect oligomerisation of the tetrameric selenoprotein.  However, Western 
blot analysis of lysates run in a non-reducing buffer showed R130-L133del presented a 
similar banding pattern to wild type, suggesting the protein is able to form a tetramer.  
The mutation may have affected enzymatic activity as the 12 base pairs cross over a c-
Abl/Arg tyrosine kinase phosphorylation site known to influence GPX1 activity (Cao et al., 
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2003a; Cao et al., 2003b), and the deletion would shorten the distance between key residues 
involved in the active site, potentially altering the tertiary structure. It would be interesting to 
assess activity of R130-L133del compared with wild-type by purifying the two enzymes in 
vitro.  Low protein levels could also be due to poor translation efficiency if the mRNA was 
destabilised by the deletion, as selenocysteine incorporation is already an inefficient process 
that is sensitive to discrete changes in the transcript sequence (Kasaikina et al., 2011).  Poor 
expression levels could be investigated by substituting the selenocysteine for a cysteine, 
which may rescue the transcript from nonsense mediated decay. 
Poor expression levels and degradation of GPX1 would reduce antioxidant defence and 
potentially increase cellular oxidative stress levels. A human model of GPX1 knockdown was 
developed by lentiviral transduction of adrenal H295R cells with shRNA targeting GPX1, 
achieving 50% mRNA and 90% protein knockdown to investigate the role of GPX1 in the 
human adrenal cortex.   
The effects of GPX1 KD on steroidogenesis were investigated by immunoblotting lysates 
with an antibody to StAR, and found to be significantly lower in GPX-KD cells compared to 
wild type, with or without hydrogen peroxide treatment.  The reduction in StAR protein 
levels posed a potential mechanism for FGD, as mutations in StAR that leave 20% of residual 
activity are a known cause of FGD (Metherell et al., 2009). Furthermore, multiple studies 
have demonstrated that ROS impairs steroidogenesis through suppression of StAR protein 
levels in a mechanism that is not fully understood (Diemer et al., 2003; Jin et al., 2011; Kil et 
al., 2012; Shi et al., 2010).   
Total GPX activity (all 8 GPX genes), measured by spectrophotometric assay, was 50% 
lower in GPX1 knockdown cells compared to wild type, suggesting GPX1 contributes 50% 
of total GPX activity and is therefore the predominant form of GPX in the adrenal cortex, and 
other GPXs do not compensate for its loss. 
I anticipated loss of 50% GPX activity would have a significant impact on oxidative stress 
levels in the adrenal cortex.  However, GPX1 KD had no effect on SOD2 or NRF2 protein 
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levels, which are usually upregulated during oxidative stress (Purdom-Dickinson et al., 2007; 
Warner et al., 1996).    
GPX1 KD cells did however, show increased basal levels of cleaved-PARP, a marker of 
apoptosis.  But this finding was not recapitulated using an MTS assay to measure cell 
viability, which showed GPX1 KD had no effect on viability under normal physiological 
conditions.  The MTS assay did show that GPX1 KD cells were more susceptible to H2O2 
induced death than wild type cells.  These experiments do reflect previously published in vivo 
studies on GPX1
-/-
 mice showing mice are more susceptible to paraquat induced lethality than 
their wild type counterparts (Cheng et al., 1998; de Haan et al., 1998), and studies on 
cultured cells from GPX1
-/-
 mice, which have higher levels of pro-apoptotic markers (Cheng 
et al., 2003), following oxidative stress and in one study under low oxidative (6% oxygen) 
conditions (Lee et al., 2006).   
Post-mortem analysis of adrenals taken from FGD patients show disorganised cells of the ZG 
and loss of the ZF (Clark and Weber, 1998).  Similarly, an autopsy of the 5-month old sibling 
of the proband revealed small adrenal with loss of the ZF.  The DNA of this individual was 
not available for sequencing, however in light of this finding the adrenals of GPX1
-/-
 mice 
were analysed by immunohistochemistry, staining with conventional H&E dyes and zonal 
specific markers IZA-1 (ZF and ZR marker) and CYP11A1 (ZG, ZF and ZR) to view 
morphology, and cleaved caspase-3, a marker of apoptosis.   
GPX1
-/-
 mice had normal adrenal morphology and zonation, and the expression of CYP11A1 
also indicated the cells had steroidogenic capacity.  Immunofluorescent staining with 
antibody to cleaved caspase-3 was pronounced in GPX1
-/-
 adrenals in an unusual pattern 
resembling that of vascular endothelial cells which ran between cells of the ZG and the 
columnar structures of the ZF, suggesting increased apoptosis in the vasculature supplying 
the adrenal gland.   
By comparison, mice harbouring a loss of function mutation in NNT have overcrowded, 
disorganised cells in the ZF with increased cleaved caspase-3 staining in the ZF, but do not 
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display the same vascular staining pattern (Meimaridou et al., 2012b).   There was no cleaved 
caspase-3 staining in steroidogenic cells of GPX1
-/-
 mice suggesting steroidogenic cells were 
not apoptotic under physiological conditions, reflecting data gained in human H295R cells by 
MTS assay.   
GPX1 has previously been implicated in the protection of vascular endothelial cells against 
ROS generated from NO during vasorelaxation, and GPX1
+/-
 mice are more susceptible to 
vascular endothelial dysfunction following treatment with agonists of NO (Forgione et al., 
2002).  Increased levels of oxidative stress in the adrenal vasculature may impact on adjacent 
steroidogenic cell function.  However, although basal corticosterone levels of GPX1
-/-
 mice 
were reduced, levels were not significantly different to wild type mice.  By comparison, NNT 
mutant mice have 50% lower basal corticosterone levels than wild type.   
The data gained from the GPX1
-/-
 mouse model indicated that absence of a functional GPX1 
did not significantly perturb steroidogenesis in the mouse adrenal cortex nor did it cause 
atrophy of the gland.  There was a trend of reduced corticosterone in GPX1
-/-
 mice compared 
to wild type, however the change was not significant. Similarly, despite 50% less GPX 
activity and a reduction in StAR protein levels in H295R GPX1-KD cells, levels of oxidative 
stress markers and cell viability showed variable degrees of change, suggesting no strong 
trend.  Furthermore, sequencing of 100 individuals with FGD did not reveal another 
homozygous mutation in GPX1.   
Taken together these data indicate GPX1 loss of function may not have a severe phenotype.  
This brought me to the conclusion that another gene defect may be present in the proband, 
which I hypothesised to be another protein involved in mitochondrial antioxidant defence like 
NNT. 
Whole exome sequencing of the proband and analysis of nucleotide level variation with a 
filtration strategy revealed a homozygous stop gain mutation in PRDX3, p.Q67X, another 
antioxidant enzyme which catalyses the conversion of H2O2 to water.  The mutation removed 
key residues for enzymatic activity which would cause a loss of function.  PRDX3 was a 
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good candidate gene because of its role in antioxidant defence as a mitochondrial peroxidase 
that contributes to a reported 90% of H2O2 removal in mouse adrenocortical cells (Cox et al., 
2010). 
However, Sanger sequencing a further 100 FGD patients of unknown aetiology revealed only 
one missense mutation in PRDX3, and DNA from this individual’s relatives was not 
available. Furthermore, Sanger sequencing of the kindred revealed the mutation did not 
segregate with the disease, as it was homozygous in the unaffected sibling, which indicated 
PRDX3 mutations alone were not capable of causing FGD.  This raised the possibility that 
digenic inheritance of both defects was necessary to cause FGD, or that mutation in GPX1 
alone was responsible for disease progression.  We hypothesised that PRDX3 and GPX1 loss 
of function had a cumulative effect in mitochondrial redox homeostasis in adrenocortical 
cells which may lead to the progression of FGD in this patient. 
Knockdown of both PRDX3 and GPX1 in H295R cells caused a significant reduction in cell 
viability at normal physiological conditions, which was not seen for PRDX3 or GPX1 
knockdown alone unless cells were treated with hydrogen peroxide.  This gave evidence to 
suggest that loss of GPX1 or PRDX3 function alone decrease viability, but a notable effect 
was only evident at physiological levels when both genes were silenced. Both genes have 
been shown to be individually implicated in modulation of apoptosis through influencing 
cellular ROS levels (Chang et al., 2004; Cheng et al., 2003; De Haan et al., 2003; De Simoni 
et al., 2008; Fu et al., 1999; Fu et al., 2001; Liddell et al., 2006a), however this is the first 
illustration of the effect of dual knockdown of these genes on cell viability in a human cell 
line. 
The effects of dual knockdown on steroidogenesis were not conclusive.  In previous 
experiments, knockdown of GPX1 alone significantly decreased StAR protein levels 
compared to the SCR control. However, when investigating dual knockdown, only a general 
trend was observed where levels of StAR protein were highest in the SCR negative control 
cell line, followed by PRDX3-KD cells, then GPX1-KD cells and lowest in the double-KD 
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cell line.  The only significant difference seen was between PRDX3-KD and SCR control cell 
lines.  
Levels of ph-p38MAPK were measured because it has been reported that H2O2 impairs StAR 
function by activating p38MAPK, which through an unknown mechanism decreases 
synthesis of StAR protein (Kil et al., 2012).  p38MAPK levels followed a similar trend, and 
significance was only reached between PRDX3-KD and SCR control cell lines.  Basal 
cortisol levels measured by immunoassay, were also lowest in the double knockdown cell 
line, but there was no significant difference to scrambled cells. 
These preliminary data suggest that even when combined, loss of function in GPX1 and 
PRDX3 presents a mild phenotype.  Knockdown of NNT in analogous cells causes a more 
severe phenotype (Meimaridou et al., 2012b).  For example, KD of NNT significantly 
reduced the GSH/GSSG ratio, which is associated with increased oxidative pressure and 
decreased viability.  GPX1 and PRDX3 KD alone or in combination did not deplete GSH 
levels.  NNT supplies NAPDH to mitochondria, which is the principle electron donor at the 
beginning of an electron transfer chain involving multiple mitochondrial antioxidants (Fig. 
6.1).  GPX1 and PRDX3 are placed at the end of this electron chain, with the least influence 
over other antioxidants, which may reduce the severity of a loss in function in these genes. 
 
Figure 6.  1: Mitochondrial antioxidants.  
Genes that have are causal or putative for FGD are underlined.  Nicotinamide 
transhydrogenase (NNT) maintains high levels of NADPH which reduce glutathione 
290 
 
reductase (GR) and mitochondrial specific thioredoxin reductase 2 (TXNRD2).  
TXNRD2 reduces glutathione, maintaining a high reduced (GSH) to oxidised (GSSG) 
glutathione ratio, and TXNRD2 reduces thioredoxin 2 (Trx2) in parallel.  GSH 
subsequently reduces glutathione peroxidase 1 (GPX1) and Trx2 reduces peroxiredoxin 
3 (PRDX3).  GPX1 and PRDX3 both reduce hydrogen peroxide (H2O2), which is the 
product of manganese superoxide dismutase (MnSOD).  
 
Although GPX1 and PRDX3 are the predominant mitochondrial peroxidases, PRDX5 and 
mtGPX4 (predominantly in testes) are also a mitochondrial with the same function, and may 
delay an accumulation of H2O2. Furthermore, the proband of this study had a relatively mild 
phenotype with late presentation.  Therefore, the effects of GPX1 and PRDX3 loss of function 
may be progressive, as are the effects of accumulated oxidative stress in conditions such as 
X-ALD where the AMN phenotype presents typically between ages 20 and 30 in hemizygous 
males (Chaudhry et al., 1996). 
However, I cannot rule out the possibility that neither GPX1 nor PRDX3 are causal genes in 
this proband.  I do believe this thesis presents strong evidence to support GPX1 and PRDX3 
as causal genes. Firstly, resequencing of the whole exome did not reveal any other potential 
candidate genes, and secondly I presented data showing the genes additively decrease 
viability of adrenal cells which could affect steroid secretion. There was also evidence that 
individual knockdown of GPX1 or PRDX3 significantly reduces StAR protein levels. 
The identification of PRDX3 and GPX1 mutations in an individual with FGD, adds to the 
increasing number of oxidative stress genes that have been associated with the condition 
(Fig.6.1).  As well as mutations in NNT, TXNRD2 mutations have recently been described in 
one kindred (Prasad et al. unpublished). TXNRD2 is a mitochondrial antioxidant that reduces 
thioredoxin, and is reduced by NADPH supplied by NNT (Fig. 6.1).  Mutations in TXNRD2 
cause a more severe phenotype of FGD than seen for my proband, and additional phenotypes 
of trivial tricuspid and mitral valve regurgitation were found in one patient. 
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Other conditions of adrenal insufficiency have also been associated with defects causing 
oxidative stress. For example, X-ALD is a condition of adrenal insufficiency and axonal 
degeneration, characterised by the accumulation of VLCFAs in the peroxisome leading to 
elevated oxidative stress (Galea et al., 2012). Triple A syndrome, characterised by adrenal 
insufficiency and neurological impairment, is caused by mutations in AAAS, which encodes a 
nuclear pore complex protein (ALADIN) involved in nuclear import of the DNA-protective 
ferritin heavy chain.  Knockdown of AAAS has been shown to reduce GSH levels in cultured 
adrenocortical and neuronal cells, but decrease cell viability only in adrenocortical cells 
(Prasad et al., 2013). 
The antioxidant genes associated with the above conditions all encode ubiquitous proteins, 
highlighting the sensitivity of the adrenal cortex to oxidative stress compared to other tissues.  
Indeed, steroidogenic cells are more likely to endure oxidative damage because of the 
additional source of ROS formed by steroidogenic enzymes.  Multiple studies have illustrated 
the impact of ROS on impairing steroidogenesis (Diemer et al., 2003; Shi et al., 2010; Tsai et 
al., 2003), and shown that StAR protein levels are reduced by oxidative stress (Diemer et al., 
2003; Jin et al., 2011; Shi et al., 2010).  In this project, I showed knockdown of GPX1 and 
PRDX3 were individually capable of reducing StAR protein levels. 
The electron donor system that supplies the steroidogenic enzymes is leaky, leading to 
superoxide radical formation.  Steroidogenic CYP enzymes are expressed at ten times the 
concentration of mitochondrial respiratory enzymes, which constitute the main source of 
ROS in non-steroidogenic cells, hence the capacity for steroidogenic cells to produce ROS is 
far greater than other cell types (Hanukoglu and Hanukoglu, 1986). The predominant source 
of electron leakage is CYP11B1, which accounts for 40% leakage compared to 15% by 
CYP11A1 (Rapoport et al., 1995).  CYP11B1 is also more sensitive to ROS than other CYP 
enzymes undergoing degradation in the absence of antioxidants (Hanukoglu et al., 1990; 
Hornsby, 1989; Hornsby et al., 1985). This increased electron dispersal and sensitivity to 
ROS may explain why defects in oxidative stress genes are able to cause isolated 
glucocorticoid deficiency with no changes to mineralocorticoid levels. 
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Concentrations of antioxidants are particularly high in the adrenal cortex, presumably to 
compensate for excess ROS produced by steroidogenic CYP enzymes (Azhar et al., 1995; 
Hanukoglu, 2006). Concentrations of vitamin C, vitamin E and glutathione are considerably 
higher in the adrenal than other tissues, and the expression and activity of antioxidant 
enzymes SOD1, SOD2 and GPX and concentration of PRDX3 are also higher particularly 
within the ZF and ZR (Azhar et al., 1995; Hanukoglu, 2006; Watabe et al., 1994).  My data 
also reported high expression of GPX1 and GPX4 in the human adrenal cortex and it has 
previously been demonstrated that PRDX3 is highly expressed in the adrenal cortex of mice 
and is the predominant antioxidant enzyme in adrenocortical mitochondria (Kil et al., 2012). 
Recent work in our laboratory has also demonstrated TXNRD2 is particularly highly 
expressed in the human adrenal cortex compared to other tissues.  
Both GPX1 and TXNRD2 are selenoproteins, which generally appear to be important in the 
adrenal cortex, as Se is preferentially retained in the adrenal and testes following Se 
deprivation in rats (Behne and Höfer-Bosse, 1984).  Other endocrine organs such as the 
thyroid also retain high levels of selenium (Beckett and Arthur, 2005).  The majority of 
selenoproteins are involved in redox homeostasis, and Se deficiency can influence thyroid 
hormone metabolism, fertility and insulin signalling (Beckett and Arthur, 2005).  Mutations 
in SBP2, part of the selenocysteine incorporation machinery, lead to a multisystem disorder 
in humans (Schoenmakers et al., 2010).  The discovery of mutations in individual 
selenoproteins causing isolated adrenal dysfunction stresses the importance of redox 
homeostasis in the adrenal cortex. Interestingly, several studies have demonstrated the benefit 
of Se supplementation in endocrine disorders such as autoimmune thyroid disorders (Drutel 
et al., 2013).  The effects of supplementation are attributed to the regulation of ROS and its 
effect on the immune system (Drutel et al., 2013). 
Likewise, in both models of X-ALD and triple A, antioxidant treatment can rescue the effects 
of oxidative stress.  In the AAAS KD model, the reduction in cortisol could be partly rescued 
by treatment of cells with N-acetylcysteine (NAC). The mouse model of X-ALD (ABCD1
-/- 
mice) is characterised by a neurodegenerative AMN-like phenotype and mice have oxidative 
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damage in the spinal cords prior to disease progression, which is thought to be due to build-
up of VLCFAs.    López-Erauskin et al. (2011) showed that a combination of antioxidants a-
tocopherol, NAC, and a-lipoic acid (LA) reversed oxidative damage to proteins in spinal 
cords and halted histopathological signs of axonal degeneration, thus preventing clinical 
progression (López-Erauskin et al., 2011). This study raised the implication that early 
intervention with antioxidant treatment could pose a potential therapeutic option for treating 
conditions of oxidative stress (López-Erauskin et al., 2011). 
The relationship between the adrenal cortex and antioxidant defence is evident by role of 
ACTH in influencing antioxidant expression and activity.  Expression and activity of 
antioxidants SOD2 and SRX, which recycles inactivated PRDX3, are both upregulated by 
ACTH (Belge et al., 2004; Kil et al., 2012; Raza and Vinson, 2000).  Furthermore, in rhesus 
monkeys, levels of antioxidants SOD2 in blood correlates with cortisol in a diurnal rhythm 
which flattens in amplitude with age, suggesting cortisol regulates SOD expression 
(Goncharova et al., 2006). Similarly, PRDX3 has been recently reported to be involved in 
intra-adrenal negative feedback loop in which ROS regulates steroidogenesis through 
inactivation of PRDX3, making PRDX3 a particularly strong candidate gene for FGD.  In 
mice levels of H2O2, PRDX-SO2, ph-p38MAPK and StAR correlate with corticosterone 
circadian rhythms and in mutant SRX mice the amplitude of oscillations and corticosterone 
levels are reduced. Interestingly, GPX and GR activities do not have diurnal rhythms and 
GPX is not upregulated by ACTH (Belge et al., 2004; Goncharova et al., 2006).  Although 
GPX1 does not follow circadian rhythms, Se deficient AN4Rppc7 adrenal cells with minimal 
GPX1 activity exhibit a marked decrease in corticosterone after cAMP stimulation compared 
to Se adequate cells. These studies suggest a strong link between antioxidant activity and the 
regulation of adrenal steroidogenesis.   
My findings and the data reported in the above studies suggest GPX1 and PRDX3 are good 
candidate genes for FGD.  It is therefore surprising that dual knockdown did not cause a 
significant reduction in cortisol production or steroidogenic capacity.  The data presented is 
preliminary and may require more experimental repeats. The H295R KD model was chosen 
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in order to investigate a human model of the adrenal cortex. Although H295R cells have been 
widely used and have a similar steroidogenic gene expression profile to the human adrenal 
cortex (Oskarsson et al., 2006), a very recent report by Kil et al. (2013), suggested that 
H295R and mouse Y-1 clonal cell lines are not suitable for in vitro models of redox 
signalling in the context or steroidogenesis, as levels of SRX are far higher and levels of 
PRDX3 are much lower than in mouse adrenals, and neither SRX or PRDX3 hyperoxidation 
are influenced by ACTH stimulation. The same characteristics are observed in mouse 
primary adrenocortical cells shortly after isolation (Kil et al., 2013). This report raises 
concerns for our future studies of human adrenal steroidogenesis where in vivo studies are not 
possible. 
In vivo mouse models of adrenal disorders have been explored, however many cases do not 
fully recapitulate the human model.  For example, whereas post-mortem analysis of adrenals 
taken from triple A patients show atrophy of the ZF,  Aaas
-/-
 mouse model shows no 
histological abnormalities compared to wild type, and only mild neurological disturbances 
(Huebner et al., 2006).  Post mortem histological analyses of FGD patient adrenals show 
disorganised glomerulosa cells and absent ZF and ZR.  However, NNT mutant mice display 
only a mild disorganisation of the ZF cells.  Furthermore, although NNT mutant mice had 
50% less basal corticosterone levels, patients are usually almost deplete of cortisol.  If GPX1 
mutations cause a mild phenotype in the adrenal cortex, it may not be surprising that a 
significant decrease in corticosterone production was not seen in the knockout mouse. 
Because of the limitations of mouse models and in vitro models, future work may need to 
apply other available in vivo models.  Non-human primates such as the rhesus monkey have 
been used in studies to characterise expression and activity levels of antioxidant enzymes in 
the adrenal cortex and the correlation of antioxidants and cortisol during aging (Goncharova 
et al., 2008; Goncharova et al., 2006; Goncharova et al., 2013).  Unlike rodents, non-human 
primates express CYP17 and therefore produce adrenal androgens, a better representation of 
human steroidogenesis.  
295 
 
Zebrafish are also emerging as a popular model to study steroidogenesis.  Steroid synthesis 
occurs in the gonads, brain and interrenal, a region of steroidogenic cells homologous to the 
adrenal cortex in head kidney cells (Tokarz et al., 2013).  Synthesis of cortisol, the major 
glucocorticoid in zebrafish, is under the control of the hypothalamic-pituitary-interrenal axis 
(Liu et al., 2011; Tokarz et al., 2013). Despite these anatomical differences the steroidogenic 
signalling pathway and steroid receptors are highly conserved between mammals and 
zebrafish (Tokarz et al., 2013).  However, a portion of the steroidogenesis pathway remains 
uncharacterised, for example steroidogenic enzymes cyp21a and cyp11b, and functional 
evidence is limited (Busby et al., 2010). In terms of practically zebrafish offer many benefits 
that make them an attractive model.   Many endocrine genes are single copies making genetic 
manipulation such as CRISPR interference straightforward.  The high numbers of progeny 
produced by single crosses are ideal for high throughput screens and the small size of fish 
makes for easy maintenance (Löhr and Hammerschmidt, 2011).  The small size also allowed 
whole fish immunostaining or in situ hybridisation and the transparency of fish during 
embryogenesis also allows for use of transgene-encoded fluorochromes (Löhr and 
Hammerschmidt, 2011). Zebrafish have been used to study the toxic effects of endocrine 
disrupting chemicals (EDCs) such as oestrogens, gestagens or selenomethionine, which 
interfere with steroidogenesis (Tokarz et al., 2013), and therefore may present a useful model 
for future studies. 
In conclusion, mutations in genes involved in antioxidant defence, or that lead to oxidative 
stress, are being increasingly associated with conditions involving adrenal insufficiency, 
emphasising the sensitivity of the adrenal cortex to oxidative changes.  In this thesis, I have 
discovered an FGD patient with mutations in two antioxidant genes and provided data to 
suggest that loss of function in GPX1 alone, or in combination with PRDX3 may cause FGD. 
Whole exome sequencing of the remaining 39% FGD patients with unknown aetiology may 
reveal further genes in the same antioxidant pathway. 
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6.3 Future directions 
The future work after this project will confirm some of findings of this thesis.  Firstly, the 
interaction of MC2R with clathrin will be checked by reciprocal co-immunoprecipitation. 
The subcellular localisation of TAP-tagged proteins should also be verified with 
compartmental markers, a step that was not taken.  In addition, to further test the efficiency of 
the TAP system, an additional control experiment should be carried out, to 
coimmunoprecipitate MC2R and MRAP, using the TAP-tag technique, for example by 
pulling down with TAP-tagged MC2R and probing for FLAG tagged MRAP.  The lysates 
would be subjected to Western blot analysis to confirm the proteins interact, and the gel 
would be stained and subjected to MS analysis to confirm whether MS was sensitive enough 
to detect the isolated proteins. 
Although the TAP-tag technique could be further optimised, the genetic approach of whole 
exome sequencing is a more time and cost effective in identifying causes of FGD, hence the 
proteomic approach would not be continued further. 
In this thesis I showed the R130-L133del protein had a shorter half-life than WT, and CHX 
treatment resulted in significantly less R130-L133del protein compared to vehicle by 10 
hours, whereas the WT protein abundance did not significantly decrease.  However there was 
no statistical difference between the percentage protein remaining for WT and R130-L133del.  
A more efficient technique to confirm degradation is the pulse-chase technique, which could 
be employed in future to confirm current data.   
I also considered the possibility that low protein abundance of R130-L133del could be due to 
reduced mRNA transcript levels due to nonsense mediated decay.  GPX1 is a prime candidate 
for nonsense mediated decay because it has a UGA codon in the middle of an exon that is at 
least 50bp away from the intron (Lubos et al., 2011; Silva and Romão, 2009).  As a 
selenoprotein GPX1 has a UGA stop codon that encodes the selenocysteine at its active site 
(Chambers et al., 1986; Kraus et al., 1983), and translation of the residue is dependent on 
selenium and the SECIS element in the 3’UTR (Berry et al., 1991; Shen et al., 1993; Shen et 
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al., 1995).  In absence of these factors, evidence suggests the residue is read as a stop codon 
and the protein subsequently undergoes nonsense mediated decay (Shen et al., 1993).   
Variants and truncations that affect mRNA stability or selenocysteine incorporation may 
render the transcript more susceptible to nonsense mediated decay.  Kasaikina et al. (2011) 
described a stop gain mutation in the naked mole rat GPX1 only five residues premature of 
the original stop codon.  Functional characterisation of this protein showed that it had poor 
protein and mRNA expression, which was rescued by substituting the selenocysteine residue 
for a cysteine, suggesting the premature stop codon affected incorporation of the 
selenocysteine and mRNA stability. Using similar methodology, I plan to investigate whether 
R130-L133del affects mRNA stability by mutating the selenocysteine to cysteine using site 
directed mutagenesis in this transcript and checking whether protein levels are partially 
rescued. 
The preliminary data collected from characterising GPX1 and PRDX3 double KD cell lines 
suggested a trend of reduced StAR and cortisol levels, however the data did not reach 
statistical significance.  One of the most important future directions is to gain more 
experimental repeats for these experiments to clarify whether this trend is real.  In addition to 
these experiments, the levels of StAR in SCR and KD cells would be measured following 
forskolin treatment, which may give a better indication to the effects of GPX1 and PRDX3 on 
steroidogenesis.  The use of DEX to deplete pre-existing StAR could also be applied before 
forskolin treatment, to remove masking of changes in abundance of newly synthesised StAR.  
Furthermore, it would be necessary to measure the 37kDa form of StAR, which has been 
reported as the active form in several studies (Miller, 2013). 
The double-KD cell line showed reduced cell viability at physiological conditions, however I 
did not measure cellular levels of ROS.  As GPX1 and PRDX3 both reduce hydrogen 
peroxide, a spectrophotometric/fluorometric assay that measures H2O2 levels would be most 
appropriate. This data would confirm higher levels of oxidative stress in adrenocortical cells 
absent of GPX1 and PRDX3 expression.  Previous studies have also shown that cells 
expressing a defective PRDX3 have altered mitochondrial morphology (Mukhopadhyay et 
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al., 2006).  It would therefore be interesting to explore the effects of double knockdown on 
the mitochondrial network in adrenocortical cells using mitochondrial markers such as 
MitoDSred. 
It has been well documented that GPX1
-/-
 mice are normal and viable and do not show 
abnormalities until 15 months (Esposito et al., 2000).  Our proband has a relatively mild 
phenotype and is in his 30’s.  Taking these factors into consideration, it would be desirable to 
study the adrenal morphology of older GPX1
-/-
 mice. A progressive effect of decreased 
antioxidant defence may be apparent on staining with conventional dyes, and greater 
differences in basal and stimulated corticosterone levels may also be apparent.  Similarly the 
Prdx3
-/-  
mouse has been described to have increased susceptibility to oxidative stress but no 
adrenal phenotype is reported (Li et al., 2007). An investigation into possible adrenal 
dysfunction in these mice might yield positive results.  Ultimately I would hope to generate a 
double knockout murine model for future studies.   
My immunofluorent studies on GPX1
-/-
 adrenals showed increased cleaved-caspase-3 staining 
suggesting increased apoptosis.  To follow up this data, I would like to co-stain adrenal 
sections with Platelet endothelial cell adhesion molecule (PECAM-1), an endothelial and 
platelet cell marker, to confirm whether it is this type of cell that has increased apoptosis.  It 
would also be interesting to further these experiments by quantifying apoptosis levels using a 
TUNEL assay to detect DNA fragmentation. 
Given that mouse models do not always fully recapitulate human disease, it would also be 
interesting to use zebrafish models to explore the effects of antioxidant gene KD on 
steroidogenesis should the orthologs be identifiable. 
Finally, since employing next generation sequencing, our research group has identified 3 
causal genes and 2 putative candidate genes in the pathogenesis of FGD. The identification of 
novel causes of FGD has accelerated in recent years, because of the low time consumption 
and high quantity of data gained from the sequencing process.  Whole exome sequencing is 
thus emerging as a useful diagnostic tool for monogenic disorders, which may allow more 
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targeted therapeutic treatment in future.  It is therefore in the interest of our research group to 
continue to employ whole exome sequencing to unveil the remaining genetic causes of the 
39% of FGD patients with unknown aetiology.  Based on recent studies and the findings of 
this thesis, I anticipate a proportion of these genes will be involved in oxidative stress.  
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Appendix 1: Whole Exome Sequencing Data 
 
1. 1: Non-synonymous missense mutations identified by whole exome sequencing of the 
proband.   
Details include: chromosome number (Chrom), genomic location (left position), 
reference nucleotide (Ref Nuc), variant nucleotide (Var nuc), total number of reads for 
the variant locus (Read depth), number of reads for the variant allele (Var freq) gene 
name, reference peptide (Ref pep) at this position and variant peptide (Var pep) 
introduced as a consequence of the variant allele (*=stop). All variants had a read 
depth> 20 . 
Chrom 
Left 
position 
Ref 
Nuc 
Var 
Nuc 
Read 
Depth 
Var 
Freq Gene Name 
Ref 
peptide 
Var 
peptide 
chr1 892284 t g 45 44 NOC2L Q P 
chr1 153941536 c t 33 32 CREB3L4 P L 
chr1 155002628 c t 32 30 DCST2 R H 
chr1 228412227 tg ca 30 28 OBSCN SA ST 
chr2 98128194 ggt cac 40 36 ANKRD36B YR CG 
chr2 232087474 at ga 34 33 ARMC9 I E 
chr3 19961330 ct tc 26 26 EFHB SV SI 
chr3 37050392 g a 46 46 MLH1 G S 
chr3 52556127 a g 24 24 STAB1 T A 
chr3 148897356 a g 40 40 CP V A 
chr3 194373832 tg ca 22 21 LSG1 TK TE 
chr3 195451880 ag ga 53 52 MUC20 R E 
chr3 195506530 c a 31 28 MUC4 R L 
chr3 195507226 a g 159 158 MUC4 V A 
chr3 195507372 c g 47 47 MUC4 Q H 
chr3 195508336 c t 23 21 MUC4 G D 
chr3 195509423 g a 25 20 MUC4 P S 
chr3 195509954 g c 106 101 MUC4 L V 
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chr3 195509974 a g 84 83 MUC4 F S 
chr3 195510943 g t 66 63 MUC4 S Y 
chr3 195511336 g c 174 153 MUC4 T S 
chr3 195511690 g c 167 156 MUC4 T S 
chr3 195511740 c g 88 86 MUC4 Q H 
chr3 195512003 tt tg 45 38 MUC4 ET DT 
chr3 195512107 t a 93 91 MUC4 D V 
chr3 195512117 c g 88 85 MUC4 A P 
chr3 195512186 t c 60 60 MUC4 I V 
chr3 195512206 a g 45 41 MUC4 L P 
chr3 195512767 tt ga 95 90 MUC4 N S 
chr3 195514956 c g 46 44 MUC4 Q H 
chr3 195514969 g a 57 55 MUC4 A V 
chr4 88536692 a g 53 52 DSPP S G 
chr4 88537035 a g 21 21 DSPP D G 
chr5 1225687 ct tc 38 38 SLC6A18 T I 
chr6 3264526 ct tc 44 43 PSMG4 L S 
chr6 31324525 cc tg 20 19 HLA-B QA HT 
chr6 31324602 tct gtc 22 17 HLA-B RE RT 
chr6 47649573 ca tg 27 27 GPR111 SK SE 
chr6 56918867 c g 21 21 KIAA1586 Q E 
chr6 143092151 t c 35 35 HIVEP2 Y C 
chr7 72738762 ca tg 45 45 TRIM50 L P 
chr7 74303828 c t 44 43 STAG3L2 R Q 
chr7 100636722 g c 30 30 MUC12 V L 
chr8 17796382 ac gt 35 35 PCM1 N S 
chr8 142446139 c t 26 25 FLJ43860 M I 
chr10 119774577 g a 54 53 RAB11FIP2 P L 
chr10 135491030 g c 23 21 LOC653544 G A 
chr10 135491030 g c 23 21 LOC653545 G A 
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chr10 135491030 g c 23 21 LOC653548 G A 
chr10 135491030 g c 23 21 LOC728410 G A 
chr11 280816 at tc 27 27 NLRP6 Y F 
chr11 57147016 at gt 30 26 PRG3 I T 
chr11 58207203 ca tg 56 54 OR5B12 C H 
chr11 63999929 c t 25 23 DNAJC4 P S 
chr12 11244230 c a 30 30 TAS2R43 C F 
chr13 46108853 tg ca 36 36 COG3 L S 
chr17 39619093 gt ac 53 51 KRT32 N S 
chr17 39742898 gc at 21 20 KRT14 C Y 
chr17 44144993 c g 35 35 KIAA1267 R P 
chr18 52265307 aa ac 21 18 C18orf26 TT TP 
chr19 39308104 t c 29 29 ECH1 N S 
chr19 40368498 aa cc 56 55 FCGBP LS LA 
chr19 41382560 a t 52 52 CYP2A7 F Y 
chr20 44038574 at gt 24 21 DBNDD2 M V 
chr21 31869285 gt gc 48 42 KRTAP19-4 Y C 
chrX 35821055 at ga 31 31 MAGEB16 M E 
chrX 54263878 t c 22 21 WNK3 K R 
chrX 70524052 c t 30 29 ITGB1BP2 R C 
chrX 114426193 g a 29 29 RBMXL3 R Q 
chrX 152482522 g c 39 39 MAGEA1 D E 
chrX 153458965 g t 52 51 OPN1MW V L 
chrX 153458965 g t 52 51 OPN1MW2 V L 
 
 
1. 2: Non-synonymous in-frame deletions identified by whole exome sequencing of the 
proband.   
Details include: chromosome number (Chrom), genomic location (left position), 
reference nucleotide (Ref Nuc), variant nucleotide (Var nuc), total number of reads for 
the variant locus (Read depth), number of reads for the variant allele (Var freq) gene 
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name, reference peptide (Ref pep) at this position and variant peptide (Var pep) 
introduced as a consequence of the variant allele (*=stop). All variants had a read 
depth> 20 . 
Chrom 
Left 
position 
Ref 
Nuc 
Var 
Nuc Read Depth 
Var 
Freq 
Gene 
Name 
Ref 
peptide 
Var 
peptide 
chr5 98192167 gag  - 31 28 CHD1 SP S 
chr9 97080947 aag  - 40 34 FAM22F PS P 
chr20 238439 tcttgg  - 28 23 DEFB132 VLA A 
chr20 1896052 cga  - 36 30 SIRPA PD P 
chrX 135474448 gat  - 22 21 GPR112 D   
 
1.  3: Frame-shift mutation identified by whole exome sequencing of the proband.   
Details include: Details include: chromosome number (Chrom), genomic location (left 
position), reference nucleotide (Ref Nuc), variant nucleotide (Var nuc), total number of 
reads for the variant locus (Read depth), number of reads for the variant allele (Var 
freq) gene name, reference peptide (Ref pep) at this position and variant peptide (Var 
pep) introduced as a consequence of the variant allele (*=stop). All variants had a read 
depth> 20 . 
Chrom 
Left 
position 
Ref 
Nuc 
Var 
Nuc 
Read 
Coverage 
Var 
Freq 
Gene 
Name 
Ref 
peptide 
Var 
peptide 
chr19 52004796 INS t 43 36 SIGLEC12     
 
1.  4: Stop-gain mutations identified by whole exome sequencing of the proband.   
Details include: variant ID number, chromosome number (Chrom), genomic location 
(left position), reference nucleotide (Ref Nuc), variant nucleotide (Var nuc), total 
number of reads for loci (Read coverage), number of reads for variant allele at loci (Var 
freq) (heterozygous variants would be 50%), gene name, reference peptide (Ref pep) 
367 
 
and variant peptide (Var pep) (*=stop). All variants had coverage of at least 20 reads. 
Grey shading highlights the variant in PRDX3 which is our ‘second hit’ candidate gene. 
 
Chrom 
Left 
position 
Ref 
Nuc 
Var 
Nuc 
Read 
Coverage 
Var 
Freq 
Gene 
Name 
Ref 
peptide 
Var 
peptide 
chr10 120934075 G a 20 20 PRDX3 Q * 
chr11 58893362 C t 41 40 FAM111B R * 
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Appendix 2: Vector maps 
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Appendix 3: GPX1 and PRDX3 cDNA sequences 
 
GPX1 cDNA (transcript 1): 
GAGCCCTCGAGGGCCCCAGCCCTTGGAAGGGTAACCTGGACCGCTGCCGCCTGGTTGCCT
GGGCCAGACCAGACATGCCTGCTGCTCCTTCCGGCTTAGGAGGAGCACGCGTCCCGCTCG
GGCGCACTCTCCAGCCTTTTCCTGGCTGAGGAGGGGCCGAGCCCTCCGGGTAGGGCGGG
GGCCGGATGAGGCGGGACCCTCAGGCCCGGAAAACTGCCTGTGCCACGTGACCCGCCGC
CGGCCAGTTAAAAGGAGGCGCCTGCTGGCCTCCCCTTACAGTGCTTGTTCGGGGCGCTCC
GCTGGCTTCTTGGACAATTGCGCCATGTGTGCTGCTCGGCTAGCGGCGGCGGCGGCGGCG
GCCCAGTCGGTGTATGCCTTCTCGGCGCGCCCGCTGGCCGGCGGGGAGCCTGTGAGCCTG
GGCTCCCTGCGGGGCAAGGTACTACTTATCGAGAATGTGGCGTCCCTCTGAGGCACCACG
GTCCGGGACTACACCCAGATGAACGAGCTGCAGCGGCGCCTCGGACCCCGGGGCCTGGT
GGTGCTCGGCTTCCCGTGCAACCAGTTTGGGCATCAGGAGAACGCCAAGAACGAAGAGA
TTCTGAATTCCCTCAAGTACGTCCGGCCTGGTGGTGGGTTCGAGCCCAACTTCATGCTCTT
CGAGAAGTGCGAGGTGAACGGTGCGGGGGCGCACCCTCTCTTCGCCTTCCTGCGGGAGG
CCCTGCCAGCTCCCAGCGACGACGCCACCGCGCTTATGACCGACCCCAAGCTCATCACCT
GGTCTCCGGTGTGTCGCAACGATGTTGCCTGGAACTTTGAGAAGTTCCTGGTGGGCCCTG
ACGGTGTGCCCCTACGCAGGTACAGCCGCCGCTTCCAGACCATTGACATCGAGCCTGACA
TCGAAGCCCTGCTGTCTCAAGGGCCCAGCTGTGCCTAGGGCGCCCCTCCTACCCCGGCTG
CTTGGCAGTTGCAGTGCTGCTGTCTCGGGGGGGTTTTCATCTATGAGGGTGTTTCCTCTAA
ACCTACGAGGGAGGAACACCTGATCTTACAGAAAATACCACCTCGAGATGGGTGCTGGT
CCTGTTGATCCCAGTCTCTGCCAGACCAAGGCGAGTTTCCCCACTAATAAAGTGCCGGGT
GTCAGCAGAA 
Grey depicts utr. Red  
PRDX3 cDNA: 
CCCTGCGTCTCTGCCCGCCCCGTGGCGCCCGAGTGCACTGAAGATGGCGGCTGCTGTAGG
ACGGTTGCTCCGAGCGTCGGTTGCCCGACATGTGAGTGCCATTCCTTGGGGCATTTCTGC
CACTGCAGCCCTCAGGCCTGCTGCATGTGGAAGAACGAGCTTGACAAATTTATTGTGTTC
TGGTTCCAGTCAAGCAAAATTATTCAGCACCAGTTCCTCATGCCATGCACCTGCTGTCAC
CCAGCATGCACCCTATTTTAAGGGTACAGCCGTTGTCAATGGAGAGTTCAAAGACCTAAG
CCTTGATGACTTTAAGGGGAAATATTTGGTGCTTTTCTTCTATCCTTTGGATTTCACCTTT
GTGTGTCCTACAGAAATTGTTGCTTTTAGTGACAAAGCTAACGAATTTCACGACGTGAAC
TGTGAAGTTGTCGCAGTCTCAGTGGATTCCCACTTTAGCCATCTTGCCTGGATAAATACA
CCAAGAAAGAATGGTGGTTTGGGCCACATGAACATCGCACTCTTGTCAGACTTAACTAA
GCAGATTTCCCGAGACTACGGTGTGCTGTTAGAAGGTTCTGGTCTTGCACTAAGAGGTCT
CTTCATAATTGACCCCAATGGAGTCATCAAGCATTTGAGCGTCAACGATCTCCCAGTGGG
CCGAAGCGTGGAAGAAACCCTCCGCTTGGTGAAGGCGTTCCAGTATGTAGAAACACATG
GAGAAGTCTGCCCAGCGAACTGGACACCGGATTCTCCTACGATCAAGCCAAGTCCAGCT
GCTTCCAAAGAGTACTTTCAGAAGGTAAATCAGTAGATCACCCATGTGTATCTGCACCTT
CTCAACTGAGAGAAGAACCACAGTTGAAACCTGCTTTTATCATTTTCAAGATGGTTATTT
GTAGAAGGCAAGGAACCAATTATGCTTGTATTCATAAGTATTACTCTAAATGTTTTGTTTT
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TGTAATTCTGGCTAAGACCTTTTAAACATGGTTAGTTGCTAGTACAAGGAATCCTTTATTG
GTAACATCTTGGTGGCTGGCTAGCTAGTTTCTACAGAACATAATTTGCCTCTATAGAAGG
CTATTCTTAGATCATGTCTCAATGGAAACACTCTTCTTTCTTAGCCTTACTTGAATCTTGC
CTATAATAAAGTAGAGCAACACACATTGAAAGCTTCTGATCAACGGTCCTGAAATTTTCA
TCTTGAATGTCTTTGTATTAAACTGAATTTTCTTTTAAGCTAACAAAGATCATAATTTTCA
ATGATTAGCCGTGTAACTCCTGCAATGAATGTTTATGTGATTGAAGCAAATGTGAATCGT
ATTATTTTAAAAAGTGGCAGAGTGACTTAACTGATCATGCATGATCCCTCATCCCTGAAA
TTGAGTTTATGTAGTCATTTTACTTATTTTATTCATTAGCTAACTTTGTCTATGTATATTTC
TAGATATTGATTAGTGTAATCGATTATAAAGGATATTTATCAAATCCAGGGATTGCATTT
TGAAATTATAATTATTTTCTTTGCTGAAGTATTCATTGTAAAACATACAAAATAAACATA
TTTTAAAACATTTGCATTTT 
Grey depicts UTR. 
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Appendix 4: Presentations and prizes relating to this thesis 
 
Oral communications 
British Society for Endocrinology annual meeting: A homozygous glutathione peroxidase 1 
mutation p.Arg130-Leu133del, in a patient with familial glucocorticoid deficiency.  
QMUL WHRI day ‘Digenic inheritance of mutations in antioxidant pathway genes in 
Familial Glucocorticoid Deficiency’ 
European Society for Paediatric Endocrinologists ‘Digenic inheritance of mutations in 
antioxidant pathway genes in Familial Glucocorticoid Deficiency’ 
Posters 
British Society of Paediatric Endocrinology and Diabetes annual meeting: A homozygous 
glutathione peroxidase 1 mutation p.Arg130-Leu133del, in a patient with familial 
glucocorticoid deficiency.  
Society for Free Radical Research International annual meeting: A homozygous glutathione 
peroxidase 1 mutation p.Arg130-Leu133del, in a patient with familial glucocorticoid 
deficiency. 
Prizes 
BES conference: Highly commended for oral communication 
BSPED conference: Poster Prize 
